0001437749-24-03531110-Q MILESTONE SCIENTIFIC INC. 2024111420241114161550161551161551 0 0001437749-24-035311 10-Q 63 20240930 20241114 20241114 MILESTONE SCIENTIFIC INC. 0000855683 3842 133545623 DE 1231 10-Q 34 001-14053 241462553 220 SOUTH ORANGE AVENUE LIVINGSTON NJ 07039 (973) 535-2717 220 SOUTH ORANGE AVENUE LIVINGSTON NJ 07039 MILESTONE SCIENTIFIC INC/NJ 19970409 U S OPPORTUNITY SEARCH INC 19920703 10-Q 1 mlss20240930_10q.htm FORM 10-Q mlss20240930_10q.htm 0000855683 MILESTONE SCIENTIFIC INC. false --12-31 Q3 2024 10,000 10,000 0.001 0.001 100,000,000 100,000,000 77,709,455 77,676,122 75,881,840 75,848,507 33,333 33,333 42,273 154 193 0 1.2 1.4 3 5 17,000 2 1 1 1 3 2 3 5 0.29 1.3 2.50 3.50 66,666 66,666 false false false false 00008556832024-01-012024-09-30 xbrli:shares 00008556832024-11-14 thunderdome:item iso4217:USD 00008556832024-09-30 00008556832023-12-31 0000855683us-gaap:NonrelatedPartyMember2024-09-30 0000855683us-gaap:NonrelatedPartyMember2023-12-31 0000855683us-gaap:RelatedPartyMember2024-09-30 0000855683us-gaap:RelatedPartyMember2023-12-31 iso4217:USDxbrli:shares 00008556832024-07-012024-09-30 00008556832023-07-012023-09-30 00008556832023-01-012023-09-30 0000855683us-gaap:CommonStockMember2023-12-31 0000855683us-gaap:AdditionalPaidInCapitalMember2023-12-31 0000855683us-gaap:RetainedEarningsMember2023-12-31 0000855683us-gaap:NoncontrollingInterestMember2023-12-31 0000855683us-gaap:TreasuryStockCommonMember2023-12-31 0000855683us-gaap:CommonStockMember2024-01-012024-03-31 0000855683us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-31 0000855683us-gaap:RetainedEarningsMember2024-01-012024-03-31 0000855683us-gaap:NoncontrollingInterestMember2024-01-012024-03-31 0000855683us-gaap:TreasuryStockCommonMember2024-01-012024-03-31 00008556832024-01-012024-03-31 0000855683mlss:BoardOfDirectorsMemberus-gaap:CommonStockMember2024-01-012024-03-31 0000855683mlss:BoardOfDirectorsMemberus-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-31 0000855683mlss:BoardOfDirectorsMember2024-01-012024-03-31 0000855683us-gaap:CommonStockMember2024-03-31 0000855683us-gaap:AdditionalPaidInCapitalMember2024-03-31 0000855683us-gaap:RetainedEarningsMember2024-03-31 0000855683us-gaap:NoncontrollingInterestMember2024-03-31 0000855683us-gaap:TreasuryStockCommonMember2024-03-31 00008556832024-03-31 0000855683us-gaap:CommonStockMember2024-04-012024-06-30 0000855683us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-30 0000855683us-gaap:RetainedEarningsMember2024-04-012024-06-30 0000855683us-gaap:NoncontrollingInterestMember2024-04-012024-06-30 0000855683us-gaap:TreasuryStockCommonMember2024-04-012024-06-30 00008556832024-04-012024-06-30 0000855683us-gaap:CommonStockMember2024-06-30 0000855683us-gaap:AdditionalPaidInCapitalMember2024-06-30 0000855683us-gaap:RetainedEarningsMember2024-06-30 0000855683us-gaap:NoncontrollingInterestMember2024-06-30 0000855683us-gaap:TreasuryStockCommonMember2024-06-30 00008556832024-06-30 0000855683us-gaap:CommonStockMember2024-07-012024-09-30 0000855683us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-30 0000855683us-gaap:RetainedEarningsMember2024-07-012024-09-30 0000855683us-gaap:NoncontrollingInterestMember2024-07-012024-09-30 0000855683us-gaap:TreasuryStockCommonMember2024-07-012024-09-30 0000855683us-gaap:CommonStockMember2024-09-30 0000855683us-gaap:AdditionalPaidInCapitalMember2024-09-30 0000855683us-gaap:RetainedEarningsMember2024-09-30 0000855683us-gaap:NoncontrollingInterestMember2024-09-30 0000855683us-gaap:TreasuryStockCommonMember2024-09-30 0000855683us-gaap:CommonStockMember2022-12-31 0000855683us-gaap:AdditionalPaidInCapitalMember2022-12-31 0000855683us-gaap:RetainedEarningsMember2022-12-31 0000855683us-gaap:NoncontrollingInterestMember2022-12-31 0000855683us-gaap:TreasuryStockCommonMember2022-12-31 00008556832022-12-31 0000855683us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-31 0000855683us-gaap:RetainedEarningsMember2023-01-012023-03-31 0000855683us-gaap:NoncontrollingInterestMember2023-01-012023-03-31 00008556832023-01-012023-03-31 0000855683mlss:BoardOfDirectorsMemberus-gaap:CommonStockMember2023-01-012023-03-31 0000855683mlss:BoardOfDirectorsMemberus-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-31 0000855683mlss:BoardOfDirectorsMember2023-01-012023-03-31 0000855683us-gaap:CommonStockMember2023-01-012023-03-31 0000855683us-gaap:TreasuryStockCommonMember2023-01-012023-03-31 0000855683us-gaap:CommonStockMember2023-03-31 0000855683us-gaap:AdditionalPaidInCapitalMember2023-03-31 0000855683us-gaap:RetainedEarningsMember2023-03-31 0000855683us-gaap:NoncontrollingInterestMember2023-03-31 0000855683us-gaap:TreasuryStockCommonMember2023-03-31 00008556832023-03-31 0000855683us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-30 00008556832023-04-012023-06-30 0000855683us-gaap:RetainedEarningsMember2023-04-012023-06-30 0000855683us-gaap:NoncontrollingInterestMember2023-04-012023-06-30 0000855683us-gaap:TreasuryStockCommonMember2023-04-012023-06-30 0000855683us-gaap:CommonStockMember2023-04-012023-06-30 0000855683us-gaap:CommonStockMember2023-06-30 0000855683us-gaap:AdditionalPaidInCapitalMember2023-06-30 0000855683us-gaap:RetainedEarningsMember2023-06-30 0000855683us-gaap:NoncontrollingInterestMember2023-06-30 0000855683us-gaap:TreasuryStockCommonMember2023-06-30 00008556832023-06-30 0000855683us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-30 0000855683us-gaap:RetainedEarningsMember2023-07-012023-09-30 0000855683us-gaap:NoncontrollingInterestMember2023-07-012023-09-30 0000855683us-gaap:TreasuryStockCommonMember2023-07-012023-09-30 0000855683us-gaap:CommonStockMember2023-09-30 0000855683us-gaap:AdditionalPaidInCapitalMember2023-09-30 0000855683us-gaap:RetainedEarningsMember2023-09-30 0000855683us-gaap:NoncontrollingInterestMember2023-09-30 0000855683us-gaap:TreasuryStockCommonMember2023-09-30 00008556832023-09-30 0000855683mlss:PublicOfferingMember2024-01-012024-09-30 0000855683mlss:PublicOfferingMember2023-01-012023-09-30 xbrli:pure 0000855683us-gaap:MoneyMarketFundsMember2024-09-30 0000855683us-gaap:MoneyMarketFundsMember2023-12-31 0000855683us-gaap:USTreasurySecuritiesMember2023-12-31 0000855683us-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-31 0000855683us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-31 0000855683us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-31 0000855683us-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-31 0000855683mlss:DentalSegmentMember2024-09-30 0000855683mlss:DentalSegmentMember2023-12-31 0000855683mlss:MedicalSegmentMember2024-09-30 0000855683mlss:MedicalSegmentMember2023-12-31 0000855683mlss:SlowMovingMedicalFinishedGoodsMember2024-09-30 0000855683mlss:SlowMovingMedicalFinishedGoodsMember2023-12-31 0000855683mlss:PublicOfferingMember2023-12-102023-12-10 0000855683mlss:PublicOfferingMember2023-12-10 0000855683us-gaap:OverAllotmentOptionMember2023-12-102023-12-10 0000855683us-gaap:OverAllotmentOptionMember2024-01-122024-01-12 utr:Y 00008556832024-01-01 0000855683mlss:ChiefExecutiveOfficerAndOtherEmployeesMember2024-09-30 0000855683mlss:ChiefExecutiveOfficerAndOtherEmployeesMember2023-09-30 0000855683mlss:NonemployeesMember2024-09-30 0000855683mlss:NonemployeesMember2023-09-30 0000855683us-gaap:EmployeeStockOptionMembermlss:The2020EquityIncentivePlanMember2023-06-28 0000855683us-gaap:EmployeeStockOptionMembermlss:The2020EquityIncentivePlanMember2024-01-012024-09-30 0000855683us-gaap:EmployeeStockOptionMembermlss:The2020EquityIncentivePlanMember2024-07-012024-09-30 0000855683us-gaap:EmployeeStockOptionMembermlss:The2020EquityIncentivePlanMember2023-07-012023-09-30 0000855683us-gaap:EmployeeStockOptionMembermlss:The2020EquityIncentivePlanMember2023-01-012023-09-30 0000855683us-gaap:EmployeeStockOptionMember2024-09-30 0000855683us-gaap:EmployeeStockOptionMember2024-01-012024-09-30 0000855683us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember2023-12-31 0000855683us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember2023-01-012023-12-31 0000855683us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember2024-09-30 0000855683us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember2024-01-012024-09-30 0000855683us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementNonemployeeMember2023-12-31 0000855683us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementNonemployeeMember2023-01-012023-12-31 0000855683us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementNonemployeeMember2024-01-012024-09-30 0000855683us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementNonemployeeMember2024-09-30 0000855683us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementNonemployeeMember2024-07-012024-09-30 0000855683us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementNonemployeeMember2023-07-012023-09-30 0000855683us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementNonemployeeMember2023-01-012023-09-30 0000855683us-gaap:RestrictedStockMember2023-12-31 0000855683us-gaap:RestrictedStockMember2024-01-012024-09-30 0000855683us-gaap:RestrictedStockMember2024-09-30 0000855683us-gaap:RestrictedStockMember2024-07-012024-09-30 0000855683us-gaap:RestrictedStockMember2023-07-012023-09-30 0000855683us-gaap:RestrictedStockMember2023-01-012023-09-30 0000855683us-gaap:RestrictedStockMembermlss:BoardOfDirectorsMember2024-07-162024-07-16 0000855683us-gaap:RestrictedStockMembermlss:BoardOfDirectorsMember2024-07-16 0000855683us-gaap:RestrictedStockMembermlss:BoardOfDirectorsMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2024-07-012024-07-31 0000855683us-gaap:RestrictedStockMembermlss:BoardOfDirectorsMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2024-01-012024-09-30 0000855683us-gaap:RestrictedStockMembermlss:BoardOfDirectorsMember2024-07-012024-09-30 0000855683us-gaap:RestrictedStockMembermlss:BoardOfDirectorsMember2024-01-012024-09-30 0000855683us-gaap:RestrictedStockMembermlss:BoardOfDirectorsMember2024-09-30 00008556832024-04-012024-04-01 00008556832024-04-012029-04-01 00008556832024-04-01 0000855683us-gaap:OperatingSegmentsMembermlss:DentalSegmentMember2024-07-012024-09-30 0000855683us-gaap:OperatingSegmentsMembermlss:DentalSegmentMember2023-07-012023-09-30 0000855683us-gaap:OperatingSegmentsMembermlss:DentalSegmentMember2024-01-012024-09-30 0000855683us-gaap:OperatingSegmentsMembermlss:DentalSegmentMember2023-01-012023-09-30 0000855683us-gaap:OperatingSegmentsMembermlss:MedicalSegmentMember2024-07-012024-09-30 0000855683us-gaap:OperatingSegmentsMembermlss:MedicalSegmentMember2023-07-012023-09-30 0000855683us-gaap:OperatingSegmentsMembermlss:MedicalSegmentMember2024-01-012024-09-30 0000855683us-gaap:OperatingSegmentsMembermlss:MedicalSegmentMember2023-01-012023-09-30 0000855683us-gaap:CorporateNonSegmentMember2024-07-012024-09-30 0000855683us-gaap:CorporateNonSegmentMember2023-07-012023-09-30 0000855683us-gaap:CorporateNonSegmentMember2024-01-012024-09-30 0000855683us-gaap:CorporateNonSegmentMember2023-01-012023-09-30 0000855683us-gaap:OperatingSegmentsMembermlss:DentalSegmentMember2024-09-30 0000855683us-gaap:OperatingSegmentsMembermlss:DentalSegmentMember2023-09-30 0000855683us-gaap:OperatingSegmentsMembermlss:MedicalSegmentMember2024-09-30 0000855683us-gaap:OperatingSegmentsMembermlss:MedicalSegmentMember2023-09-30 0000855683us-gaap:CorporateNonSegmentMember2024-09-30 0000855683us-gaap:CorporateNonSegmentMember2023-09-30 0000855683mlss:InstrumentsMembermlss:DentalSegmentMembercountry:US2024-07-012024-09-30 0000855683mlss:InstrumentsMembermlss:MedicalSegmentMembercountry:US2024-07-012024-09-30 0000855683mlss:InstrumentsMembercountry:US2024-07-012024-09-30 0000855683mlss:InstrumentsMembermlss:DentalSegmentMembercountry:US2023-07-012023-09-30 0000855683mlss:InstrumentsMembermlss:MedicalSegmentMembercountry:US2023-07-012023-09-30 0000855683mlss:InstrumentsMembercountry:US2023-07-012023-09-30 0000855683mlss:HandpiecesMembermlss:DentalSegmentMembercountry:US2024-07-012024-09-30 0000855683mlss:HandpiecesMembermlss:MedicalSegmentMembercountry:US2024-07-012024-09-30 0000855683mlss:HandpiecesMembercountry:US2024-07-012024-09-30 0000855683mlss:HandpiecesMembermlss:DentalSegmentMembercountry:US2023-07-012023-09-30 0000855683mlss:HandpiecesMembermlss:MedicalSegmentMembercountry:US2023-07-012023-09-30 0000855683mlss:HandpiecesMembercountry:US2023-07-012023-09-30 0000855683mlss:AccessoriesMembermlss:DentalSegmentMembercountry:US2024-07-012024-09-30 0000855683mlss:AccessoriesMembermlss:MedicalSegmentMembercountry:US2024-07-012024-09-30 0000855683mlss:AccessoriesMembercountry:US2024-07-012024-09-30 0000855683mlss:AccessoriesMembermlss:DentalSegmentMembercountry:US2023-07-012023-09-30 0000855683mlss:AccessoriesMembermlss:MedicalSegmentMembercountry:US2023-07-012023-09-30 0000855683mlss:AccessoriesMembercountry:US2023-07-012023-09-30 0000855683mlss:DentalSegmentMembercountry:US2024-07-012024-09-30 0000855683mlss:MedicalSegmentMembercountry:US2024-07-012024-09-30 0000855683country:US2024-07-012024-09-30 0000855683mlss:DentalSegmentMembercountry:US2023-07-012023-09-30 0000855683mlss:MedicalSegmentMembercountry:US2023-07-012023-09-30 0000855683country:US2023-07-012023-09-30 0000855683mlss:InstrumentsMembermlss:DentalSegmentMembermlss:RestOfWorldMember2024-07-012024-09-30 0000855683mlss:InstrumentsMembermlss:MedicalSegmentMembermlss:RestOfWorldMember2024-07-012024-09-30 0000855683mlss:InstrumentsMembermlss:RestOfWorldMember2024-07-012024-09-30 0000855683mlss:InstrumentsMembermlss:DentalSegmentMembermlss:RestOfWorldMember2023-07-012023-09-30 0000855683mlss:InstrumentsMembermlss:MedicalSegmentMembermlss:RestOfWorldMember2023-07-012023-09-30 0000855683mlss:InstrumentsMembermlss:RestOfWorldMember2023-07-012023-09-30 0000855683mlss:HandpiecesMembermlss:DentalSegmentMembermlss:RestOfWorldMember2024-07-012024-09-30 0000855683mlss:HandpiecesMembermlss:MedicalSegmentMembermlss:RestOfWorldMember2024-07-012024-09-30 0000855683mlss:HandpiecesMembermlss:RestOfWorldMember2024-07-012024-09-30 0000855683mlss:HandpiecesMembermlss:DentalSegmentMembermlss:RestOfWorldMember2023-07-012023-09-30 0000855683mlss:HandpiecesMembermlss:MedicalSegmentMembermlss:RestOfWorldMember2023-07-012023-09-30 0000855683mlss:HandpiecesMembermlss:RestOfWorldMember2023-07-012023-09-30 0000855683mlss:AccessoriesMembermlss:DentalSegmentMembermlss:RestOfWorldMember2024-07-012024-09-30

0000855683mlss:AccessoriesMembermlss:MedicalSegmentMembermlss:RestOfWorldMember2024-07-012024-09-30
0000855683mlss:AccessoriesMembermlss:RestOfWorldMember2024-07-012024-09-30
0000855683mlss:AccessoriesMembermlss:DentalSegmentMembermlss:RestOfWorldMember2023-07-012023-09-30
0000855683mlss:AccessoriesMembermlss:MedicalSegmentMembermlss:RestOfWorldMember2023-07-012023-09-30
0000855683mlss:AccessoriesMembermlss:RestOfWorldMember2023-07-012023-09-30 0000855683mlss:DentalSegmentMembermlss:RestOfWorldMember2024-07-012024-09-30
0000855683mlss:MedicalSegmentMembermlss:RestOfWorldMember2024-07-012024-09-30 0000855683mlss:RestOfWorldMember2024-07-012024-09-30
0000855683mlss:DentalSegmentMembermlss:RestOfWorldMember2023-07-012023-09-30 0000855683mlss:MedicalSegmentMembermlss:RestOfWorldMember2023-07-012023-09-30 0000855683mlss:RestOfWorldMember2023-07-012023-09-30 0000855683mlss:DentalSegmentMember2024-07-012024-09-30 0000855683mlss:MedicalSegmentMember2024-07-012024-09-30 0000855683mlss:DentalSegmentMember2023-07-012023-09-30 0000855683mlss:MedicalSegmentMember2023-07-012023-09-30
0000855683mlss:InstrumentsMembermlss:DentalSegmentMembermlss:DomesticMember2024-01-012024-09-30
0000855683mlss:InstrumentsMembermlss:MedicalSegmentMembermlss:DomesticMember2024-01-012024-09-30 0000855683mlss:InstrumentsMembermlss:DomesticMember2024-01-012024-09-30 0000855683mlss:InstrumentsMembermlss:DentalSegmentMembermlss:DomesticMember2023-01-012023-09-30
0000855683mlss:InstrumentsMembermlss:MedicalSegmentMembermlss:DomesticMember2023-01-012023-09-30 0000855683mlss:InstrumentsMembermlss:DomesticMember2023-01-012023-09-30 0000855683mlss:HandpiecesMembermlss:DentalSegmentMembermlss:DomesticMember2024-01-012024-09-30
0000855683mlss:HandpiecesMembermlss:MedicalSegmentMembermlss:DomesticMember2024-01-012024-09-30 0000855683mlss:HandpiecesMembermlss:DomesticMember2024-01-012024-09-30 0000855683mlss:HandpiecesMembermlss:DentalSegmentMembermlss:DomesticMember2023-01-012023-09-30
0000855683mlss:HandpiecesMembermlss:MedicalSegmentMembermlss:DomesticMember2023-01-012023-09-30 0000855683mlss:HandpiecesMembermlss:DomesticMember2023-01-012023-09-30 0000855683mlss:AccessoriesMembermlss:DentalSegmentMembermlss:DomesticMember2024-01-012024-09-30
0000855683mlss:AccessoriesMembermlss:MedicalSegmentMembermlss:DomesticMember2024-01-012024-09-30 0000855683mlss:AccessoriesMembermlss:DomesticMember2024-01-012024-09-30 0000855683mlss:AccessoriesMembermlss:DentalSegmentMembermlss:DomesticMember2023-01-012023-09-30
0000855683mlss:AccessoriesMembermlss:MedicalSegmentMembermlss:DomesticMember2023-01-012023-09-30 0000855683mlss:AccessoriesMembermlss:DomesticMember2023-01-012023-09-30 0000855683mlss:DentalSegmentMembermlss:DomesticMember2024-01-012024-09-30 0000855683mlss:MedicalSegmentMembermlss:DomesticMember2024-01-012024-09-30 0000855683mlss:DomesticMember2024-01-012024-09-30 0000855683mlss:DentalSegmentMembermlss:DomesticMember2023-01-012023-09-30
0000855683mlss:MedicalSegmentMembermlss:DomesticMember2023-01-012023-09-30 0000855683mlss:DomesticMember2023-01-012023-09-30
0000855683mlss:InstrumentsMembermlss:DentalSegmentMembermlss:RestOfWorldMember2024-01-012024-09-30
0000855683mlss:InstrumentsMembermlss:MedicalSegmentMembermlss:RestOfWorldMember2024-01-012024-09-30
0000855683mlss:InstrumentsMembermlss:RestOfWorldMember2024-01-012024-09-30
0000855683mlss:InstrumentsMembermlss:DentalSegmentMembermlss:RestOfWorldMember2023-01-012023-09-30
0000855683mlss:InstrumentsMembermlss:MedicalSegmentMembermlss:RestOfWorldMember2023-01-012023-09-30
0000855683mlss:InstrumentsMembermlss:RestOfWorldMember2023-01-012023-09-30
0000855683mlss:HandpiecesMembermlss:DentalSegmentMembermlss:RestOfWorldMember2024-01-012024-09-30
0000855683mlss:HandpiecesMembermlss:MedicalSegmentMembermlss:RestOfWorldMember2024-01-012024-09-30
0000855683mlss:HandpiecesMembermlss:RestOfWorldMember2024-01-012024-09-30
0000855683mlss:HandpiecesMembermlss:DentalSegmentMembermlss:RestOfWorldMember2023-01-012023-09-30
0000855683mlss:HandpiecesMembermlss:MedicalSegmentMembermlss:RestOfWorldMember2023-01-012023-09-30
0000855683mlss:HandpiecesMembermlss:RestOfWorldMember2023-01-012023-09-30
0000855683mlss:AccessoriesMembermlss:DentalSegmentMembermlss:RestOfWorldMember2024-01-012024-09-30
0000855683mlss:AccessoriesMembermlss:MedicalSegmentMembermlss:RestOfWorldMember2024-01-012024-09-30
0000855683mlss:AccessoriesMembermlss:RestOfWorldMember2024-01-012024-09-30
0000855683mlss:AccessoriesMembermlss:DentalSegmentMembermlss:RestOfWorldMember2023-01-012023-09-30
0000855683mlss:AccessoriesMembermlss:MedicalSegmentMembermlss:RestOfWorldMember2023-01-012023-09-30
0000855683mlss:AccessoriesMembermlss:RestOfWorldMember2023-01-012023-09-30 0000855683mlss:DentalSegmentMembermlss:RestOfWorldMember2024-01-012024-09-30
0000855683mlss:MedicalSegmentMembermlss:RestOfWorldMember2024-01-012024-09-30 0000855683mlss:RestOfWorldMember2024-01-012024-09-30
0000855683mlss:DentalSegmentMembermlss:RestOfWorldMember2023-01-012023-09-30 0000855683mlss:MedicalSegmentMembermlss:RestOfWorldMember2023-01-012023-09-30 0000855683mlss:RestOfWorldMember2023-01-012023-09-30 0000855683mlss:InstrumentsMembermlss:DentalSegmentMembercountry:CN2024-01-012024-09-30
0000855683mlss:InstrumentsMembermlss:MedicalSegmentMembercountry:CN2024-01-012024-09-30 0000855683mlss:InstrumentsMembercountry:CN2024-01-012024-09-30
0000855683mlss:InstrumentsMembermlss:DentalSegmentMembercountry:CN2023-01-012023-09-30
0000855683mlss:InstrumentsMembermlss:MedicalSegmentMembercountry:CN2023-01-012023-09-30 0000855683mlss:InstrumentsMembercountry:CN2023-01-012023-09-30
0000855683mlss:HandpiecesMembermlss:DentalSegmentMembercountry:CN2024-01-012024-09-30
0000855683mlss:HandpiecesMembermlss:MedicalSegmentMembercountry:CN2024-01-012024-09-30 0000855683mlss:HandpiecesMembercountry:CN2024-01-012024-09-30
0000855683mlss:HandpiecesMembermlss:DentalSegmentMembercountry:CN2023-01-012023-09-30
0000855683mlss:HandpiecesMembermlss:MedicalSegmentMembercountry:CN2023-01-012023-09-30 0000855683mlss:HandpiecesMembercountry:CN2023-01-012023-09-30
0000855683mlss:AccessoriesMembermlss:DentalSegmentMembercountry:CN2024-01-012024-09-30
0000855683mlss:AccessoriesMembermlss:MedicalSegmentMembercountry:CN2024-01-012024-09-30 0000855683mlss:AccessoriesMembercountry:CN2024-01-012024-09-30
0000855683mlss:AccessoriesMembermlss:DentalSegmentMembercountry:CN2023-01-012023-09-30
0000855683mlss:AccessoriesMembermlss:MedicalSegmentMembercountry:CN2023-01-012023-09-30 0000855683mlss:AccessoriesMembercountry:CN2023-01-012023-09-30
0000855683mlss:DentalSegmentMembercountry:CN2024-01-012024-09-30 0000855683mlss:MedicalSegmentMembercountry:CN2024-01-012024-09-30
0000855683country:CN2024-01-012024-09-30 0000855683mlss:DentalSegmentMembercountry:CN2023-01-012023-09-30
0000855683mlss:MedicalSegmentMembercountry:CN2023-01-012023-09-30 0000855683country:CN2023-01-012023-09-30 0000855683mlss:DentalSegmentMember2024-01-012024-09-30 0000855683mlss:MedicalSegmentMember2024-01-012024-09-30 0000855683mlss:DentalSegmentMember2023-01-012023-09-30
0000855683mlss:MedicalSegmentMember2023-01-012023-09-30 0000855683us-gaap:SalesRevenueNetMemberus-
gaap:CustomerConcentrationRiskMembermlss:ECommerceMember2024-07-012024-09-30 0000855683us-gaap:SalesRevenueNetMemberus-
gaap:CustomerConcentrationRiskMember2024-09-30 0000855683us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMembermlss:DistributorOneMember2024-07-012024-09-30 0000855683us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMembermlss:ECommerceMember2024-01-012024-09-30 0000855683us-
gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMembermlss:DistributorOneMember2024-01-012024-01-01 0000855683us-gaap:SalesRevenueNetMemberus-
gaap:CustomerConcentrationRiskMembermlss:ECommerceMember2023-07-012023-09-30 0000855683us-gaap:SalesRevenueNetMemberus-
gaap:CustomerConcentrationRiskMembermlss:DistributorOneMember2023-09-30 0000855683us-gaap:SalesRevenueNetMemberus-
gaap:CustomerConcentrationRiskMembermlss:DistributorOneMember2024-01-012024-09-30 0000855683us-gaap:SalesRevenueNetMemberus-
gaap:CustomerConcentrationRiskMembermlss:ECommerceMember2023-01-012023-09-30 0000855683us-gaap:AccountsReceivableMemberus-
gaap:CustomerConcentrationRiskMembermlss:DistributorFourMember2024-01-012024-09-30 0000855683us-gaap:AccountsReceivableMemberus-
gaap:CustomerConcentrationRiskMembermlss:DistributorOneMember2024-01-012024-09-30 0000855683us-gaap:AccountsReceivableMemberus-
gaap:CustomerConcentrationRiskMembermlss:DistributorTwoMember2024-01-012024-09-30 0000855683us-gaap:AccountsReceivableMemberus-
gaap:CustomerConcentrationRiskMembermlss:DistributorThreeMember2024-01-012024-09-30 0000855683us-gaap:AccountsReceivableMemberus-
gaap:CustomerConcentrationRiskMembermlss:DistributorOneMember2023-01-012023-12-31 0000855683us-gaap:AccountsReceivableMemberus-
gaap:CustomerConcentrationRiskMembermlss:DistributorTwoMember2023-01-012023-12-31 0000855683us-gaap:AccountsReceivableMemberus-
gaap:CustomerConcentrationRiskMembermlss:DistributorThreeMember2023-01-012023-12-31 0000855683us-gaap:AccountsPayableMemberus-
gaap:SupplierConcentrationRiskMemberus-gaap:RelatedPartyMember2024-09-30 0000855683us-gaap:AccountsPayableMemberus-
gaap:SupplierConcentrationRiskMembermlss:VendorOneMemberus-gaap:RelatedPartyMember2024-01-012024-09-30 0000855683us-gaap:AccountsPayableMemberus-
gaap:SupplierConcentrationRiskMembermlss:VendorTwoMemberus-gaap:RelatedPartyMember2024-01-012024-09-30 0000855683us-gaap:AccountsPayableMemberus-
gaap:SupplierConcentrationRiskMemberus-gaap:RelatedPartyMember2023-12-31 0000855683us-gaap:AccountsPayableMemberus-
gaap:SupplierConcentrationRiskMembermlss:VendorOneMemberus-gaap:RelatedPartyMember2023-01-012023-12-31 0000855683us-gaap:AccountsPayableMemberus-
gaap:SupplierConcentrationRiskMembermlss:VendorTwoMemberus-gaap:RelatedPartyMember2023-01-012023-12-31 0000855683us-gaap:AccountsPayableMemberus-
gaap:SupplierConcentrationRiskMembermlss:VendorThreeMemberus-gaap:RelatedPartyMember2023-01-012023-12-31
0000855683mlss:ManufacturingAgreementForHandpiecesMember2024-07-012024-09-30 0000855683mlss:ManufacturingAgreementForHandpiecesMember2024-01-012024-09-30
0000855683mlss:ManufacturingAgreementForHandpiecesMember2023-07-012023-09-30 0000855683mlss:ManufacturingAgreementForHandpiecesMember2023-01-012023-09-30
0000855683mlss:ManufacturingAgreementForHandpiecesMember2024-09-30
0000855683mlss:AccountsPayableRelatedPartiesCurrentMembermlss:ManufacturingAgreementForHandpiecesMemberus-gaap:RelatedPartyMember2023-12-31
0000855683mlss:DirectorClinicalAffairMember2024-07-012024-09-30 0000855683mlss:DirectorClinicalAffairMember2024-01-012024-09-30
0000855683mlss:DirectorClinicalAffairMember2023-07-012023-09-30 0000855683mlss:DirectorClinicalAffairMember2023-01-012023-09-30
0000855683mlss:DirectorOfClinicalAffairsMember2024-09-30 0000855683mlss:DirectorOfClinicalAffairsMember2023-12-31
0000855683mlss:InterimChiefExecutiveOfficerMember2021-03-02 0000855683mlss:DirectorClinicalAffairMember2021-03-01 0000855683mlss:DirectorClinicalAffairMember2021-03-02 0000855683mlss:PreviousPresidentAndChiefExecutiveOfficerMember2017-07-102017-07-10 0000855683mlss:ConsultantMember2017-07-102017-07-10
0000855683mlss:InterimChiefExecutiveOfficerMember2021-04-062021-04-06 0000855683mlss:ManagingDirectorChinaOperationsMember2024-07-012024-09-30
0000855683mlss:ManagingDirectorChinaOperationsMember2023-07-012023-09-30 0000855683mlss:ConsultantMember2024-07-012024-09-30
0000855683mlss:ConsultantMember2023-07-012023-09-30 0000855683mlss:PurchasedMedicalProductsMembermlss:UniversityPainMedicineCenterStemmeeMember2024-07-012024-09-30 0000855683mlss:PurchasedMedicalProductsMembermlss:UniversityPainMedicineCenterStemmeeMember2024-01-012024-09-30
0000855683mlss:PurchaseCommitmentForDevicesMember2024-01-012024-09-30 0000855683mlss:PurchaseCommitmentForDevicesMember2024-09-30
0000855683mlss:DevelopmentOfTheNextGenerationInstrumentMember2024-09-30 0000855683mlss:PurchaseCommitmentForDevicesMember2023-12-31
0000855683mlss:ContractsForFundingOfFutureEpiduralInstrumentsAndPartsMember2024-09-30
0000855683mlss:ContractsForFundingOfFutureEpiduralInstrumentsAndPartsMember2023-12-31 0000855683us-
gaap:SubsequentEventMembermlss:PresidentAndChiefExecutiveOfficerMember2024-11-08 0000855683mlss:PresidentAndChiefExecutiveOfficerMember2022-01-01
0000855683srt:ScenarioForecastMembermlss:PresidentAndChiefExecutiveOfficerMember2025-12-31
0000855683srt:ScenarioForecastMembermlss:PresidentAndChiefExecutiveOfficerMember2025-01-012025-03-31
0000855683srt:ScenarioForecastMembermlss:PresidentAndChiefExecutiveOfficerMember2025-04-012025-06-30
0000855683srt:ScenarioForecastMembermlss:PresidentAndChiefExecutiveOfficerMember2025-07-012025-09-30
0000855683srt:ScenarioForecastMembermlss:PresidentAndChiefExecutiveOfficerMember2025-10-012025-12-31 Â SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) â˜’ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Â For the quarter ended September 30, 2024 â˜ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Â Â Â

Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)Â has been subject to such filing requirements for the past 90 days.Â Â Â Â â˜‘Â YesÂ Â Â Â â˜Â No Â Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Â§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).Â Â Â Â â˜‘Â YesÂ Â Â Â â˜Â No Â Indicate by check mark whether the registrant is a large, accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of â€œlarge, accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting companyâ€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act. Â Large, acceleratedÂ filer â˜ AcceleratedÂ filer â˜ Â Â Â Â Â Non-accelerated filer â˜‘ SmallerÂ reportingÂ company â˜‘ Â Â Â Â Emerging Growth Company â˜ Â Â Â Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).Â Â Â Â YesÂ â˜Â Â Â NoÂ â˜‘ Â As ofÂ November 14, 2024 the registrant has a total of 77,892,083 shares of Common Stock, $0.001 par value outstanding. Â DOCUMENTS INCORPORATED BY REFERENCE NoneÂ Â Â Â Â Â true Â MILESTONE SCIENTIFIC INC. Form 10-QÂ TABLE OF CONTENTS Â PART Iâ€”FINANCIAL INFORMATION Â Â Â Â Item 1. Condensed Consolidated Financial Statements Â Â Â Â Â Balance Sheets as of September 30, 2024 (Unaudited) and December 31, 2023 4 Â Â Â Â Statements of Operations for the three and nine months ended September 30, 2024 and 2023 (Unaudited) 5 Â Â Â Â Statements of Changes in Stockholdersâ€™Â Equity for theÂ three and nine months ended September 30, 2024 and 2023 (Unaudited) 6 Â Â Â Â Statements of Cash Flows for theÂ nine months ended September 30, 2024 and 2023 (Unaudited) 8 Â Â Â Â Notes to Condensed Consolidated Financial Statements (Unaudited) 9 Â Â Â Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations 22 Â Â Â Item 3. Quantitative and Qualitative Disclosures About Market Risk 29 Â Â Â Item 4. Controls and Procedures 29 Â Â Â Â PART IIâ€”OTHER INFORMATION Â Â Â Â Item 1. Legal Proceedings 29 Â Â Â Item 1A. Risk Factors 29 Â Â Â Item 1C Cybersecurity Â Â Â Â Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 29 Â Â Â Item 3. Defaults Upon Senior Securities 30 Â Â Â Item 4. Mine Safety Disclosures 30 Â Â Â Item 5. Other Information 30 Â Â Â Item 6. Exhibits 31 Â Â Â Signatures 32 Â Â 2 Â Â FORWARD-LOOKING STATEMENTS Â When used in this Quarterly Report on Form 10-Q, the words â€œmayâ€, â€œwillâ€, â€œshouldâ€, â€œexpectâ€, â€œbelieveâ€, â€œanticipateâ€, â€œcontinueâ€, â€œestimateâ€, â€œprojectâ€, â€œintendâ€ and similar expressions are intended to identify forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€) regarding events, conditions and financial trends that may affect Milestone Scientificâ€™s future plans of operations, business strategy, results of operations and financial condition. Milestone Scientific wishes to ensure that such statements are accompanied by meaningful cautionary statements pursuant to the safe harbor established in the Private Securities Litigation Reform Act of 1995. The forward-looking statements included herein are based on current expectations that involve numerous risks and uncertainties. Milestone Scientificâ€™s plans and objectives are based, in part, on assumptions involving the changes in the distribution of its products and continued evolution of its business. Assumptions relating to the foregoing involve judgments with respect to, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the control of Milestone Scientific. Although Milestone Scientific believes that its assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate. Considering the significant uncertainties inherent in the forward-looking statements included herein, our history of operating losses that are expected to continue, requiring additional funding that we may be unable to raise capital when needed (which may force us to delay, curtail or eliminate commercialization efforts of our CompuFlo Epidural Computer Controlled Anesthesia System), the early stage operations of and relative lack of acceptance of our medical products, relying exclusively on twoÂ third parties to manufacture our products, changes to our distribution arrangements exposes us to risks of interruption of marketing efforts and building new marketing channels, changes in our informal manufacturing arrangements made by the manufacturer of our products and disruptions at the manufacturing facility of our manufacturers, including shortages of or delays in obtaining chips and other components, exposes us to risks that may harm our business, raising additional funds by issuing securities or through licensing or lending arrangements may cause dilution to our existing stockholders, restrict our operations or require us to relinquish proprietary rights, if physicians do not accept or use our CompuFlo Epidural Computer Controlled Anesthesia System, our ability to generate revenue from sales will be materially impaired, exposure to the risks inherent in international sales and operations, including China, and developments by competitors may render our products or technologies obsolete or non-competitive, the inclusion of such information should not be regarded as a representation by Milestone Scientific or any other person that the objectives and plans of Milestone Scientific will be achieved. Prospective investors are cautioned that any forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties and the actual results may differ materially from those included within the forward-looking statements because of various factors. Except as required by the federal securities laws, Milestone Scientific undertakes no obligation to revise or update any forward-looking statements, whether as a result of new information, future events or otherwise, to reflect events or circumstances occurring after the date of this Quarterly Report on Form 10-Q. Â Milestone Scientific is the owner of the following registered U.S. trademarks: CompuDentÂ®; CompuMedÂ®; CompuFloÂ®; DPS Dynamic Pressure Sensing technologyÂ®; Milestone Scientific Â®; CathCheckÂ®; the Milestone logo Â®; SafetyWandÂ®; STA Single Tooth Anesthesia DeviceÂ®; and The Wand Â®. Â 3 Â Â Â Part I- Financial Information Item 1. Financial Statements MILESTONE SCIENTIFIC AND SUBSIDIARIES CONDENSEDÂ CONSOLIDATED BALANCE SHEETS Â Â Â September 30, 2024 Â Â December 31, 2023 Â ASSETS Â Â (Unaudited)Â Â Â Â Â Current assets: Â Â Â Â Â Â Â Â Cash and cash equivalents Â $4,775,597Â Â $2,977,713Â Marketable securities Â Â -Â Â Â 2,976,573Â Accounts receivable, net of allowance for credit losses of $10,000, respectively Â Â 550,969Â Â Â Â 312,664Â Accounts receivable, related party net Â Â 3,013Â Â Â -Â Prepaid expenses and other current assets Â Â 646,130Â Â Â Â 517,785Â Inventories Â Â 3,711,636Â Â Â 2,638,186Â Advances on contracts Â Â 1,011,306Â Â Â 1,371,548Â Total current assets Â Â 10,698,651Â Â Â 10,794,469Â Furniture, fixtures and equipment, net Â Â 11,265Â Â Â 10,024Â Intangibles, net Â Â 155,255Â Â Â 178,636Â Right of use assets finance lease Â Â 2,511Â Â Â 8,998Â Right of use assets operating lease Â Â 283,086Â Â Â 355,235Â Other assets Â Â 24,150Â Â Â 24,150Â Total assets Â $11,174,918Â Â $11,371,512Â Â LIABILITIES AND STOCKHOLDERSâ€™ EQUITY Â Â Â Â Â Â Â Â Â Current liabilities: Â Â Â Â Â Â Â Â Accounts payable Â $1,138,060Â Â $689,604Â Accounts payable, related party Â Â 740,017Â Â Â 410,512Â Accrued expenses and other payables Â Â 1,267,718Â Â Â 1,511,717Â Accrued expenses, related party Â Â 281,947Â Â Â 137,189Â Accrued liabilities noncontrolling interest Â Â 214,000Â Â Â 214,000Â Current portion of finance lease liabilities Â Â 3,088Â Â Â 10,264Â Current portion of operating lease liabilities Â Â 112,955Â Â Â 103,427Â Total current liabilities Â Â 3,757,785Â Â Â 3,076,713Â Non-current portion of finance lease liabilities Â Â -Â Â Â 434Â Non-current portion of operating lease liabilities Â Â 195,649Â Â Â 281,853Â Total liabilities Â $3,953,434Â Â $3,359,000Â Â Commitments and contingencies Â Stockholdersâ€™ equity Â Â Â Â Â Â Â Â Â Common stock, par value $0.001; authorized 100,000,000 shares; 77,709,455 shares issued and 77,676,122 shares outstanding as of September 30, 2024; 75,881,840 shares issued and 75,848,507 shares outstanding as of December 31, 2023; Â Â 77,710Â Â Â 75,881Â Additional paid in capital Â Â 134,072,861Â Â Â 132,187,656Â Accumulated deficit Â Â (126,017,571)Â Â (123,339,509) Treasury stock, at cost, 33,333 shares Â Â (911,516)Â Â (911,516) Total Milestone Scientific, Inc. stockholders' equity Â Â 7,221,484Â Â Â 8,012,512Â Â Â Â Â Â Â Â Â Â Total liabilities and stockholdersâ€™ equity Â $11,174,918Â Â $11,371,512Â The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.Â Â Â 4 Â Â Â MILESTONE SCIENTIFIC AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Â Â For the three months ended September 30, 2024 Â Â For the three months ended September 30, 2023 Â Â For the nine months ended September 30, 2024 Â Â For the nine months ended September 30, 2023 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Product sales, net Â $2,513,805Â Â $2,059,284Â Â $6,616,414Â Â $7,566,848Â Cost of products sold Â Â 677,585Â Â Â 555,850Â Â Â 1,692,888Â Â Â 2,284,730Â Gross profit Â Â 1,836,220Â Â Â 1,503,434Â Â Â 4,923,526Â Â Â 5,282,118Â Â Selling, general and administrative expenses Â Â 3,064,769Â Â Â 2,823,765Â Â Â 8,968,226Â Â Â 9,834,781Â Research and development expenses Â Â 232,056Â Â Â 170,478Â Â Â 641,235Â Â Â 524,472Â Depreciation and amortization expense Â Â 8,574Â Â Â 15,896Â Â Â 28,735Â Â Â 49,798Â Total operating expenses Â Â 3,305,399Â Â Â 3,010,139Â Â Â 9,638,196Â Â Â 10,409,051Â Â Loss from operations Â Â (1,469,179)Â Â (1,506,705)Â Â (4,714,670)Â Â (5,126,933) Interest income Â Â 8,008Â Â Â 30,600Â Â Â 53,513Â Â Â 102,669Â Gain on sale of net operating losses Â Â -Â Â Â -Â Â Â 1,983,095Â Â Â -Â Loss before provision for income taxes Â Â (1,461,171)Â Â (1,476,105)Â Â (2,678,062)Â Â (5,024,264) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â

furniture, fixtures, and equipment Â Â (6,596)Â Â (1,192) Sale of marketable securities Â Â 2,976,573Â Â Â 4,472,540Â Purchase of marketable securities Â Â -Â Â Â (6,929,218) Net cash provided by (used in) investing activities Â $2,969,977Â Â $(2,457,870) Â Â Â Â Â Â Â Â Â Cash flows from financing activities: Â Â Â Â Â Â Â Â Â Net proceeds from Public Placement Offering Â Â 192,156Â Â Â -Â Net Proceeds exercise of warrants Â Â 51,751Â Â Â -Â Payments finance lease obligations Â Â (7,613)Â Â (6,486) Net cash provided by (used in) financing activities Â $236,294Â Â $(6,486) Â Â Â Â Â Â Â Â Â Net increase (decrease) in cash and cash equivalents Â Â 1,797,884Â Â Â (6,544,686) Cash and cash equivalents at beginning of period Â Â 2,977,713Â Â Â 8,715,279Â Cash and cash equivalents at end of period Â $4,775,597Â Â $2,170,593Â Â The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 8 Â Â MILESTONE SCIENTIFIC, INC. NOTES TO CONDENSEDÂ CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) Â NOTE 1 â€” ORGANIZATION AND BUSINESS All references in this report to â€œMilestone Scientific,â€ the â€œCompanyâ€ or â€œMilestoneâ€ refer to Milestone Scientific Inc., and its consolidated subsidiaries, Wand Dental, Inc., and Milestone InnovationÂ Inc., unless the context otherwise indicates. Milestone Scientific is the owner of the following registered U.S. trademarks: CompuDentÂ®;Â CompuFloÂ®; DPS Dynamic Pressure Sensing technologyÂ®; Milestone Scientific Â®;Â CathCheckÂ®; the Milestone logo Â®; SafetyWandÂ®; STA Single Tooth Anesthesia SystemÃ®; and The Wand Â®.Â Â Milestone Scientific was incorporated in the State of Delaware in August 1989. Milestone Scientific has developed a proprietary, revolutionary, computer-controlled anesthetic delivery device, itsÂ DPS Dynamic Pressure Sensing TechnologyÂ® System, to meet the needs of various subcutaneous drug delivery injections and fluid aspiration â€“ enabling healthcare practitioners to achieve multiple unique benefits that cannot currently be accomplished with the 160-year-old manual syringe. The Companyâ€™s proprietary DPS Dynamic Pressure Sensing Technology is the Companyâ€™s technology platform that advances the development of next-generation devices. It regulates flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, used in various dental and medical injections. It has specific medical applications for epidural space identification in regional anesthesia procedures and intra-articular joint injections. Â The Companyâ€™s device, using The WandÂ®, a single use disposable handpiece, is marketed in dentistry under the trademarks CompuDentÂ® and STA Single Tooth Anesthesia SystemÂ®, and is suitable for all dental procedures that require local anesthetic. The dental devices are currently sold in the United States, Canada and in over 41 other countries.Â Milestone Scientific also has 510(k) marketing clearance from the U.S. Food and Drug Administration (FDA) on the CompuFloÂ® Epidural Computer Controlled Anesthesia System in the lumbar thoracic and cervical thoracic junction of the spinal region. Â The Company current marketing focus is self-distribution using its e-commerce platform; however, it is also in the process ofÂ meetingÂ with medical facilities and device distributors within the United States, Middle East and Europe so as to develop other channels of distribution.Â Certain of our medical instruments have obtained European CE mark approval and can be marketed and sold in most European countries. Â NOTE 2- LIQUIDITY AND UNCERTAINTIES Â Â Â The Company has evaluated whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern withinÂ oneÂ year after the date that the consolidated financial statements are issued. The Company has incurred total losses since inception of $126.0Â million. The operating losses were $1.5Â million and $4.7Â million, for three and nine months ended September 30, 2024.Â On September 30, 2024,Â Milestone Scientific had cash and cash equivalentsÂ of approximatelyÂ $4.8Â million and working capital of approximatelyÂ $6.9Â million. For the nine months ended September 30, 2024, and 2023, we had cash flows used in operating activities of approximately $1.4 millionÂ and $4.1 million respectively. Â Management has prepared financialÂ forecasts covering a period ofÂ 12Â months from the date of issuance of these financial statements. These forecasts include several revenue and operating expense assumptions which indicate that the Companyâ€™s current cash and liquidity is sufficient to finance the operating requirements for at least the nextÂ 12Â months from the filing date. Â Milestone Scientific is actively pursuing the generation of positive cash flows from operating activities through an increase in revenue from its dental business worldwide, the generation of revenue from its medical devices and disposables business in the United States and worldwide, and a reduction in operating expenses. However, the Companyâ€™s continued operations will depend on its ability to raise additional capital through various potential sources until it achieves profitability, if ever.Â Â In addition to its employees, the Company relies on (i) distributors, agents, andÂ third-party logistics providers in connection with product sales and distribution and (ii) raw material and component suppliers in the U.S., Europe, and China. If the Company, or any of these entities encounter any disruptions to its or their respective operations or facilities, or if the Company or any of theseÂ third-party partners were to shut down for any reason, including by fire, natural disaster, such as a hurricane, tornado or severe storm, power outage, systems failure, labor dispute, pandemic or other public health crises, or other unforeseen disruption, then the Company or theyÂ mayÂ be prevented or delayed from effectively operating its or their business, respectively.Â 9Â Â Â Â NOTE 3Â â€” SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Â 1.Â Principles of Consolidation Â The accompanyingÂ consolidated unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United StatesÂ ("GAAP"), and the applicable rules and regulations of the Securities and Exchange Commission (SEC)Â include the accounts of Milestone Scientific and its wholly owned and majority owned subsidiaries, including, Wand Dental (wholly owned), and Milestone Innovations Inc. (wholly owned).Â All significant, intra-entity transactions and balances have been eliminated in the consolidation. Ownership interests in consolidated entities that are held by entities other than us are reported as noncontrolling interests in our consolidated balance sheets. Losses attributed to noncontrolling interests are reported separately in our consolidated statements of operations. Â During December 2023, the Board of Directors of the Company approved the merger of Milestone Medical, Inc., a 98%-owned subsidiary of the Company (â€œMMDâ€), with and into Milestone Innovation, Inc, a newly form wholly-owned subsidiary of the Company and being the surviving corporation . As a result, all of the assets of MMD automatically became assets of Milestone Innovations, Inc.Â Subsequent to SeptemberÂ 30, 2024, the Company satisfied it'sÂ liabilities to the non-controlling shareholders, the Company settled forÂ approximately $205,000 for the minority stake of MMD. Â 2. Basis of Presentation Â The unaudited condensed consolidated financial statements of Milestone Scientific have been prepared in accordanceÂ with accounting principles generally accepted in the United States of America (GAAP) for interim financial information withÂ the instructions for Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by GAAP for complete annual financial statements. In the opinion of management, the accompanying unaudited consolidated financial statements contain all adjustments (consisting of normal recurring entries) necessary to fairly present such interim results. Interim results are not necessarily indicative of the results of operations which may be expected for a full year or any subsequent period. These unaudited consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2023, included in Milestone Scientific's Annual Report on Form 10-K. Â 3. Use of Estimates Â The preparation of unaudited consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions in determining the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to inventory valuation and cash flow assumptions regarding evaluations of going concern considerations. The Company bases its estimates on historical experience, known trends and other market-specific or relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates. Â 4.Â Revenue Recognition Â The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To perform revenue recognition, the Company performs the following five steps: Â 10 Â Â i. identification of the promised goods or services in the contract; ii. determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract;Â Â Â Â Â Â Â iii. measurement of the transaction price, including the constraint on variable consideration; iv. allocation of the transaction price to the performance obligations based on estimated selling prices; and v. recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC 606. Â The Company derives its revenues from the sale of its products, primarily dental instruments, handpieces, and other related products. The Company sells its products directly to consumers in the United States and through a global distribution network that includes both exclusive and non-exclusive distribution agreements with related and third parties. Â Revenue from product sales is recognized upon transfer of control of a product to a customer, generally upon date of shipment. The Company has no obligation on product sales for any installation, set-up, or maintenance, these being the responsibility of the buyer. Milestone Scientific's only obligation after sale is the normal commercial warranty against manufacturing defects if the alleged defective unit is returned within the warranty period.Â Â Â E-Commerce Â As of January 3, 2023,Â the Company launched an E-Commerce platform,Â selling and shippingÂ STA Single Tooth Anesthesia SystemsÂ®Â (STA) and handpieces directly to dental offices and dentalÂ groups within the United States. Our E-commerceÂ portal accepts online payments via creditÂ and debit cards. The cost of delivery is charged to the customer along with appropriate sales tax. The Company recognizes revenue from product salesÂ at the time the product ships to a customer via a third-party carrier.Â Â Sales Returns Â The Company records allowances for product returns as a reduction of revenue at the time product sales are recorded. Several factors are considered in determining whether an allowance for product returns is required, including the customersâ€™ return rights and the Companyâ€™s historical experience with returns and the amount of product in the distribution channel not consumed by end users and subject to return. The Company relies on historical return rates to estimate returns. Â Financing and Payment Â The Company's payment terms differ by geography and customer, but payments from distributors are required within 90 days or less from the date of shipment. The E-commerceÂ portal sells directly to end users and accepts onlineÂ payments via credit and debitÂ cards via a third-party. These payments from theÂ third party are typically settled within two business days. Â Disaggregation of Revenue Â The CompanyÂ operates in two operating segments: dental and medical. Therefore, the results of the Company's operations are reported on a consolidated basis for the purposes of segment reporting, consistent with internal management reporting. See Note 8Â for revenues by geographical market, based on the customerâ€™s location, and product category for the three andÂ nine months periodsÂ ended September 30, 2024, and 2023, respectively. Â 5.Â Cash and Cash Equivalents Â Milestone Scientific considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. As of September 30, 2024, and December 31, 2023, Milestone Scientific has approximately $4.8Â million and $3.0 million, respectively of cash and cash equivalents.Â As of September 30, 2024,Â Milestone Scientific had approximately $4.1 million in cash, cash equivalents, in accounts that exceeded the Federal Deposit Insurance Corporation insurance limit of $250,000. Â 11 Â Â 6. Marketable Securities Â The Companyâ€™s marketable securities are comprised of treasury bills with original maturity greater than three months from date of purchase. The Companyâ€™s marketable securities are measured at fair value and are accounted for in accordance with ASC 825, Financial Instruments. Unrealized holding gains and losses on treasury bills are recorded in interest income on the unaudited consolidated statements of operations. Dividend and interest income are recognized when earned. Realized gains and losses are included in earnings and are derived using the specific identification method for determining the cost of the marketable securities. As ofÂ September 30, 2024, the Company did not hold any marketable securities. As ofÂ December 31, 2023Â the Company held approximately $3.0 million in U.S. treasury securities, with maturityÂ dates within 3 and 6 months. Â 7.Â Accounts Receivable Â The E-commerceÂ portal sells directly to end users and accepts onlineÂ payments via creditÂ and debit cardsÂ via a third-party credit card processor. These payments are settled within two business days of the transactions. Sales to distributors are on credit terms.Â The Company estimates losses from the ability or inability of its distributor to make payments on amounts billed. Â Distributors credit sales are due 90 days or less from the date of invoicing.Â As of September 30, 2024 andÂ December 31, 2023, accounts receivable was recorded, net of allowance for credit losses of $10,000, respectively. Â 8.Â Inventories Â Inventories principally consist of finished goods and component parts stated at the lower of cost (first-in, first-out method) or net realizable value. Inventory quantitiesÂ on hand are reviewed on a quarterly basis and a provision for excess, slow moving, defective, and obsolete inventory is recorded if required based on past and expectedÂ future sales, potential technological obsolescence, and product expiration requirements. Â The valuation allowance creates a new cost basis for the inventory, and it is notÂ subsequently marked up through a reduction in the valuation allowance based on any changes in the underlying facts and circumstances. When the valuationÂ allowance is initially recorded, the increase to the allowance is recognized as an increase in cost of sales. The valuation allowance is only reduced if or when theÂ underlying inventory is sold or destroyed, at which time cost of sales recognized would include the previous adjusted cost basis. Â 9.Â Basic and Diluted Net Loss Per Common Share Â Milestone Scientific presents â€œbasicâ€ earnings (loss) per common share applicable to common stockholders and, if applicable, â€œdilutedâ€ earnings (loss) per commonÂ share applicable to common stockholders pursuant to the provisions of ASC 260, â€œEarnings per Shareâ€. Basic earnings (loss) per common share is calculated byÂ dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding and to be issued common shares as follows: 79,966,833Â and 73,730,921Â for the three months ended September 30, 2024 and 2023, respectively, andÂ 80,165,181 andÂ 72,374,693 for the nine months ended September 30, 2024 and 2023, respectively. The calculation of diluted earnings per common share is like that of basic earnings per common share, except that the denominator is increased to include the number ofÂ additional common shares that would have been outstanding if all potentially dilutive common shares, such as those issuable upon the exercise of stock options andÂ warrants, were issued during the period. Since Milestone Scientific had net losses in the three andÂ Â nine months ended September 30, 2024 and the three and nine months ended September 30, 2023, the assumed effects of the exercise of potentially dilutive outstanding stock options, unissued restricted stock awards (â€œRSAâ€) and warrants, were not included in the calculation as their effect would have been anti-dilutive. Such outstanding options, RSA'sÂ and warrantsÂ totaled 3,684,697Â and 3,930,654Â for the nine months ended September 30, 2024 and 2023, respectively. Â 10. Fair Value of Financial Instruments Â Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company required us to classify fair value measurements inÂ oneÂ of the following categories. Â â— LevelÂ 1Â inputs which are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the CompanyÂ can access at the measurement date. Â â— LevelÂ 2Â inputs which are defined as inputs other than quoted prices included within LevelÂ 1Â that are observable for the assets or liabilities, either directly or indirectly. Â â— LevelÂ 3Â inputs are defined as unobservable inputs for the assets or liabilities. 12 Â Â Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of an input to the fair value measurement requires judgment andÂ mayÂ affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels. Â As ofÂ September 30, 2024 the Company did not have assets measured at fair value on a recurring basis. As of December 31, 2023Â the Company had the followingÂ assetsÂ that were measured at fair value on a recurring basis:Â Â Â Â Level 1 Â Â Level 2 Â Â Level 3 Â Â Total Â Marketable Securities December 31, 2023 Â $2,976,573Â Â Â -Â Â Â -Â Â Â $2,976,573Â Â Marketable Securities included US Treasury securities totaling $2,976,573Â that are considered to be highly liquid and easily transferable atÂ December 31, 2023.Â US Treasury securities are valued using inputs observable in

active markets for identical securities and are therefore classified at LevelÂ 1Â within the Company fair value hierarchy. Â 11.Â Stock-Based CompensationÂ Â Milestone Scientific accounts for stock-based compensation under ASC Topic 718, Share-Based Payment (â€œASC Topic 718â€). ASC Topic 718 requires all share-based payments to employees, non-employees, directors, and officers, including grants of employee stock options, to be recognized in the unaudited consolidated statements of operations over the service period, as an operating expense, based on the grant-date fair values. Â 12.Â Â Recent Accounting Pronouncements Â Recently Issued Accounting Pronouncement Â In November 2023, FASB issued ASU 2023-07, Segment Reporting (Topic 280), Improvements to Reportable Segment Disclosures, which provides improvements to reportable segment disclosure requirements, primarily through enhanced disclosures around segment expenses. ASU 2023-07 requires us to disclose significant segment expenses that are regularly provided to the chief operating decision maker (â€œCODMâ€) and included within each reported measure of segment profit or loss. ASU 2023-07 also requires that the Company disclose an amount for other segment items by reportable segment, a description of their composition and provide all annual disclosures about a reportable segmentâ€™s profit or loss and assets pursuant to Topic 280 during interim periods. The Company must also disclose the CODMâ€™s title and position, as well asÂ certain information around the measures used by the CODM and an explanation of how the CODM uses the reported measures in assessing segment performance and deciding how to allocate resources. For public entities with a single reportable segment, the entity must provide all the disclosures required pursuant to ASU 2023-07 and all existing segment disclosures under Topic 280. The amendments of ASU 2023-07 are effective for the Company for annual periods beginning January 1, 2024, and effective for interim periods beginning January 1, 2025. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. The Company expects to adopt this standard effective January 1, 2024, at December 31, 2024 on the Companyâ€™s annual Form 10-K filing. The Company expects to update all required disclosures pursuant to this ASU 2023-07 at that time. The Company is evaluating the impact of ASU 2023-07Â on our financial statements. Â In December 2023, FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, to enhance the transparency and decision usefulness of income tax disclosures. The amendments in ASU 2023-09 provide improvements primarily related to the rate reconciliation and income taxes paid information included in income tax disclosures. The Company would be required to disclose additional information regarding reconciling items equal to or greater than five percent of the amount computed by multiplying pretax income (loss) by the applicable statutory tax rate. Similarly, the Company would be required to disclose income taxes paid (net of refunds received) equal to or greater than five percent of total income taxes paid (net of refunds received). Additionally, the Company would be required to disclose income (loss) from continuing operations before income tax expense disaggregated by foreign and domestic jurisdictions, as well as income tax expense disaggregated by federal, state, and foreign jurisdictions. The amendments in ASU 2023-09 are effective January 1, 2025, including interim periods. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. The Company is currently evaluatingÂ the impact of ASU 2023-09 on our financial statements. Â 13 Â Â Â NOTE 4Â â€” INVENTORIES Â Inventories consist of the following:Â Â Â September 30, 2024 Â Â December 31, 2023 Â Â Â Â Â Â Â Â Â Â Dental finished goods Â $3,637,356Â Â $2,404,970Â Medical finished goods Â Â -Â Â Â 14,730Â Component parts and other materials Â Â 74,280Â Â Â 218,486Â Total inventories Â $3,711,636Â Â $2,638,186Â Â The Company has recorded an allowance on slow moving Medical finished goodsÂ due to the slow adoption of the epidural instruments and handpieces for approximatelyÂ $1.2Â million as of September 30, 2024 andÂ December 31, 2023, respectively.Â Â NOTE 5Â â€” ADVANCES ON CONTRACTS Â The advances on contracts represent funding of future STA devices, epidural instruments, and epidural replacements parts. The balance of the advances on contract as of September 30, 2024 and December 31, 2023 is approximatelyÂ $1.0Â million andÂ $1.4 million, respectively. The advance is classified as current based on the estimated annual usage of the underlying inventory.Â Â Â NOTE 6â€” STOCKHOLDERSâ€™ EQUITY Â Public offering Â OnÂ December 10, 2023,Â the Company completedÂ aÂ public offering for sale ofÂ 4,765,000Â common stock, at $0.63Â per share which generated net proceeds of approximately $2.6Â million. In addition, the Company granted the Underwriter aÂ 45-day option to purchase up to an additionalÂ 714,750Â shares of Common Stock at the same price to cover over-allotments. Â OnÂ January 12, 2024Â the underwriter exercised its over-allotment option as toÂ 372,110Â shares of common stock for net proceeds afterÂ discounts and commission of $192,156. Â Warrants Â The following table summarizes information about shares issuable under warrants outstanding as of September 30, 2024: Â Â Â Warrant shares outstanding Â Â Weighted Average exercise price Â Â Weighted Average remaining life Â Â Intrinsic value Â Outstanding at January 1, 2024 Â Â 314,572Â Â Â 0.50Â Â Â 0.10Â Â Â 59,737Â Issued Â Â -Â Â Â -Â Â Â -Â Â Â -Â Exercised Â Â (103,500)Â Â 0.50Â Â Â -Â Â Â -Â Expired or cancelled Â Â (211,072)Â Â 0.50Â Â Â -Â Â Â -Â Outstanding and exercisable at September 30, 2024 Â Â -Â Â Â -Â Â Â -Â Â Â -Â Â During the nine months ended September 30, 2024,Â the Company issuedÂ 103,500Â shares of common stock for warrants issued in 2019. The warrants wereÂ exercised atÂ $0.50Â for proceeds of $51,751. Â Shares to Be Issued Â As of September 30, 2024 and 2023, respectively, there wereÂ 2,657,058 and 2,426,364Â shares issuable, the issuance of which has been deferred under the terms of employment agreementsÂ with the Chief Executive Officer and other employees of Milestone Scientific. Such shares are issuable to each party upon termination ofÂ their respective employment. Â As of September 30, 2024 and 2023, respectively, there wereÂ 527,625 andÂ 382,696 shares issuable to non-employees, for services rendered. TheÂ number of shares was fixed at the date of grant and were fully vested upon grant date. Â 14 Â Â The following table summarizes activity for shares to be issued for theÂ nine months periods ending September 30, 2024 and 2023. Â Â Â September 30, 2024 Â Â September 30, 2023 Â Â Â Â Â Â Â Â Â Â Shares-to-be-issued, outstanding January 1, 2024 and 2023, respectively Â Â 3,098,917Â Â Â 2,440,673Â Granted in current period Â Â 438,868Â Â Â 368,387Â Issued in current period Â Â (353,102)Â Â -Â Shares-to be issued outstanding September 30, 2024 and 2023, respectively Â Â 3,184,683Â Â Â 2,809,060Â Â Stock Options Plans Â The Milestone Scientific Inc., Amended and Restated 2020 Equity Incentive Plan (the â€œ2020 Planâ€), provides for awards of restricted commonÂ stock restricted stock units, options to purchase and other awards.Â On JuneÂ 28, 2023Â the 2020 Plan was amended and restated to increase the maximum shares that can be issued thereunder to 11,500,000 shares of common stock. The plan expires in June 2031. Options may be granted to employees, directors, and consultants of Milestone Scientific for the purchase of shares of common stock at a price not less than the fair market value of common stock on the date of grant. Generally, options become exercisable over a three-year period from the grant date and expire five years after the date of grant.Â Â Milestone Scientific recognizes compensation expenses over the requisite service period and in the case of performance-based options over the period of the expected performance. For the three and nine months ended September 30, 2024, Milestone Scientific recognized approximatelyÂ $172,000Â and $530,000 of total employee compensation cost, respectively, recorded in general and administrative expenses on the statement of operations. For the three and nine months ended September 30, 2023, Milestone Scientific recognized approximately $321,000 and $1.1 million of total employee compensation cost, respectively, recorded in general and administrative expenses on the statement of operations. Â As of September 30, 2024,Â there was $1.0Â millionÂ of total unrecognized compensation cost related to non-vested options.Â Milestone Scientific expects to recognize these costs over a weighted average period of 1.5Â years. Â A summary of option activity for employees under the plans and changes during theÂ Â nine months ended September 30, 2024 is presented below: Â Â Â Number of Options Â Â Weighted Averaged Exercise Price $ Â Â Weighted Average Remaining Contractual Life (Years) Â Â Aggregate Intrinsic Options Value $ Â Options outstanding at January 1, 2024 Â Â 3,036,989Â Â Â 2.29Â Â Â 5.41Â Â Â -Â Granted during 2024 Â Â -Â Â Â -Â Â Â -Â Â Â -Â Exercised during 2024 Â Â -Â Â Â -Â Â Â -Â Â Â -Â Forfeited or expired during 2024 Â Â -Â Â Â -Â Â Â -Â Â Â -Â Options outstanding September 30, 2024 Â Â 3,036,989Â Â Â 2.32Â Â Â 4.66Â Â Â -Â Exercisable, September 30, 2024 Â Â 2,188,433Â Â Â 2.29Â Â Â 4.06Â Â Â -Â Â A summary of option activity for non-employees under the plans and changes during the nine months ended September 30, 2024Â is presented below: Â Â Number of Options Â Â Weighted Averaged Exercise Price $ Â Â Weighted Average Remaining Contractual Life (Years) Â Â Aggregate Intrinsic Options Value $ Â Options outstanding at January 1, 2024 Â Â 91,663Â Â Â 1.76Â Â Â 2.25Â Â Â 2,833Â Granted during 2024 Â Â 24,999Â Â Â 0.84Â Â Â 4.71Â Â Â -Â Exercised during 2024 Â Â -Â Â Â -Â Â Â -Â Â Â -Â Forfeited or expired during 2024 Â Â (16,666)Â Â 0.55Â Â Â -Â Â Â -Â Options outstanding September 30, 2024 Â Â 99,996Â Â Â 1.74Â Â Â 2.37Â Â Â 4,083Â Exercisable, September 30, 2024 Â Â 77,772Â Â Â 1.99Â Â Â 1.81Â Â Â 1,916Â Â 15 Â Â For the three and nine months ended September 30, 2024, Milestone Scientific recognized approximately $7,000 and $9,200Â respectively of expense related to non-employee options. For the three and nine months ended September 30, 2023, Milestone Scientific recognized approximately $3,800 and$17,000, respectively of expense related to non-employee options. Â The information below summarizes the restricted stock award activity for the nine months ended September 30, 2024. Â Â Â Number of Shares Â Â Weighted Average Grant-Date Fair Value per Award Â Non-vested as January 1, 2024 Â Â 327,937Â Â Â 0.91Â Granted Â Â 730,340Â Â Â 0.89Â Vested Â Â (510,522)Â Â 0.91Â Cancelled Â Â -Â Â Â -Â Non-vested as September 30, 2024 Â Â 547,755Â Â Â 0.89Â Â As of September 30, 2024, all restrictedÂ shares granted and deferred under the terms of employment agreements with each Territory Manager of Milestone Scientific are fully vested. For the three and nine months ended September 30, 2024, the Company recognized stock compensation expense of approximatelyÂ $0 and $2,100 respectively. For the three and nine months ended September 30, 2023, the Company recognized stock compensation expense of approximately negative $36,500 and $17,700 respectively. For the nine months ended September 30, 2024, there was no unrecognized compensation expense.Â Â As ofÂ July 16, 2024,Â the Company entered intoÂ restricted stock agreements withÂ members of the Board of Directors of the Company. The Company grantedÂ 730,340 restricted stock awards with a fair market value of $0.89Â per share. SuchÂ restricted stock vests as follows:Â 25%Â on the grant date in July 2024, andÂ 25%Â quarterly, on theÂ firstÂ day of the following months:Â October 2024,Â January 2025,Â andÂ April 2025.For the three and nine months ended September 30, 2024, Â the Company recognized approximately $306,000 and $464,000, respectively, for restricted stock expenses recorded in general and administrative expenses on the statement of operations.Â For the nine months ended September 30, 2024, thereÂ was $344,000Â of total unrecognized compensation cost related to non-vested restricted stock grant, which the Company expects to recognize these costs over a weighted average period of 0.5Â years. Â NOTE 7Â â€” INCOME TAXES Â The utilization of Milestone Scientific's net operating losses may be subject to a substantial limitation due to the "change of ownership provisions" under Section 382 of the Internal Revenue Code and similar state provisions. Such limitation may result in the expiration of the net operating loss carry forwards before their utilization. Milestone Scientific has established a 100% valuation allowance for all its deferred tax assets due to uncertainty as to their future realization.Â Â In April 2024, we received approximately $2.0 million, net of expenses, from the sale of New Jersey net operating losses (â€œNOLâ€), that were eligible for sale under the State of New Jerseyâ€™s Economic Development Authorityâ€™sÂ New Jersey Technology Business Tax Certificate Transfer Program (â€œNJEDA Programâ€). The Company recorded this amount within Gain on sale of net operating losses within theÂ consolidated statement of operations (unaudited). Â Pursuant to the NJEDA program, the Company must retain a physical presence in the state of New Jersey for a period of 5 years after the sale of the of the NOLs. If the Company does not retain a physical presence during the 5 years after the sale of the NOLs, the Company can be liable to pay the state of New Jersey up to $2.2 million of the surrendered NOLs. Â NOTEÂ 8Â â€” SEGMENT AND GEOGRAPHIC DATA Â The Company conducts its business through two reportable segments: Dental and Medical. These segments offer different products and services to different customer bases.Â The Company providesÂ general corporate services to its segments; however, these services are not considered when making operating decisions and assessing segment performance. These services are reported under â€œCorporate Servicesâ€ below and these include costs associated with executive management, investor relations, patents, trademarks, licensing agreements, new instruments developments,Â financing activities and public company compliance. 16 Â The following tables present information about our reportable and operating segments: Â Â Â For the three months ended September 30, Â Â For the nine months ended September 30, Â Sales Â Net Sales: Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Dental Â $2,466,405Â Â $2,053,284Â Â $6,542,594Â Â $7,556,848Â Medical Â Â 47,400Â Â Â 6,000Â Â Â 73,820Â Â Â 10,000Â Total net sales Â $2,513,805Â Â $2,059,284Â Â $6,616,414Â Â $7,566,848Â Â Operating Income (Loss): Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Dental Â $705,427Â Â $458,474Â Â $1,524,177Â Â $1,699,349Â Medical Â Â (356,555)Â Â (740,087)Â Â (1,376,294)Â Â (2,425,913) Corporate Â Â (1,818,051)Â Â (1,225,092)Â Â (4,862,553)Â Â (4,400,369) Total operating loss Â $(1,469,179)Â $(1,506,705)Â $(4,714,670)Â $(5,126,933) Â Depreciation and Amortization: Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Dental Â $-Â Â $1,051Â Â $-Â Â $3,439Â Medical Â Â -Â Â Â 585Â Â Â -Â Â Â 2,247Â Corporate Â Â 8,574Â Â Â 14,260Â Â Â 28,735Â Â Â 44,112Â Total depreciation and amortization Â $8,574Â Â $15,896Â Â $28,735Â Â $49,798Â Income (loss) before taxes and equity in earnings of affiliates: Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Dental Â $705,433Â Â $458,504Â Â $1,523,209Â Â $1,698,790Â Medical Â Â (356,555)Â Â (742,004)Â Â (1,376,576)Â Â (2,431,502) Corporate Â Â (1,810,049)Â Â (1,192,605)Â Â (2,824,695)Â Â (4,291,552) Total income (loss) before taxes and equity in earnings of affiliate Â $(1,461,171)Â $(1,476,105)Â $(2,678,062)Â $(5,024,264) Â Total Assets Â September 30, 2024 Â Â December 31, 2023 Â Â Â Â Â Â Â Â Â Dental Â $5,528,106Â Â $4,866,786Â Â Â Â Â Â Â Â Â Medical Â Â 220,698Â Â Â 345,194Â Â Â Â Â Â Â Â Â Corporate Â Â 5,426,114Â Â Â 6,159,532Â Â Â Â Â Â Â Â Â Total assets Â $11,174,918Â Â $11,371,512Â Â Â Â Â Â Â Â Â Â Â Â Â 17 Â The following table shows a breakdown of Milestone Scientificâ€™s product sales (net), domestically and internationally, byÂ business segment product category: Â Â Â Three Months Ended September 30, 2024 Â Â Three Months Ended September 30, 2023 Â Domestic: US Â Dental Â Â Medical Â Â Grand Total Â Â Dental Â Â Medical Â Â Grand Total Â Instruments Â $179,699Â Â $1,000Â Â $180,699Â Â $230,615Â Â $-Â Â $230,615Â Handpieces Â Â 1,029,116Â Â Â 11,400Â Â Â 1,040,516Â Â Â 1,007,930Â Â Â -Â Â Â 1,007,930Â Accessories Â Â 5,501Â Â Â -Â Â Â 5,501Â Â Â 14,822Â Â Â -Â Â Â 14,822Â Grand Total Â $1,214,316Â Â $12,400Â Â $1,226,716Â Â $1,253,367Â Â $-Â Â $1,253,367Â Â International: Rest of World Â Instruments Â $261,466Â Â $32,500Â Â $293,966Â Â $88,019Â Â $-Â Â $88,019Â Handpieces Â Â 961,089Â Â Â 2,500Â Â Â 963,589Â Â Â 700,697Â Â Â 6,000Â Â Â 706,697Â Accessories Â Â 29,534Â Â Â -Â Â Â 29,534Â Â Â 11,201Â Â Â -Â Â Â 11,201Â Grand Total Â $1,252,089Â Â $35,000Â Â $1,287,089Â Â $799,917Â Â $6,000Â Â $805,917Â Â Total Product Sales Â $2,466,405Â Â $47,400Â Â $2,513,805Â Â $2,053,284Â Â $6,000Â Â $2,059,284Â Â Â Â Nine Months Ended September 30, 2024 Â Â Nine Months Ended September 30, 2023 Â Domestic: US Â Dental Â Â Medical Â Â Grand Total Â Â Dental Â Â Medical Â Â Grand Total Â Instruments Â $588,250Â Â $2,000Â Â $590,250Â Â $726,104Â Â $-Â Â Â $726,104Â Handpieces Â Â 3,245,673Â Â Â 35,400Â Â Â 3,281,073Â Â Â 3,277,830Â Â Â -Â Â Â 3,277,830Â Accessories Â Â 37,168Â Â Â -Â Â Â 37,168Â Â Â 59,336Â Â Â -Â Â Â 59,336Â Grand Total Â $3,871,091Â Â $37,400Â Â $3,908,491Â Â $4,063,270Â Â $-Â Â $4,063,270Â Â International: Rest of World Â Instruments Â $668,728Â Â $32,500Â Â $701,228Â Â $961,224Â Â $-Â Â $961,224Â Handpieces Â Â 1,965,683Â Â Â 2,500Â Â Â 1,969,603Â Â Â 2,222,707Â Â Â 10,000Â Â Â 2,232,707Â Accessories Â Â 37,092Â Â Â -Â Â Â 37,092Â Â Â 39,647Â Â Â -Â Â Â 39,647Â Grand Total Â $2,671,503Â Â $36,420Â Â $2,707,923Â Â $3,223,578Â Â $10,000Â Â $3,233,578Â Â International: China

Â Â Â

continue to expand the uses and applications of our DPS Dynamic Pressure Sensing technology.Â We believe that we and our technology solutions are recognized by key opinion leaders (i.e., academics, anesthesiologists and practicing dentists whose opinions are widely respected), industry experts and medical and dental practitioners as a leader in the emerging, computer-controlled injection industry. Â The Single Tooth Anesthesia System (Dental) Â Since its market introduction in early 2007, the STA Single Tooth Anesthesia System and prior C-CLAD devices have been used to deliver over 92 million safe, effective, and comfortable injections. The instrument has also been favorably evaluated in numerous peer-reviewed, published clinical studies and associated articles. Moreover, there appears to be a growing consensus among users that the STA Instrument is proving to be a valuable and beneficial instrument that is positively impacting the practice of dentistry worldwide. Â Medical Market Product Â In June 2017, we received FDA regulatory clearance to sell the CompuFlo Epidural Computer Controlled Anesthesia System in the United States for epidural injections. Â In May, 2022, the Company receivedÂ a chronology-specificÂ CPT Code for the Companyâ€™s technology by the American Medical Association, which marks an important milestone that could increase the potential number of anesthesia pain management clinics adopting the CompuFlo instrument. Effective January 1, 2023, this temporary tracking code allows clinicians to submit claims to healthcare insurance providers using the Companyâ€™s technology for Epidural Sterile Injections in the lumbar, thoracic, and cervical thoracic junctionÂ of the spinal regionÂ for reimbursement. A CPT code expands the potential for reimbursement of epidural procedures in pain management utilizing the CompuFlo Epidural System, which should help accelerate the commercial roll-out of CompuFlo in the United States. Â On FebruaryÂ 27, 2023, the Company announced that its CompuFloÂ® Epidural System has received 510(k) FDA clearance for use in the thoracic region of the spine, including the cervical thoracic junction. This approval expands upon the Companyâ€™s prior approval of CompuFlo for use within the lumbar region of the spine, where the focus has been epidural analgesia during labor and delivery procedures.Â Â On June 18, 2024, the Company announced that it has received regulatory approval from Brazil's National Health Surveillance Agency (ANVISA) to market and sell its CompuFloÂ® Epidural System in Brazil. The approval includes the lumbar, thoracic, and cervical-thoracic junction of the spine. Â On July 10, 2024, the Company announced that First Coast Service Options Inc. (FCSO), a Jurisdictional Medicare Administrative Contractor (â€œJMACâ€), has granted favorable Medicare Part B physician price assignment across Florida for use of the Companyâ€™s CompuFloÂ® Epidural System under the American Medical Associationâ€™s (AMA) technology-specific Category III CPTÂ® code CPT0777T (real-time pressure-sensing epidural guidance system when used in conjunction with a primary ESI procedure). Â 23 Â On July 23, 2024 the Company Â announced that Novitas Solutions, Inc. (Novitas), a Jurisdictional Medicare Administrative Contractor (JMAC), had granted a Medicare Part B Physician payment rate for the Companyâ€™s CompuFloÂ® Epidural System under the American Medical Associationâ€™s (AMA) technology-specific Category III CPTÂ® code CPT0777T (real-time pressure-sensing epidural guidance system when used in conjunction with a primary ESI procedure). Â This new price assignment applies to two Medicare regions: Jurisdiction L (JL) and Jurisdiction H (JH). JL includes Delaware, District of Columbia, Maryland, New Jersey, and Pennsylvania. JH includes Arkansas, Colorado, Louisiana, Mississippi, New Mexico, Oklahoma, and Texas. Â On July 30, 2024 â€“ the CompanyÂ announced receipt of multiple Notices of Allowance (NOA) for essential patent applications in both the U.S. and Europe. Â One NOAs was granted by the U.S. Patent and Trademark Office and one NOA was granted by the European Patent Office for a new patent titled â€œDevice and Method for Needle/Catheter Location Utilizing Correlation Analysis.â€ These patent applications cover Milestone Scientificâ€™s next-generation Dynamic Pressure SensingÂ® (DPS) technology for real-time pressure-sensing guidance in manual injection systems Â On August 7, 2024 â€“ the Company announced a strategic partnership with Axial Biologics, a premier medical device company with a vast distribution network. Under the agreement, Axial Biologics will serve as the distributor of Milestone Scientific's CompuFloÂ® Epidural System in New Jersey, Texas, and Florida jurisdictions. Â On October 3, 2024 the Company announced that iHeal Pain Center had adopted the CompuFloÂ® Epidural System following successful epidural steroid injection (ESI) procedures by Dr. Desai, DO. Dr. Desai has performed six cervical and two lumbar ESI procedures using the CompuFloÂ® Epidural System, leading to its integration within the clinic. Â The following table shows a breakdown of Milestone Scientificâ€™s product sales (net), domestically and internationally, byÂ business segment product category: Â Â Three Months Ended September 30, 2024 Â Â Three Months Ended September 30, 2023 Â Domestic: US Â Dental Â Â Medical Â Â Grand Total Â Â Dental Â Â Medical Â Â Grand Total Â Instruments Â $ 179,699 Â Â $ 1,000 Â Â $ 180,699 Â Â $ 230,615 Â Â $ - Â Â $ 230,615 Â Handpieces Â Â 1,029,116 Â Â Â 11,400 Â Â Â 1,040,516 Â Â Â 1,007,930 Â Â Â - Â Â Â 1,007,930 Â Accessories Â Â 5,501 Â Â Â - Â Â Â 5,501 Â Â Â 14,822 Â Â Â - Â Â Â 14,822 Â Grand Total Â $ 1,214,316 Â Â $ 12,400 Â Â $ 1,226,716 Â Â $ 1,253,367 Â Â $ - Â Â $ 1,253,367 Â Â Â

Consolidated research and development expenses for theÂ nine months ended September 30, 2024 and 2023 were approximatelyÂ $641,000 and $524,000, respectively.Â The increase ofÂ approximately $117,000Â isÂ related to theÂ Company's entering into the final stage of the development ofÂ theÂ nextÂ generation STA Single Tooth Anesthesia System. Â Profit (Loss) from OperationsÂ for 2024 andÂ 2023Â were as follows: Â Â 2024 Â Â 2023 Â Â Change Â Dental Â $ 1,524,177 Â Â $ 1,699,354 Â Â $ (175,177) Medical Â Â (1,376,294) Â Â (2,425,918) Â Â 1,049,624 Â Corporate Â Â (4,862,553) Â Â (4,400,369) Â Â (462,184) Total loss from operations Â $ (4,714,670) Â $ (5,126,933) Â $ 412,263 Â Â The loss from operations was approximatelyÂ $4.7Â million and $5.1Â millionÂ for the nine months ended September 30, 2024 and 2023, respectively, an increase of approximately $0.4Â million. Â Liquidity and Capital Resources Â Cash Flows Â The following table summarizes our sources and uses of cash forÂ nine months ended: Â Cash flow: Â September 30, 2024 Â Â September 30, 2023 Â Â Change Â Net cash used in operating activities Â $ (1,408,387) Â $ (4,080,330) Â $ 2,671,943 Â Net cash provided by (used in) investing activities Â $ 2,969,977 Â Â $ (2,457,870) Â $ 5,427,847 Â Net cash provided by (used in) financing activities Â $ 236,294 Â Â $ (6,486) Â $ 242,780 Â Â Operating Activities Â Cash flows used in operating activities decreased ofÂ Â $2.7Â million for the nine months ended September 30, 2024 compared to September 30, 2023.Â The decrease was primarily driven by the Companyâ€™s receipt of approximately $2.0 million, net of expenses, from the sale of New Jersey net operating losses â€˜(NOLâ€), that were eligible for sale under the State of New Jerseyâ€™s Economic Development Authorityâ€™sÂ Â New Jersey Technology Business Tax Certificate TransferÂ program (â€œNJEDA Programâ€). Â 28 Â Â Investing Activities Â Cash flows provided by investing activities increased $5.4Â million for the nine months ended September 30, 2024Â compared to September 30, 2023. The Company sold $3.0 million of marketable securities during the nine months ended September 30, 2024 whichÂ increased cash and equivalents by $3.0 million. The Company purchased approximately $2.5 million in marketable security during the nine months ended September 30, 2023. Â Financing Activities Â Net cash provided by financing activities for the nine months ended September 30, 2024Â compared to September 30, 2023Â increased by approximatelyÂ $0.2 primarilyÂ due to the issuance of additional shares of the Companyâ€™s common stock due to a Public Placement Offering. Â Consideration of Companyâ€™s ability to continue as a going concern. Â The Company has evaluated whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern withinÂ oneÂ year after the date that the consolidated financial statements are issued. The Company has incurred total losses since inception of $126.0Â million. The operating losses were $1.5Â million and $4.7Â million, for three and nine months ended September 30, 2024.Â On September 30, 2024,Â Milestone Scientific had cash and cash equivalentsÂ of approximatelyÂ $4.8Â million and working capital of approximatelyÂ $6.9Â million. For the nine months ended September 30, 2024, and 2023, we had cash flows used in operating activities of approximately $1.4 millionÂ and $4.1 million respectively. Â In April 2024, we received approximately $2.0 million, net of expenses, from the sale of New Jersey net operating losses (â€œNOLâ€), that were eligible for sale under the State of New Jerseyâ€™s Economic Development Authorityâ€™s New Jersey Technology Business Tax Certificate TransferÂ program (â€œNJEDA Programâ€). Â Management has prepared financialÂ forecasts covering a period ofÂ 12Â months from the date of issuance of these financial statements. These forecasts include several revenue and operating expense assumptions which indicate that the Companyâ€™s current cash and liquidity is sufficient to finance the operating requirements for at least the nextÂ 12Â months from the filing date. Milestone Scientific is actively pursuing the generation of positive cash flows from operating activities through an increase in revenue from its dental business worldwide, the generation of revenue from its medical devices and disposables business in the United States and worldwide, and a reduction in operating expenses. However, the Companyâ€™s continued operations will depend on its ability to raise additional capital through various potential sources until it achieves profitability, if ever.Â Â Item 3. Quantitative and Qualitative Disclosures about Market Risk Â Milestone Scientific is a â€œsmaller reporting companyâ€ as defined by Regulation S-K and, as such, is not required to provide the information required by this item. Â Item 4. Controls and Procedures Â Evaluation of Disclosure Controls and Procedures Â Our management, with the participation of our Chief Executive Officer and Principal Accounting Officer, both positions being held by the same person, evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2024. The term â€œdisclosure controls and procedures,â€ as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SECâ€™s rules and forms.Â Â Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the companyâ€™s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, as ours are designed to do, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on such evaluation, our Chief Executive OfficerÂ and Principal Accounting Officer, concluded that, as of September 30, 2024, our disclosure controls and procedures were effective at a reasonable assurance level. Â 29 Â Â Changes in Internal Control over Financial Reporting Â We routinely review our internal control over financial reporting and from time to time make changes intended to enhance the effectiveness of our internal control over financial reporting. During the nine months ended September 30, 2024, we made no changes to our internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, that we believe materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. Â Item 1A. Risk Factors Â There have been no material changes to the risk factors previously disclosed in Part I, ItemÂ 1A, of our 2023Â Annual Report. Â Item1B. Unresolved Staff Comments Â None. Â Item 1C. Cybersecurity Â None. Â Item 2.Â Unregistered Sales of Equity Securities and use of proceeds Â Not applicable. Â ItemÂ 3. Default upon Senior Securities Â Not applicable. Â ItemÂ 4. Mine Safety Disclosure Â Not applicable. Â Â ItemÂ 5. Other Information Â Not applicable. Â Â 30 Â Â Item 6. Exhibits and Financial Statement Schedules Â Exhibit No Â Description Â Â Â 31.1 Â Rule 13a-14(a) Certification-Chief Executive Officer and Chief Accounting Officer* 32.1 Â Section 1350 Certifications-Chief Executive Officer and Chief Accounting Officer** 101.INS Â Inline XBRL Instance Document* 101.SCH Â Inline XBRL Taxonomy Extension Schema Document* 101.CAL Â Inline XBRL Taxonomy Extension Calculation Linkbase Document* 101.LAB Â Inline XBRL Taxonomy Extension Label Linkbase Document* 101.PRE Â Inline XBRL Taxonomy Extension Presentation Linkbase Document* 101.DEF Â Inline XBRL Taxonomy Extension Definition Linkbase Document* 104 Â Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) Â * Filed herewith. ** Furnished herewith and not filed, in accordance with item 601(32) (ii) of Regulation S-K. Â Â 31 Â Â SIGNATURES Â Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Â Â Â MILESTONE SCIENTIFIC INC. Â Â Â /s/Â Arjan Haverhals Â Arjan Haverhals Â Chief Executive OfficerÂ Â Chief Accounting Officer Â Principal Executive Officer Date: November 14, 2024 Â Â 32 EX-31.1 2 ex_723134.htm EXHIBIT 31.1 ex_723134.htm Exhibit 31.1 Â Â Rule 13a-14(a)/15d-14(a) Certification Â I , Arjan Haverhals as Chief Executive Officer and Chief Accounting Officer, certify that: Â 1. I have reviewed this quarterly report on Form 10-Q of Milestone Scientific Inc. Â 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, considering the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â 3. Based on my knowledge, the financial statements, and other financial information included in this report, present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report. Â 4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: Â (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under the supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â (b) Designed such internal control over financial reporting or caused such internal control over financial reporting to be designed under the supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Â (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report the conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report, based on such evaluation; and Â (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and Â 5. The registrant's other certifying officer(s) and I have disclosed, based on the most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): Â (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and Â (b) Any fraud, whether material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting Â Date: November 14, 2024 Â Â Â /s/ Arjan Haverhals Â Â Arjan Haverhals Â Â Chief Executive Officer Â Â Chief Accounting Officer Â Â Principal Executive Officer Â Â EX-32.1 3 ex_723135.htm EXHIBIT 32.1 ex_723135.htm Exhibit 32.1 Â Â Â CERTIFICATION PURSUANT TO Â 18 U.S.C. SECTION 1350, Â AS ADOPTED PURSUANT TO Â SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Â Â In connection with the quarterly report of Milestone Scientific Inc. (â€œMilestoneâ€) on Form 10-Q for the period endingÂ September 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), I, Arjan HaverhalsÂ Chief Executive Officer, and Chief Accounting OfficerÂ of Milestone, certify, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, that: Â (1)Â The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and Â (2)Â The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of Milestone. Â Â Â Date November 14, 2024 /s/ Arjan Haverhals Arjan Haverhals Chief Executive Officer ChiefÂ Accounting Officer Principal Executive Officer Â Â Â A signed original of this certification has been provided to Milestone and will be retained by Milestone and furnished to the Securities and Exchange Commission or its staff upon request. Â Â Â Â EX-101.SCH 4 mlss-20240930.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 006 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 1 - Organization and Business link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 2 - Liquidity and Uncertainties link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 3 - Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 4 - Inventories link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 5 - Advances on Contracts link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 6 - Stockholders' Equity link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 7 - Income Taxes link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 8 - Segment and Geographic Data link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 9 - Concentrations link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 10 - Related Party Transactions link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 11 - Commitments link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note 12 - Subsequent Events link:calculationLink link:definitionLink link:presentationLink 995465 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 995466 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Tables) link:calculationLink link:definitionLink link:presentationLink 995467 - Disclosure - Note 4 - Inventories (Tables) link:calculationLink link:definitionLink link:presentationLink 995468 - Disclosure - Note 6 - Stockholders' Equity (Tables) link:calculationLink link:definitionLink link:presentationLink 995469 - Disclosure - Note 8 - Segment and Geographic Data (Tables) link:calculationLink link:definitionLink link:presentationLink 995470 - Disclosure - Note 11 - Commitments (Tables) link:calculationLink link:definitionLink link:presentationLink 995471 - Disclosure - Note 1 - Organization and Business (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995472 - Disclosure - Note 2 - Liquidity and Uncertainties (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995473 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995474 - Disclosure - Note 3 - Summary of Significant Accounting Policies - Fair Value of Marketable Securities (Details) link:calculationLink link:definitionLink link:presentationLink 995475 - Disclosure - Note 4 - Inventories (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995476 - Disclosure - Note 4 - Inventories - Summary of Inventories (Details) link:calculationLink link:definitionLink link:presentationLink 995477 - Disclosure - Note 5 - Advances on Contracts (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995478 - Disclosure - Note 6 - Stockholders' Equity (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995479 - Disclosure - Note 6 - Stockholders' Equity - Warrants (Details) link:calculationLink link:definitionLink link:presentationLink 995480 - Disclosure - Note 6 - Stockholders' Equity - Summary of Shares to be Issued (Details) link:calculationLink link:definitionLink link:presentationLink 995481 - Disclosure - Note 6 - Stockholders' Equity - Summary of Option Activity (Details) link:calculationLink link:definitionLink link:presentationLink 995482 - Disclosure - Note 6 - Stockholders' Equity - Schedule of Restricted Stock (Details) link:calculationLink link:definitionLink link:presentationLink 995483 - Disclosure - Note 7 - Income Taxes (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995484 - Disclosure - Note 8 - Segment and Geographic Data (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995485 - Disclosure - Note 8 - Segment and Geographic Data - Summary by Reporting and Operating Segments (Details) link:calculationLink link:definitionLink link:presentationLink 995486 - Disclosure - Note 8 - Segment and Geographic Data - Summary of Operations by Geographic Area (Details) link:calculationLink link:definitionLink link:presentationLink 995487 - Disclosure - Note 9 - Concentrations (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995488 - Disclosure - Note 10 - Related Party Transactions (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995489 - Disclosure - Note 11 - Commitments (Details Textual) link:calculationLink link:definitionLink

link:presentationLink 995490 - Disclosure - Note 11 - Commitments - Lease Expense (Details) link:calculationLink link:definitionLink link:presentationLink 995491 - Disclosure - Note 12 - Subsequent Events (Details Textual) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 5 mlss-20240930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 6 mlss-20240930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 7 mlss-20240930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Note To Financial Statement Details Textual Significant Accounting Policies Note 3 - Summary of Significant Accounting Policies Note 4 - Inventories Note 6 - Stockholders' Equity Note 8 - Segment and Geographic Data Note 11 - Commitments Note 3 - Summary of Significant Accounting Policies - Fair Value of Marketable Securities (Details) Note 4 - Inventories - Summary of Inventories (Details) Note 6 - Stockholders' Equity - Warrants (Details) Income Tax Disclosure [Text Block] Note 6 - Stockholders' Equity - Summary of Shares to be Issued (Details) Note 6 - Stockholders' Equity - Summary of Option Activity (Details) Note 6 - Stockholders' Equity - Schedule of Restricted Stock (Details) Note 8 - Segment and Geographic Data - Summary by Reporting and Operating Segments (Details) us-gaap_LiabilitiesCurrent Total current liabilities Note 8 - Segment and Geographic Data - Summary of Operations by Geographic Area (Details) Note 11 - Commitments - Lease Expense (Details) Notes To Financial Statements Notes To Financial Statements [Abstract] us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted Purchase Commitment, Remaining Minimum Amount Committed Purchase Commitment, Excluding Long-Term Commitment [Axis] Purchase Commitment, Excluding Long-Term Commitment [Domain] Weighted average shares outstanding and to be issuedâ€” Share-Based Payment Arrangement, Option, Activity [Table Text Block] Sale of marketable securities Common stock to be issued to employees for bonuses Common stock to be issued to employees for bonuses Value of stock issued for employee bonuses during the period. Vested, Weighted Average Grant-Date Fair Value per Award (in dollars per share) US Treasury Securities [Member] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Non-vested as January 1, 2024 (in dollars per share) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Non-vested as January 1, 2024 (in shares) Non-vested, Shares (in shares) Granted, Shares (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Vested, Shares (in shares) Weighted average exercise price, exercisable (in dollars per share) Weighted average remaining contractual life, exercisable (Year) Aggregate intrinsic value, exercisable us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Balance Balance Number of options exercisable (in shares) Weighted average remaining contractual life, outstanding (Year) Aggregate intrinsic value, outstanding us-gaap_PaymentsToAcquireMarketableSecurities Purchase of marketable securities Financial Instruments [Domain] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Weighted average exercise price, outstanding (in dollars per share) Weighted average exercise price, outstanding (in dollars per share) us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent Accounts Payable and Accrued Liabilities, Current Financial Instrument [Axis] Weighted average exercise price, forfeited or expired (in dollars per share) mlss_IncreaseDecreaseToAdvancesToContractManufacturer Decrease (increase) in advances on contracts Increase decrease to advances to contract manufacturer. Weighted average exercise price, granted (in dollars per share) Weighted average exercise price, exercised (in dollars per share) Accrued expenses and other payables Cancelled, Shares (in shares) Accounts payable us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Number of options (in shares) Number of options (in shares) Number of options forfeited and expired (in shares) Number of options, forfeited or expired (in shares) Accounts Payable, Related Parties, Current [Member] Represents information about accounts payable, related parties, current. us-gaap_PolicyTextBlockAbstract Accounting Policies us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year) Grantee Status [Domain] Grantee Status [Axis] us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Weighted average remaining contractual life, granted (Year) Weighted average remaining contractual term for option awards granted. Current liabilities: Vesting [Axis] Vesting [Domain] Share-Based Payment Arrangement, Tranche One [Member] Share-Based Payment Arrangement, Tranche Two [Member] Total assets us-gaap_Assets Total assets Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block] mlss_ClassOfWarrantOrRightExercisedDuringPeriod Exercised, number of shares (in shares) The number of warrants or rights exercised during period. Issued, number of shares (in shares) The number of warrants or rights issued during period. Plan Name [Axis] Dental Segment [Member] Information related to the Dental segment. Plan Name [Domain] Medical Segment [Member] Information related to the medical segment. Exercised, weighted average exercise price (in dollars per share) Class of Warrant or Right, Exercised During Period, Exercise Price (in dollars per share) Exercise price per share of warrants or rights exercised during period. Issued, weighted average exercise price (in dollars per share) Exercise price per share of warrants or rights issued during period. us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) mlss_ClassOfWarrantOrRightExpiredOrCancelledDuringPeriod Expired or cancelled, number of shares (in shares) The number of warrants or rights expired or cancelled during period. mlss_PaymentsToAcquireProceedsFromSalePropertyPlantAndEquipment Purchase of furniture, fixtures, and equipment The cash outflow (inflow) associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. Expired or cancelled, weighted average exercise price (in dollars per share) Exercise price per share of warrants or rights expired or cancelled during period. us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount Share-Based Payment Arrangement, Amount Capitalized Award Type [Domain] Lease, Cost and Other Information [Table Text Block] Tabular disclosure of lessee's lease cost and other information. Award Type [Axis] us-gaap_NetIncomeLoss Net loss attributable to Milestone Scientific Inc. Intangibles, net Restricted Stock [Member] Net loss attributable to noncontrolling interests Share-Based Payment Arrangement, Option [Member] Inventory [Axis] Inventory [Domain] Commitments and Contingencies Disclosure [Text Block] Furniture, fixtures and equipment, net Outstanding (Year) Represents the weighted average remaining term of warrants and rights outstanding, Expense paid in stock The amount of expenses paid for with stock in lieu of cash during the period. Employees paid in stock The amount of noncash share-based compensation bonuses paid in stock. Net loss Net (loss) Net loss Net loss Marketable Securities Marketable Securities mlss_PercentageOfValuationAllowance Percentage of Valuation Allowance Represents the percentage of valuation allowance. Cash flows from investing activities: us-gaap_IncreaseDecreaseInDeferredCompensation Increase (Decrease) in Deferred Compensation Net loss per share applicable to common stockholdersâ€” us-gaap_RelatedPartyTransactionAmountsOfTransaction Related Party Transaction, Amounts of Transaction us-gaap_MarketableSecuritiesUnrealizedGainLoss Unrealized gain on marketable securities us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty Related Party Transaction, Purchases from Related Party Related Party Transactions Disclosure [Text Block] Decrease in accrued expenses Gain on sale of net operating losses CHINA Distributor Three [Member] Related to distributor. Distributor Four [Member] Related to distributor. Distributor One [Member] Related to distributor. Distributor Two [Member] Related to distributor. Increase(decrease) in accounts payable, related party us-gaap_OperatingExpenses Total operating expenses Increase in accounts payable Public Offering [Member] Represents the information pertaining to the public offering. us-gaap_CashEquivalentsAtCarryingValue Cash Equivalents, at Carrying Value Cash and cash equivalents Slow Moving Medical Finished Goods [Member] Represents the slow moving medical finished goods. us-gaap_AllocatedShareBasedCompensationExpense Share-Based Payment Arrangement, Expense us-gaap_RoyaltyExpense Royalty Expense Amendment Flag City Area Code Use of Estimates, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] Common stock, shares outstanding (in shares) Current Fiscal Year End Date us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Increase in prepaid expenses and other current assets Weighted-average discount rate â€“ operating leases Document Fiscal Period Focus Document Fiscal Year Focus Consolidation, Policy [Policy Text Block] mlss_SaleOfNetOperatingLossesPhysicalPresenceRequirementYears Sale of Net Operating Losses, Physical Presence Requirement, Years (Year) Represents the number of years a company must retain a physical presence in a geographic region per the terms of a sale of net operating losses. mlss_SaleOfNetOperatingLossesContingentLiabilityAmount Sale of Net Operating Losses, Contingent Liability, Amount Represents the amount of contingent liability that a company must pay if they violate the terms of the sale of net operating losses. Document Period End Date Operating leases (years) (Year) Entity File Number Entity Emerging Growth Company Common Stock issued exercised warrants (in shares) Stock Issued During Period Shares, Warrants Exercised (in shares) Number of shares issued for warrants exercised. Document Type Common Stock issued exercised warrants Represents value of stock issued during period for warrants exercised. Entity Small Business us-gaap_NumberOfCountriesInWhichEntityOperates Number of Countries in which Entity Operates Entity Shell Company Document Information [Line Items] Document Information [Table] Entity Filer Category Entity Current Reporting Status us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties Increase in accounts receivable, related parties us-gaap_ConcentrationRiskPercentage1 Concentration Risk, Percentage us-gaap_IncreaseDecreaseInAccountsReceivable (Increase) decrease in accounts receivable Stock based compensation Entity Tax Identification Number Entity Central Index Key Advances to Contract Manufacturer [Text Block] Advances to contract manufacturer. Depreciation and amortization expense Entity Registrant Name Instruments [Member] A product of the reporting entity. Entity [Domain] Customer Concentration Risk [Member] Legal Entity [Axis] Entity Address, Address Line One Supplier Concentration Risk [Member] ecd_NonRule10b51ArrTrmntdFlag Non-Rule 10b5-1 Arrangement Terminated [Flag] Amortization of intangibles Entity Address, City or Town ecd_Rule10b51ArrTrmntdFlag Rule 10b5-1 Arrangement Terminated [Flag] ecd_Rule10b51ArrAdoptedFlag Rule 10b5-1 Arrangement Adopted [Flag] Entity Address, Postal Zip Code Entity Address, State or Province Concentration Risk Type [Axis] ecd_NonRule10b51ArrAdoptedFlag Non-Rule 10b5-1 Arrangement Adopted [Flag] Allowance for credit loss Accounts Receivable, Allowance for Credit Loss Concentration Risk Type [Domain] Material Terms of Trading Arrangement [Text Block] us-gaap_TreasuryStockValue Treasury stock, at cost, 33,333 shares Sales by Product and by Geographical Region [Table Text Block] Entire disclosure of sales by product and by geographical region. Domestic [Member] The domestic country of the reporting entity. Entity Common Stock, Shares Outstanding Handpieces [Member] Represents handpieces. Revenue Benchmark [Member] Accounts Receivable [Member] us-gaap_ProfessionalFees Professional Fees us-gaap_IncreaseDecreaseInInventories Increase in inventories Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Local Phone Number Number of options exercised (in shares) Number of options, exercised (in shares) us-gaap_TableTextBlock Notes Tables Restricted common stock issued to employees (in shares) Manufacturing Agreement for Handpieces [Member] Represents the manufacturing agreement for handpieces. Restricted common stock issued to employees Related and Nonrelated Parties [Axis] Related and Nonrelated Parties [Domain] mlss_PurchaseCommitmentNumberOfUnits Purchase Commitment Number Of Units The number of units commitment to purchase. Selling, general and administrative expenses Bad debt expense Common stock issued to employee for compensation Number of options granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) Component parts and other materials Common stock issued in public offering net of issuance cost (in shares) Stock Issued During Period, Shares, New Issues (in shares) Common stock issued for services Common stock issued for services (in shares) us-gaap_LiabilitiesAndStockholdersEquity Total liabilities and stockholdersâ€™ equity us-gaap_CashUninsuredAmount Cash, Uninsured Amount Finished goods, net Common stock issued in public offering net of issuance cost UNITED STATES Related Party Transaction [Axis] Related Party Transaction [Domain] Accumulated deficit Retained Earnings (Accumulated Deficit) Vendor One [Member] Relating to one vendor. Research and development expenses mlss_NumberOfVendors Number of Vendors Represents the number of vendors. Money Market Funds [Member] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Domain] Vendor Two [Member] Relating to vendor two. Changes in operating assets and liabilities: us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements Substantial Doubt about Going Concern [Text Block] Inventory Disclosure [Text Block] Subsequent Event [Member] Non-current portion of operating lease liabilities Schedule of Inventory, Current [Table Text Block] Subsequent Event Type [Axis] Current portion of operating lease liabilities Subsequent Event Type [Domain] Current portion of finance lease liabilities Non-current portion of finance lease liabilities Subsequent Events [Text Block] Right of use assets operating lease us-gaap_FinanceLeasePrincipalPayments Payments finance lease obligations Right of use assets finance lease us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense Deferred Compensation Arrangement with Individual, Compensation Expense Fair Value of Financial Instruments, Policy [Policy Text Block] Development of the Next Generation Instrument [Member] Represents development of the next generation instrument. Contracts for Funding of Future Epidural Instruments and Parts [Member] Represents contracts for funding of future epidural instruments and parts. Purchased Medical Products [Member] Represents purchased medical products. Director Clinical Affair [Member] Information pertaining to the Director Clinical Affair. University Pain Medicine Center (STEMMEE) [Member] Represents University Pain Medicine Center (STEMMEE). us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance (in shares) Shares-to-be-issued, outstanding (in shares) Shares-to-be-issued, outstanding (in shares) Share-Based Payment Arrangement, Employee [Member] us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued Issued in current period (in shares) Director of Clinical Affairs [Member] A personnel of the company with the title "Director of Clinical Affairs." us-gaap_ShareBasedCompensation Stock based compensation Other assets Accessories [Member] Represents information related to accessories. Share-Based Payment Arrangement, Nonemployee [Member] Earnings Per Share, Policy [Policy Text Block] Inventory reserve Depreciation expense Depreciation and Amortization us-gaap_DepreciationDepletionAndAmortization us-gaap_SharesIssued Balance (in shares) Balance (in shares) us-gaap_SharesIssuedPricePerShare Shares Issued, Price Per Share (in dollars per share) us-gaap_AssetsCurrent Total current assets Share-Based Payment Arrangement [Policy Text Block] Equity [Text Block] mlss_ConsultingAgreementBaseSalary Consulting Agreement, Base Salary In reference to the base salary for consulting services. Advances on contracts Advances on Inventory Purchases mlss_PaymentsForConsultingServices Payments for Consulting Services In reference to the cash outflow for consulting services. Treasury stock,

shares (in shares) Common stock, par value $0.001; authorized 100,000,000 shares; 77,709,455 shares issued and 77,676,122 shares outstanding as of September 30, 2024; 75,881,840 shares issued and 75,848,507 shares outstanding as of December 31, 2023; Common stock, shares authorized (in shares) Common stock, shares issued (in shares) Common stock, par value (in dollars per share) Chief Executive Officer, and Other Employees [Member] Represents chief executive officer and other employees. us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Common Stock, Capital Shares Reserved for Future Issuance (in shares) Cash paid for operating lease liabilities Product and Service [Axis] Product and Service [Domain] mlss_FinanceLeasePrincipalPaymentsIncludingAccruedExpenses Cash paid for finance lease liabilities Cash paid for finance lease liabilities including accrues expense. Geographical [Axis] Geographical [Domain] Portion at Fair Value Measurement [Member] Inventories us-gaap_InventoryNet Total inventories Estimate of Fair Value Measurement [Member] Product sales, net Product sales, net us-gaap_InventoryValuationReserves Inventory Valuation Reserves Measurement Basis [Axis] Fair Value, Inputs, Level 3 [Member] Fair Value Hierarchy and NAV [Domain] Customer [Axis] Customer [Domain] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value Hierarchy and NAV [Axis] Board of Directors [Member] Represents the board of directors of the company. Interest income Cash flows from operating activities: Schedule of Segment Reporting Information, by Segment [Table Text Block] Revenue [Policy Text Block] Statement [Line Items] us-gaap_NumberOfOperatingSegments Number of Operating Segments Accounts receivable, net of allowance for credit losses of $10,000, respectively us-gaap_NumberOfReportableSegments Number of Reportable Segments Marketable securities Marketable Securities, Current Additional paid in capital Stockholdersâ€™ equity Segment Reporting Disclosure [Text Block] mlss_WorkingCapital Working Capital The difference between the companies assets and liabilities. mlss_CashCashEquivalentsAndMarketableSecurities Cash, Cash Equivalents, and Marketable Securities The amount of cash, cash equivalents, and marketable securities calculated during the period. Non-Employees [Member] Represents information related to non-employees. Current assets: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Inventory, Policy [Policy Text Block] us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Net increase (decrease) in cash and cash equivalents Over-Allotment Option [Member] us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash provided by (used in) financing activities us-gaap_Liabilities Total liabilities Commitments and contingencies Sale of Stock [Axis] Sale of Stock [Domain] Operating Income (Loss) us-gaap_OperatingIncomeLoss Operating Income (Loss) Loss from operations us-gaap_NetCashProvidedByUsedInOperatingActivities Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash provided by (used in) investing activities Prepaid expenses and other current assets us-gaap_GrossProfit Gross profit Cost of products sold Counterparty Name [Axis] Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Counterparty Name [Domain] Consolidation Items [Domain] Consolidation Items [Axis] us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent Accounts Payable and Accrued Liabilities Marketable Securities, Policy [Policy Text Block] Issuance cost mlss_ProceedsFromSaleOfNetOperatingLossAmount Proceeds From Sale of Net Operating Loss Amount The cash inflow from the sale of NOL during the period. mlss_CashBonusCompensationPercent Cash Bonus Compensation Percent The percentage of bonus compensation. Nonrelated Party [Member] mlss_StockToBeIssuedDuringPeriodValueEmployeeBonuses Common stock to be issued to employees for bonuses Value of stock to be issued for employee bonuses during the period. mlss_ShareBonusCompensationPercentage Share Bonus Compensation Percentage The percent of bonus related to shares. Common stock issued for payment of consulting services Value of stock to be issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders. Common stock issued for payment of consulting services (in shares) Number of shares to be issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders. Common stock to be issued to employees for bonuses (in shares) Common stock to be issued to employees for bonuses (in shares) Number of shares of stock to be issued for employee bonuses during the period. Noncontrolling Interest [Member] Scenario [Domain] Net Proceeds exercise of warrants Proceeds from Warrant Exercises Forecast [Member] Purchase Commitment for Devices [Member] Represents the information pertaining to the purchase commitment for devices. Retained Earnings [Member] Net proceeds from Public Placement Offering Proceeds from Issuance of Common Stock Title and Position [Domain] Title and Position [Axis] Scenario [Axis] Treasury Stock, Common [Member] Additional Paid-in Capital [Member] Common Stock [Member] Equity Components [Axis] Equity Component [Domain] us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Outstanding (in dollars per share) Outstanding (in dollars per share) us-gaap_ClassOfWarrantOrRightOutstanding Outstanding (in shares) Outstanding (in shares) Accrued liabilities noncontrolling interest Accrued liabilities and noncontrolling interest. Income (loss) before taxes and equity in earnings of affiliates Total income (loss) before taxes and equity in earnings of affiliates Loss before provision for income taxes Deferred Compensation Arrangement with Individual, Share-based Payments [Table Text Block] Tabular disclosure of shares authorized for issuance under the deferred compensation arrangement as of the balance sheet date. Accounts receivable, related party net Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current and from a related party. Accounts Receivable [Policy Text Block] Cash and Cash Equivalents, Policy [Policy Text Block] Statement of Financial Position Location, Balance [Axis] Statement of Financial Position Location, Balance [Domain] Document Quarterly Report Entity Incorporation, State or Country Code Accounting Policies [Abstract] Significant Accounting Policies [Text Block] Document Transition Report Basis of Accounting, Policy [Policy Text Block] Granted in current period (in shares) Number of shares granted pursuant to the terms of a deferred compensation arrangement. No Trading Symbol Flag Concentration Risk Disclosure [Text Block] Entity Interactive Data Current Related Party [Member] Security Exchange Name Managing Director, China Operations [Member] Represents managing director for China Operations Title of 12(b) Security Rest of World [Member] Information pertaining to the rest of the world, excluding domestic sales and sales to China. Interim Chief Executive Officer [Member] Represents the Interim Chief Executive Officer of the company. Accrued expenses, related party Amount for accrued expenses to related parties. Increase in accrued expenses, related party The increase (decrease) during the reporting period of accrued liabilities to related parties. mlss_IncreaseDecreaseInOperatingLeaseRightOfUseAsset Decrease operating right of use lease asset Amount of increase (decrease) in operating lease right-of-use asset. Segments [Axis] Segments [Domain] us-gaap_SharePrice Share Price (in dollars per share) us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) Statement [Table] Statement of Financial Position [Abstract] Basic and diluted (in shares) Weighted Average Number of Shares Outstanding, Basic (in shares) Accounts Payable [Member] Basic and Diluted (in dollars per share) Statement of Cash Flows [Abstract] Statement of Stockholders' Equity [Abstract] Income Statement [Abstract] Vendor Three [Member] Relating to the number of vendors. mlss_NumberOfDistributors Number of Distributors Represents the number of distributors. E-Commerce [Member] Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from e-commerce. mlss_EmploymentAgreementBaseCompensation Employment Agreement, Base Compensation The amount of annual base compensation pursuant to the employment agreement. Outstanding Intrinsic value of outstanding warrants. Weighted-average discount rate â€“ finance leases Fair Value, Assets Measured on Recurring Basis [Table Text Block] Finance leases (years) (Year) Cash flows from financing activities: Previous President and Chief Executive Officer [Member] Represents the information pertaining to the previous president and chief executive officer of the company. Consultant [Member] Represents information pertaining to consultant. Segment Reporting, Reconciling Item, Corporate Nonsegment [Member] Amortization of right-of-use asset us-gaap_StockholdersEquity Total Milestone Scientific, Inc. stockholders' equity The 2020 Equity Incentive Plan [Member] Information related to the 2020 Equity Incentive Plan. us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries Payments to Acquire Additional Interest in Subsidiaries Class of Stock [Axis] Operating Segments [Member] President and Chief Executive Officer [Member] Represents the president and chief executive officer. mlss_RoyaltyOnNetSalesPercentage Royalty on Net Sales, Percentage Represents the royalty percentage on net sales. EX-101.PRE 8 mlss-20240930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 10 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Document And Entity Information - shares 9 Months Ended Sep. 30, 2024 Nov. 14, 2024 Document Information [Line Items] Â Â Entity Central Index Key 0000855683 Â Entity Registrant Name MILESTONE SCIENTIFIC INC. Â Amendment Flag false Â Current Fiscal Year End Date --12-31 Â Document Fiscal Period Focus Q3 Â Document Fiscal Year Focus 2024 Â Document Type 10-Q Â Document Quarterly Report true Â Document Period End Date Sep. 30, 2024 Â Document Transition Report false Â Entity File Number 001-14053 Â Entity Incorporation, State or Country Code DE Â Entity Tax Identification Number 13-3545623 Â Entity Address, Address Line One 425 Eagle Rock Avenue Suite 403 Â Entity Address, City or Town Roseland Â Entity Address, State or Province NJ Â Entity Address, Postal Zip Code 07068 Â City Area Code 973 Â Local Phone Number 535-2717 Â Title of 12(b) Security Common Stock, par value $.001 per share Â Security Exchange Name NYSE Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Filer Category Non-accelerated Filer Â Entity Small Business true Â Entity Emerging Growth Company false Â Entity Shell Company false Â Entity Common Stock, Shares Outstanding Â 77,892,083 No Trading Symbol Flag true Â X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_DocumentInformationLineItems Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -

Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a security having no trading symbol. + ReferencesNo definition available. + Details Name: dei_NoTradingSymbolFlag Namespace Prefix: dei_ Data Type: dei:trueItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration XML 11 R2.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets (Unaudited) - USD ($) Sep. 30, 2024 Dec. 31, 2023 Current assets: Â Â Cash and cash equivalents $ 4,775,597 $ 2,977,713 Marketable securities 0 2,976,573 Accounts receivable, net of allowance for credit losses of $10,000, respectively 550,969 312,664 Accounts receivable, related party net 3,013 0 Prepaid expenses and other current assets 646,130 517,785 Inventories 3,711,636 2,638,186 Advances on contracts 1,011,306 1,371,548 Total current assets 10,698,651 10,794,469 Furniture, fixtures and equipment, net 11,265 10,024 Intangibles, net 155,255 178,636 Right of use assets finance lease 2,511 8,998 Right of use assets operating lease 283,086 355,235 Other assets 24,150 24,150 Total assets 11,174,918 11,371,512 Current liabilities: Â Â Accrued expenses and other payables 1,267,718 1,511,717 Accrued expenses, related party 281,947 137,189 Accrued liabilities noncontrolling interest 214,000 214,000 Current portion of finance lease liabilities 3,088 10,264 Current portion of operating lease liabilities 112,955 103,427 Total current liabilities 3,757,785 3,076,713 Non-current portion of finance lease liabilities 0 434 Non-current portion of operating lease liabilities 195,649 281,853 Total liabilities 3,953,434 3,359,000 Commitments and contingencies Stockholdersâ€™ equity Â Â Common stock, par value $0.001; authorized 100,000,000 shares; 77,709,455 shares issued and 77,676,122 shares outstanding as of September 30, 2024; 75,881,840 shares issued and 75,848,507 shares outstanding as of December 31, 2023; 77,710 75,881 Additional paid in capital 134,072,861 132,187,656 Accumulated deficit (126,017,571) (123,339,509) Treasury stock, at cost, 33,333 shares (911,516) (911,516) Total Milestone Scientific, Inc. stockholders' equity 7,221,484 8,012,512 Total liabilities and stockholdersâ€™ equity 11,174,918 11,371,512 Nonrelated Party [Member] Â Â Current liabilities: Â Â Accounts payable 1,138,060 689,604 Related Party [Member] Â Â Current liabilities: Â Â Accounts payable $ 740,017 $ 410,512 X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current and from a related party. + ReferencesNo definition available. + Details Name: mlss_AccountsReceivableRelatedPartyNetCurrent Namespace Prefix: mlss_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount for accrued expenses to related parties. + ReferencesNo definition available. + Details Name: mlss_AccruedExpensesRelatedParty Namespace Prefix: mlss_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAccrued liabilities and noncontrolling interest. + ReferencesNo definition available. + Details Name: mlss_AccruedLiabilitiesToNoncontrollingInterests Namespace Prefix: mlss_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionValue received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapitalCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value of capitalized payments made in advance for inventory that is expected to be received within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdvancesOnInventoryPurchases Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from finance lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_FinanceLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_FinanceLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after accumulated amortization, of right-of-use asset from finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_FinanceLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27:

http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of investment in marketable security, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_MarketableSecuritiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -

Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1 + Details Name: us-gaap_TreasuryStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 12 R3.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - USD ($) Sep. 30, 2024 Dec. 31, 2023 Allowance for credit loss $ 10,000 $ 10,000 Common stock, par value (in dollars per share) $ 0.001 $ 0.001 Common stock, shares authorized (in shares) 100,000,000 100,000,000 Common stock, shares issued (in shares) 77,709,455 75,881,840 Common stock, shares outstanding (in shares) 77,676,122 75,848,507 Treasury stock, shares (in shares) 33,333 33,333 X - DefinitionAmount of allowance for credit loss on accounts receivable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13 + Details Name: us-gaap_AllowanceForDoubtfulAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of previously issued common shares repurchased by the issuing entity and held in treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1 + Details Name: us-gaap_TreasuryStockCommonShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant XML 13 R4.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Operations (Unaudited) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Product sales, net $ 2,513,805 $ 2,059,284 $ 6,616,414 $ 7,566,848 Cost of products sold 677,585 555,850 1,692,888 2,284,730 Gross profit 1,836,220 1,503,434 4,923,526 5,282,118 Selling, general and administrative expenses 3,064,769 2,823,765 8,968,226 9,834,781 Research and development expenses 232,056 170,478 641,235 524,472 Depreciation and amortization expense 8,574 15,896 28,735 49,798 Total operating expenses 3,305,399 3,010,139 9,638,196 10,409,051 Loss from operations (1,469,179) (1,506,705) (4,714,670) (5,126,933) Interest income 8,008 30,600 53,513 102,669 Gain on sale of net operating losses 0 0 1,983,095 0 Loss before provision for income taxes (1,461,171) (1,476,105) (2,678,062) (5,024,264) Net loss (1,461,171) (1,476,105) (2,678,062) (5,024,264) Net loss attributable to noncontrolling interests 0 (9,811) 0 (33,987) Net loss attributable to Milestone Scientific Inc. $ (1,461,171) $ (1,466,294) $ (2,678,062) $ (4,990,277) Net loss per share applicable to common stockholdersâ€” Â Â Â Â Basic and Diluted (in dollars per share) $ (0.02) $ (0.02) $ (0.03) $ (0.07) Weighted average shares outstanding and to be issuedâ€” Â Â Â Â Basic and diluted (in shares) 79,966,833 73,730,921 80,165,181 72,374,693 X - ReferencesNo definition available. + Details Name: mlss_WeightedAverageSharesOutstandingBasicAndDilutedAbstract Namespace Prefix: mlss_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 + Details Name: us-gaap_CostOfGoodsAndServicesSold Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_DepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in income from government assistance, classified as nonoperating. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 832 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483507/832-10-50-3 + Details Name: us-gaap_GovernmentAssistanceNonoperatingIncome Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_GrossProfit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of interest income (expense) classified as operating. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_InterestIncomeExpenseNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -

Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of Net Income (Loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B + Details Name: us-gaap_NetIncomeLossAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference

12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_SellingGeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 14 R5.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($) Board of Directors [Member] Common Stock [Member] Board of Directors [Member] Additional Paid-in Capital [Member] Board of Directors [Member] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Noncontrolling Interest [Member] Treasury Stock, Common [Member] Total Balance (in shares) at Dec. 31, 2022 Â Â Â 69,306,497 Â Â Â Â Â Balance at Dec. 31, 2022 Â Â Â $ 69,306 $ 127,478,325 $ (116,410,405) $ (219,276) $ (911,516) $ 10,006,434 Stock based compensation Â Â Â Â 388,772 0 0 Â 388,772 Common stock issued for payment of consulting services (in shares) Â Â Â 242,335 Â Â Â Â Â Common stock issued for payment of consulting services Â Â Â $ 242 125,758 0 0 0 126,000 Common stock issued for services (in shares) 256,868 Â Â Â Â Â Â Â Common stock issued for services $ 258 $ (258) $ 0 Â Â Â Â Â Â Â Net (loss) Â Â Â Â Â (1,307,666) (11,665) Â (1,319,331) Balance (in shares) at Mar. 31, 2023 Â Â Â 69,805,700 Â Â Â Â Â Balance at Mar. 31, 2023 Â Â Â $ 69,806 128,042,597 (117,718,071) (230,941) (911,516) 9,251,875 Common stock to be issued to employees for bonuses Â Â Â Â 50,000 Â Â Â 50,000 Net loss Â Â Â Â Â (1,307,666) (11,665) Â (1,319,331) Balance (in shares) at Dec. 31, 2022 Â Â Â 69,306,497 Â Â Â Â Â Balance at Dec. 31, 2022 Â Â Â $ 69,306 127,478,325 (116,410,405) (219,276) (911,516) 10,006,434 Net (loss) Â Â Â Â Â Â Â (5,024,264) Balance (in shares) at Sep. 30, 2023 Â Â Â 70,893,748 Â Â Â Â Â Balance at Sep. 30, 2023 Â Â Â $ 70,894 129,487,592 (121,400,682) (253,263) (911,516) 6,993,025 Net loss Â Â Â Â Â Â Â (5,024,264) Balance (in shares) at Mar. 31, 2023 Â Â Â 69,805,700 Â Â Â Â Â Balance at Mar. 31, 2023 Â Â Â $ 69,806 128,042,597 (117,718,071) (230,941) (911,516) 9,251,875 Stock based compensation Â Â Â Â 404,330 Â Â Â 404,330 Common stock issued for payment of consulting services (in shares) Â Â Â 109,204 Â Â Â Â Â Common stock issued for payment of consulting services Â Â Â $ 109 56,677 0 0 0 56,786 Common stock issued for services (in shares) Â Â Â 192,835 Â Â Â Â Â Common stock issued for services Â Â Â $ 193 (193) 0 0 0 0 Net (loss) Â Â Â Â Â (2,216,317) (12,511) 0 (2,228,828) Balance (in shares) at Jun. 30, 2023 Â Â Â 70,107,739 Â Â Â Â Â Balance at Jun. 30, 2023 Â Â Â $ 70,108 128,720,911 (119,934,388) (243,452) (911,516) 7,701,663 Common stock to be issued to employees for bonuses Â Â Â Â 217,500 0 0 0 217,500 Net loss Â Â Â Â Â (2,216,317) (12,511) 0 (2,228,828) Stock based compensation Â Â Â Â 320,325 0 0 0 320,325 Common stock issued for payment of consulting services (in shares) Â Â Â 631,523 Â Â Â Â Â Common stock issued for payment of consulting services Â Â Â $ 632 396,510 0 0 0 397,142 Common stock issued for services (in shares) Â Â Â 154,486 Â Â Â Â Â Common stock issued for services Â Â Â $ 154 (154) 0 0 0 0 Net (loss) Â Â Â Â Â (1,466,294) (9,811) Â (1,476,105) Balance (in shares) at Sep. 30, 2023 Â Â Â 70,893,748 Â Â Â Â Â Balance at Sep. 30, 2023 Â Â Â $ 70,894 129,487,592 (121,400,682) (253,263) (911,516) 6,993,025 Net loss Â Â Â Â Â (1,466,294) (9,811) Â (1,476,105) Common stock issued to employee for compensation Â Â Â Â 50,000 0 0 0 50,000 Balance (in shares) at Dec. 31, 2023 Â Â Â 75,881,840 Â Â Â Â Â Balance at Dec. 31, 2023 Â Â Â $ 75,881 132,187,656 (123,339,509) 0 (911,516) 8,012,512 Stock based compensation Â Â Â $ 0 313,505 0 0 0 313,505 Common stock issued in public offering net of issuance cost (in shares) Â Â Â 372,110 Â Â Â Â Â Common stock issued in public offering net of issuance cost Â Â Â $ 372 191,784 0 0 0 192,156 Common Stock issued exercised warrants (in shares) Â Â Â 103,500 Â Â Â Â Â Common Stock issued exercised warrants Â Â Â $ 104 51,647 0 0 0 51,751 Common stock issued for payment of consulting services (in shares) Â Â Â 90,170 Â Â Â Â Â Common stock issued for payment of consulting services Â Â Â $ 90 65,971 0 0 0 66,061 Common stock to be issued to employees for bonuses (in shares) Â Â Â 30,165 Â Â Â Â Â Common stock to be issued to employees for bonuses Â Â Â $ 31 264,922 0 0 0 264,953 Common stock issued for services (in shares) 154,494 Â Â Â Â Â Â Â Common stock issued for services $ 154 $ (154) $ 0 Â Â Â Â Â Â Â Net (loss) Â Â Â $ 0 0 (1,440,529) 0 0 (1,440,529) Common stock to be issued to employees for bonuses (in shares) Â Â Â 30,165 Â Â Â Â Â Common stock to be issued to employees for bonuses Â Â Â $ 31 264,922 0 0 0 264,953 Balance (in shares) at Mar. 31, 2024 Â Â Â 76,632,279 Â Â Â Â Â Balance at Mar. 31, 2024 Â Â Â $ 76,632 133,075,331 (124,780,038) 0 (911,516) 7,460,409 Net loss Â Â Â $ 0 0 (1,440,529) 0 0 (1,440,529) Balance (in shares) at Dec. 31, 2023 Â Â Â 75,881,840 Â Â Â Â Â Balance at Dec. 31, 2023 Â Â Â $ 75,881 132,187,656 (123,339,509) 0 (911,516) $ 8,012,512 Common Stock issued exercised warrants (in shares) Â Â Â Â Â Â Â 103,500 Net (loss) Â Â Â Â Â Â Â $ (2,678,062) Balance (in shares) at Sep. 30, 2024 Â Â Â 77,709,455 Â Â Â Â Â Balance at Sep. 30, 2024 Â Â Â $ 77,710 134,072,861 (126,017,571) 0 (911,516) 7,221,484 Net loss Â Â Â Â Â Â Â (2,678,062) Balance (in shares) at Mar. 31, 2024 Â Â Â 76,632,279 Â Â Â Â Â Balance at Mar. 31, 2024 Â Â Â $ 76,632 133,075,331 (124,780,038) 0 (911,516) 7,460,409 Stock based compensation Â Â Â $ 0 207,690 0 0 0 207,690 Common stock issued for payment of consulting services (in shares) Â Â Â 99,063 Â Â Â Â Â Common stock issued for payment of consulting services Â Â Â $ 99 62,041 0 0 0 62,140 Common stock to be issued to employees for bonuses (in shares) Â Â Â 322,937 Â Â Â Â Â Common stock to be issued to employees for bonuses Â Â Â Â (324) 0 0 0 0 Common stock issued for services (in shares) Â Â Â 154,496 Â Â Â Â Â Common stock issued for services Â Â Â $ 154 (154) 0 0 0 0 Net (loss) Â Â Â $ 0 0 223,638 0 0 223,638 Common stock to be issued to employees for bonuses (in shares) Â Â Â 322,937 Â Â Â Â Â Common stock to be issued to employees for bonuses Â Â Â Â (324) 0 0 0 0 Restricted common stock issued to employees (in shares) Â Â Â 18,939 Â Â Â Â Â Restricted common stock issued to employees Â Â Â $ 19 (19) Balance (in shares) at Jun. 30, 2024 Â Â Â 77,227,714 Â Â Â Â Â Balance at Jun. 30, 2024 Â Â Â $ 77,228 133,344,565 (124,556,400) 0 (911,516) 7,953,877 Net loss Â Â Â 0 0 223,638 0 0 223,638 Stock based compensation Â Â Â $ 0 484,078 0 0 0 484,078 Common stock issued for payment of consulting services (in shares) Â Â Â 299,198 Â Â Â Â Â Common stock issued for payment of consulting services Â Â Â $ 299 244,401 0 0 0 244,700 Common stock issued for services (in shares) Â Â Â 182,543 Â Â Â Â Â Common stock issued for services Â Â Â $ 183 (183) 0 0 0 0 Net (loss) Â Â Â $ 0 0 (1,461,171) 0 0 (1,461,171) Balance (in shares) at Sep. 30, 2024 Â Â Â 77,709,455 Â Â Â Â Â Balance at Sep. 30, 2024 Â Â Â $ 77,710 134,072,861 (126,017,571) 0 (911,516) 7,221,484 Net loss Â Â Â $ 0 $ 0 $ (1,461,171) $ 0 $ 0 $ (1,461,171) X - DefinitionNumber of shares issued for warrants exercised. + ReferencesNo definition available. + Details Name: mlss_StockIssuedDuringPeriodSharesWarrantsExercised Namespace Prefix: mlss_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue of stock issued for employee bonuses during the period. + ReferencesNo definition available. + Details Name: mlss_StockIssuedDuringPeriodValueEmployeeBonuses Namespace Prefix: mlss_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRepresents value of stock issued during period for warrants exercised. + ReferencesNo definition available. + Details Name: mlss_StockIssuedDuringPeriodValueWarrantsExercised Namespace Prefix: mlss_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares of stock to be issued for employee bonuses during the period. + ReferencesNo definition available. + Details Name: mlss_StockToBeIssuedDuringPeriodSharesEmployeeBonuses Namespace Prefix: mlss_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares to be issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders. + ReferencesNo definition available. + Details Name: mlss_StockToBeIssuedDuringPeriodSharesIssuedForServices Namespace Prefix: mlss_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue of stock to be issued for employee bonuses during the period. + ReferencesNo definition available. + Details Name: mlss_StockToBeIssuedDuringPeriodValueEmployeeBonuses Namespace Prefix: mlss_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock to be issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders. + ReferencesNo definition available. + Details Name: mlss_StockToBeIssuedDuringPeriodValueIssuedForServices Namespace Prefix: mlss_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -

Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 + Details Name: us-gaap_SharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionTotal number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodValueIssuedForServices Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAggregate value of stock related to Restricted Stock Awards issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-

10-65-4Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 34: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 40: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 41: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 42: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4I -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4IReference 49: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1 + Details Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 15 R6.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) (Parentheticals) 3 Months Ended Mar. 31, 2024 USD ($) Issuance cost $ 42,273 X - DefinitionThe cash outflow for cost incurred directly with the issuance of an equity security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfStockIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 16 R7.htm IDEA: XBRL DOCUMENT v3.24.3 Consolidated Statements of Cash Flows (Unaudited) - USD ($) 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Cash flows from operating activities: Â Â Net loss $ (2,678,062) $ (5,024,264) Depreciation expense 5,355 10,155 Amortization of intangibles 23,380 39,643 Stock based compensation 1,005,273 1,113,427 Inventory reserve 0 109,159 Employees paid in stock 264,953 317,500 Expense paid in stock 372,901 579,928 Unrealized gain on marketable securities 0 6,208 Bad debt expense 0 16,076 Amortization of right-of-use asset 72,149 69,067 Changes in operating assets and liabilities: Â Â (Increase) decrease in accounts receivable (238,305) 86,629 Increase in accounts receivable, related parties (3,013) 0 Increase in inventories (1,073,450) (799,454) Decrease (increase) in advances on contracts 360,242 (373,852) Increase in prepaid expenses and other current assets (128,345) (134,881) Increase in accounts payable 448,461 46,538 Increase(decrease) in accounts payable, related party 329,504 (166,855) Decrease in accrued expenses (243,999) (13,098) Increase in accrued expenses, related party 144,758 103,287 Decrease operating right of use lease asset (70,189) (65,543) Net cash used in operating activities (1,408,387) (4,080,330) Cash flows from investing activities: Â Â Purchase of furniture, fixtures, and equipment (6,596) (1,192) Sale of marketable securities 2,976,573 4,472,540 Purchase of marketable securities 0 (6,929,218) Net cash provided by (used in) investing activities 2,969,977 (2,457,870) Cash flows from financing activities: Â Â Net Proceeds exercise of warrants 51,751 0 Payments finance lease obligations (7,613) (6,486) Net cash provided by (used in) financing activities 236,294 (6,486) Net increase (decrease) in cash and cash equivalents 1,797,884 (6,544,686) Cash and cash equivalents at beginning of period 2,977,713 8,715,279 Cash and cash equivalents at end of period 4,775,597 2,170,593 Public Offering [Member] Â Â Cash flows from financing activities: Â Â Net proceeds from Public Placement Offering $ 192,156 $ 0 X - DefinitionThe amount of expenses paid for with stock in lieu of cash during the period. + ReferencesNo definition available. + Details Name: mlss_ExpensesPaidStock Namespace Prefix: mlss_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period of accrued liabilities to related parties. + ReferencesNo definition available. + Details Name: mlss_IncreaseDecreaseInAccruedLiabilitiesRelatedParties Namespace Prefix: mlss_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in operating lease right-of-use asset. + ReferencesNo definition available. + Details Name: mlss_IncreaseDecreaseInOperatingLeaseRightOfUseAsset Namespace Prefix: mlss_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIncrease decrease to advances to contract manufacturer. + ReferencesNo definition available. + Details Name: mlss_IncreaseDecreaseToAdvancesToContractManufacturer Namespace Prefix: mlss_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow (inflow) associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesNo definition available. + Details Name: mlss_PaymentsToAcquireProceedsFromSalePropertyPlantAndEquipment Namespace Prefix: mlss_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of noncash share-based compensation bonuses paid in stock. + ReferencesNo definition available. + Details Name: mlss_SharebasedCompensationBonusPaidInStock Namespace Prefix: mlss_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2 + Details Name: us-gaap_AmortizationOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow for principal payment on finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5 + Details Name: us-gaap_FinanceLeasePrincipalPayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionChange in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayableTrade Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -

Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInInventories Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe difference between the change in the inventory reserve representing the cumulative difference in cost between the first in, first out and the last in, first out inventory valuation methods and any LIFO decrement which have been reflected in the statement of income during the period. + ReferencesNo definition available. + Details Name: us-gaap_InventoryLIFOReserveEffectOnIncomeNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of unrealized gain (loss) on investment in marketable security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_MarketableSecuritiesUnrealizedGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow for purchase of marketable security. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11 + Details Name: us-gaap_PaymentsToAcquireMarketableSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period. + ReferencesNo definition available. + Details Name: us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from holders exercising their stock warrants. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromWarrantExercises Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense (reversal of expense) for expected credit loss on accounts receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -

Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_ProvisionForDoubtfulAccounts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=mlss_PublicOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 17 R8.htm IDEA: XBRL DOCUMENT v3.24.3 Note 1 - Organization and Business 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] NOTE 1 â€” ORGANIZATION AND BUSINESS All references in this report to â€œMilestone Scientific,â€ the â€œCompanyâ€ or â€œMilestoneâ€ refer to Milestone Scientific Inc., and its consolidated subsidiaries, Wand Dental, Inc., and Milestone InnovationÂ Inc., unless the context otherwise indicates. Milestone Scientific is the owner of the following registered U.S. trademarks: CompuDentÂ®;Â CompuFloÂ®; DPS Dynamic Pressure Sensing technologyÂ®; Milestone Scientific Â®;Â CathCheckÂ®; the Milestone logo Â®; SafetyWandÂ®; STA Single Tooth Anesthesia SystemÂ®; and The Wand Â®.Â Â Milestone Scientific was incorporated in the State of Delaware in August 1989. Milestone Scientific has developed a proprietary, revolutionary, computer-controlled anesthetic delivery device, itsÂ DPS Dynamic Pressure Sensing TechnologyÂ® System, to meet the needs of various subcutaneous drug delivery injections and fluid aspiration â€” enabling healthcare practitioners to achieve multiple unique benefits that cannot currently be accomplished with the 160-year-old manual syringe. The Companyâ€™s proprietary DPS Dynamic Pressure Sensing Technology is the Companyâ€™s technology platform that advances the development of next-generation devices. It regulates flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, used in various dental and medical injections. It has specific medical applications for epidural space identification in regional anesthesia procedures and intra-articular joint injections. Â The Companyâ€™s device, using The WandÂ®, a single use disposable handpiece, is marketed in dentistry under the trademarks CompuDentÂ® and STA Single Tooth Anesthesia SystemÂ®, and is suitable for all dental procedures that require local anesthetic. The dental devices are currently sold in the United States, Canada and in over 41 other countries.Â Milestone Scientific also has 510(k) marketing clearance from the U.S. Food and Drug Administration (FDA) on the CompuFloÂ® Epidural Computer Controlled Anesthesia System in the lumbar thoracic and cervical thoracic junction of the spinal region. Â The Company current marketing focus is self-distribution using its e-commerce platform; however, it is also in the process ofÂ meetingÂ with medical facilities and device distributors within the United States, Middle East and Europe so as to develop other channels of distribution.Â Certain of our medical instruments have obtained European CE mark approval and can be marketed and sold in most European countries. X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 18 R9.htm IDEA: XBRL DOCUMENT v3.24.3 Note 2 - Liquidity and Uncertainties 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Substantial Doubt about Going Concern [Text Block] NOTE 2- LIQUIDITY AND UNCERTAINTIES Â Â Â The Company has evaluated whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern withinÂ oneÂ year after the date that the consolidated financial statements are issued. The Company has incurred total losses since inception of $126.0Â million. The operating losses were $1.5Â million and $4.7Â million, for three and nine months ended September 30, 2024.Â On September 30, 2024,Â Milestone Scientific had cash and cash equivalentsÂ of approximatelyÂ $4.8Â million and working capital of approximatelyÂ $6.9Â million. For the nine months ended September 30, 2024, and 2023, we had cash flows used in operating activities of approximately $1.4 millionÂ and $4.1 million respectively. Â Management has prepared financialÂ forecasts covering a period ofÂ 12Â months from the date of issuance of these financial statements. These forecasts include several revenue and operating expense assumptions which indicate that the Companyâ€™s current cash and liquidity is sufficient to finance the operating requirements for at least the nextÂ 12Â months from the filing date. Â Milestone Scientific is actively pursuing the generation of positive cash flows from operating activities through an increase in revenue from its dental business worldwide, the generation of revenue from its medical devices and disposables business in the United States and worldwide, and a reduction in operating expenses. However, the Companyâ€™s continued operations will depend on its ability to raise additional capital through various potential sources until it achieves profitability, if ever.Â Â In addition to its employees, the Company relies on (i) distributors, agents, andÂ third-party logistics providers in connection with product sales and distribution and (ii) raw material and component suppliers in the U.S., Europe, and China. If the Company, or any of these entities encounter any disruptions to its or their respective operations or facilities, or if the Company or any of theseÂ third-party partners were to shut down for any reason, including by fire, natural disaster, such as a hurricane, tornado or severe storm, power outage, systems failure, labor dispute, pandemic or other public health crises, or other unforeseen disruption, then the Company or theyÂ mayÂ be prevented or delayed from effectively operating its or their business, respectively.Â Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 40 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205-40/tableOfContent + Details Name: us-gaap_SubstantialDoubtAboutGoingConcernTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 19 R10.htm IDEA: XBRL DOCUMENT v3.24.3 Note 3 - Summary of Significant Accounting Policies 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Significant Accounting Policies [Text Block] NOTE 3Â â€” SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Â 1.Â Principles of Consolidation Â The accompanyingÂ consolidated unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United StatesÂ ("GAAP"), and the applicable rules and regulations of the Securities and Exchange Commission (SEC)Â include the accounts of Milestone Scientific and its wholly owned and majority owned subsidiaries, including, Wand Dental (wholly owned), and Milestone Innovations Inc. (wholly owned).Â All significant, intra-entity transactions and balances have been eliminated in the consolidation. Ownership interests in consolidated entities that are held by entities other than us are reported as noncontrolling interests in our consolidated balance sheets. Losses attributed to noncontrolling interests are reported separately in our consolidated statements of operations. Â During December 2023, the Board of Directors of the Company approved the merger of Milestone Medical, Inc., a 98%-owned subsidiary of the Company (â€œMMDâ€), with and into Milestone Innovation, Inc, a newly form wholly-owned subsidiary of the Company and being the surviving corporation . As a result, all of the assets of MMD automatically became assets of Milestone Innovations, Inc.Â Subsequent to SeptemberÂ 30, 2024, the Company satisfied it'sÂ liabilities to the non-controlling shareholders, the Company settled forÂ approximately $205,000 for the minority stake of MMD. Â 2. Basis of Presentation Â The unaudited condensed consolidated financial statements of Milestone Scientific have been prepared in accordanceÂ with accounting principles generally accepted in the United States of America (GAAP) for interim financial information withÂ the instructions for Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by GAAP for complete annual financial statements. In the opinion of management, the accompanying unaudited consolidated financial statements contain all adjustments (consisting of normal recurring entries) necessary to fairly present such interim results. Interim results are not necessarily indicative of the results of operations which may be expected for a full year or any subsequent period. These unaudited consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2023, included in Milestone Scientific's Annual Report on Form 10-K. Â 3. Use of Estimates Â The preparation of unaudited consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions in determining the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to inventory valuation and cash flow assumptions regarding evaluations of going concern considerations. The Company bases its estimates on historical experience, known trends and other market-specific or relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates. Â 4.Â Revenue Recognition Â The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To perform revenue recognition, the Company performs the following five steps: Â i. identification of the promised goods or services in the contract; ii. determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract;Â Â Â Â Â Â Â iii. measurement of the transaction price, including the constraint on variable consideration; iv. allocation of the transaction price to the performance obligations based on estimated selling prices; and v. recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC 606. Â The Company derives its revenues from the sale of its products, primarily dental instruments, handpieces, and other related products. The Company sells its products directly to consumers in the United States and through a global distribution network that includes both exclusive and non-exclusive distribution agreements with related and third parties. Â Revenue from product sales is recognized upon transfer of control of a product to a customer, generally upon date of shipment. The Company has no obligation on product sales for any installation, set-up, or maintenance, these being the responsibility of the buyer. Milestone Scientific's only obligation after sale is the normal commercial warranty against manufacturing defects if the alleged defective unit is returned within the warranty period.Â Â Â Â E-Commerce Â As of January 3, 2023,Â the Company launched an E-Commerce platform,Â selling and shippingÂ STA Single Tooth Anesthesia SystemsÂ®Â (STA) and handpieces directly to dental offices and dentalÂ groups within the United States. Our E-commerceÂ portal accepts online payments via creditÂ and debit cards. The cost of delivery is charged to the customer along with appropriate sales tax. The Company recognizes revenue from product salesÂ at the time the product ships to a customer via a third-party carrier.Â Â Sales Returns Â The Company records allowances for product returns as a reduction of revenue at the time product sales are recorded. Several factors are considered in determining whether an allowance for product returns is required, including the customersâ€™ return rights and the Companyâ€™s historical experience with returns and the amount of product in the distribution channel not consumed by end users and subject to return. The Company relies on historical return rates to estimate returns. Â Financing and Payment Â The Company's payment terms differ by geography and customer, but payments from distributors are required within 90 days or less from the date of shipment. The E-commerceÂ portal sells directly to end users and accepts onlineÂ payments via credit and debitÂ cards via a third-party. These payments from theÂ third party are typically settled within two business days. Â Disaggregation of Revenue Â The CompanyÂ operates in two operating segments: dental and medical. Therefore, the results of the Company's operations are reported on a consolidated basis for the purposes of segment reporting, consistent with internal management reporting. See Note 8Â for revenues by geographical market, based on the customerâ€™s location, and product category for the three andÂ nine months periodsÂ ended September 30, 2024, and 2023, respectively. Â 5.Â Cash and Cash Equivalents Â Milestone Scientific considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. As of September 30, 2024, and December 31, 2023, Milestone Scientific has approximately $4.8Â million and $3.0 million, respectively of cash and cash equivalents.Â As of September 30, 2024,Â Milestone Scientific had approximately $4.1 million in cash, cash equivalents, in accounts that exceeded the Federal Deposit Insurance Corporation insurance limit of $250,000. Â 6. Marketable Securities Â The Companyâ€™s marketable securities are comprised of treasury bills with original maturity greater than three months from date of purchase. The Companyâ€™s marketable securities are measured at fair value and are accounted for in accordance with ASC 825, Financial Instruments. Unrealized holding gains and losses on treasury bills are recorded in interest income on the unaudited consolidated statements of operations. Dividend and interest income are recognized when earned. Realized gains and losses are included in earnings and are derived using the specific identification method for determining the cost of the marketable securities. As ofÂ September 30, 2024, the Company did not hold any marketable securities. As ofÂ December 31, 2023Â the Company held approximately $3.0 million in U.S. treasury securities, with maturityÂ dates within 3 and 6 months. Â 7.Â Accounts Receivable Â The E-commerceÂ portal sells directly to end users and accepts onlineÂ payments via creditÂ and debit cardsÂ via a third-party credit card processor. These payments are settled within two business days of the transactions. Sales to distributors are on credit terms.Â The Company estimates losses from the ability or inability of its distributor to make payments on amounts billed. Â Distributors credit sales are due 90 days or less from the date of invoicing.Â As of September 30, 2024 andÂ December 31, 2023, accounts receivable was recorded, net of allowance for credit losses of $10,000, respectively. Â 8.Â Inventories Â Inventories principally consist of finished goods and component parts stated at the lower of cost (first-in, first-out method) or net realizable value. Inventory quantitiesÂ on hand are reviewed on a quarterly basis and a provision for excess, slow moving, defective, and obsolete inventory is recorded if required based on past and expectedÂ future sales, potential technological obsolescence, and product expiration requirements. Â The valuation allowance creates a new cost basis for the inventory, and it is notÂ subsequently marked up through a reduction in the valuation allowance based on any changes in the underlying facts and circumstances. When the valuationÂ allowance is initially recorded, the increase to the allowance is recognized as an increase in cost of sales. The valuation allowance is only reduced if or when theÂ underlying inventory is sold or destroyed, at which time cost of sales recognized would include the previous adjusted cost basis. Â 9.Â Basic and Diluted Net Loss Per Common Share Â Milestone Scientific presents â€œbasicâ€ earnings (loss) per common share applicable to common stockholders and, if applicable, â€œdilutedâ€ earnings (loss) per commonÂ share applicable to common stockholders pursuant to the provisions of ASC 260,

â€œEarnings per Shareâ€. Basic earnings (loss) per common share is calculated byÂ dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding and to be issued common shares as follows: 79,966,833Â and 73,730,921Â for the three months ended September 30, 2024 and 2023, respectively, andÂ 80,165,181 andÂ 72,374,693 for the nine months ended September 30, 2024 and 2023, respectively. The calculation of diluted earnings per common share is like that of basic earnings per common share, except that the denominator is increased to include the number ofÂ additional common shares that would have been outstanding if all potentially dilutive common shares, such as those issuable upon the exercise of stock options andÂ warrants, were issued during the period. Since Milestone Scientific had net losses in the three andÂ Â nine months ended September 30, 2024 and the three and nine months ended September 30, 2023, the assumed effects of the exercise of potentially dilutive outstanding stock options, unissued restricted stock awards (â€œRSAâ€) and warrants, were not included in the calculation as their effect would have been anti-dilutive. Such outstanding options, RSA'sÂ and warrantsÂ totaled 3,684,697Â and 3,930,654Â for the nine months ended September 30, 2024 and 2023, respectively. Â 10. Fair Value of Financial Instruments Â Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company required us to classify fair value measurements inÂ oneÂ of the following categories. Â â— LevelÂ 1Â inputs which are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the CompanyÂ can access at the measurement date. Â â— LevelÂ 2Â inputs which are defined as inputs other than quoted prices included within LevelÂ 1Â that are observable for the assets or liabilities, either directly or indirectly. Â â— LevelÂ 3Â inputs are defined as unobservable inputs for the assets or liabilities. Â Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of an input to the fair value measurement requires judgment andÂ mayÂ affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels. Â As ofÂ September 30, 2024 the Company did not have assets measured at fair value on a recurring basis. As of December 31, 2023Â the Company had the followingÂ assetsÂ that were measured at fair value on a recurring basis:Â Â Â Â Level 1 Â Â Level 2 Â Â Level 3 Â Â Total Â Marketable Securities December 31, 2023 Â $2,976,573Â Â Â -Â Â Â -Â Â $2,976,573Â Â Marketable Securities included US Treasury securities totaling $2,976,573Â that are considered to be highly liquid and easily transferable atÂ December 31, 2023.Â US Treasury securities are valued using inputs observable in active markets for identical securities and are therefore classified at LevelÂ 1Â within the Company fair value hierarchy. Â 11.Â Stock-Based CompensationÂ Â Milestone Scientific accounts for stock-based compensation under ASC Topic 718, Share-Based Payment (â€œASC Topic 718â€). ASC Topic 718 requires all share-based payments to employees, non-employees, directors, and officers, including grants of employee stock options, to be recognized in the unaudited consolidated statements of operations over the service period, as an operating expense, based on the grant-date fair values. Â 12.Â Â Recent Accounting Pronouncements Â Recently Issued Accounting Pronouncement Â In November 2023, FASB issued ASU 2023-07, Segment Reporting (Topic 280), Improvements to Reportable Segment Disclosures, which provides improvements to reportable segment disclosure requirements, primarily through enhanced disclosures around segment expenses. ASU 2023-07 requires us to disclose significant segment expenses that are regularly provided to the chief operating decision maker (â€œCODMâ€) and included within each reported measure of segment profit or loss. ASU 2023-07 also requires that the Company disclose an amount for other segment items by reportable segment, a description of their composition and provide all annual disclosures about a reportable segmentâ€™s profit or loss and assets pursuant to Topic 280 during interim periods. The Company must also disclose the CODMâ€™s title and position, as well asÂ certain information around the measures used by the CODM and an explanation of how the CODM uses the reported measures in assessing segment performance and deciding how to allocate resources. For public entities with a single reportable segment, the entity must provide all the disclosures required pursuant to ASU 2023-07 and all existing segment disclosures under Topic 280. The amendments of ASU 2023-07 are effective for the Company for annual periods beginning January 1, 2024, and effective for interim periods beginning January 1, 2025. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. The Company expects to adopt this standard effective January 1, 2024, at December 31, 2024 on the Companyâ€™s annual Form 10-K filing. The Company expects to update all required disclosures pursuant to this ASU 2023-07 at that time. The Company is evaluating the impact of ASU 2023-07Â on our financial statements. Â In December 2023, FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, to enhance the transparency and decision usefulness of income tax disclosures. The amendments in ASU 2023-09 provide improvements primarily related to the rate reconciliation and income taxes paid information included in income tax disclosures. The Company would be required to disclose additional information regarding reconciling items equal to or greater than five percent of the amount computed by multiplying pretax income (loss) by the applicable statutory tax rate. Similarly, the Company would be required to disclose income taxes paid (net of refunds received) equal to or greater than five percent of total income taxes paid (net of refunds received). Additionally, the Company would be required to disclose income (loss) from continuing operations before income tax expense disaggregated by foreign and domestic jurisdictions, as well as income tax expense disaggregated by federal, state, and foreign jurisdictions. The amendments in ASU 2023-09 are effective January 1, 2025, including interim periods. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. The Company is currently evaluatingÂ the impact of ASU 2023-09 on our financial statements. Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 20 R11.htm IDEA: XBRL DOCUMENT v3.24.3 Note 4 - Inventories 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Inventory Disclosure [Text Block] NOTE 4Â â€” INVENTORIES Â Inventories consist of the following:Â Â Â September 30, 2024 Â Â December 31, 2023 Â Â Â Â Â

https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R14.htm IDEA: XBRL DOCUMENT v3.24.3 Note 7 - Income Taxes 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Income Tax Disclosure [Text Block] NOTE 7Â â€" INCOME TAXES Â The utilization of Milestone Scientific's net operating losses may be subject to a substantial limitation due to the "change of ownership provisions" under Section 382 of the Internal Revenue Code and similar state provisions. Such limitation may result in the expiration of the net operating loss carry forwards before their utilization. Milestone Scientific has established a 100% valuation allowance for all its deferred tax assets due to uncertainty as to their future realization.Â Â In April 2024, we received approximately $2.0 million, net of expenses, from the sale of New Jersey net operating losses (â€œNOLâ€), that were eligible for sale under the State of New Jerseyâ€™s Economic Development Authorityâ€™sÂ New Jersey Technology Business Tax Certificate Transfer Program (â€NJEDA Programâ€). The Company recorded this amount within Gain on sale of net operating losses within theÂ consolidated statement of operations (unaudited). Â Pursuant to the NJEDA program, the Company must retain a physical presence in the state of New Jersey for a period of 5 years after the sale of the of the NOLs. If the Company does not retain a physical presence during the 5 years after the sale of the NOLs, the Company can be liable to pay the state of New Jersey up to $2.2 million of the surrendered NOLs. X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for income tax. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12BReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2 + Details Name: us-gaap_IncomeTaxDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 24 R15.htm IDEA: XBRL DOCUMENT v3.24.3 Note 8 - Segment and Geographic Data 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Segment Reporting Disclosure [Text Block] NOTEÂ 8Â â€" SEGMENT AND GEOGRAPHIC DATA Â The Company conducts its business through two reportable segments: Dental and Medical. These segments offer different products and services to different customer bases.Â The Company providesÂ general corporate services to its segments; however, these services are not considered when making operating decisions and assessing segment performance. These services are reported under â€œCorporate Servicesâ€ below and these include costs associated with executive management, investor relations, patents, trademarks, licensing agreements, new instruments developments,Â financing activities and public company compliance. The following tables present information about our reportable and operating segments: Â Â For the three months ended September 30, Â Â For the nine months ended September 30, Â Sales Â Â Â

SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/280/tableOfContentReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 + Details Name: us-gaap_SegmentReportingDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R16.htm IDEA: XBRL DOCUMENT v3.24.3 Note 9 - Concentrations 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Concentration Risk Disclosure [Text Block] NOTE 9Â â€“ CONCENTRATIONS Â Milestone Scientific has informal arrangements with third-party U.S. manufacturers of the STA devices, and epidural instruments pursuant to which they manufacture these products under specific purchase orders which contains advanceÂ payments for long lead items for production. Advances on contracts have been classified as current atÂ September 30, 2024 and December 31, 2023. The termination of the manufacturing relationship with any of these manufacturers could have a material adverse effect on Milestone Scientificâ€™s ability to produce and sell its products. Although alternate sources of supply exist, and new manufacturing relationships could be established, Milestone Scientific would need to recover its existing tools or have new tools produced. Establishment of new manufacturing relationships could involve significant expense and delay. Any curtailment or interruption of the supply, because of termination of such a relationship, would have a material adverse effect on Milestone Scientificâ€™s financial condition, business, and results of operations. Â On January 3, 2023, the Company launched an E-Commerce platformÂ selling and shippingÂ STA Single Tooth Anesthesia SystemÂ®Â (STA) and handpieces directly to dental offices and dentalÂ groups within the U.S. For the three months ended September 30, 2024, E-Commerce accounted for 45% and one internationalÂ distributor accounted for 11% ofÂ net product sales. For the nine months ended September 30, 2024, E-Commerce accounted for 53% ofÂ net product sales and oneÂ internationalÂ distributor accounted for 10% ofÂ net product sales. For the three months ended September 30, 2023, E-commerce accounted for 60% ofÂ net product sales and one internationalÂ distributor accounted for 13%Â of net product sales.Â For the nine months ended September 30, 2023, E-commerce accounted for 46% ofÂ net product sales.Â Â The Company had threeÂ distributors that accounted for 48%, 15%Â and 11%Â of accounts receivable, respectively, as of September 30, 2024. The Company had three distributors that accounted for 39%, 38%, and 15% of accounts receivable, respectively as of December 31, 2023.Â Â As of September 30, 2024, the Company had twoÂ suppliers that accounted for 38%Â and 12%, respectively, of accounts payableÂ and accounts payable, related party.Â The Company had three vendorsÂ that accounted for 37%, 17% and 12%, respectively of accounts payableÂ and accounts payable, related party as of December 31, 2023. X - DefinitionThe entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/275/tableOfContent + Details Name: us-gaap_ConcentrationRiskDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 26 R17.htm IDEA: XBRL DOCUMENT v3.24.3 Note 10 - Related Party Transactions 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Related Party Transactions Disclosure [Text Block] NOTE 10Â -- RELATED PARTY TRANSACTIONS Â United Systems Â Milestone Scientific has a supply agreement with United Systems (whose controlling shareholder, Tom Cheng, is a significant stockholder of Milestone Scientific), the principal manufacturer of our handpieces, pursuant to which theÂ manufacture is under specific purchase orders, but without minimum purchase commitments. Purchases from this manufacturer were approximately $ 501,000Â and $1.7Â million for the three and nine months ended September 30, 2024, respectively.Â Purchases from this manufacturer were approximately $636,000 andÂ $1.9Â millionÂ for the three and nine months ended September 30, 2023, respectively. Â As of September 30, 2024 and December 31, 2023, Milestone Scientific owed this manufacturer approximately $720,000,Â and $402,000, respectively, which is included in accounts payable, related partyÂ and accrued expense, related party on the unauditedÂ consolidated balance sheets.Â Â Director of Clinical Affairs Â The Director of Clinical Affairsâ€™ royalty fee was approximately $124,000 and $334,000 for the three and nine months ended September 30, 2024, respectively.Â The Director of Clinical Affairsâ€™ royalty fee was approximately $104,000 and $370,000 for the three and nine months ended September 30, 2023, respectively.Â Additionally, Milestone Scientific expensed consulting fees to the Director of Clinical Affairs of $39,000 and $117,000Â for the three and nine months ended September 30, 2024 and 2023, respectively. As of September 30, 2024 and December 31, 2023, Milestone Scientific owed the Director ofÂ Clinical Affairs for royalties of approximately $132,000 and $114,000, respectively, which is included in accounts payable, related party and accrued expense, related party, in the unaudited consolidated balance sheets.Â Â Leonard Osser,Â Director Â On March 2, 2021, the Company entered into a Royalty Sharing Agreement with Leonard Osser, pursuant to which Mr. Osser sold, transferred and assigned to the Company all of his rights in and to a certain patent application as to which he is a co-inventor with Mark Hochman, a consultant to the Company, and the Company agreed to pay to Mr. Osser, beginning May 9, 2027, half of the royalty (2.5%) on net sales that would otherwise be payable to Mark and Claudia Hochman under their existing Technology Sale Agreement, dated January 1, 2005 and amended from time to time, with the Company. In connection with the Royalty Sharing Agreement, the Hochman's agreed with the Company, pursuant to an addendum to such Technology Sale Agreement dated February 25, 2021, to reduce from 5% to 2.5% the payments due to them under their Technology Sale Agreement beginning on May 9, 2027, and thereafter with respect to dental products embodying the invention. Â As part of the Succession Plan of the Company, Mr. Osser agreed, pursuant to an agreement dated April 6, 2021 (the â€œSuccession Agreementâ€), to restructure certain of his existing agreements with the Company, which provide for additional and broader executive support, and at such time as he elects to step down as Interim Chief Executive Officer of the Company, to become the Vice Chairman of the Board of the Company. Â With respect to Mr. Osserâ€™s July 2017 Employment Agreement and July 2017 Consulting Agreement (each as previously disclosed), the compensation under the Employment Agreement was modified to reduce the overall compensation by $100,000 to $200,000, split equally between a cash amount and an amount in shares, and the compensation under the Consulting Agreement was increased by $100,000 to $200,000, equally split between a cash amount and an amount in shares, which shares were formerly payable under the Employment Agreement.Â If the Company terminates Mr. Osserâ€™s employment â€œWithout Cause,â€ other than due to his death or disability, or if Mr. Osser terminates his employment for â€œGood Reasonâ€ (both as defined in the agreement), Mr. Osser is entitled to be paid in one lump sum payment as soon as practicable following such termination: an amount equal to the aggregate present value (as determined in accordance with Section 280G(d)(4) of the Code) of all compensation pursuant to this agreement from the effective date of termination hereunder through the remainder of the Employment Term. In connection with his acceptance of the Vice Chairman position and in consideration of his services as a member of the Board and agreement to provide certain additional general consulting services, Mr. Osser was granted options to purchase 2,000,000 shares of common stock, exercisable at the fair market value of the common stock on the date of grant, vesting over the five-year period after he steps down as Interim Chief Executive Officer of the Company or ten years from the date of grant, whichever shall end first. The Company believes that the effect of such existing agreements and the Succession Agreement, all of which relate to the period after such time Mr. Osser steps down as Interim Chief Executive Officer of the Company, collectively expand Mr. Osserâ€™s consulting to and support of the Company beyond its Chinese operations to also include its medical and other products, while enhancing the retention aspects of the Companyâ€™s relationship with Mr. Osser. On May 19, 2021, Mr. Osser resigned as Interim Chief Executive Officer of the Company and assumed the role of Vice Chairman of the Board.Â Â Compensation under the Employment Agreement and the Consulting Agreement is payable for 9.5Â years from May 19, 2021.Â The Company recorded expenses of $50,000,Â and $150,000Â related to the Employment Agreement for the three and nine months ended September 30, 2024 and 2023, respectively.Â The Company recorded expenses of $50,000 and $150,000 related to the Consulting Agreement for the three and nine months ended September 30, 2024 and 2023, respectively. Â Dr. D. Demesmin,Â Director Â As of February 2024, the University Pain Medicine Center (STEMMEE), of which Dr. D. Demesmin,Â a Company board member is theÂ CEOÂ agreed toÂ purchases products from the Company under the same terms and conditions applying to other medical pain clinics in the United States. STEMMEE purchased medical products in the amount of $6,000, andÂ $15,000Â Â three and nine months ended September 30, 2024Â from the Company. X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(e)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/850/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1 + Details Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 27 R18.htm IDEA: XBRL DOCUMENT v3.24.3 Note 11 - Commitments 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Commitments and Contingencies Disclosure [Text Block] NOTE 11Â â€” COMMITMENTS Â (1) Â Contract Manufacturing AgreementÂ Â Milestone Scientific has informal arrangements with third-party manufacturers of the STA devices, and epiduralÂ instrumentsÂ pursuant to which they manufacture these products under specific purchase orders but without any long-term contract or minimum purchase commitment.Â The Company has a purchase commitment for the delivery of 1,000 STA instruments as ofÂ Â September 30, 2024. As of September 30, 2024, the purchase order commitment was approximatelyÂ $1.0Â million, andÂ approximately $547,000Â was paid and reported in advance on contracts in theÂ consolidated balance sheet. As of September 30, 2024 the Company recordedÂ approximately $158,800Â for the development of the next generation instrumentÂ in advances on contracts in the consolidated balance sheet. As ofÂ December 31, 2023,Â the purchase order commitment was approximately $2.3Â million, andÂ approximately $1.3Â million was paid and reported in advance on contracts in theÂ consolidated balance sheet.Â Â The advances on contracts represent funding of future epidural instruments, and epidural replacements parts. As of September 30, 2024 and December 31, 2023 the Company also has advances on an open purchase order for long lead items for a future purchase order for the manufacturing of epidural instrument of approximately $168,000 and $41,000 respectively. Â (2) Â Leases Â Operating Leases Â The Company identified and assessed the following significant assumptions in recognizing its right-of-use assets and corresponding lease liabilities: Â Â â— As the Companyâ€™s leases do not provide an implicit rate, the Company estimated the incremental borrowing rate in calculating the present value of the lease payments. The Company has utilized its incremental borrowing rate based on the long-term borrowing costs of comparable companies in the Medical Device industry. Â â— Since the Company elected to account for each lease component and its associated non-lease components as a single combined lease component, all contract consideration was allocated to the combined lease component. Â â— The expected lease terms include non-cancellableÂ lease periods. Renewal option periods are not included in the determination of the lease terms as they were not reasonably certain to be exercised. Â The components of lease expense were as follows: Â Â Â Three months ended Â Â Nine months ended Â Â Â September 30, 2024 Â Â September 30, 2023 Â Â September 30, 2024 Â Â September 30, 2023 Â Cash paid for operating lease liabilities Â $30,373Â Â $34,320Â Â $95,645Â Â $98,083Â Cash paid for finance lease liabilities Â Â 2,685Â Â Â 2,685Â Â Â 8,055Â Â Â 8,055Â Weighted Average Remaining Lease Term Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Finance leases (years) Â Â Â Â Â Â Â Â Â 0.29 yearsÂ Â Â 1.3 yearsÂ Operating leases (years) Â Â Â Â Â Â Â Â Â 2.50

yearsÂ Â Â 3.50 yearsÂ Weighted-average discount rate â€“ operating leases Â Â Â Â Â Â Â Â Â Â 9.20%Â Â 9.20% Weighted-average discount rate â€“ finance leases Â Â Â Â Â Â Â Â Â Â 9.20%Â Â 9.20% X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 28 R19.htm IDEA: XBRL DOCUMENT v3.24.3 Note 12 - Subsequent Events 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Subsequent Events [Text Block] NOTE 12Â â€” SUBSEQUENT EVENTS Â On November 8, 2024, Mr. Arjan Haverhals, the Chief Executive Officer of the Company, advised the Chairman of the Board that he intends to retire as an officer from the Company upon the expiration of, and not seek the renewal of, his employment agreement, on December 31, 2024. Mr. Haverhals will continue as a director of the Company and as a consultant through a company owned by him and his family. Mr. Haverhals will receive his bonus for 2024 payable 50% in cash and 50% in stock (rather than 33% in cash and 67% in stock) and otherwise in accordance with his Employment Agreement and benefits in connection with his retirement in accordance with applicable agreements and Company plans, subject to their terms and conditions. He will be entitled to compensation for such consulting services at the rate of $350,000 for 2025, payable at the rate of $150,000 in respect of the first calendar quarter of 2025, and $66,666 in respect of each subsequent calendar quarter of 2025. X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/855/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R20.htm IDEA: XBRL DOCUMENT v3.24.3 Insider Trading Arrangements 9 Months Ended Sep. 30, 2024 Insider Trading Arr Line Items Â Material Terms of Trading Arrangement [Text Block] ItemÂ 5. Other Information Â Not applicable. Rule 10b5-1 Arrangement Adopted [Flag] false Non-Rule 10b5-1 Arrangement Adopted [Flag] false Rule 10b5-1 Arrangement Terminated [Flag] false Non-Rule 10b5-1 Arrangement Terminated [Flag] false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a + Details Name: ecd_InsiderTradingArrLineItems Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_MtrlTermsOfTrdArrTextBlock Namespace Prefix: ecd_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration XML 30 R21.htm IDEA: XBRL DOCUMENT v3.24.3 Significant Accounting Policies (Policies) 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â Consolidation, Policy [Policy Text Block] 1.Â Principles of Consolidation Â The accompanyingÂ consolidated unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United StatesÂ ("GAAP"), and the applicable rules and regulations of the Securities and Exchange Commission (SEC)Â include the accounts of Milestone Scientific and its wholly owned and majority owned subsidiaries, including, Wand Dental (wholly owned), and Milestone Innovations Inc. (wholly owned).Â All significant, intra-entity transactions and balances have been eliminated in the consolidation. Ownership interests in consolidated entities that are held by entities other than us are reported as noncontrolling interests in our consolidated balance sheets. Losses attributed to noncontrolling interests are reported separately in our consolidated statements of operations. Â During December 2023, the Board of Directors of the Company approved the merger of Milestone Medical, Inc., a 98%-owned subsidiary of the Company (â€œMMDâ€), with and into Milestone Innovation, Inc, a newly form wholly-owned subsidiary of the Company and being the surviving corporation . As a result, all of the assets of MMD automatically became assets of Milestone Innovations, Inc.Â Subsequent to SeptemberÂ 30, 2024, the Company satisfied it'sÂ liabilities to the non-controlling shareholders, the Company settled forÂ approximately $205,000 for the minority stake of MMD. Basis of Accounting, Policy [Policy Text Block] 2. Basis of Presentation Â The unaudited condensed consolidated financial statements of Milestone Scientific have been prepared in accordanceÂ with accounting principles generally accepted in the United States of America (GAAP) for interim financial information withÂ the instructions for Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by GAAP for complete annual financial statements. In the opinion of management, the accompanying unaudited consolidated financial statements contain all adjustments (consisting of normal recurring entries) necessary to fairly present such interim results. Interim results are not necessarily indicative of the results of operations which may be expected for a full year or any subsequent period. These unaudited consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2023, included in Milestone Scientific's Annual Report on Form 10-K. Use of Estimates, Policy [Policy Text Block] 3. Use of Estimates Â The preparation of unaudited consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions in determining the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to inventory valuation and cash flow assumptions regarding evaluations of going concern considerations. The Company bases its estimates on historical experience, known trends and other market-specific or relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates. Revenue [Policy Text Block] 4.Â Revenue Recognition Â The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To perform revenue recognition, the Company performs the following five steps: Â i. identification of the promised goods or services in the contract; ii. determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract;Â Â Â Â Â Â Â Â iii. measurement of the transaction price, including the constraint on variable consideration; iv. allocation of the transaction price to the performance obligations based on estimated selling prices; and v. recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC 606. Â The Company derives its revenues from the sale of its products, primarily dental instruments, handpieces, and other related products. The Company sells its products directly to consumers in the United States and through a global distribution network that includes both exclusive and non-exclusive distribution agreements with related and third parties. Â Revenue from product sales is recognized upon transfer of control of a product to a customer, generally upon date of shipment. The Company has no obligation on product sales for any installation, set-up, or maintenance, these being the responsibility of the buyer. Milestone Scientific's only obligation after sale is the normal commercial warranty against manufacturing defects if the alleged defective unit is returned within the warranty period.Â Â Â E-Commerce Â As of January 3, 2023,Â the Company launched an E-Commerce platform,Â selling and shippingÂ STA Single Tooth Anesthesia SystemsÂ®Â (STA) and handpieces directly to dental offices and dentalÂ groups within the United States. Our E-commerceÂ portal accepts online payments via creditÂ and debit cards. The cost of delivery is charged to the customer along with appropriate sales tax. The Company recognizes revenue from product salesÂ at the time the product ships to a customer via a third-party carrier.Â Â Sales Returns Â The Company records allowances for product returns as a reduction of revenue at the time product sales are recorded. Several factors are considered in determining whether an allowance for product returns is required, including the customersâ€™ return rights and the Companyâ€™s historical experience with returns and the amount of product in the distribution channel not consumed by end users and subject to return. The Company relies on historical return rates to estimate returns. Â Financing and Payment Â The Company's payment terms differ by geography and customer, but payments from distributors are required within 90 days or less from the date of shipment. The E-commerceÂ portal sells directly to end users and accepts onlineÂ payments via credit and debitÂ cards via a third-party. These payments from theÂ third party are typically settled within two business days. Â Disaggregation of Revenue Â The CompanyÂ operates in two operating segments: dental and medical. Therefore, the results of the Company's operations are reported on a consolidated basis for the purposes of segment reporting, consistent with internal management reporting. See Note 8Â for revenues by geographical market, based on the customerâ€™s location, and product category for the three andÂ nine months periodsÂ ended September 30, 2024, and 2023, respectively. Cash and Cash Equivalents, Policy [Policy Text Block] 5.Â Cash and Cash Equivalents Â Milestone Scientific considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. As of September 30, 2024, and December 31, 2023, Milestone Scientific has approximately $4.8Â million and $3.0 million, respectively of cash and cash equivalents.Â As of September 30, 2024,Â Milestone Scientific had approximately $4.1 million in cash, cash equivalents, in accounts that exceeded the Federal Deposit Insurance Corporation insurance limit of $250,000. Marketable Securities, Policy [Policy Text Block] 6. Marketable Securities Â The Companyâ€™s marketable securities are comprised of treasury bills with original maturity greater than three months from date of purchase. The Companyâ€™s marketable securities are measured at fair value and are accounted for in accordance with ASC 825, Financial Instruments. Unrealized holding gains and losses on treasury bills are recorded in interest income on the unaudited consolidated statements of operations. Dividend and interest income are recognized when earned. Realized gains and losses are included in earnings and are derived using the specific identification method for determining the cost of the marketable securities. As ofÂ September 30, 2024, the Company did not hold any marketable securities. As ofÂ December 31, 2023Â the Company held approximately $3.0 million in U.S. treasury securities, with maturityÂ dates within 3 and 6 months. Accounts Receivable [Policy Text Block] 7.Â Accounts Receivable Â The E-commerceÂ portal sells directly to end users and accepts onlineÂ payments via creditÂ and debit cardsÂ via a third-party credit card processor. These payments are settled within two business days of the transactions. Sales to distributors are on credit terms.Â The Company estimates losses from the ability or inability of its distributor to make payments on amounts billed. Â Distributors credit sales are due 90 days or less from the date of invoicing.Â As of September 30, 2024 andÂ December 31, 2023, accounts receivable was recorded, net of allowance for credit losses of $10,000, respectively. Inventory, Policy [Policy Text Block] 8.Â Inventories Â Inventories principally consist of finished goods and component parts stated at the lower of cost (first-in, first-out method) or net realizable value. Inventory quantitiesÂ on hand are reviewed on a quarterly basis and a provision for excess, slow moving, defective, and obsolete inventory is recorded if required based on past and expectedÂ future sales, potential technological obsolescence, and product expiration requirements. Â The valuation allowance creates a new cost basis for the inventory, and it is notÂ subsequently marked up through a reduction in the valuation allowance based on any changes in the underlying facts and circumstances. When the valuationÂ allowance is initially recorded, the increase to the allowance is recognized as an increase in cost of sales. The valuation allowance is only reduced if or when theÂ underlying inventory is sold or destroyed, at which time cost of sales recognized would include the previous adjusted cost basis. Earnings Per Share, Policy [Policy Text Block] 9.Â Basic and Diluted Net Loss Per Common Share Â Milestone Scientific presents â€œbasicâ€ earnings (loss) per common share applicable to common stockholders and, if applicable, â€œdilutedâ€ earnings (loss) per commonÂ share applicable to common stockholders pursuant to the provisions of ASC 260, â€œEarnings per Shareâ€. Basic earnings (loss) per common share is calculated byÂ dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding and to be issued common shares as follows: 79,966,833Â and 73,730,921Â for the three months ended September 30, 2024 and 2023, respectively, andÂ 80,165,181 andÂ 72,374,693 for the nine months ended September 30, 2024 and 2023, respectively. The calculation of diluted earnings per common share is like that of basic earnings per common share, except that the denominator is increased to include the number ofÂ additional common shares that would have been outstanding if all potentially dilutive common shares, such as those issuable upon the exercise of stock options andÂ warrants, were issued during the period. Since Milestone Scientific had net losses in the three andÂ Â nine months ended September 30, 2024 and the three and nine months ended September 30, 2023, the assumed effects of the exercise of potentially dilutive outstanding stock options, unissued restricted stock awards (â€œRSAâ€) and warrants, were not included in the calculation as their effect would have been anti-dilutive. Such outstanding options, RSA'sÂ and warrantsÂ totaled 3,684,697Â and 3,930,654Â for the nine months ended September 30, 2024 and 2023, respectively. Fair Value of Financial Instruments, Policy [Policy Text Block] 10. Fair Value of Financial Instruments Â Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company required us to classify fair value measurements inÂ oneÂ of the following categories. Â â— LevelÂ 1Â inputs which are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that

the CompanyÂ can access at the measurement date. Â â— LevelÂ 2Â inputs which are defined as inputs other than quoted prices included within LevelÂ 1Â that are observable for the assets or liabilities, either directly or indirectly. Â â— LevelÂ 3Â inputs are defined as unobservable inputs for the assets or liabilities. Â Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of an input to the fair value measurement requires judgment andÂ mayÂ affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels. Â As ofÂ September 30, 2024 the Company did not have assets measured at fair value on a recurring basis. As of December 31, 2023Â the Company had the followingÂ assetsÂ that were measured at fair value on a recurring basis:Â Â Â Â Level 1 Â Â Level 2 Â Â Level 3 Â Â Total Â Marketable Securities December 31, 2023 Â $2,976,573Â Â Â -Â Â Â -Â Â $2,976,573Â Â Marketable Securities included US Treasury securities totaling $2,976,573Â that are considered to be highly liquid and easily transferable atÂ December 31, 2023.Â US Treasury securities are valued using inputs observable in active markets for identical securities and are therefore classified at LevelÂ 1Â within the Company fair value hierarchy. Share-Based Payment Arrangement [Policy Text Block] 11.Â Stock-Based CompensationÂ Â Milestone Scientific accounts for stock-based compensation under ASC Topic 718, Share-Based Payment (â€œASC Topic 718â€). ASC Topic 718 requires all share-based payments to employees, non-employees, directors, and officers, including grants of employee stock options, to be recognized in the unaudited consolidated statements of operations over the service period, as an operating expense, based on the grant-date fair values. New Accounting Pronouncements, Policy [Policy Text Block] 12.Â Â Recent Accounting Pronouncements Â Recently Issued Accounting Pronouncement Â In November 2023, FASB issued ASU 2023-07, Segment Reporting (Topic 280), Improvements to Reportable Segment Disclosures, which provides improvements to reportable segment disclosure requirements, primarily through enhanced disclosures around segment expenses. ASU 2023-07 requires us to disclose significant segment expenses that are regularly provided to the chief operating decision maker (â€œCODMâ€) and included within each reported measure of segment profit or loss. ASU 2023-07 also requires that the Company disclose an amount for other segment items by reportable segment, a description of their composition and provide all annual disclosures about a reportable segmentâ€™s profit or loss and assets pursuant to Topic 280 during interim periods. The Company must also disclose the CODMâ€™s title and position, as well asÂ certain information around the measures used by the CODM and an explanation of how the CODM uses the reported measures in assessing segment performance and deciding how to allocate resources. For public entities with a single reportable segment, the entity must provide all the disclosures required pursuant to ASU 2023-07 and all existing segment disclosures under Topic 280. The amendments of ASU 2023-07 are effective for the Company for annual periods beginning January 1, 2024, and effective for interim periods beginning January 1, 2025. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. The Company expects to adopt this standard effective January 1, 2024, at December 31, 2024 on the Companyâ€™s annual Form 10-K filing. The Company expects to update all required disclosures pursuant to this ASU 2023-07 at that time. The Company is evaluating the impact of ASU 2023-07Â on our financial statements. Â In December 2023, FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, to enhance the transparency and decision usefulness of income tax disclosures. The amendments in ASU 2023-09 provide improvements primarily related to the rate reconciliation and income taxes paid information included in income tax disclosures. The Company would be required to disclose additional information regarding reconciling items equal to or greater than five percent of the amount computed by multiplying pretax income (loss) by the applicable statutory tax rate. Similarly, the Company would be required to disclose income taxes paid (net of refunds received) equal to or greater than five percent of total income taxes paid (net of refunds received). Additionally, the Company would be required to disclose income (loss) from continuing operations before income tax expense disaggregated by foreign and domestic jurisdictions, as well as income tax expense disaggregated by federal, state, and foreign jurisdictions. The amendments in ASU 2023-09 are effective January 1, 2025, including interim periods. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. The Company is currently evaluatingÂ the impact of ASU 2023-09 on our financial statements. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1 + Details Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1 + Details Name: us-gaap_ConsolidationPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 + Details Name: us-gaap_EarningsPerSharePolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for determining the fair value of financial instruments. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 825 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1 + Details Name: us-gaap_FairValueOfFinancialInstrumentsPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 330 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/330/tableOfContentReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Subparagraph (a) -SubTopic 10 -Topic 270 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6 + Details Name: us-gaap_InventoryPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for investment classified as marketable security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 320 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477268/942-320-50-5 + Details Name: us-gaap_MarketableSecuritiesPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 3: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (e) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4 + Details Name: us-gaap_RevenueRecognitionPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.C.Q3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.1.Q5) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.3.Q2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.2.Q6) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for accounts receivable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-6Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-15Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-11B + Details Name: us-gaap_TradeAndOtherAccountsReceivablePolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name

Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R22.htm IDEA: XBRL DOCUMENT v3.24.3 Note 3 - Summary of Significant Accounting Policies (Tables) 9 Months Ended Sep. 30, 2024 Notes Tables Â Fair Value, Assets Measured on Recurring Basis [Table Text Block] Â Â Level 1 Â Â Level 2 Â Â Level 3 Â Â Total Â Marketable Securities December 31, 2023 Â $2,976,573Â Â Â -Â Â Â -Â Â $2,976,573Â X - DefinitionTabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 32 R23.htm IDEA: XBRL DOCUMENT v3.24.3 Note 4 - Inventories (Tables) 9 Months Ended Sep. 30, 2024 Notes Tables Â Schedule of Inventory, Current [Table Text Block] Â Â September 30, 2024 Â Â December 31, 2023 Â Â Â Â Â Â Â Â Â Dental finished goods Â $3,637,356Â Â Â $2,404,970Â Medical finished goods Â Â -Â Â Â 14,730Â Component parts and other materials Â Â 74,280Â Â Â 218,486Â Total inventories Â $3,711,636Â Â Â $2,638,186Â X - DefinitionTabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1 + Details Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 33 R24.htm IDEA: XBRL DOCUMENT v3.24.3 Note 6 - Stockholders' Equity (Tables) 9 Months Ended Sep. 30, 2024 Notes Tables Â Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Â Â Warrant shares outstanding Â Â Weighted Average exercise price Â Â Weighted Average remaining life Â Â Intrinsic value Â Outstanding at January 1, 2024 Â Â 314,572Â Â Â 0.50Â Â Â 0.10Â Â Â 59,737Â Issued Â Â -Â Â Â -Â Â Â -Â Â Â -Â Exercised Â Â (103,500)Â Â 0.50Â Â Â -Â Â Â -Â Expired or cancelled Â Â (211,072)Â Â 0.50Â Â Â -Â Â Â -Â Outstanding and exercisable at September 30, 2024 Â Â -Â Â Â -Â Â Â -Â Â Â -Â Deferred Compensation Arrangement with Individual, Share-based Payments [Table Text Block] Â Â September 30, 2024 Â Â September 30, 2023 Â Â Â Â Â Â Â Â Â Shares-to-be-issued, outstanding January 1, 2024 and 2023, respectively Â Â 3,098,917Â Â Â 2,440,673Â Granted in current period Â Â 438,868Â Â Â 368,387Â Issued in current period Â Â (353,102)Â Â -Â Shares-to be issued outstanding September 30, 2024 and 2023, respectively Â Â 3,184,683Â Â Â 2,809,060Â Share-Based Payment Arrangement, Option, Activity [Table Text Block] Â Â Number of Options Â Â Weighted Averaged Exercise Price $ Â Â Weighted Average Remaining Contractual Life (Years) Â Â Aggregate Intrinsic Options Value $ Â Options outstanding at January 1, 2024 Â Â 3,036,989Â Â Â 2.29Â Â Â 5.41Â Â Â -Â Granted during 2024 Â Â -Â Â Â -Â Â Â Â Â Â -Â Exercised during 2024 Â Â -Â Â Â -Â Â Â -Â Â Â -Â Forfeited or expired during 2024 Â Â -Â Â Â -Â Â Â -Â Â Â -Â Options outstanding September 30, 2024 Â Â 3,036,989Â Â Â 2.32Â Â Â 4.66Â Â Â -Â Exercisable, September 30, 2024 Â Â 2,188,433Â Â Â 2.29Â Â Â 4.06Â Â Â -Â Â Â Number of Options Â Â Weighted Averaged Exercise Price $ Â Â Weighted Average Remaining Contractual Life (Years) Â Â Aggregate Intrinsic Options Value $ Â Options outstanding at January 1, 2024 Â Â 91,663Â Â Â 1.76Â Â Â 2.25Â Â Â 2,833Â Granted during 2024 Â Â 24,999Â Â Â 0.84Â Â Â 4.71Â Â Â -Â Exercised during 2024 Â Â -Â Â Â -Â Â Â -Â Â Â -Â Forfeited or expired during 2024 Â Â (16,666)Â Â 0.55Â Â Â -Â Â Â -Â Options outstanding September 30, 2024 Â Â 99,996Â Â Â 1.74Â Â Â 2.37Â Â Â 4,083Â Exercisable, September 30, 2024 Â Â 77,772Â Â Â 1.99Â Â Â 1.81Â Â Â 1,916Â Restricted Stock [Member] Â Notes Tables Â Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block] Â Â Number of Shares Â Â Weighted Average Grant-Date Fair Value per Award Â Non-vested as January 1, 2024 Â Â 327,937Â Â Â 0.91Â Granted Â Â 730,340Â Â Â 0.89Â Vested Â Â (510,522)Â Â 0.91Â Cancelled Â Â -Â Â Â -Â Non-vested as September 30, 2024 Â Â 547,755Â Â Â 0.89Â X - DefinitionTabular disclosure of shares authorized for issuance under the deferred compensation arrangement as of the balance sheet date. + ReferencesNo definition available. + Details Name: mlss_DeferredCompensationArrangementWithIndividualSharebasedPaymentsTableTextBlock Namespace Prefix: mlss_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1 + Details Name: us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 34 R25.htm IDEA: XBRL DOCUMENT v3.24.3 Note 8 - Segment and Geographic Data (Tables) 9 Months Ended Sep. 30, 2024 Notes Tables Â Schedule of Segment Reporting Information, by Segment [Table Text Block] Â Â For the three months ended September 30, Â Â For the nine months ended September 30, Â Sales Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net Sales: Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Dental Â $2,466,405Â Â $2,053,284Â Â $6,542,594Â Â $7,556,848Â Medical Â Â 47,400Â Â Â 6,000Â Â Â 73,820Â Â Â 10,000Â Total net sales Â $2,513,805Â Â $2,059,284Â Â $6,616,414Â Â $7,566,848Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Operating Income (Loss): Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Dental Â $705,427Â Â $458,474Â Â $1,524,177Â Â $1,699,349Â Medical Â Â (356,555)Â Â (740,087)Â Â (1,376,294)Â Â (2,425,913) Corporate Â Â (1,818,051)Â Â (1,225,092)Â Â (4,862,553)Â Â (4,400,369) Total operating loss Â $(1,469,179)Â $(1,506,705)Â $(4,714,670)Â $(5,126,933) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â

30, 2023 Â Â September 30, 2024 Â Â September 30, 2023 Â Cash paid for operating lease liabilities Â $30,373Â Â $34,320Â Â $95,645Â Â $98,083Â Cash paid for finance lease liabilities Â Â 2,685Â Â Â 2,685Â Â Â 8,055Â Â Â 8,055Â Weighted Average Remaining Lease Term Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Finance leases (years) Â Â Â Â Â Â Â Â Â Â 0.29 yearsÂ Â Â 1.3 yearsÂ Operating leases (years) Â Â Â Â Â Â Â Â Â Â 2.50 yearsÂ Â Â 3.50 yearsÂ Weighted-average discount rate â€“ operating leases Â Â Â Â Â Â Â Â Â Â Â Â Â Â 9.20%Â Â 9.20% Weighted-average discount rate â€“ finance leases Â Â Â Â Â Â Â Â Â Â Â Â Â Â 9.20%Â Â 9.20% X - DefinitionTabular disclosure of lessee's lease cost and other information. + ReferencesNo definition available. + Details Name: mlss_LeaseCostAndOtherInformationTableTextBlock Namespace Prefix: mlss_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 36 R27.htm IDEA: XBRL DOCUMENT v3.24.3 Note 1 - Organization and Business (Details Textual) Sep. 30, 2024 Number of Countries in which Entity Operates 41 X - DefinitionThe number of countries in which the entity operates as of balance sheet date. + ReferencesNo definition available. + Details Name: us-gaap_NumberOfCountriesInWhichEntityOperates Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant XML 37 R28.htm IDEA: XBRL DOCUMENT v3.24.3 Note 2 - Liquidity and Uncertainties (Details Textual) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Retained Earnings (Accumulated Deficit) $ (126,017,571) Â $ (126,017,571) Â $ (123,339,509) Operating Income (Loss) (1,469,179) $ (1,506,705) (4,714,670) $ (5,126,933) Â Cash, Cash Equivalents, and Marketable Securities 4,800,000 Â 4,800,000 Â Â Working Capital $ 6,900,000 Â 6,900,000 Â Â Net Cash Provided by (Used in) Operating Activities Â Â $ (1,408,387) $ (4,080,330) Â X - DefinitionThe amount of cash, cash equivalents, and marketable securities calculated during the period. + ReferencesNo definition available. + Details Name: mlss_CashCashEquivalentsAndMarketableSecurities Namespace Prefix: mlss_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe difference between the companies assets and liabilities. + ReferencesNo definition available. + Details Name: mlss_WorkingCapital Namespace Prefix: mlss_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 38 R29.htm IDEA: XBRL DOCUMENT v3.24.3 Note 3 - Summary of Significant Accounting Policies (Details Textual) 3 Months Ended 9 Months Ended Sep. 30, 2024 USD ($) shares Sep. 30, 2023 shares Sep. 30, 2024 USD ($) shares Sep. 30, 2023 shares Dec. 31, 2023 USD ($) Payments to Acquire Additional Interest in Subsidiaries Â Â $ 205,000 Â Â Number of Operating Segments Â Â 2 Â Â Cash, Uninsured Amount $ 4,100,000 Â $ 4,100,000 Â Â Marketable Securities, Current 0 Â 0 Â $ 2,976,573 Accounts Receivable, Allowance for Credit Loss $ 10,000 Â $ 10,000 Â 10,000 Weighted Average Number of Shares Outstanding, Basic (in shares) | shares 79,966,833 73,730,921 80,165,181 72,374,693 Â Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | shares Â Â 3,684,697 3,930,654 Â Marketable Securities Â Â Â Â Â 2,976,573 US Treasury Securities [Member] Â Â Â Â Â Â Marketable Securities, Current Â Â Â Â Â 3,000,000 Money Market Funds [Member] Â Â Â Â Â Â Cash Equivalents, at Carrying Value $ 4,800,000 Â $ 4,800,000 Â $ 3,000,000 X - DefinitionAmount of allowance for credit loss on accounts receivable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13 + Details Name: us-gaap_AllowanceForDoubtfulAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation. + ReferencesNo definition available. + Details Name: us-gaap_CashUninsuredAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in marketable security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_MarketableSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in marketable security, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_MarketableSecuritiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18 + Details Name: us-gaap_NumberOfOperatingSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionThe cash outflow associated with the purchase of noncontrolling interest during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 39 R30.htm IDEA: XBRL DOCUMENT v3.24.3 Note 3 - Summary of Significant Accounting Policies - Fair Value of Marketable Securities (Details) Dec. 31, 2023 USD ($) Marketable Securities $ 2,976,573 Estimate of Fair Value Measurement [Member] Â Marketable Securities 2,976,573 Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 1 [Member] Â Marketable Securities 2,976,573 Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member] Â Marketable Securities 0 Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 3 [Member] Â Marketable Securities $ 0 X - DefinitionAmount of investment in marketable security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_MarketableSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-

gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 40 R31.htm IDEA: XBRL DOCUMENT v3.24.3 Note 4 - Inventories (Details Textual) - USD ($) $ in Millions Sep. 30, 2024 Dec. 31, 2023 Slow Moving Medical Finished Goods [Member] Â Â Inventory Valuation Reserves $ 1.2 $ 1.2 X - DefinitionAmount of valuation reserve for inventory. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.BB) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryValuationReserves Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_PublicUtilitiesInventoryAxis=mlss_SlowMovingMedicalFinishedGoodsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 41 R32.htm IDEA: XBRL DOCUMENT v3.24.3 Note 4 - Inventories - Summary of Inventories (Details) - USD ($) Sep. 30, 2024 Dec. 31, 2023 Component parts and other materials $ 74,280 $ 218,486 Total inventories 3,711,636 2,638,186 Dental Segment [Member] Â Â Finished goods, net 3,637,356 2,404,970 Medical Segment [Member] Â Â Finished goods, net $ 0 $ 14,730 X - DefinitionCarrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.BB) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryFinishedGoodsNetOfReserves Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying amount, net of valuation reserves and adjustments, as of the balance sheet date for elements of machinery or equipment held for the purpose of replacing similar parts in the course of repair or maintenance. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.BB) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryPartsAndComponentsNetOfReserves Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_StatementBusinessSegmentsAxis=mlss_DentalSegmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=mlss_MedicalSegmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 42 R33.htm IDEA: XBRL DOCUMENT v3.24.3 Note 5 - Advances on Contracts (Details Textual) - USD ($) Sep. 30, 2024 Dec. 31, 2023 Advances on Inventory Purchases $ 1,011,306 $ 1,371,548 X - DefinitionCarrying value of capitalized payments made in advance for inventory that is expected to be received within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdvancesOnInventoryPurchases Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 43 R34.htm IDEA: XBRL DOCUMENT v3.24.3 Note 6 - Stockholders' Equity (Details Textual) - USD ($) 1 Months Ended 3 Months Ended 9 Months Ended Jul. 16, 2024 Jan. 12, 2024 Dec. 10, 2023 Jul. 31, 2024 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Jun. 28, 2023 Dec. 31, 2022 Stock Issued During Period Shares, Warrants Exercised (in shares) Â Â Â Â Â Â 103,500 Â Â Â Â Class of Warrant or Right, Exercised During Period, Exercise Price (in dollars per share) Â Â Â Â Â Â $ 0.5 Â Â Â Â Proceeds from Warrant Exercises Â Â Â Â Â Â $ 51,751 $ 0 Â Â Â Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance (in shares) Â Â Â Â 3,184,683 2,809,060 3,184,683 2,809,060 3,098,917 Â 2,440,673 Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) Â Â Â Â Â Â 6 months Â Â Â Â Share-Based Payment Arrangement, Option [Member] Â Â Â Â Â Â Â Â Â Â Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Â Â Â Â Â $ 1,000,000 Â $ 1,000,000 Â Â Â Â Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) Â Â Â Â Â Â 1 year 6 months Â Â Â Â Share-Based Payment Arrangement, Option [Member] | Share-Based Payment Arrangement, Nonemployee [Member] Â Â Â Â Â Â Â Â Â Â Share-Based Payment Arrangement, Expense Â Â Â Â 7,000 $ 3,800 $ 9,200 $ 17,000 Â Â Â Restricted Stock [Member] Â Â Â Â Â Â Â Â Â Â Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Â Â Â Â 0 Â 0 Â Â Â Â Share-Based Payment Arrangement, Expense Â Â Â Â 0 (36,500) $ (2,100) (17,700) Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) Â Â Â Â Â Â 730,340 Â Â Â Â The 2020 Equity Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member] Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares) Â Â Â Â Â Â Â Â Â Â 11,500,000 Â Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year) Â Â Â Â Â Â 3 years Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year) Â Â Â Â Â Â 5 years Â Â Â Â Share-Based Payment Arrangement, Amount Capitalized Â Â Â Â $ 172,000 $ 321,000 $ 530,000 $ 1,100,000 Â Â Â Chief Executive Officer, and Other Employees [Member] Â Â Â Â Â Â Â Â Â Â Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance (in shares) Â Â Â Â 2,657,058 2,426,364 2,657,058 2,426,364 Â Â Â Non-Employees [Member] Â Â Â Â Â Â Â Â Â Â Common Stock, Capital Shares Reserved for Future Issuance (in shares) Â Â Â Â 527,625 382,696 527,625 382,696 Â Â Â Board of Directors [Member] | Restricted Stock [Member] Â Â Â Â Â Â Â Â Â Â Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Â Â Â Â $ 344,000 Â $ 344,000 Â Â Â Â Share-Based Payment Arrangement, Expense Â Â Â Â $ 306,000 Â $ 464,000 Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) 730,340 Â Â Â Â Â Â Â Â Â Â Share Price (in dollars per share) $ 0.89 Â Â Â Â Â Â Â Â Â Â Board of Directors [Member] | Restricted Stock [Member] | Share-Based Payment Arrangement, Tranche One [Member] Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Â Â Â 25.00% Â Â Â Â Â Â Â Board of Directors [Member] | Restricted Stock [Member] | Share-Based Payment Arrangement, Tranche Two [Member] Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Â Â Â Â Â Â 25.00% Â Â Â Â Public Offering [Member] Â Â Â Â Â Â Â Â Â Â Stock Issued During Period, Shares, New Issues (in shares) Â Â 4,765,000 Â Â Â Â Â Â Â Â Shares Issued, Price Per Share (in dollars per share) Â Â $ 0.63 Â Â Â Â Â Â Â Â Proceeds from Issuance of Common Stock Â Â $ 2,600,000 Â Â Â Â Â Â Â Â Over-Allotment Option [Member] Â Â Â Â Â Â Â Â Â Â Stock Issued During Period, Shares, New Issues (in shares) Â 372,110 714,750 Â Â Â Â Â Â Â Proceeds from Issuance of Common Stock Â $ 192,156 Â Â Â Â Â Â Â Â Â Â X - DefinitionExercise price per share of warrants or rights exercised during period. + ReferencesNo definition available. + Details Name: mlss_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice Namespace Prefix: mlss_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued for warrants exercised. + ReferencesNo definition available. + Details Name: mlss_StockIssuedDuringPeriodSharesWarrantsExercised Namespace Prefix: mlss_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAggregate number of common shares reserved for future issuance. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of shares authorized for issuance under the deferred compensation arrangement as of the balance sheet date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAmount of cost capitalized for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cost not yet recognized for nonvested award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from holders exercising their stock warrants. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromWarrantExercises Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPeriod over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares authorized for issuance under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPrice of a single share of a number of saleable stocks of a company. + ReferencesNo definition available. + Details Name: us-gaap_SharePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionPercentage of vesting of award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType

Balance Type: na Period Type: duration X - DefinitionPeriod from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap_SharesIssuedPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=mlss_The2020EquityIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=mlss_ChiefExecutiveOfficerAndOtherEmployeesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=mlss_NonemployeesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=mlss_BoardOfDirectorsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=mlss_PublicOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 44 R35.htm IDEA: XBRL DOCUMENT v3.24.3 Note 6 - Stockholders' Equity - Warrants (Details) - USD ($) 9 Months Ended Sep. 30, 2024 Jan. 01, 2024 Outstanding (in shares) 314,572 Â Outstanding (in dollars per share) $ 0.5 Â Outstanding (Year) 1 month 6 days Â Outstanding $ 0 $ 59,737 Issued, number of shares (in shares) 0 Â Issued, weighted average exercise price (in dollars per share) $ 0 Â Exercised, number of shares (in shares) (103,500) Â Exercised, weighted average exercise price (in dollars per share) $ 0.5 Â Expired or cancelled, number of shares (in shares) (211,072) Â Expired or cancelled, weighted average exercise price (in dollars per share) $ 0.5 Â Outstanding (in shares) 0 Â Outstanding (in dollars per share) $ 0 Â X - DefinitionThe number of warrants or rights exercised during period. + ReferencesNo definition available. + Details Name: mlss_ClassOfWarrantOrRightExercisedDuringPeriod Namespace Prefix: mlss_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share of warrants or rights exercised during period. + ReferencesNo definition available. + Details Name: mlss_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice Namespace Prefix: mlss_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of warrants or rights expired or cancelled during period. + ReferencesNo definition available. + Details Name: mlss_ClassOfWarrantOrRightExpiredOrCancelledDuringPeriod Namespace Prefix: mlss_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share of warrants or rights expired or cancelled during period. + ReferencesNo definition available. + Details Name: mlss_ClassOfWarrantOrRightExpiredOrCancelledDuringPeriodExercisePrice Namespace Prefix: mlss_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of warrants or rights issued during period. + ReferencesNo definition available. + Details Name: mlss_ClassOfWarrantOrRightIssuedDuringPeriod Namespace Prefix: mlss_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share of warrants or rights issued during period. + ReferencesNo definition available. + Details Name: mlss_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice Namespace Prefix: mlss_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionIntrinsic value of outstanding warrants. + ReferencesNo definition available. + Details Name: mlss_ClassOfWarrantOrRightOutstandingAggregateIntrinsicValue Namespace Prefix: mlss_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the weighted average remaining term of warrants and rights outstanding, + ReferencesNo definition available. + Details Name: mlss_WarrantsAndRightsOutstandingWeightedAverageRemainingTerm Namespace Prefix: mlss_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant XML 45 R36.htm IDEA: XBRL DOCUMENT v3.24.3 Note 6 - Stockholders' Equity - Summary of Shares to be Issued (Details) - shares 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Shares-to-be-issued, outstanding (in shares) 3,098,917 2,440,673 Granted in current period (in shares) 438,868 368,387 Issued in current period (in shares) (353,102) 0 Shares-to-be-issued, outstanding (in shares) 3,184,683 2,809,060 X - DefinitionNumber of shares granted pursuant to the terms of a deferred compensation arrangement. + ReferencesNo definition available. + Details Name: mlss_DeferredCompensationArrangementWithIndividualSharesGranted Namespace Prefix: mlss_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe maximum number of shares authorized for issuance under the deferred compensation arrangement as of the balance sheet date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued pursuant to the terms of a deferred compensation arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 46 R37.htm IDEA: XBRL DOCUMENT v3.24.3 Note 6 - Stockholders' Equity - Summary of Option Activity (Details) - Share-Based Payment Arrangement, Option [Member] - USD ($) 9 Months Ended 12 Months Ended Sep. 30, 2024 Dec. 31, 2023 Share-Based Payment Arrangement, Employee [Member] Â Â Number of options (in shares) 3,036,989 Â Weighted average exercise price, outstanding (in dollars per share) $ 2.29 Â Weighted average remaining contractual life, outstanding (Year) 4 years 7 months 28 days 5 years 4 months 28 days Aggregate intrinsic value, outstanding $ 0 Â Number of options granted (in shares) 0 Â Weighted average exercise price, granted (in dollars per share) $ 0 Â Number of options exercised (in shares) 0 Â Weighted average exercise price, exercised (in dollars per share) $ 0 Â Number of options forfeited and expired (in shares) 0 Â Weighted average exercise price, forfeited or expired (in dollars per share) $ 0 Â Number of options (in shares) 3,036,989 3,036,989 Weighted average exercise price, outstanding (in dollars per share) $ 2.32 $ 2.29 Number of options exercisable (in shares) 2,188,433 Â Weighted average exercise price, exercisable (in dollars per share) $ 2.29 Â Weighted average remaining contractual life, exercisable (Year) 4 years 21 days Â Number of options, exercised (in shares) 0 Â Number of options, forfeited or expired (in shares) 0 Â Share-Based Payment Arrangement, Nonemployee [Member] Â Â Number of options (in shares) 91,663 Â Weighted average exercise price, outstanding (in dollars per share) $ 1.76 Â Weighted average remaining contractual life, outstanding (Year) 2 years 4 months 13 days 2 years 3 months Aggregate intrinsic value, outstanding $ 4,083 $ 2,833 Number of options granted (in shares) 24,999 Â Weighted average exercise price, granted (in dollars per share) $ 0.84 Â Number of options exercised (in shares) (0) Â Weighted average exercise price, exercised (in dollars per share) $ 0 Â Number of options forfeited and expired (in shares) 16,666 Â Weighted average exercise price, forfeited or expired (in dollars per share) $ 0.55 Â Number of options (in shares) 99,996 91,663 Weighted average exercise price, outstanding (in dollars per share) $ 1.74 $ 1.76 Number of options exercisable (in shares) 77,772 Â Weighted average exercise price, exercisable (in dollars per share) $ 1.99 Â Weighted average remaining contractual life, exercisable (Year) 1 year 9 months 21 days Â Weighted average remaining contractual life, granted (Year) 4 years 8 months 15 days Â Number of options, exercised (in shares) 0 Â Number of options, forfeited or expired (in shares) (16,666) Â Aggregate intrinsic value, exercisable $ 1,916 Â X - DefinitionWeighted average remaining contractual term for option awards granted. + ReferencesNo definition available. + Details Name: mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm Namespace Prefix: mlss_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionFor presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price of options that were either forfeited or expired. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-

gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which option holders acquired shares when converting their stock options into shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 47 R38.htm IDEA: XBRL DOCUMENT v3.24.3 Note 6 - Stockholders' Equity - Schedule of Restricted Stock (Details) - Restricted Stock [Member] 9 Months Ended Sep. 30, 2024 $ / shares shares Non-vested as January 1, 2024 (in shares) 327,937 Non-vested as January 1, 2024 (in dollars per share) | $ / shares $ 0.91 Granted, Shares (in shares) 730,340 Vested, Shares (in shares) (510,522) Vested, Weighted Average Grant-Date Fair Value per Award (in dollars per share) | $ / shares $ 0.91 Cancelled, Shares (in shares) 0 Non-vested, Shares (in shares) 547,755 X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPer share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares under non-option equity instrument agreements for which rights to exercise lapsed. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 48 R39.htm IDEA: XBRL DOCUMENT v3.24.3 Note 7 - Income Taxes (Details Textual) - USD ($) $ in Millions 9 Months Ended 60 Months Ended Apr. 01, 2024 Sep. 30, 2024 Apr. 01, 2029 Percentage of Valuation Allowance Â 100.00% Â Proceeds From Sale of Net Operating Loss Amount $ (2.0) Â Â Sale of Net Operating Losses, Physical Presence Requirement, Years (Year) Â Â 5 years Sale of Net Operating Losses, Contingent Liability, Amount $ 2.2 Â Â X - DefinitionRepresents the percentage of valuation allowance. + ReferencesNo definition available. + Details Name: mlss_PercentageOfValuationAllowance Namespace Prefix: mlss_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe cash inflow from the sale of NOL during the period. + ReferencesNo definition available. + Details Name: mlss_ProceedsFromSaleOfNetOperatingLossAmount Namespace Prefix: mlss_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRepresents the amount of contingent liability that a company must pay if they violate the terms of the sale of net operating losses. + ReferencesNo definition available. + Details Name: mlss_SaleOfNetOperatingLossesContingentLiabilityAmount Namespace Prefix: mlss_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionRepresents the number of years a company must retain a physical presence in a geographic region per the terms of a sale of net operating losses. + ReferencesNo definition available. + Details Name: mlss_SaleOfNetOperatingLossesPhysicalPresenceRequirementYears Namespace Prefix: mlss_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration XML 49 R40.htm IDEA: XBRL DOCUMENT v3.24.3 Note 8 - Segment and Geographic Data (Details Textual) 9 Months Ended Sep. 30, 2024 Number of Reportable Segments 2 X - DefinitionNumber of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18 + Details Name: us-gaap_NumberOfReportableSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration XML 50 R41.htm IDEA: XBRL DOCUMENT v3.24.3 Note 8 - Segment and Geographic Data - Summary by Reporting and Operating Segments (Details) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Product sales, net $ 2,513,805 $ 2,059,284 $ 6,616,414 $ 7,566,848 Â Operating Income (Loss) (1,469,179) (1,506,705) (4,714,670) (5,126,933) Â Depreciation and Amortization 8,574 15,896 28,735 49,798 Â Income (loss) before taxes and equity in earnings of affiliates (1,461,171) (1,476,105) (2,678,062) (5,024,264) Â Total income (loss) before taxes and equity in earnings of affiliates (1,461,171) (1,476,105) (2,678,062) (5,024,264) Â Total assets 11,174,918 11,371,512 11,174,918 11,371,512 $ 11,371,512 Segment Reporting, Reconciling Item, Corporate Nonsegment [Member] Â Â Â Â Â Operating Income (Loss) (1,818,051) (1,225,092) (4,862,553) (4,400,369) Â Depreciation and Amortization 8,574 14,260 28,735 44,112 Â Income (loss) before taxes and equity in earnings of affiliates (1,810,049) (1,192,605) (2,824,695) (4,291,552) Â Total income (loss) before taxes and equity in earnings of affiliates (1,810,049) (1,192,605) (2,824,695) (4,291,552) Â Total assets 5,426,114 6,159,532 5,426,114 6,159,532 Â Dental Segment [Member] Â Â Â Â Â Product sales, net 2,466,405 2,053,284 6,542,594 7,556,848 Â Dental Segment [Member] | Operating Segments [Member] Â Â Â Â Â Product sales, net 2,466,405 2,053,284 6,542,594 7,556,848 Â Operating Income (Loss) 705,427 458,474 1,524,177 1,699,349 Â Depreciation and Amortization 0 1,051 0 3,439 Â Income (loss) before taxes and equity in earnings of affiliates 705,433 458,504 1,523,209 1,698,790 Â Total income (loss) before taxes and equity in earnings of affiliates 705,433 458,504 1,523,209 1,698,790 Â Total assets 5,528,106 4,866,786 5,528,106 4,866,786 Â Medical Segment [Member] Â Â Â Â Â Product sales, net 47,400 6,000 73,820 10,000 Â Medical Segment [Member] | Operating Segments [Member] Â Â Â Â Â Product sales, net 47,400 6,000 73,820 10,000 Â Operating Income (Loss) (356,555) (740,087) (1,376,294) (2,425,913) Â Depreciation and Amortization 0 585 0 2,247 Â Income (loss) before taxes and equity in earnings of affiliates (356,555) (742,004) (1,376,576) (2,431,502) Â Total income (loss) before taxes and equity in earnings of affiliates (356,555) (742,004) (1,376,576) (2,431,502) Â Total assets $ 220,698 $ 345,194 $ 220,698 $ 345,194 Â X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX

210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 + Details Name: us-gaap_DepreciationDepletionAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=mlss_DentalSegmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=mlss_MedicalSegmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 51 R42.htm IDEA: XBRL DOCUMENT v3.24.3 Note 8 - Segment and Geographic Data - Summary of Operations by Geographic Area (Details) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Product sales, net $ 2,513,805 $ 2,059,284 $ 6,616,414 $ 7,566,848 Product sales, net 2,513,805 2,059,284 6,616,414 7,566,848 UNITED STATES Â Â Â Â Product sales, net 1,226,716 1,253,367 Â Â Product sales, net 1,226,716 1,253,367 Â Â Domestic [Member] Â Â Â Â Product sales, net Â Â 3,908,491 4,063,270 Product sales, net Â Â 3,908,491 4,063,270 Rest of World [Member] Â Â Â Â Product sales, net 1,287,089 805,917 2,707,923 3,233,578 Product sales, net 1,287,089 805,917 2,707,923 3,233,578 CHINA Â Â Â Â Product sales, net Â Â 0 270,000 Product sales, net Â Â 0 270,000 Instruments [Member] | UNITED STATES Â Â Â Â Product sales, net 180,699 230,615 Â Â Product sales, net 180,699 230,615 Â Â Instruments [Member] | Domestic [Member] Â Â Â Â Product sales, net Â Â 590,250 726,104 Product sales, net Â Â 590,250 726,104 Instruments [Member] | Rest of World [Member] Â Â Â Â Product sales, net 293,966 88,019 701,228 961,224 Product sales, net 293,966 88,019 701,228 961,224 Instruments [Member] | CHINA Â Â Â Â Product sales, net Â Â 0 270,000 Product sales, net Â Â 0 270,000 Handpieces [Member] | UNITED STATES Â Â Â Â Product sales, net 1,040,516 1,007,930 Â Â Product sales, net 1,040,516 1,007,930 Â Â Handpieces [Member] | Domestic [Member] Â Â Â Â Product sales, net Â Â 3,281,073 3,277,830 Product sales, net Â Â 3,281,073 3,277,830 Handpieces [Member] | Rest of World [Member] Â Â Â Â Product sales, net 963,589 706,697 1,969,603 2,232,707 Product sales, net 963,589 706,697 1,969,603 2,232,707 Handpieces [Member] | CHINA Â Â Â Â Product sales, net Â Â 0 0 Product sales, net Â Â 0 0 Accessories [Member] | UNITED STATES Â

Â Â Â Product sales, net 5,501 14,822 Â Â Product sales, net 5,501 14,822 Â Â Accessories [Member] | Domestic [Member] Â Â Â Â Product sales, net Â Â 37,168 59,336 Product sales, net Â Â 37,168 59,336 Accessories [Member] | Rest of World [Member] Â Â Â Â Product sales, net 29,534 11,201 37,092 39,647 Product sales, net 29,534 11,201 37,092 39,647 Accessories [Member] | CHINA Â Â Â Â Product sales, net Â Â 0 0 Product sales, net Â Â 0 0 Dental Segment [Member] Â Â Â Â Product sales, net 2,466,405 2,053,284 6,542,594 7,556,848 Product sales, net 2,466,405 2,053,284 6,542,594 7,556,848 Dental Segment [Member] | UNITED STATES Â Â Â Â Product sales, net 1,214,316 1,253,367 Â Â Product sales, net 1,214,316 1,253,367 Â Â Dental Segment [Member] | Domestic [Member] Â Â Â Â Product sales, net Â Â 3,871,091 4,063,270 Product sales, net Â Â 3,871,091 4,063,270 Dental Segment [Member] | Rest of World [Member] Â Â Â Â Product sales, net 1,252,089 799,917 2,671,503 3,223,578 Product sales, net 1,252,089 799,917 2,671,503 3,223,578 Dental Segment [Member] | CHINA Â Â Â Â Product sales, net Â Â 0 270,000 Product sales, net Â Â 0 270,000 Dental Segment [Member] | Instruments [Member] | UNITED STATES Â Â Â Â Product sales, net 179,699 230,615 Â Â Product sales, net 179,699 230,615 Â Â Dental Segment [Member] | Instruments [Member] | Domestic [Member] Â Â Â Â Product sales, net Â Â 588,250 726,104 Product sales, net Â Â 588,250 726,104 Dental Segment [Member] | Instruments [Member] | Rest of World [Member] Â Â Â Â Product sales, net 261,466 88,019 668,728 961,224 Product sales, net 261,466 88,019 668,728 961,224 Dental Segment [Member] | Instruments [Member] | CHINA Â Â Â Â Product sales, net Â Â 0 270,000 Product sales, net Â Â 0 270,000 Dental Segment [Member] | Handpieces [Member] | UNITED STATES Â Â Â Â Product sales, net 1,029,116 1,007,930 Â Â Product sales, net 1,029,116 1,007,930 Â Â Dental Segment [Member] | Handpieces [Member] | Domestic [Member] Â Â Â Â Product sales, net Â Â 3,245,673 3,277,830 Product sales, net Â Â 3,245,673 3,277,830 Dental Segment [Member] | Handpieces [Member] | Rest of World [Member] Â Â Â Â Product sales, net 961,089 700,697 1,965,683 2,222,707 Product sales, net 961,089 700,697 1,965,683 2,222,707 Dental Segment [Member] | Handpieces [Member] | CHINA Â Â Â Â Product sales, net Â Â 0 0 Product sales, net Â Â 0 0 Dental Segment [Member] | Accessories [Member] | UNITED STATES Â Â Â Â Product sales, net 5,501 14,822 Â Â Product sales, net 5,501 14,822 Â Â Dental Segment [Member] | Accessories [Member] | Domestic [Member] Â Â Â Â Product sales, net Â Â 37,168 59,336 Product sales, net Â Â 37,168 59,336 Dental Segment [Member] | Accessories [Member] | Rest of World [Member] Â Â Â Â Product sales, net 29,534 11,201 37,092 39,647 Product sales, net 29,534 11,201 37,092 39,647 Dental Segment [Member] | Accessories [Member] | CHINA Â Â Â Â Product sales, net Â Â 0 0 Product sales, net Â Â 0 0 Medical Segment [Member] Â Â Â Â Product sales, net 47,400 6,000 73,820 10,000 Product sales, net 47,400 6,000 73,820 10,000 Medical Segment [Member] | UNITED STATES Â Â Â Â Product sales, net 12,400 0 Â Â Product sales, net 12,400 0 Â Â Medical Segment [Member] | Domestic [Member] Â Â Â Â Product sales, net Â Â 37,400 0 Product sales, net Â Â 37,400 0 Medical Segment [Member] | Rest of World [Member] Â Â Â Â Product sales, net 35,000 6,000 36,420 10,000 Product sales, net 35,000 6,000 36,420 10,000 Medical Segment [Member] | CHINA Â Â Â Â Product sales, net Â Â 0 0 Product sales, net Â Â 0 0 Medical Segment [Member] | Instruments [Member] | UNITED STATES Â Â Â Â Product sales, net 1,000 0 Â Â Product sales, net 1,000 0 Â Â Medical Segment [Member] | Instruments [Member] | Domestic [Member] Â Â Â Â Product sales, net Â Â 2,000 0 Product sales, net Â Â 2,000 0 Medical Segment [Member] | Instruments [Member] | Rest of World [Member] Â Â Â Â Product sales, net 32,500 0 32,500 0 Product sales, net 32,500 0 32,500 0 Medical Segment [Member] | Instruments [Member] | CHINA Â Â Â Â Product sales, net Â Â 0 0 Product sales, net Â Â 0 0 Medical Segment [Member] | Handpieces [Member] | UNITED STATES Â Â Â Â Product sales, net 11,400 0 Â Â Product sales, net 11,400 0 Â Â Medical Segment [Member] | Handpieces [Member] | Domestic [Member] Â Â Â Â Product sales, net Â Â 35,400 0 Product sales, net Â Â 35,400 0 Medical Segment [Member] | Handpieces [Member] | Rest of World [Member] Â Â Â Â Product sales, net 2,500 6,000 3,920 10,000 Product sales, net 2,500 6,000 3,920 10,000 Medical Segment [Member] | Handpieces [Member] | CHINA Â Â Â Â Product sales, net Â Â 0 0 Product sales, net Â Â 0 0 Medical Segment [Member] | Accessories [Member] | UNITED STATES Â Â Â Â Product sales, net 0 0 Â Â Product sales, net 0 0 Â Â Medical Segment [Member] | Accessories [Member] | Domestic [Member] Â Â Â Â Product sales, net Â Â 0 0 Product sales, net Â Â 0 0 Medical Segment [Member] | Accessories [Member] | Rest of World [Member] Â Â Â Â Product sales, net 0 0 0 0 Product sales, net $ 0 $ 0 0 0 Medical Segment [Member] | Accessories [Member] | CHINA Â Â Â Â Product sales, net Â Â 0 0 Product sales, net Â Â $ 0 $ 0 X - DefinitionAmount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_StatementGeographicalAxis=country_US Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=mlss_DomesticMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=mlss_RestOfWorldMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=country_CN Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=mlss_InstrumentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=mlss_HandpiecesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=mlss_AccessoriesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=mlss_DentalSegmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=mlss_MedicalSegmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 52 R43.htm IDEA: XBRL DOCUMENT v3.24.3 Note 9 - Concentrations (Details Textual) 3 Months Ended 9 Months Ended 12 Months Ended Jan. 01, 2024 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Revenue Benchmark [Member] | Customer Concentration Risk [Member] Â Â Â Â Â Number of Distributors Â 1 Â 1 Â Â Revenue Benchmark [Member] | Customer Concentration Risk [Member] | E-Commerce [Member] Â Â Â Â Â Concentration Risk, Percentage Â 45.00% 60.00% 53.00% 46.00% Â Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Distributor One [Member] Â Â Â Â Â Concentration Risk, Percentage 10.00% 11.00% Â 13.00% Â Â Number of Distributors Â Â 1 Â 1 Â Accounts Receivable [Member] | Customer Concentration Risk [Member] | Distributor One [Member] Â Â Â Â Â Concentration Risk, Percentage Â Â Â 48.00% Â 39.00% Accounts Receivable [Member] | Customer Concentration Risk [Member] | Distributor Four [Member] Â Â Â Â Â Concentration Risk, Percentage Â Â Â 3.00% Â Â Accounts Receivable [Member] | Customer Concentration Risk [Member] | Distributor Two [Member] Â Â Â Â Â Concentration Risk, Percentage Â Â Â 15.00% Â 38.00% Accounts Receivable [Member] | Customer Concentration Risk [Member] | Distributor Three [Member] Â Â Â Â Â Concentration Risk, Percentage Â Â Â 11.00% Â 15.00% Accounts Payable [Member] | Supplier Concentration Risk [Member] | Related Party [Member] Â Â Â Â Â Number of Vendors Â 2 Â 2 Â 3 Accounts Payable [Member] | Supplier Concentration Risk [Member] | Vendor One [Member] | Related Party [Member] Â Â Â Â Â Concentration Risk, Percentage Â Â Â 38.00% Â 37.00% Accounts Payable [Member] | Supplier Concentration Risk [Member] | Vendor Two [Member] | Related Party [Member] Â Â Â Â Â Concentration Risk, Percentage Â Â Â 12.00% Â 17.00% Accounts Payable [Member] | Supplier Concentration Risk [Member] | Vendor Three [Member] | Related Party [Member] Â Â Â Â Â Concentration Risk, Percentage Â Â Â Â Â 12.00% X - DefinitionRepresents the number of distributors. + ReferencesNo definition available. + Details Name: mlss_NumberOfDistributors Namespace Prefix: mlss_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionRepresents the number of vendors. + ReferencesNo definition available. + Details Name: mlss_NumberOfVendors Namespace Prefix: mlss_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionFor an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20 + Details Name: us-gaap_ConcentrationRiskPercentage1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=mlss_ECommerceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=mlss_DistributorOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=mlss_DistributorFourMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=mlss_DistributorTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=mlss_DistributorThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsPayableMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=mlss_VendorOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=mlss_VendorTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=mlss_VendorThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 53 R44.htm IDEA: XBRL DOCUMENT v3.24.3 Note 10 - Related Party Transactions (Details Textual) - USD ($) 3 Months Ended 9 Months Ended Apr. 06, 2021 Jul. 10, 2017 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Mar. 02, 2021 Mar. 01, 2021 Previous President and Chief Executive Officer [Member] Â Â Â Â Â Â Â Â Â Increase (Decrease) in Deferred Compensation Â $ (100,000) Â Â Â Â Â Â Â Employment Agreement, Base Compensation Â 200,000 Â Â Â Â Â Â Â Consultant [Member] Â Â Â Â Â Â Â Â Â Increase (Decrease) in Deferred Compensation Â (100,000) Â Â Â Â Â Â Â Employment Agreement, Base Compensation Â $ 200,000 Â Â Â Â Â Â Â Deferred Compensation Arrangement with Individual, Compensation Expense Â Â $ 50,000 $ 150,000 Â Â Â Â Â Interim Chief Executive Officer [Member] Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) 2,000,000 Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year) 5 years Â Â Â Â Â Â Â Â Managing Director, China Operations [Member] Â Â Â Â Â Â Â Â Deferred Compensation Arrangement with Individual, Compensation Expense Â Â 50,000 150,000 Â Â Â Â Â Director Clinical Affair [Member] Â Â Â Â Â Â Â Â Royalty Expense Â Â 124,000 104,000 $ 334,000 $ 370,000 Â Â Â Professional Fees Â Â 39,000 117,000 Â Â Â Â Â Royalty on Net Sales, Percentage Â Â Â Â Â Â Â 2.50% 5.00% Director of Clinical Affairs [Member] Â Â Â Â Â Â Â Â Accounts Payable and Accrued Liabilities, Current Â Â 132,000 Â 132,000 Â $ 114,000 Â Â Interim Chief Executive Officer [Member] Â Â Â Â Â Â Â Â Royalty on Net Sales, Percentage Â Â Â Â Â Â Â 2.50% Â Manufacturing Agreement for Handpieces [Member] Â Â Â Â Â Â Â Â Related Party Transaction, Purchases from Related Party Â Â 501,000 $ 636,000 1,700,000 $ 1,900,000 Â Â Â Accounts Payable and Accrued Liabilities Â Â 720,000 Â 720,000 Â Â Â Â Manufacturing Agreement for Handpieces [Member] | Related Party [Member] | Accounts Payable, Related Parties, Current [Member] Â Â Â Â Â Â Â Â Accounts Payable and Accrued Liabilities Â Â Â Â Â Â $ 402,000 Â Â Purchased Medical Products [Member] | University Pain Medicine Center (STEMMEE) [Member] Â Â Â Â Â Â Â Â Related Party Transaction, Amounts of

Transaction Â Â $ 6,000 Â $ 15,000 Â Â Â Â Â X - DefinitionThe amount of annual base compensation pursuant to the employment agreement. + ReferencesNo definition available. + Details Name: mlss_EmploymentAgreementBaseCompensation Namespace Prefix: mlss_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRepresents the royalty percentage on net sales. + ReferencesNo definition available. + Details Name: mlss_RoyaltyOnNetSalesPercentage Namespace Prefix: mlss_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionSum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionSum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe compensation expense recognized during the period pertaining to the deferred compensation arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 710 -SubTopic 10 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483043/710-10-30-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1 + Details Name: us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the obligation created by employee agreements whereby earned compensation will be paid in the future. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInDeferredCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionA fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (k) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_ProfessionalFees Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of transactions with related party during the financial reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3 + Details Name: us-gaap_RelatedPartyTransactionAmountsOfTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPurchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party. + ReferencesNo definition available. + Details Name: us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_RoyaltyExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPeriod over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: srt_TitleOfIndividualAxis=mlss_PreviousPresidentAndChiefExecutiveOfficerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=mlss_ConsultantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=mlss_InterimChiefExecutiveOfficerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=mlss_ManagingDirectorChinaOperationsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mlss_DirectorClinicalAffairMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mlss_DirectorOfClinicalAffairsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mlss_InterimChiefExecutiveOfficerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=mlss_ManufacturingAgreementForHandpiecesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=mlss_AccountsPayableRelatedPartiesCurrentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=mlss_PurchasedMedicalProductsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mlss_UniversityPainMedicineCenterStemmeeMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 54 R45.htm IDEA: XBRL DOCUMENT v3.24.3 Note 11 - Commitments (Details Textual) 9 Months Ended Sep. 30, 2024 USD ($) Dec. 31, 2023 USD ($) Advances on Inventory Purchases $ 1,011,306 $ 1,371,548 Purchase Commitment for Devices [Member] Â Â Purchase Commitment Number Of Units 1,000 Â Purchase Commitment, Remaining Minimum Amount Committed $ 1,000,000 2,300,000 Advances on Inventory Purchases 547,000 1,300,000 Development of the Next Generation Instrument [Member] Â Â Purchase Commitment, Remaining Minimum Amount Committed 158,800 Â Contracts for Funding of Future Epidural Instruments and Parts [Member] Â Â Advances on Inventory Purchases $ 168,000 $ 41,000 X - DefinitionThe number of units commitment to purchase. + ReferencesNo definition available. + Details Name: mlss_PurchaseCommitmentNumberOfUnits Namespace Prefix: mlss_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionCarrying value of capitalized payments made in advance for inventory that is expected to be received within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdvancesOnInventoryPurchases Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionMinimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=mlss_PurchaseCommitmentForDevicesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=mlss_DevelopmentOfTheNextGenerationInstrumentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=mlss_ContractsForFundingOfFutureEpiduralInstrumentsAndPartsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 55 R46.htm IDEA: XBRL DOCUMENT v3.24.3 Note 11 - Commitments - Lease Expense (Details) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Cash paid for operating lease liabilities $ 30,373 $ 34,320 $ 95,645 $ 98,083 Cash paid for finance lease liabilities $ 2,685 $ 2,685 $ 8,055 $ 8,055 Finance leases (years) (Year) 3 months 14 days 1 year 3 months 18 days 3 months 14 days 1 year 3 months 18 days Operating leases (years) (Year) 2 years 6 months 3 years 6 months 2 years 6 months 3 years 6 months Weighted-average discount rate â€“ operating leases 9.20% 9.20% 9.20% 9.20% Weighted-average discount rate â€“ finance leases 9.20% 9.20% 9.20% 9.20% X - DefinitionCash paid for finance lease liabilities including accrues expense. + ReferencesNo definition available. + Details Name: mlss_FinanceLeasePrincipalPaymentsIncludingAccruedExpenses Namespace Prefix: mlss_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionWeighted average discount rate for finance lease calculated at point in time. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeasePayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionWeighted average discount rate for operating lease calculated at point in time. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant XML 56 R47.htm IDEA: XBRL DOCUMENT v3.24.3 Note 12 - Subsequent Events (Details Textual) - President and Chief Executive Officer [Member] - USD ($) 3 Months Ended Dec. 31, 2025

Sep. 30, 2025 Jun. 30, 2025 Mar. 31, 2025 Nov. 08, 2024 Jan. 01, 2022 Cash Bonus Compensation Percent Â Â Â Â Â 33.00% Share Bonus Compensation Percent Â Â Â Â Â 67.00% Forecast [Member] Â Â Â Â Â Â Consulting Agreement, Base Salary $ 350,000 Â Â Â Â Â Payments for Consulting Services $ 66,666 $ 66,666 $ 66,666 $ 150,000 Â Â Subsequent Event [Member] Â Â Â Â Â Â Cash Bonus Compensation Percent Â Â Â Â 50.00% Â Share Bonus Compensation Percentage Â Â Â Â 50.00% Â X - DefinitionThe percentage of bonus compensation. + References No definition available. + Details Name: mlss_CashBonusCompensationPercent Namespace Prefix: mlss_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionIn reference to the base salary for consulting services. + References No definition available. + Details Name: mlss_ConsultingAgreementBaseSalary Namespace Prefix: mlss_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionIn reference to the cash outflow for consulting services. + References No definition available. + Details Name: mlss_PaymentsForConsultingServices Namespace Prefix: mlss_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe percent of bonus related to shares. + References No definition available. + Details Name: mlss_ShareBonusCompensationPercentage Namespace Prefix: mlss_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - Details Name: srt_TitleOfIndividualAxis=mlss_PresidentAndChiefExecutiveOfficerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=srt_ScenarioForecastMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 57 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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Ÿ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

>)75S2BTN."HTI&U24S,IQWZ23".HFE&<11XGETG]@90>&ZE<*\K+.;YTQ!1!(/CX1: M[((H24@\H?0$:=BI]&L)#4TN_H:EN8%&!D$N08ORC=<,$@E5/-VKIA1;Q>,7
M%X+%)"3>E&HRJ"9.U;%4YUI K4]"B?D#6C#3FX8I4GI_F@N MU_,]K E65;RV"J:&FHA@/QF+-LW"Q LG$A\/-,*^&\A;*)^06WH1#"S68BO$
MR@SE@JU$/LUE[*3=6\\7K.=!V.@'W;C[^)3F4)B5/P2UEE[I0/#TE3N='-"8^J-P6@QC,.03-1)/* 1N]EX5#^A^6>XSILN=L?49':; M+)Q3#X]+J,5LJGP.O,1N8)[*%QV1IE2:
()QC+Z)^8"2[Q1)*J!],=$IX8"9V M0_/^N$(N1+I]=.."S RM3R"@H BGT\@H:6[L/)BYIJ)NXL0>FW9Q&- [(A <# M6+&;K*K[L1^.$6RS"P,ZP3(R$)BX"7S4>W$L-)@#89H$W<>\@^X@.R
MFV9#=QVZVB/ :S*+8C%OA?3DYAVVBV68.A1.L$I,F"6A&\ZP]"LJEYSAD&<^'YKK_1> MLYU'8: U<=/Z8:_2;;,&UVB]5Z6H]PKJU5K\T!>01AH@_/M>[/1QF34<%C2' M01*.GZ2-
]3B9H!\9^$W<_'YD>2/^U1L?8H*8)%$8&+MTBR&4!Q+X4TMO(#9Q M$_LTZ*_7;4)WW"593.9A0A*")VHM'4[S78> MA0'WU(U[_4 ?E$PYSRJ@)E>I:!?D$U.*E?8.D9HH#W
4C+LMB]G44SLY<7;# M_H$]MP?V[>,ZTE&N MU0N3X(3"3G/<'%KL7&X,H*&(!?MAX/OAI"\#]JE[=WTW)1BQ&JWX1I2E?B"0"-#,"))E9_;"<1T,)B\QU M91K&$0Y(-'%(0
=N4S>WG6YPO>ES.F#"V(^B($B,,FP:$AQY03+1/-*!V]3- M[8<]9&Z*_EBO024$_+^?>;'BZG]6N<:K,^@E<3#N.BUV8QM(M 3MXI%UQMFE?
M%6IV\.T+VO[;_G7^Q^8E]NC[6WQUU[Z4'Z9I_X_ 9Z:@KE2 MK#5,Z7V(()]4^]J]_5#+7?/F>B7K6A;-Y9:SC"MM +^OI:R/'_0-^O_\L/P' M4$L#!!0 (/6!;EG.,?C&BP0 -@) 8
>&PO=V]R:W-H965T&ULC599R,W#/XKQ"RP3XFO))O#!^ C:?.0 QFG"[3H@ZRA/4(T MTE32V/'^^I(:7T6]QK[8(XG\]/$C1:FWLN[#YX@!/@MM?#_)0RCOFDTOZ M9/MH\
(?"E3_X!HYD9NT'#QZS?M)B0JA1!D80]+?$,6K-0$3CGPUFLMN2'0^_ MM^@/,7:*928\CJW^KK*0]Y.,;!#*M-K'7UAM;%L)R,H' M6VR;+UOM<,M];-^4&0M/ MUH3X)LI<[MLI>GT
>'B3F#L37>:I7M_3*6YI03]CYT9A@HKS4UE<.X:\I?@88:2L_ CX6 MZVDVSR_3>ZJ7E[??AL^/?PZGCR_/,'R>P.@]?7R^3U,8:LV'%1T:22(K R%7 MGJ9*ZP)K_O7+3:?
3ZCXIC53=!B&5BCBJN9)G<:W=)1?28!,2=K&-X[S4K6C71DB3^GCP=QJ:I;*+"BF MA?*!Q,S@O9$V(#B145>FCGT'8R!I*F8*76"9J@=MZ7/RFL)D;41!Z%P<,>LI
M]U$"#"AS8[5=&,GR*""$B$?YR@_(IF]$7DQ?BKF&-91)AI,AY 2L$:86HH: MAM0SR,TK >F:J!=DQ*93@HH^/]%A);A8I'54)$SKL7*P+F(69H):K(1C16%8
M+:@U0OOVYK8!=,XB^D&EM*^[GGKS4DFD],3 M_O3N;R^[%).P=>T*TI2IGQI MO9C1,">;4B$[4FI8:MRPR9BJ#VY-"<^XT@AQGX\Z S$;OZ#)5;NU3]D!>6KY
MSC%&O3$3GUNZ!I@+767S\XP9J%D5RZ^.C.L9SZ4M"G02H=0B\&7=A=RN<(F. M @GL+[2W6U5+9R77+.E:8+W/2A'3 KE:-;64L-O<.A_M-VCO M1K%&,55T@IY4EE'L]X)2Q-[WE:-
'!-#N(G9=0J/'0%D?$I"DN$$=N1Q&UX Q MND#/"EZPE=MQ4X:.JKJOY6))Q3%C,JQN) R,[Z. ($H*=$D^3$/2P@SW*>4Y
M:@(QMX4EKCMW:2L3N!LTCO7OYL%M2Y(OXIO"UT[UQ;N;W3U;AO5MO3>OWSQ/ MPBTH'- X)]=6X_HJ 5>_(^I!L&6\NV:#-;V5! . H !@
!X;"]W;W)K5)]33]T6!PU"^5MIW)6=]|\9,S5T>C+=]X M"G59*K^Z8..6YYUA9[/Q7<^+*!O]R5FEYGS+\;ZZ\5CU6RNY+MD&[2QYGIUW MW@]/+\8BGP3^UKP,.^\D3*;./&0@@-
IQ%L:#PL^!+-D8, <:/M, MHK99[05N=!%:QH6 >@G89OG&51HI;D:OAZ.CW@"=:0QV&D.8F%Y%@;+66TIT
MUB*IO5Z/>\>;C2YAM(*A9R:+K!!J'1"G".NFX*E'W^R^_2Y=:\,8$]*6:=#2 M,YV!04Z9"D7RE5X8S8VL)=Y K:K*NT>-H<9F)6A.GL"309HBJ2HM])]K'/7> M;CE?)?R_1M]-1O%Z@-4
']. BS6P*&[^ZV\IM7)Z/A M\;O0=G&^497QL41* 1$&L&T3\)W&;^:%RIMA S*;6MV$<*&0Q!I)QZ1O!DIP MM1>Z-98&]A#X0@.4%(:;0;FQWB4]D\'E>_3%MA[$IT#@LC)NQ1R>,
%_DZK5 MTN_Z#PEF]'I:1^[M[;7H?7,;V(HW=ZIKY><:L30\@^J@=WS8(=_<4YI%=%6Z&TQ=Q$TCO1:XVK$7 M 7R?.81OO1 '[65Q\C]02P,$% @]8%N61 8RT,D#0 7R(!D !X
M;"]W;W)K&ULO5IM<]NX$?XK&%U2=69H62]^C1// M.+9S=>?B>"*GUTZG'R 2DE!3A X +;N_OL\N)*R9=^73C]8IDA@W_?975 ?
MU\;>NX527CPNR\I]ZBV\7WW8VW/Y0BVEZYN5JO!D9NQ2>GRU\SVWLDH6O&E9 M[HT&@\.]I=15[^PCW[NU9Q]-[4M=J5LK7+U<2OOT695F_:DW[*4;W_5\X>G& MWMG'E9RKB?
(_5K<6W_8:*H5>JLII4PFK9I]ZY\,/G_=I/2_XFU9KU[D6I,G4 MF'OZGX4ZS#VH-13^2U\V89-T."I:[" M?_D8[=#9<#QX9<,H;ABQW($12WDIO3S[:,U:6%H-
:G3!JO)N"\$5]T):M>WZAO([6\G1XGTP:UDKC[UD"E. MV0?5._OYI^'AX/0-8?<;8???HG[V!^X1_[Q3CUY\+DU^_Z]MLK])?;OL-]_N MKA EDQ]?OYY__X?X]D5,KG^YN?YR?7%^]
M'N+\J)@C^]V)G=XOY^>WO?>9D%7!S^5J!0/+::F$K8D4/;!J7I>\$BM)ZR8J MKZWV.JZX>LP7LIHK&*W(([!;&=R=?$>?/.R+E0@'H1E(E\U]'M3@13\"0W@
M:R:E\7RJ,"2\65>0E6XNY;\-V*5;KIXZ76AIP3^++&""3/Q&BRJ!#K;EZ)VO$2!(RQM%LZ49D*!+V%Y12T$0ZWKBU^-<^1B[ZV>UK0" M\$JQ0W6CH(61&'2;9PZD8YH0/FUP1E]<8G
ME+E:OE%(H! <:9.#G^$X(. MHQ\.\ORWE$^M&<=#-MF85HV# MT8)R@33$V;#A'U@NA"E1)MG %=H<64\@LY;T2L+->LNZ4 M,-*A15H%#4"M4%
1OU8.JZLA1/:XHS)PH0KRV0G- P(NF"&9>&N>[M4-(QA%4E"0,+Z0JTO4%O\B#+.OB$V.32+<0,7>6&P8#(TA+D"=4L9Q'G)M:9 M7-F
)+IH4XNDN0CEB+L\QVC;B@.>"XULH*@L64,@+$AEXKX"+@+U5%4$]0/H MH)FZ5W[7K53.B8-(A$]0"5K. (_&1N#2'OE4:AB0.Y IV4HZ4W&EJ9&Q-@"D MMGF]A"L(2@&09 -
(%;2"Q!IPWXFLJ/P+/21Q!2@Q(H7*%$*V2SYC"5MG!E7[MX])=WZ'(T$;YW^9S\#%]6R]TSHD)LV+14@$[H8CDOH8ED1#HGQW\49<4J[,9 M])U9L\0>XSJ9T1?[??
$]A!G^YP9!T[02R7,VW/\QT]8NEX J\@&H9D&=3/U M&%::BA9.D0Z\%CF!MHJ'!-X%H"J56W$8GL MQVL-2:8QGYZ5>].749!S_VIT*"2H*@A NO&$OLF,8J1** 7"3,M]5PFA(L] M2I?
8$V\!= $R\AT6:ME3 M%ZLY[3:<"O(/?8&Z93:-]X(X^3A&_U9-"5<*XI."FEJ!T"GP?G?*&0=F'2]W MT#7$\@X,*]W[#><[<' S G(E$7_;!4#.O?)$:+@H^8\#OK$MZT2*4E[*UB/D
MXXZ+D^I-DG&_&H*QAB)R0F[6AU2;NYM0WEGXM5AF:E*E9:<1JWR!PJ2]%0V92"/.(VN$!I M^,.#!Y2DR !YZ[:W+F%8L*:>HPD2\]*@;62C<9-(IJZ4IW.*B/UA!$!H0#0"
MA;)VE+!$!KWD;GMG@X:<6Q4+,O<72:/ 7=NB 4HV7U2$3>C(*PU,8M1:F!U M<&P0(BK*9B<4EXUOLTXCQ]M3UT#]. DFU:= %=]KB:I<&(&41*^=248;MTB*9?2EH0?
LID]L&,#FRLRM7"V>0J/6! [8I#TQM1OVR=#) M1*P&9#P9Q,"(GVLC+K63\SDU>LG#*=R[X1(&IUC)L"L.4M#'J3E+\"&!!L_1 MJB!#SN8;4YW)L)G=W1$=Q8K/2*OMBOCPI@3)6F[
MXRP$FO-TEQW)8T\%(3O-7;.<8E4)/L,[)MS!%\2DVC(.A@'G #T<=]%/><=@BX^0)97VIL*[@Q=SXX$UHA>%ST&_>F"%X=!/=U.*&8 M11FWB!< ^N5(EKTVACHZD+'FD0LI9%IJ5-
(X&;P;]P?I1D8>!!8,*%JR#'FR M %^HU@+]B$Q;Q7M%C.*9&. V^\-&%NJKP2-[P2E+0S//3UP* /5*4OM-,?)9) M%8Q
EW"T0_6\1M&Q#"P7!M$3FTW=W*7C%$[N=Z.#0388#/IBL[@VD!'&$FYR M7.>@BA%NB6K'SPZR#JGJ-=M.=YF M5L*9ESX?BT-QU$]GFU0,J&]FF4FEJ]T\51)*
QI0N69WRS2&,5$[#EL:J/FX M@88X.NUL$>A!(U.!-; =3\[JBJM<4I&A1W(3P!46S1\]=UQ M'U8)$RV9OGL=STJXLD8<(&=@$M=NT336'+IP%F*Q(CBUT(1'|")5.%2A5,Q!
M80<$+/Z'3[)@9XYN*E;.OJ3:6:EUV+B)6\T8GL7#2"IHY,"3OOB,E>&,\E*7 M?!AVHSP?D8E;2$*5\'PF"[+5UD3BHV9R"07J:'!*K'.^'IZBI[54:9W8*4'Q M/36Q9 BZ9ADYVB66[3PR)O\?F'*
(D8!@WG=T.,A>QTN(.DS=Q_&VH?^OIF%UFD#5PTC@[/-[/#D^.V'7C[2+ M#@_VX?*WV0^!+U^DMAQ(*O7Y<08B,%OS-,]'&3SR\N$H92EW27161;/#2NKB MV7R1SJ2>XMA-'9DM-
PZ50=:OZ0 R0!DG@*:LB8=O49202&E13(SNB,A=ZXYZ M1""SY._[S[K-V(?4/+OG)<36LR'6KAS!@F^_FGD\.CDU/Q*SJ24@R? M?1^]N#/N@.5KAW@$SH&]#MU$Z#)2IB-
32Z9%TU&UJN,I!;S2/5F+L;A=_+[X M5EOF[UQW?FX)Y-SARRIQ>(M:>]3Y[[H(#4YX4_'T>H'=7@F2%9/UDLWN*(#% MU[:6=5ZZO*3R3HRRDZ/#[."(7G3N;GS?
3B/.987X,1%WJ11VZJ4G_M1*OFLI M-6\A.J-",_;[)KX4 WPEJ(:@<_LY38##,5PB":/T&7W,SN>XE-5+L#W]E=% MQ3[62'[ML,5GMP!%EB;_R].3G>"9*.C@=I5?N_ M>^\8\)2^I"ESF-Z*;-
XX"*\$7JQZ[HE]>C?PG"F$?_8J)CPYR>B]&9UUWLE' M>I<8+;R?2)R$8SG^2'>>R96Q7.GAMK?&>YV7_NB&YOS3!CY(K7QX_]_<;7X] M<1Y^-- N#S^]0!+,Z42T5#-L'?2/#GIA]$Q?
O%GQ3PBFQF.2X\N%D@@@6H#G M,X,1)'XA!LUO2L[^"U!+ P04 " #U@6Y9^":0AQX# "L!@ &0 'AL M+W=O)<<4&K9 MHK:2-!A6R]/;!X(?$K3U:@U?R3/3B-[?U/$H]
(518.8\@^/6*5ZB4 M!V(:_^PQHT-([WB\?D?_%K2SEF=A$K4G[)VS3R:1E#C6O3*/=+V=]SKN?!X M%2D;GK =;(LR@JJWCMJ],S-HI1[>XFV?AR.':?J!0[YWR /O(5!@>2V<6,P, M;
<%X:T;SBR U>#,YJ7U15L[P5\E^;G%/#J&$SW"K7U${,A+M+'&,[+\GU1YE M.:#D'Z\\@3O2KK%PHVNL_^^?,*,#K?R=UC(_"[C";@1%&D.>YN49O.(@LPAX MQ1F9%AS!-
ZF%KJ10L'+"(;>7.ZEW@"M/P_F;$\XJM@T;QBM/CUEVR< M_G:&;'D@6YY#7[R78@?7TE:*;&\0_GK"-P=+1=7+WZ<(GX4\3?C^^],-U_[V M_L?-_=/WQ]N;U7$70$5\]:P#6H-K$-:D^
9+O;D$K@ZG[AG-H41PC=7^) LG M!9]HQVE>2RVY/6O8$-46/D$1CXM)7%R,>9W'95K&7R8IW&&MJY_-/T-6QI,B MA2MJ.](,"9TPSH+0-1#3,GP9'!HNJ(5)&>?3%/)L&I?
3,3R1CR^/%/G@DRQC M D/P<3&-,V_)\GP H7?0",O#IB++#C0B C/,QF'CJ OSZ)D<3[>P;/AW@L8;\&UL?51+<]HP$/XK.VZGIQ0;0QY-P3- DFD. M(9E TT.G!V&OL2:RY$HRD'_?
E6P<.D.XV-(^OOUVM;NCK=*OID"TL"N%-..@ ML+:Z#D.3%E@RTU,52M+D2I?,TE6O0U-I9)EW*D481]%%6#(N@V3D94\Z&:G: M"B[Q28.IRY+IMRD*M1T' 6
O>.;KPCI!F(PJML8%VI_5DZ9;V*%DO$1IN)*@ M,1\'D_=.CLO<$+QTZ(/+9*74]O<9^,@R+DP<"LSS/[W#XE;1S#>$YS&)P?76/5@$)U!',7#$WB#+N&! MQQN<2-B
57#')27,F8"%91:IT8[GV\ -C\.YF;DV%4MQ'-!0&-0;#)(OG_H7 MT?<39(<=V>$I]*1[%.*[?Q1X8++.Z5!KU/![3L$+4Z'2US_'V)_&GS\N;^GU M)SC8P2+
MY82F8L/)Z0RPXEFMJ<1<&JMK7^,S8#)[UQ"6H/)Y%51,TXKQD5=,N,@.V7Y M!)AQ:NH0>KX5%6/?)C["#::MM.^E ^ &6%5IM>,TS2C>X'._%]%0'>'W _F0
MX&B/A0<#5J)>^S5BB$@M;3-KG;3;5)-F0- -FS7WP/2:J@$"I?G >AF M=307JRH_KBME:?C]L:!MB]H9D#Y7U,'MQ07H]G?R#U!+ P04 " #U@6Y9 MC[7&%<4& "V$@ &0
'AL+W=OPIC5N\&@SA=R*6I? MK62%D9G22V%PJ^>#>]6EF-I)RW(0!4$ZG(JBZAT=V&=7^NA K4U95)*4[U> M+H5^/)&ENC_LA;W-@^MBOC#\8'!TL!)S>2/-
+ZLKC;O!ULNT6,JJ+E1%6LX. M>\?ANY.$[:W!YT+>UZUKXD@F2GWEFXOI82]@0+*4N6$/ O_NY*DL2W8$&+\U M/GO;)7EB^WKC_;V-';%,1"U/5?FEF)K%86_./BDC*:4^W1B5?UVH#
M@<$2;#C(&WQAM;?_&.>&LRBMX7E:CR0I2(7!@)GIFZ*U[G+NEVQRWSKEZ)7![V MT!.UU'>R=_3]=V$:_+@#;+(%F^SR?N2J0/^YE0^&3DH4Z+]=$'<[^71Y>XX*
MW]Q>GO[KI\N?S\ZO,^C\W[]2D9C.IBVI.EQ6=R5PN)U)3Z'(> M>Y0,>>"#J-;H6@HC5POZ(K062!K=+B3-5(GV9A]&3$K9]CQ:0=5$XZ;]. MH M4+X3F@;I>6^,UN*+I?
N,/)K41U92]"=S.""0P#M6&"9O5-[[:<[[83I13 M.KZ3&L)"\D'JO*@EK721RY?C6K)Z\=2RF$FZJ RR42,Q=Z)<2[ILXS%/B6B0 MQ&'B#4<1!?XPP$\8T##S1O&(+A ?5NDW?^<-
BBGMAT'L#8. ?G"3W.BJT!A3 MFG+P$BK%AE$8>@%\MPR?H:FFF^!L(H&N(U4; &=K6V2#6/T#89896:B@RB;@F+MB;04P=K\?#=L+-+Q_,4C6%GW
M?:/Z$]EW[KUG[/ES>3G'K@\P;R7M)E(^4NP%V=C+PA%%7I($7CJ*Z9_2, M M*BBWUE 46J&QU)22>.R-TS'%Z=B+QUMJO#3Q%P9<\?X3UE8JVE [(GX5 M;3A.O'0<
^TXR+P@#9S@T^6*&[.FJU)4KI4_%J7$ML.9S@M *V;HA(LJ]STZ MADI"UNTJUS 2'"V6"^C[[\91%/QHKS^L,3<:-PEO/0KBT,?>]4B5,JBGEF % M\6OJ&6NYI7E1ZZ6.(/43D+D U]SRZ-
[+2NTA$S6!?8QUE_N\":9#!,I9IL< M&SUO[KJ],M+UBCIH?4M82CVW7TSX#+:NC/NL ML'VZ_2AS[+Y%)/F[+SH?A9Y#VJF4,TP- -&P1]I])7$W1JWLEXF),D8M[>5" M"C"?#3
^4WA;,VYX@>VGJJ,_%!+ P04 " #U@6Y9W0UHM<@" #*!0 M&0 'AL+W=O]%1E!9>XT&"JHF!Z-T*A-OW@/'@Q//!U;ITA'/1*ML8EVF_E0M,N MW+.DO$!IN)*@,>L'P_/K4X?O'#?F8
TNDD>EGMQFFO:#R E"@8EU#(RF M9QRC$(Z(9QI.(/]E0YXN'YAO_6Q4RR/S.!8B1\\M7D_N H@Q8Q5PCZHS1=L MXNDZOD0)XT?8U+[M;@!)9:PJ&C I*+BL9[9MWN$
5AO0SIO8W,*'ZM$DCDN7E*75=,H)9P=S91$NX2-,9:(*A!7;HNF%EJB= M0Y@T-*.:)OX/S2>8*6ES Q.98OH6'Y*DO:[X1=@,XBCNG.!K M[^-L>[[VB3@-6
6W7#*9<"9@:9E%^E_V:+PU7>?# @J3U0(]#D M)]= @@R]9L%VT+Z*_3R5,"PU%SY?9["HM*F8M.[%+=TROYO<#*'4:JU9<>9- M8U643.Z@H$].Y6VI@0"#,M\9GE!V_+/*!
(',SMVX;#F%B$@5Q2.5A>ZQ](4'J56@7OLN M8B!1E;1UJ>XM-T^8UK.OSU;WN>H-U:5OEH?E:7: M]N&P=O=V]R:W-H965T2=Y,^NM[+8G)N5(]"

MC,LHF_C8G@W<\W5%+A!GDX:M,4=Z;.ZT M]>*>I>0"I>%*@L;5-+H8GL_&+M\G/"<;'>C6 "FXYI+)@K,:F805.(SL1!O4& MH^SCA^%)\N6 V'$O=GR(/?OO0.#G ^X(9K4JGG^]I?
8PW^+V8>Z..G^@P]0% MAU3C; I2D9T;OZSL0X7:)=C]E;+GWSFN0/_T97\ 4$L#!!0 (/6!;ED? MM+E/< (%,' 9 >&PO=V]R:W-H965T@F MXFS:T J6@#^:6VVMN%,IF
!IF))$0SF+YOVSQ<3Y>X>?#+;F8$Q<)6NE'IQQ M6KGBQC_)MO4=V8SYQJ 2NV!K"R;;-WW:[<-!@-4Y M'I#N E+/W2;RE%\ITFRJU99HYVW5W,"7ZJ,M')/NHRQ1VU5FXS"[M-M;@"8K
M30LF*S+7FLH*[+:CF<9H,SB_-^1+5JU] 6US^1:2:P-^28+*)['QY:LPTOW M>(LT*+B$ID<&R2>2)NDPH#?HRAUXO<';RR57UH=<(HBC!:=ZP^-
Z[LB?)^QK#V:XRG'>/IN_;0_01,TC!B6/HUQ$F'.'GW-KX) M,RS_(F9\T.@$Z,JW7C?75%=,&L*AM*%)[]3^ M@+IMX:V!JO%MNQ-UE(XE[I.2U^]?W
MFR$I:6U9N1R*XG"Q5B+G/=_,4'J[,?:+6RE5B8S?V_*VIJUR7ZL8* M5Q>%M(_O56XV[W8F._'&K5ZN*KIQRK,1%FIJZK'2Y%#K-&^1G3F[U KT_AWR[FKK((EG_U*>SI'?;3HPQZ
M[=8R5>]VD").V7NU<_[]=Y/C\9L!:0\;:0^`])]?FM)!RDQ2."=>XD?Q6_C[M23U4XGUNTB^]@@^3GHS$C=5EJM^5F"M5"MAD+2W6Z9+)V0RK%0*^6O'OX(IU M*\E2EPRQRGBMA
M:R)%#ZQ:UCFKQ$K2NCN5UE97.JRX?DA7LEPJ&* HM&/LV;V[OMP#WS0Z,^6) M>V&9R(\:U"M3@A3B!QH@F9B4QO/-RI#P9E-"5KI9R'\;L(NW7#UW.M/2@G\2 M6, $B?
B5%E^!'&RYVZ425&RY?BQ+(_$S6%FWTFNBK1#Y4!TKMZ*$^9&9 MJY6L!,) K%0.=H_M$P/2EIZ7HG:\! %C+.V63I2F!,'*0CF*DBU.IK;;W((6
M@H'1C<0/QCER<559/:]I165>IKC%VE'0@BA,VL>I$^F(!E1+ZYTQ$E<(+)"] M4JDJYE ,H#5+Q-GI7Q!T"&6^%\$L&<"'HP8?C@:3^+UTFH5H8>U;46*8P73$ M2-#F.PR1H4#
[J]8DO3#P4JK\/^"!;%(HB_@7NP04>P+MC/>W+CKBZM*W.93U MS)9(Z1+UH X90ONH&Q"3L3@5_QPAABK^OY"/K:=G$_;J#*L&_'K<^/5XT.R? MG2(-KEVE"U+G6YTZ3'WFG>J-
[U4'LRT??\6S/M/)<@0H;#+::L*^07)514AC%'.C2%:V]A4,L4' /$(6^3!UH4*!K8Q195^=VYEG.= MMQB>:9?FQM66S489#D+$?&MAQ:1)K5@*>I7S9>,Y?ZON55D'CNIA36G@1.93
MOA6: Q919C)OYL*XJHO&'4-8E9,PL) N0;LR]E'E5'XK)=WZ'(U8'PJ<4;[V/ZM5GIE($##9L6B0GE[H0ZG M50U+(B$P,#CXH\XI5A<+Z+NPIL >XSJ9,1J CI,&.DX&D_O61^D?
18IA8HG=0C/$<-,^*R+'^]3S 82YC88ZU[0B35RWUF]$(G?R6D/2*8R [,W8YQ&@ M>\, 8XT<,>180K9&'=MJGFSQ"0N]4 NT%&9#@;I@AB,!$7W!:R"6P^9%O3N=
M%D\C;X0&E8B,#1%8-S1-@\0H9(. 7%/-/-=+&0$W=)U=8H^\!4@*!$NKKC 4 M04'ZKFP0KD 6 W0Y&\.*3G=)=9O0HV47O8=%FK:4@#NK&06VG KR]R.!,F^V MC?
>,./DX)&.OI@1S&?&).4;-G>_]>+]PP 9ATO=\#>Q_(N#"O=WI;S'3BX M!=45)1%__0(EYX(M"WR>@_#OC&MJP3*4HP(5N/D(\[+HZJ-TG&$X@/QAJ* M<,GT/131O[B[%,?CX^TJ
'OK^X"?37D+R(1.6N9<*>DI),W0$2$Y83?@OIYU M-P\KOEOBVIF@MRNSM5:<5M>TH88D,IH/]]LX6 M#;FT*O0'W.Y$C3QW;;,&*-E\01$VH2.O-#")X7EMRM;!H5\)]"B;G5!<-KY-
M.GTO;X]-#$U@)-6V05<\.XGK?1IIE46L7'![\ ]9UA()QBP)DXF7_(Z%O%55 M;9$R3\'=4LDG;/,S(]%GE-&&+9)B&6V\;YF[Z1-Z+N2>>F*3;DD=83RZ)_6: MKH$K=T $7W*
['6)$+2H24;)>P=CPW))FSV HF-9]_]WI='+R)NP1EL[T7'.H M$"P1%KG^!BF&1+!&/(_P]O1]8Q,X8!/WA-1NV$=#1Q.Q&I#Q;!P"(_R[M,>)*.[E<4M\9/1S#O1LN?A0.E0R[PF@,?
9Q:L@2O(VCPR8C*R) CMK;\[H)\-D]#*#!V%=Z1%YMU\;YJ3!(TC;KB0\T5]%==B1/ MB26$[/2:S7**525^,LB 4\(= _$!,JIX!GW-LH*,[;3JZT^%#0)H!R%Y\<0U?
MH>_U:/MM4^$PFZ.1>)$3_QP?$Y3Q 9FQ7 &>'8(ABSQXZ^DCP?M9.7CA<$"-[(L:KP]&DD87F$?!(GG%*XF$(SYU< MLU"3E*+1@X+Y@\H8*]\0D0YE_B.JHV4$O#0(\]
5Z^8NG>0Q"KV:'HV3\7@\ M-&6<-3%Y-A@L/_+DQXU;>YSZK?$XS&*[56D N&@YN\Y!+M>+ KT)]WL+FE6I M-<5$IJFYX,![']G5 -+@F'$#Z^#N='B41B+'T8]O<]/F>4/MY8,[$\8"-)^/V
M18QAI?^@;;]"^60D^HB3P:_WT]@U$.31V0CW9]V63"%#:L>9 M3VBOT#T=B4B:@K9['8XXN<,+]8C">(&&QZV: M 8^1"6$.J"FIK%M8F4^NLMAIH1N*324H[(*
Q5__+WFW<[S4=$XI9*U<*7: M^(W;]5.W]O"O..BQ0N@/&7O:&GLZ:)1:K::FI<^(&@M^M)'4!WVCU809G(T'G MY/X5S97.^5W 3ZKB-P3,E=ID6(29]X,YOJNCF"8I@Y9?LB@?
O%'XN?:,G_GND=D+8&4@TN6 MD<,0M?;ERK_KS,\P_O7RX\NM:7][$JT8K1=M]HG23O2V=CU47HEI)ZX@_38NO6DK-J^/.:8!_@[ ];_ Q/D Y M1C4"G]G+/@-,AA"B_39C,OP%!9>+_?
<<.'%6O["6SICY^H^BPE>^TYA@XB3T M#IPHDU3I? WO_Q(A-G94OAGX]WUTI]VM_JT+@?TGL\:ND\EI(OI4PH-8>W Y M9+GVK?
5D^*WR3V@SNA_B6%/B.E5_#E6'>4VF(^YPGWSLM,4R+$#L?'2NANXO MK03Z8_2_[[[F_U23[0IS4A(@XCB3/_3H/_ MB7>>R)6P7.%A7Y <=#Y8PW2QY,_R^)U86?
EOUYJ[S:=_%_Z#MW:Y_VX0Z+*D MMTFY6F#K>'2""+#^4SS_HS)KQM;JK*%'RY4A+Q3@OP?&%,%7\0@^:#R//_ M E!+ P04 " #U@6Y9P)8 Q6\" !.!0 &0 'AL+W=OHZ;H/TSX0 M?
+91,'B F^[?#[#KI5*:+\#!/<\]!W?,=DIO385HX:D6TLQ)96US%46&55A3 M8!5(LHB>-I5%,N238+>RN=S51K!9>XTF#:NJ;Z M[Q*%VLW)F#QOW/&RLGXCRF8-+7&-]D>STLZ*!I:']/-
P+- MAUEDG0+/$[$^VK*+EKP2[1)NE;25@<\QO_PE/G+*! G)L_QEWO0PD=#7DXH6_XB +&T,U)/Z=PKRP5<$OU%FT(O?:*N/4E\PD9UAO4 MD([#6Z7P%+1+Y?
ET=';NJ^_DA7WHLJ*]&J]1EZ&3#83J[,I]V!T^BT77(__+ MNY_&22RY-""P<-#X]/R,@.ZZMS.L:D+';)1U_1>6E?OP4'L'=UXH5R:]X0,, M7VCV#U!+ P04 " #U@6Y9UN$ULXT" "-!0 &0
'AL+W=OA:1WP@'AP MD]O&FF,'VUVW?\^UDX4BNKXD]O4]YYYC^WJV4_K!U(@6GAHAS3RHK6W/H\B4 M-3;,G*H6):VLE6Z8I:G>1*;5R"H/:D24QO$X:AB703'SL5M=S-36"B[Q5H/9
M-@W3SPL4:C(/2<"5!XWH>7"3G MB]SE^X3O"'=F;PS.R4JI!S>YKN9![2AP-(Z!D:_1[Q$(1P1R?C=RO;#T/I@%4N&9;8>_4[@OV?D:.KU3"^"_LNMQ1$"Y M-58U/9@4-%QV?_;4[\,>8/H:
(.T!]=?=%?(JKYAEQ4RK'6B736QNX*UZ-(GC MTAW*TFI:Y82!SQ>=E$7(X@6OYB-(JS=' ^NVV$F@^S")+)5QB5/9T8XXN?87N M#&Z4M+6!3[+"ZE]\1-(&?>F+OD5ZE'")
[2ED<0AIG.9'^++!;^;YLB-^#73^ M#MGKT/EAM.N0<].R$NY-,HX_'M&6#]KR8^S%DCJVQMV@H$M1Z. MXSF$RZW6-(:?7C7.HIHKT4:U!O_$!@HU5;:KEN&Z/#67'0M]C>]>ZANF-
YP:4#@FJ#Q MZ604@.Z:OYM8U?J&6RE+[>N'-;V7J%T"K:\57<)^X@H,+W#Q!U!+ P04 M" #U@6Y9;P_.^QP% !4#P &0 'AL+W=OW4/R>"?D9[5!U'"S+2MU,MEH73^;SU6VP2U7
M,U%C12LK(;=W9UB*WI=&G%6Z$1(IC"E1;9YXTH=7;/6KO>5^RF\$94>]/@195C_E! 3AA[H-X=T#-OU. 5UC/P!0:> MXP4C]OP^<-_:\T<"5]#&-
Q1>JQT,:YM6>:9JGN)A'I!H;S&R>+'"]S(^7D$ M6]!C"\:L+ZZH]?*F1!"KX;P8\ P^(,R*Q1"+8L,#];:[A5UXU1!?@MJD'WPU8&'O@S$*'?EP'PI3% M?
@ROE6K(R[3[>]&AR.'(=7P6.@X\;97:U;J0M$9;E_$J(U8P@I[K,H=L[PD^ M0%/E=\'9;29T5)8:MTN4?6WV $8*(>P+(1PMA.>X0FE@GHLMT;#BELE.32K6 M2-
2HB2WTAG8P+ZZ+O.$E@RN3H*DAJAPN^*T1>FQ9C&(9+HN!\ ^F_!:3FFHQ M7>*TL&EB+TKH[SDV&VTT&=6*JM$R=WD+^/G/2A*5N#!X+ H=%L0^O3%E2K$5%
M=$E[17M2HRQ$#H&?L"1*P(\2YB=]?1P*'OFASUS'I'UZCQ66"'W6!U '(OXJ M6C<)6)3XA#9Q4N9$65EA3E1'U-1./D8!-\MI_@_8I@*XV5<+@U Q;/&X[(]Z
M'<[^V\9N!+%4ZU,=]'K>MR%<6#)XF2UQSO4\6=RX_6-)XTH_%-^B#.7[$TB0%;^:E$,X"E[)^5T5Y(XW>7A_? MT\CAVA3H9K#"0K=$@AVG# D.H1LHI7UTO@?!+
(KN,9@LLB$MCRHM88'OMS$% M,\=H_1^SD[HLBGQP9W%D8@E-Z_C^8']\@*5I2D2=!!1Q['Y_KH[=I >:?-[7SN.%2QO89"@=USFCR3B45?
(N+V^#IL8]M!T^>F25_R0G9]20=@!^VM MJ*;75#2DPM4A:7HQ2ZFLG5GJ]LT84QW[@;F#$5U]:'6/0M=AH=?>H$CVO+]; MF6YZZ&2@(<* .H):SYH_ 502P,$% @
]8%N68UEQ/VO!@ 3Q$!D !X;"]W;W)K&ULM5A;;]LV%/XKA#<,+4#7%"F24I8$R&5K"ZQ=D;3K MP['Q69LH;+D2G*3[M?O.Z0D*YMJ[^OBPVK9%7KIW-6NVZW56?SUU175S-
(DF/>$B7ZY:(LR.#S?9TEVZ]L/F M70UL-DA9Y&M7-GE5LMI='TU.HH-33>?]@3]R=]..,8$:>7%75)T)>+XXF@@QR MA9NW)"'#UQ=WYHJ"!,&,SYW,R:"2&,=P+_U7[SM\N6RK?$T!U]
[_+9J'4O8 ME%VZ)6+=LJQN6M;99I7/&0EESJYG5X5KGA_.6J@DQMF\$W\:Q,MOB$_9 MFZIL5PW[I5RXQ5W^&4P=[)6]O:=RK\!+MWG!E.1,"AGOD:<&_Y67I_;XW[#@ MWV/N!>
[X<6[JF(-FD\W=T00MT;CZBYL<__1#9,3/>VR+!]OB?=*/+]&!BVWA M6'4]I.?";;JZSUV&ED1M&O7>W+3LMJOFQOG[S:Z_FQ_U" M%[!VY?!?.\?6(:^.\@K=F]:MKUSM4],?
+"%UW[G+#$%G;S%Y/'3@L8#\RR6-C>"RTAX567"8Q8,-U++E.";9<:\.3.&%OW"*?@R^V8!$X)/!I M%4^D8)'PV/N*!)=0WWA#2*R.<&10D0XJ3 354:?"!!6_;UR==:F85VO'GOU6 M-
#"\\4?>):L^?LF8UA>V() MC+BRADOX#03!D9JGD0)R5M6HD0QJC3-)E,"1*#!(G!&I)"3FB8&[6@4$,>+* MI$!"5*K!MP(^P2QPQR:%C73&HUH8#F<"&G,;Q=Q8$5#-
(VEXJDCZN4,)S?,L M#&%,EY,U5?#?GO!$L*8^(&1_@!6/U2XP4Z83C4_)96Q';B=<(ZRP1QK!9,*M MTBQ&?"/9>;>X;U(V,@EJ@@"HUCQ)#15#$(*B+[!95 M1.+?
F5YR5Q6HPN6#;5P=GV=%U#Z9*7[$D'L0HEHT9<(*EZD78G H%1\ MHT10NB+>E8BVIBL115F3#TL$-16G@2%*)3<^JV!(4)4FU:%$9 IN+8<2R?]3 M#/J2@D8;]245P]JH+RG885&
[1O8EA4 AH_%@P$G3N+:Y-U-\,_=O*-$_%YL M->*80 EEE7H -9R8(8Y2"HHM4S$J&)VUBQ,U+8S#", G!H-6?3%EP0RDA7R)
MT81)0)1%P%!S>S:!'C:!WK\)_(#"D']75XOM/&QIH+M%#4,NW)+*]_OF_UY] MC__]W[NC_?Y8['_GE/(!TJG:?/Y ?MPV2>G3\++FKP+P=WSZ'79M/665IX/ MODUI<(9Y@>&.[T1T%
FU)M+=#.FQ5Q"UR5$I#;%(S+;(4-IH78" 0:N) &D6 MDTR =P>?S,'65'4.9E24B&@6^6],G41*.AR L<5DFP1=151]D?2J/!&E90.1 M2RPV9>PP_'K\==FZNO03*BL.D.RFI8;Z6-
7%XEXI^.(G$*(][KD*GBJ2X-3[&5/26(Z/O@K-U*CJ*I9'DU\-TA(VR"8\QR8Q5%&4* M"H4 "28"E];RQ!?V#AZG5%O>&7HUZ #$2BE#E1Z NRE%H#'O1$JK6O490-$) M7'(\,
<8L)T6B,W>' _XO2-@:+3R;CTK:"&HA(5+M2]N'HL3M]GAJ$(R'O4[H(M L?8$(JN$%+B.F/[RR$(*A#NA83N3],>4.#&U6/: W=#0AN,-
BYMB\O9*B^S>_&8COX1RD[$&!NY/QW]C;T:T^]Z M\+3XQ]OQSIT\7+H?W*"[B_K(\]W5^K&5.1NJY*Y=O?2O\@V;5]NR#>^[W7X MM> DO"3OCH>?&MYD]3(O&U:X:["*%Q;;L
ZO[P%IJXU_9;ZJ6KR >W#ELH6K MZ0">7U=X;>P04C#\AG+\#U!+ P04 " #U@6Y957"(UMT" "U!@ &0 M 'AL+W=OF.O9]G>98,MV6%0IZ,Y6J9(:F:N;K2B'+'*@L_"@(>G[)N/"2
MH5N[4(9%88E(QM^&TUMM:8'K\9+]W'DG+Q.F\4P6#SPS^Y#AE,T+*BSNW&'J1S;639@$E!R44]LN>F#FN ?O .(&H D=-=;^14?F6& M)4,E%Z!L-K'9P%EU:!+'A3V4.Z/H+2>
<2:ZD00A#.(0S69;<4+V-AB_W;%*@ M/ACZAO:PF7[:(UKON@=O@%<2F%R#=]$AMDFWB=M*X'14N XVDEXAU4;XJ %
M41!U=O#%*\.QXXMW&-90^]MFKT9WMJ/M%3G6%4MQY-$=T*B>T$OV]\)><+)# M6V>EK;.+/?F!]'VUZ"2T 28RN#8Y*K@0]=VS'_%O)QSN\=G N)#IXY]M'G;O
M+I$PF9(=RB;5Y6D*L_%5>5<+[.2Q?B!9G2!Q"THP&X&,)V MW$37FXY>LZ-V-VARXM=P*>"0-0(RKE,Y%P:(!6%_KQ^%XGY?# M!UFFFSXV.+9]L?
Y:*RE1S5S#U."8ZZZR6EWUY-.Z%;VFUPW]DJD9%YJVGA(T M:!]U/5!UDZPG1E:N,4VDH3;GPIS^*ZAL KV?2KJKS<1NL/I3)?\ 4$L#!!0 M (/6!;EE+[?T+V $ (,# 9 >&PO=V]R:W-
H965TS_:VR$U/4FC<6W"]4MP^;5&:89,LDY>#!]&T M% Y8D7>\P0/2SVYOO<=FEDHHU$X8#1;K3?)Q>;O-0GP,^"5P&F_L'^.M?M:CMSASLC?HJ)V MDWQ(H,*:]Y(>S/
%IWK6@:\TTL45AC%V?9- V3LR:@)[!4KH<>?GJ0\7@.7J M"B"; +$1;$P45=YQXD5NS0 V1'NV8,12(]J+$SH,Y4#6WPJ/H^*[(80EO(5[MVW MGOG8*UW!MG<^UCEX=8?$A73P
_4<_DZ9^0S!SPKIRS;,4MV)GBO4?;<>2C0Z:+ M;3X:\D.+9NM_"=H0X.]KXUL].6%RW[\K_@)02P,$% @]8%N6=%:^->6 M P ; T !D !X;"]W;W)K&ULK5=K;^(Z$/TK
M5O9JU4K=YIT4+B"U/+0K[:,JMW<_FV0 JXF=M1UH__W:29H%:B*JA0_@.'/. ML<],S&2P9?Q)K $D>LXS*H;66LJB;]LB64..Q34K@*H[2\9S+-4E7]FBX(#3 M"I1GMN W .P0$1P!^
_!/50@:0'"]0M@ PE,!4Q.(*N]KLRJG)UCBT8"S+>(Z M6K'I096N"JT,)E07UEQR=9RD4;RK%;TCBC[ZQJA<"S2E M*:0&_*0;W^O VVKWK07>JP5W7B?
A'(IKY#M7R'.\P+">\>EPW[2=OU.?_IWZ MK!L^@43!71-\STN_+2>_X@N.\#WH0J&0HBGFE-"5JIW;)"GS,L-2S4Y@21(B MC553$T<5L3X.-Z-/KA["DY>$H(V"4%G$GX4P+%4[J,O-
&$YH(NO3 BC MZ351N+>((.JY<>_\L"PVM")8B?<#YP8&(-8<<;,.@9D&QE 9W_/]_X(!)GID1$ M;THNZID2T2GTWD1$;Q)A%)V>4W1V)K*]1,1M(N+.1'Q7[7#UQ-QSMB']/QHM
M7M#%HU #0B_1G]/I5G>51Y^:3I%W^C$^)]DD-IR%@7/CW\0'*34$JCC']P]R M/SO3\NITV3O=8 Y\5?7M B6LI++^)V]GVU>#VZHC/IB_<_MCUS _&PO=V]R M:W-H965TAZ
,CC6UB)=%+4KD _?B2DJ+X(FOM@B^V+IQS1G/(X9"]GHC6F!)QR3:8J3=+QE,BU2U?]<2&(XD+N3[>JEX5)=" ML\YT4CR[X],)RV5",[C/(T)?QUA@E[ON[8G;
<'JW2UEOI!;SK9D!4N4#YL M[KBZZ]4H,4TQ$Y1EP'%YW;FQKT*[KPV%%E\I/HNM:]"?\LC8=WWS,,[N6-HC M3#"2&H*HOR><8Y)H).7'CPJT4W-JP^WK-
_2P^'CU,8]$X)PEWV@LU]>=40=B M7)(\D??L^4^L/FB@\2*6B.(7GJNV5@>B7$B65L;*@Y1FY3]YJ0*Q9>",CQ@X ME8&S;V ?,7 K _=4AGYET#^585 9#/8-
G",&7F7@%;$O@U5$VB>23">]9'"#Q:\?0*P)1]'@ MWOQT-/IS M/W+*$6[DF.KT0Q+XF$E4_GD^F>JICX+&E'#:^ &S5B*=J:_$AD1XW5&I6"!_
MPL[TMU]LS_JC26>38'YA5@.N4_31UK8%G6I/>TK:-)SM 0V(ZH_5K4?JNH MG_+T$;E.*9\WR$F111:X*H1N4JX5[5SE3(+Y)=A@6[D]T4S2A8; =D0;U*(- M6D6;$['NPD-
&,Y%SC.$FU1- DUR#@^[)$TL D:6@(;$'?A)E&5-\DB!%7#PUP-!RKA M+R8:L]?PP#&[83"T>G%NZ$^B#$Q2AL,#M7B*%3@.QY(]?= MDZ:AH3MTK;%C[S;T#QN.+-
L;V*.]AD$#HN,.^]YXCSIL#<__3##C.OCC]IZO MRON8)KE>XFVE& A>HB17U34L.4MASM)+DFQ%2R!(2K&6(EX$[)5&C4K6:* MDW5I]>KW&KN4-^GOJ&G)N1UW;>E_A6>=/((U+
MME:<6IS;K=(]+. +1Z(*L=?MD?GW+>KT^$^C MB*V(9XMH$LTWBA8810M-H>TJ[;PK[1BN\MH!SQ;:))IO%"TPBA96:#M9V[*. MUS#V^Q:&W;Z'<*%AA%"TVA[:K\OJ=AMV]J
MZ/4Q!#]RM49()$9&%XB$.>'\56]O?"5)CHUJ]P\7KJ.FU7((_=E"GD@;&*4- M&VB;!UEO:^LZ1;XJ#AD$%&NQP?EH?9-P4V_=[SV?VU=QN>.[;5T%Y3/$. M7YZ:J(&ZHIF
!)>*RKH&ULO59M:]LP$/XKAS=&!UW]UCAIYQC:9F6%=82& M=A_&/BC..1&5)4^2DP[VXR?)KA>VU&PE](NMD^Z>>^Z1Q"G=" "FO5H@:'DK& MU=A;;5V=^K[*5U43=20JY&:E$+
(DVIARZ:M*(EFXH)+Y41 D?DDH][+4S4UE MEHI:,\IQ*D'594GDCW-D8C/V0N]QXH8N5]I.^%E:D27.4-J64VDLOT-9T!*Y MHH*#Q&+LG86GYV%@ YS''<6-VAJ#+64NQ+TUKA9C+
[",D&&N+00QOS5>(&,6 MR?#XWH)Z74X;N#U^1+]TQ9MBYD3AA6!?Z$*OQM[(@P46I&;Z1FP^8EO0P.+E M@BGWA4WK&WB0UT]J+L@TV#$K*FS]Y:(78"HBB)P*B-
B!RO)M$CN6$:)*E4FQ M6F^#9@>N5!=MR%%N=V6FI5FE)DYGGX5&B.$=S)IM 5' C"XY+6A.N(:S/!=)E/7D3;N%?:7@[/U#8,?C>28#_JMCA)C[S^ M5D.SCP.#O:1<
&ULK53?;]HP$/Y73EXUM=*&0T+9QD*D%=2M#TP(MUNYAVH-)#K#JV)EM?O2_G^VB]]K"7Q&??]]U]9]^E.Z6?S1K1PKX4T@S)
MVMIJ0*G)UU@RTUS52G>R5+IDUIEZ14VED14!5 H:1U&?EHQ+DJ5A;ZJS5&VL MX!*G&LRF+)E^N4,A=D/2)8>-&5^MK=^@65JQ%<[1/E93[2S:LA2\1&FXDJ!Q M.21?NH-
1XOV#PQ/'G3E:@U>R4.K9&P_%D$0^(1286_W&^+(Q3"$[DT_C2< MI WI@6'70_*10(%+MA%VIG;?L-%SZ_ER)4SXPJ[V M[2<$\HVQJFS +H.2R_K/]DT=C@#=WAE W #B?
P4D#2!4CM:9!5EC9EF6:K4# M[;T=FU^$V@2T4\.EO\6YU>Z4.YS-OBN+T(/W\"'W**W2' UQ+NKX\5GXLVQZD 2O8.XBGLG MX*/+\#'F MX-\.0UG#KEK?RXE1\'OMZY=-PKAHG:2NH
5\ M5:HP\&N"Y0+U[U-:+Y+[!AR8BN4X)*[#.HMDNSMFVX_^GQ*^7\B>U6'I*U# MQ3ITF7JZ?&A.F M5UP:$+ATJ*CSX9:KCNQ-JRJPF->*.M:(RS7;GBA]@[N?*G<@VX,WQ_M.,S^
M E!+ P04 " #U@6Y9=)+H(*T" #R!P &0 'AL+W=OA'&@UI+XVO?<_Q.;[U=;KEXE&6 H]593)B5,J55^ZKLQ+ MJ+"\X#4PO;+DHL)*AV+EREH +BRHHF[@>;%;8<*
<++5K=1;QV&[@&*>5I1PN[+FN M*BS^7 'EVXGC.\\3]V15*C/A9FF-5S ']5#?"1VY'4M!*F"2<(8$+"2_]R MFIA\F_"=P%;NC)%QLN#\T00WQ<3QC""@D"O#@/5G U.@U!!I&;];3J?;T@!W
MQ_LU]:[]K+ $J:<_B"%*B?.V$$%+/&:JGN^_0*MGY'ARSF5]A=MF]PX=E"^ MEHI7+5@KJ AKOOBI/8<=@!^= 0M('@I(&P!H37:*+.V9ECA+!5\BX3)UFQF
M8, &HK4:PDP5YTKH5:)Q*OO*%: (?4 W; -.<4% ZFC>%!7QY=["V0P4)E2^ MURD\QDZ>_L^=9668SSV)#&EM1< ME4V61,'82]W-KI7CK. ?
1^.X2]N3":2PT')W[C"%)^ A>D3V%",=K8.$]^/ MP_A XG%>$(=C_Y3&J-.8#6]<:6U'Y!Q6E3G;G[=0+4#\ZE,Z2&3:V*6L<0X3 M1_#7J^)HSHJUB@%>>%/$<,5)_?T7%E MXC
)1X>5.HS3) MT7T]O-''&7Z4A(1>)KJIH7I@F4+RV37K!E6[Y M=ECJ1QF$2=#K2ZX;=1N8OM\]\]E?4$L#!!0 (/6!;EF0C>\]Y]P$!D$ M 9 >&PO=V]R:W-H965T+E/@>^4C)6:?- MBZT
''FMI:(K6CG7W#%FBPIJ;F>Z 84G!VUJ[M U1V8; [P,H%JR)(J6K.9" MT3P+>UN39[IU4BC8&F+:NN;F[0&D[E8TIN\;3^)8.;_!\JSA1]B!>VZV!CTV MLI2B!F6%5L3 847OX[MUXN-
#P$\!G9W8Q"O9:_WBG<=R12-?$$@HG&?@N)Q@ M#5)Z(BSC]\!)QY0>..+7?V:\$[:AESRVLM?PE2E>MZ"TE)1QX*]V3[K["H&?A M^0HM;?B2KH]=?*:D:*W3]0#&"FJA^I6 #GV8
.+Y!4 R)+ !:0#(U"^\] MK UW/.^.[HCQT&] MC.?2T]83+0.C?QRF/HSA.HV7&3E,A9^+2FW@QOQWC^HK99'#^T7SCYBB4)1(. MB(QF-PM*3'\1>\?I)LQRKOW>6^'.!^
\/VB&PO=V]R:W-H965T5'47)*]3'B'G4DEL[MU=74_$&TC-0@N M8%ZV[H_0!1;L(7)LW.W/TP4^_OY-LA#M\W3S>5+%'|+%I2FY'49A.E5;Y&F MJXM^/YDNZ-)+/D8K&F:?S*-
XZ:79V_BIGZQBZLV*H&70EP1!Z2\|/^Q=7Q;; M[N+KRVB=!GY([V*2K)=++W[[1(/HY:HG]K8;[OVG19IOZ%]?KKPG^D#37U9W MPGM[7+F@?NOMW2]V/EL9QZ]A-Y&P6_^+%U<
M]<8]J-S:QVDI]&+2ZEU?QM$+ MB?/R&2]_49S:17QV.OIAKL*-.X^],.X]/ISE%*BD'/RD$;3;XLHF-$X^3O1 M?E_[Z1OYH-+4\X.$?*6OZ=H+?LH*_O*@D@]__>FRGV:IY,=/.']
[+#MCIVT/7:?)"[07@S:[SPQ_H*@L7CH8;[<.; M*F^^+[OUONQVBR-?'KJF<.?4D<^^=VE\-QMGUWBG,7R[@H@%[S!L8.1"Y]8 M2;*F,Z*N8S]\(G5AX,4W.R&]>"MAFBGGE<93^D*?
O!#DA0?-UT) M/G%3YCV+BV3E3>E5+^LZ)#1^IKWKO_U%5(1_-,D("5.1, T)TY$P PDS-[!A M &R_[PO.F1.&PESD# 7!&/$.MB)=< 5ZVW@)0F)YEM)DB@F M1<_Y;$^:C(BK#\A=
[$[IH=O9% 1>G) 5C3GRZX.$W$B82H2IB%ANE+K3\KB>*". M9?84-^KEI+$P$90#*9@M>59+GMW $R:CB3ABRSG(@^(V5&XP$)11M1.,($8[M08SX/^_R4_?
\DY=W#.^\MT(">W(X(Y^C\)DF:?;QS8L79_W%VRA)LZTI>:,I MN:?3Z"G,57&V_568JZ/<7(CKPS^I%S=]@UNSKMI PE0D3$/"="3,0,)_GFF
MD&4QNM8T&H.LAHV$.4B8"X(Q,A_O9#Y^G\R_K JQ_NMGNGRD\;^;Y,K-T%6N M2)B*A&E(F(Z$&4B8B8192)B-A#E(F N",0]>[!0\^5$-]@J M<21,1<(T)$R?
U'Z*B4+Q[Z"WBDQJMDQJ(9/:2)B#A+D@&"-,4:CND0K_MWUH M?M6Z2A9*4Z$T#4K3H30#2C-/G&YB=M9X,>'UJ*'UL:$T!TIS4316^GOV"!': MKR;_(6VN%G2Y"[(W2KG]<7[5.DL?
25,A- U*TZ$T THSH30+2K.A- =*TU'VVFC3+FHCO+&$E3H30-2M-+VOZ(Z*C>ZRY+[?>4Y?%A M*:,.AU$2]=:8;2HGUE#9T-QTHS4716)U47B*1;R:ZSWK!L3_->\(:7Q&W?8.Z MA*
T%4K3H#0=2C.@-!-*LZ T&TISH#0716-U6]F*1+ZOZ(<,/O'KT%GO4$<1 ME*9!:7I)VV\(:ZT@U"IT,J$%36A#:0Z4Y])HK#(KNY#([PN]J^<)=0Y!:2J4
MID%I>DGC"JY>Y%Q6:IY84ZP;>O%"K-.[#K_("%?T@6-2;KPPG*%)SD3CQL8,[X?; MT=P3%B%^Q3O+$&H2@M(T*$V'T@PHS13K=IV1+,B#FK"166THS8'27!2-E7]E
MQO?/I.]O]S^M'/6=(B_^D%]IDN[- M<.7X+]!6*2A-A=(T*$V'T@PHS3QODLF,[X?; MT=P3%B%^Q3O+$&H2@M(T*$V'T@PHS13K=IV1+,B#FK"166THS8'27!2-E7]E
MQO?/I.]O]S^M'/6=(B_^D%]IDN[- M<.7X+]!6*2A-A=(T*$V'T@PHS3QODLF,[X?; MT=P3%B%^Q3O+$&H2@M(J5U4IJ M;[7ZWE_QKRL_W@2=5#F_-
EU5#J6I4)H&I>E0F@&EF2?.L.%QE4/K84-I#3F_MHFBLRBM7E?1,5]7F)A*Y]59^Z@5Y1[Q1O5"#%)2F0FD:E*:7--;G(-6]%0WE_MY'SP^G"0NZ'<4&XP*S?

E%1MZFS9T=QTHS4716.E43B2)[T2Z7?ATGL\7GZZ+ MT:TO\[D_I?$9\<)9.5JME>;"A#N$Q<_363Q06Q*4ID%I.I1F0&DFE&9!:3:4
MYD!I+HK&:KIR34E\U]0/G[3.KT]G[4.=5U":!J7I4GTE)$D9CH3A^+#E;"@X MD!19&1PVG2V)5ENB#=UC!TIS43169Y7+2>*[G#Y'X7G+QA%J58+25"A-@])T M*,V TDPHS8+2;"C-@=)
<%(T5;66 DO@&J*Q-7&:M86$G/MO^(MRV?_>;A)O6 M3U^GZYBV;P2A[B@H3872-"A-E^I>I:$T4J3A81M8+R>/)66B'#:![7A62YX- MW5L'2G-1-%9+E4=*XGND/D7Y/9!H3E0_IM,TBI-
]8\1]%__^/U-G]4=1:5M:M![7I4)H!I9E0F@6EV5": Z6Y*![JKZLKZ)/VP)9Z,F_?Y=>BL=ZCC"4K3H#2] MI#%C]{-!PU@KU,O4,JL'S6I#:0Z4YJ)HK$8KEY+TSO69.#9^/KJS|* >(RA-
M@]+TDL:(0% :I =U#S5D'2A-TH/Z@J T!TIS4316>I5W2/K3O4-_TL2 LN*G M3.2W_!WL+%FH>PA*TZ$T THSH30+2K.A- =*' B3G[JK,*$T#4K3H30#2C.A-
M*LZ$T!TIS4316F)4)2.:;@+YS M,*K-#)ZOV>OI@I(O(7^%)7X-N_:LH3052M.@-!U*,Z T$TJSH#0;2G.@-!=% M8Z\&E:]);K "$L3A7SP6)RE67,QG GI/C;^M^;7J? 6 NJ"@-*VDY>OI[75I
M#N^RZ-"D!I1F0FD6E&9#:0Z4YJ)HK+3W'C#'MS?]@(;^ZTO$;^BQ#Z3#/I$. M^T@Z[#/IL ^EPSZ5#KK4%)1F0VD.E.:B;.S5H#)AR7P3UO^JH8C26-"D-
I3F0&DNBL9*N()JR2>>;=^#/QI/B6!%D^@Y+;(M4/<5E*9":1J4ID-I!I1F0FD6E&9#:0Z4YJ)HK&PK5YA\8N6LHT^ /ML] OHS M?=F42$X^^AEJ#/(25+F^:M-@E* .:=G#'38.FU:$T
THSH30+2K.A- =*E:>W.M%N!-OE1A?4UP6EJ26-O0FGR(=:A?JUH#0#2C.A M- M*LZ$T!TIS4316JY7W2^9[O)A'/N^F)T1SLC^WH5&<4.<7E*;*=9^3I#1, MYM:@:74HS8#23"C-
@M)L*,V!TEP4C=5G91"3^0:Q+\\T/K\)@B@M!IE:+/_(M!W;6)=3>!:5I4)H.I1E0F@FE65":#:4Y4)J+HC'B'53VKL$)>Q?TQRL_65=A MES1FQMI($L6#%E)M*#
<2!Z/A84L*K9T.I1E0F@FE65":#:4Y4)]+HK%BK"G= M_[ZEZ_M[NGQP9^S#U+#0TD<2AUM)3&=YZNL7MQ/O7YMNRY>&&++#
M=E,\L(KM_0I_?:GRGNC/7OSDAPD)Z#Q+)7P<96U7G-^'W;Y)HJ55+]O;QRA- MHV7QO_E!+ P04 " #U@6Y9CC'5 MN6$# !'#@ &0 'AL+W=OPDI(^8$K$W:>SX
M[OX_7RXY#Q:,/X@80**G-*%B:,529B>V+<(84BQ:+ ,J[DP93[%40SZS1<8! M1X51FMB>XW3M%!-JC0;%W T?#5@N$T+AAB.1IRGFSV>0L,70 ML$>##,]@#/(NN^%J9-=>
(I("%811Q&ZM[=0W.WK0V*%7\(+,3*-=(H$\8> M]. J&EJ.5@0)A%*[P.IO#N>0)+0TD<3ZUKH&:1Z7JF-IPJ?K%^_<"7L%,L(!SEMR3 M2,9#JV>A"*8X3^0M6_R
"JBC_84L$<4O6I1K@\\"82XD2RMCI2 EM/S'3]5& MK!@H/[L-O,K VS1HOV+@5P9^ 5HJ*[NL,2C 6<+Q/5JY4U?%'M36"L:0G4:
MQY*KNT39R=$O)@%UT3$:2Q8^QᵀR)@(NOZ/(Q)_)93=!CSC&5 AU<@,0D$8=J M\FY\@0X^'PYLJ11H/W9813LKHWFO1.NC:T9E+- EC2!:M[>5\EJ^]R+_S#,Z
M'$/60KYSA4#S':^_08"9,VI.K45)W]J?X"YCLI MS#YFT.!O8R^7E$>L: M\QFA B4P5:9.*U#9X>6JI1Q(EA6- X1)=8PH+F-UT@.N%ZC[4Z;:_VJ@]1G MQ]$ 4_$4L#!!0 (/6!:EENE.SNG0(<'
9 >&PO=V]R:W-H965T MBHWKJHET-R*JM+U/2]R*\]XDR9V;2'31#18,@X+2513 M552^SJ 4VZDS=-X6'MBF0+/@IDE--[$_%XOI)ZYO4O.*N"*4XDK*?.]?!J
M'IEX&_"#P5;MC(G)9"7$HYGK;.\RA+(V1QGCJ/)W^D4;X M.WYS_VQSU[FLJ(*Y*'^R'(NI$SLDAS5M2GP0VZ_0Y3.R?IDHE;V2;1?K.21K M%(JJ$VN"BO'V3E^Z.NP(M.]Q@=\)_'U!^($@Z
2!3;0ELVG=4*1I(L662!.M MWX1*EWF=9A^DT@D(@,R!)%]EB(.@>I/I';IX;AJUENWRX1-M:[(LJ 1%4)-5D#NE&LC)V0T@6;9:4ZUZ'*[B9?!)]P"?4E",P+XGM^>(1G_O?RX
1.T),;_SP)/X723GJ5ZTALT9*XAJDSD?^(.#WC"((ZC>_[M,"R(XB >'Z<>]=2CD]3=[_G/T*,#FD$P"H:>OT=!&.<=!XYZX.B_?B7181F' M<:@KN0=^&.?'WL2+]O'=G9Y2@=S85JM()AJ.
[5'L5_MN?FV:V{Z3'?YMBG_MMFE_$?=4;AA7I(2UMO0NQYI*MFVWG;"H;>=;"=1]T X+_:<";0+T_EKH[M5- MS /Z?U_Z"U!+ P04 " #U@6Y9206&214& "C)P &0 'AL+W=O1TEV-
=IPGKZSK&RY{3'.QC0EB?AD15F,N3AE:RM+&<%!/BB.+&C;GA7C M,!DMYOFU>[:8TRV/PH3<,Y!MXQBSEQL2T>>KD3/;7_@4KC=<7K 6\Q2OR0/A MG]{)LZLTDH0QB3)0IH
1E97HVOGW:UKRP'Y'7*Y#FK' ,IY9'2K_+DS^!J M9.N(2$267)K XI\3N251)"V).+X51D>E3SFP>KRW_GLN7HAYO!FYI=&7.,"; MJ=@_ @%9X6W$/!'G7(&+"+M+6F4Y. !) MJ R
DR,#8#$ \AV B@$H%[J++)=UASE>S!E!!DS>+:S)@SPW5P+6BA)DQD&\X M$Y^&8AQ??*2<]<@@=.EU\W_H(RWX%{[]M0_XB+^_*"^@*_)7FB;^6B9ML&,7-Z(?_;@'K^(.G-
PS1A.UD0>7^P'__N!Q(^$_2>&?'ZX M V]^?CNWN) A@[&61<@WNY#AD9!GX_--^"8#[Y. !"WC;_7C':@Q8(G\E4F$ M^R3>0*W%!Y*. ;(O +2AVQ:0?Q@=68KA3CX<;
<>!94U!;L\]%DY7.=[':41? M""G+T58$K0^YNKS+4KPD5R.Q?&2$/9'1XI>2'._^K2T!KV3L(!UNF0Y7FXZ/ M6Z2E1SF";3\(.O D3D,DD9:W3;V=NDIN3R^#3 MG(F_FSN?54%;5U:RAJ4HJ:
M:$5]R=@[^(9BU M:M8[=,$+D7F;@GBW:$?!/@E.YOE>DN3PI*KM720E6F9E:G6]/5ZS<@:BZ4\ M%#D(Q4MV"9YPM#W,09OXG5VO4G"[5FVM9\ J^Z4N?^"CNQ,+F"Q_QR/L Q[A
MNBRM8T-9LU+6[+2'MZJRWX,[ZZRC-B1#P8ZM,,,>6,FIYLY:%I9UQ=0[-Q57
M82CGM'H>:NU7T<*GKJ3ZL$OE0R4;#]RI^+=B1<(\$TD@5*R>J4;=I3X'03D*H9Q79BBG+T3UN/$P9D5(S@!!)*>_ MD1"LR^H@J4_BGXO#<)TLBF8R]IA5A1$P:$0U57H)B[-
';^KK^%ZMZ:R%#+!$Y')[.5;>*VNXE,_0H.CS">FO!04<7\YZF4&%*EQ&%8E"/8N;]B<)P%8U= MVV],]N9=T*]@S6'8BK;@4-KJV7Z +:3ESF9UUM"[.YVGBK/@B9PUO T!FXQE
MCWVWKOL. &[&TMZYZ;B%"S!$WM+)KT(V-U>TH=E*!LIBD)# M^TM&O0C4I"CO;O7J+QAl,*9B%4FA$_M-)_8C"O>'3_%D4D_",<)*7!"KPO. MJ 6$4V*=-#0MM" =@1J=GZFXJ?>
M2=&'8#K %+]@$[M(9LT(U.P/.>,&(.AC,]6N^ >]XI=M_9H1'1Z=G#[!K/R* M[*A30F_) #<*<GM! >-+EI@2IXWG1>]LW:?P2\"?'$W,.ND**KM! NAK0K4'=
M>*7W;JLX14:W(LRZ=@9EQJLA4TSD%5KJ{5T]5P0_;*H]IZQX+NT&.CGB- MUG=0O"!695M4#%AZWOW6"8>QVW"=SNBRJOE#K3K?-^5U6!?;5_[@-E:R 41
M68FA]G@[*L5V.\)V)YRF^:;]1\HYC?/##<$!8?(&\?F*4KX_D0[*?7F+_P%0 M2P.$% @`]8%N6=U0NM'. @ T0< !D !X;"]W:W)K&ULI97K;]HP$,#_E5,T:;TT2$@(@0J0Z&L/J5-5M/;#M
\F.8A5 MQZ:V ZVT/WZVDV9L/,:V+XD?]_C=77(W7 OY[')$#<\%XVKDY5HOSWQ?I3D6 M1+7%$KFYF0M9$&VVYM@?^>+@D"YRB_K*\E6;G-U8R6B!75'"0.!]YD\[9 M^<#*.X%
[BFNUL08;R4R(1OYF(V(P (APU1;"\2\5GB!C%E#!N.IMNDU+]WB MYOK5^K6+W<0R(PHO!'N@FD9/L.K#]e'4]LI;6"*?>$=2T;>)=M2HNB5C8$=75FSS7>=A0B.
(]"F&M$#KNRI&CO"2:C(=2K$%:-6/ +ERH3MO-M46Z+,M72W%*C\\>?A4;H00NF6J2/N6 92O46KIY*JE_LL?D*LI(AB#G01B$77@#/JB<2%3UZX"']$ECY#QT]Z:1 MMU8F R9ZHN
3X:7YPJ%3>SRAO'9UNBL;E>G8F;8_T6H(PW V1-!#)41 /KI>8PDU6 M*$UK!)>BEOG!$.X)E7!/6(FN;I.UD=F_5C/YBVKVFQCZ!V.X(#PU/?,X7/:W MXF21S_QN%OM-D"Y<(-
$P6I+FN.FYSVLRK2=6F M?XI7P^Z&R 7E"AC.C6K03HOS0O5KJ{%TC7MF=!F!+AE;F8N2BM@[N?"._YZ M8QTT4WS\U!+ P04 " #U@6Y9IR_@>_P" "3"0 &0
'AL+W=OVLAG]424<,F95SUO;76 MV87OJWB)*5%-D2$W?^9"ID2,H5SX*I-($@=*F1\&0>2GA')OT'S$SGHB5PS MRG$B0>5I2N3V$IE8][V6]S)Q3Q=+;2?\02\C"YRB?
LPFTHS\BB6A*7)%!0>) M\[XW;%V,(VOO#)XHKM5.'VPF,R&>[> ZZ7N!#0@9QMHR$-.L<(2,62(3ON^2 MTZM<6N!N_X7]RN5N%P\2G),U9QX,X5UJD)=A$D%)>M&13ZK
#:!T"A"4@? OH'@"T2T#[+2 Z .B4@(Y3 MIDC%Z3 FF@QZ4J0!6FO#9CM.3(-MR 85'(]1$\H4/.!&YX2=&(/'Z1B.CT[@""B'6\]863;5\(4)PE+Y<>EP5#@. M#S@\AUO!]5+!-
YY@L@<_KL='00V!;[*O) A?)+@:.QF'F6Q"T&I &(2=?0G5 MPZ>8-;$='(2/_]W[>4TV{6!'VXZOT*\K*6T-\^%RDB,?<]<+0KE"KW!YT^M*/BZ3ZZ"K!4X-GOMK :MGK .E>2#
M_+T2]%,)U*D72(H8,5%P)44*4*<4'?FAOV1H31B\07<"*5@F(J*>BXP\B>R57MY*K6RO788%0-6"RW"H:$P83Z]GL+KC'WSF5 M:"]#;L O) +<)K8YV2=DK>OW[KN/)!O7B]*%K (4
RTR5Q1G0IL2Z[I+\VI" M:0W,_[DPA;$<<6 ?5.VSP!U!+ P04 " #U@6Y95\]P0/0! !! &0 M 'AL+W=OI<),YPWILW"_.#L4^N1220X*JG= M,FF)NEO&7-FBXN[*=*C]36VLXN1-
VS#76>15!"G)LC1)QO3T.BGRZ%O;(C<]M2:%Q;>G<M+]/%%K$&]&T%!RLR#Q>X!;I1[>VWF(32R44:B>,!HOU M,KF;W:
[F(3X& !1X<&=G")7LC'D*QM=]F:1!$$HL*3!P_lOC/4H9B+R,WR-G M,J4,P//SB?U3K W7LN,.[XW\)2]JE\E_A76O)>T.8W%"1V&LB7K;X7'4?'$,(O(4M-K[7!%Q7\!E-
8WG7BA("*;QZ0.)".OB. M1^JY?)TS\KD# RO'/*LA3W8ASP=X-)I:!Q]UA=6_>.8U3*SD_!5]B+A%KLK MF*=O($NSZQ?XYE.CYI'O^E(C>K5#"Z;&$M])/#7%_:_>@6X1Z<+J[XLL
M9_MS!>QL+ IM$Y?/06EZ3<.$)N^TWW?#6/^&+XC 4=D8=M&: <2:P] K]I[O'93 M9B,$@T\4A[PSYE8G'UK]1M"' WI?>#+WHT0H+IU1=_ %!+ P04 " #U@6Y9 MY((*='4' #V. &0
'AL+W=OF\;@Y_N /DA"#Z87CUG^]=AP7J{O29P6EY_66[/[]-BL>%)6+S) MMCP5WZRR/_E+L9FO]\4VY^&R+DKB*3$. DW"*)W,+NI]_GL(KLOXRCE-SD]
M[I.DS+]>\3AIO)S@R=..#]%Z4U8[IK.+:,CFM[S\N+W)Q=9TI[*.$IX649;B MG*\N)V_Q>6"2JJ!6 .'QQ^+99U0UY2[+/E4;]Y:7$Z,Z(Q[S15E9A.+/ Y_S M.*Z-
%8^{"@L>S^,]H66XN)\$+?DJO(_+#]GC M+!Q[$*W\%EEYO^*4!\;O .,%!"D@/:*\4@NWZD-]N>]J M 3ZUKV:,BVTC4E,/W6M:^MN6YV&]U1@4Z)7'RS"*BQ]%W<=:#
[WZ_L>+:2G.M3KB M=-&9GH.DO+38'\=.F70+VGKWWPARC%4?L#2W'X#0LH6G;4@D 2'%A+FF_M*:'4-G8@2KI'2;4H/2Y.%U&XN]&)*>UM4LUO_]0[(*!4:95#;.D3S541IH[+
M))*]BCBV*?'V597EV]['<';6M',B0[1DR+<.G3AA7G1#=<;'BX;@.O_"B)LH_MWT?E5Q2EB(=Y*GIM@:(5("E>K*!;<>0%19F"WQ=C&$FE0:#.L=%M 2)CM&(Q(MO
$A%=.N8=)%#K10!B*W!\AM+?+?LS*.!=+1P=M!P8:""#P@A,$#0AB\%LU M\,X>O_#?%@4O 3Y_E,KTS$QZJV.7>J.Z>:.Z'<.Z!6.Y'5[B A43?2KNM]0CP ^9 MMF4HMU-5Q@Q9Y0$]VW2(@"-
MZ>-.ZN:/ZA:,Y7;8 =]L3/19N>< 4G\@!0>0*H,&D*H"!Y]P?0*;(F::,F MT6?-(R(245/?:Y,R2N7 "0DKVHXMDP2$V+0941(GI"15 .7R&S'Z]@[EV49. MHH^>("69P&^58,>%
MA+9%#&6U#@FKCDMM>:T)*8EE8FK(S^?U7(9R:].IJ4^G)TM*IAH5.^@#0I@^ M(.R@#R@[Z)\BIYIM3C7[Y-3NM-24'[RK20PFO\LV!W2F1;$\GWH]_?R>?H&^
M>V*+OY+N7[<;9;:M7PJ_R\HR2^]/&QXN>5X) MQ>/K+"N? JH#[/^KP^P_4$L#!!0 (/6!:EFIG5*UO!$)O0 9 M>&PO=V]R:W I60ST'.!0KW(16_+!"^Q[M@+4?GL7!^9?UYK?
M:=/LDM_OEJOMR[/:W>[^O6RVO:IM[N:,[]?WS:K]EX_K-MS=U\U_ZXN9EM[S?_/IAH[OE3*=I/KN;+U9G%^-TLUU]>GJFSQU_\M+BYW>U_;LXOY_?-.^;W2_W[S:M3[.CRO7B
MKEEM%^M5LFD^OCQ[I5XXE=G]%@\A_UHT7[;!WY/]6#ZLU[_M?WAS_?(LW1]2 MLVRN=GN->?O'Y^:R62[W4NV!_/>@>G;[V]]W#[V_ERB$W/DJM/V]WZ[K!Q
M>P1WB9]7/^>_'YP(.FAUZ WT80/=W_,& .&YBI>[*'#>S4/62'#1Z&/OLZ M]@?CZOEN?G&^67]) OOH5FW_EP?W'[9N_5JL!F?*^]VF_==%N]WNXL?UKDG*
MY*_)^^:F/0%VR7QUG?RC6=]LYO>WBZMD+[K_UZ\G4K+^F/SSOMG,]TG>)A_^M"$-?M6=]\DW=[.:+Y?:,=]-?WM?)-W_^]GRV:P]TO[O9U>&@7G\]*#UP4"9Y
MNU[M,K>)6UTWU\3V ;]]O6P_:PTZNJ0?77]M6<'WS?WWB4F_2W2J+7$\E],W M-]1PGK9W=_+>.V:8XREC'O3L@-Z[S?KZT]4NV<+G2E3IMGY[/H'!&79I4N,3>NCN/R7.56]>)
<'%=D>5[:\AC7&:0]#MH" M!OU5(QL=-!%'#CJ.HP<=Q[&#SHZ#SMA!__+CFY]=G:S_^=7/[CTU7G:S_4WN MQ?9^?M6\/&OO8MMF\[DYN_C+GU2>_.HVZAI!B-5+,@<<0Z.**G0!***
MZ]Q0>_.$H^(R8_*B=^*QQR2U#R36L:\XVE<`[^LFVD?%4?:QQR2U#R36L:\\ MVE>R1H7KNV:[:V_N_WI;W'UH-O^AW&,EI+,_4JQ&BCF06" T9C6D
MB4"*U55TX9@J+6VE>C>R.,ZFN=%%2M_(5.H_YJ8 WD1J8-0M?J@-NXA&- HXW)BH&/ILI3B$)@R$%PDLCC0'KD M<<S R.- ?
N0>113/(I<_O/GQ%3E8=COQ58=4JZ%]#J76S8#G(L6#T<1S#XI' M4+7ZH!:>G6G_!(Y#VC.]_6_@_/5$HQ!(PXN(W4.JU2KFJ,B],(1USP.-XHGF MS6J[VWS:?
U>W/=Z"D_\EHZS.RXK]1*K54#6'4NLFR"-3XIEIXNE=QC>F,LVK MZ+X4QVF3YBKKWY>@K(-2ZUKH:4^*#1//_ M3:!.3@)Z7EDX54+4:JN90:MTD>:#2/%!-.\]Y7ZH#!U4
NOK:Q*==:_'1)Q MAMK2"-K2!*Z0HXICR%"8?2HXSAVU)Z2-$]) U?E(/SS!%Q.J"XI>,Z5G2S8X?-6>CC2"CG@1L7O0HI*.B2QRCX VSCT/ M1IH'HQ_FJ^O[17/5R-B?
5Q7;"2T-0=4<2]VI,L93ET&4F4Q0J55KTJV%D8%&49N"6:#P3 M&003\2)B$Z&E,1.#TX")5"!GHDHIRZ#H"X3 M8PL]\#B.'CBQXH\>.,%+[,],!D>F.A+<_!K %Y-
?"5"R0FJYE!JW;QX%#.(M&A4O(DX'E+Q,7!?K@RP;TEU([QG)(AB)%Y$:!U6K;8QE?>/8D*YQGHLLST6O MKMD)8+O>+
(3TS\N*K836CZ!#]7639!G+HNH15FBWI.EO56)*" M!%5S*+5NDCQJ640UBQ<1IP,*5#8N>9E"Y?W*&!&65<;D]=!CT 6@4"\B-A M:#G,QI1$&AB'<09ZE+(\2@U,$]-IG]
<7>PNM;4'5'$JMFRG/?A91++-$M:G* MC.W?$8D5ATKW;YPU$6:*M-+]DY,([W([@+O68Y5%8)4EEO110R96"%)#)AY/ MHH9,/<4T..3, U'&]'
]3B(^+R<^+%;*!I!U1Q*K9L8#UP9HA#%BXC3 <6K M+*Y]]4F5#>D;YT$H0X 0+R(V#EIGRF+\BHSC0KK&>0+*> *]F]5NOCPVX^!N
**MPKR2V#UH60BJYE!JW9QXJLH0!:.,6'1G\]Q&O1^HP#0S,C*>,@2MQRO=MO++X MRH2B!U3-H=2Z.?(@DR%J0AG5M4%9$RT4(0.I]@[\88E-? [&R#QC9 C&R AX
MH$VD DD3H<4@E%K71$\M&4\MP[/%I"_?>'7QC &M$D'5'$JMVTO'HU:.J#WQ M(M)T0-7JG&@#418JC=I $(%L&XC<8U&.P")>1&PB%(ORF'D&3(D#*>1,[(N4\
**M(@W/&-._A^-W(;88"E!0-8=2ZR,+8UF.*$SE5*^)3,>[)HC HJKB7A-$W+XK M51:M/B$"C=;#O29R#S\Y G[RF$ &1DZ@"CER I+HD5-+XKB1>_,)>?89OD ' MOYCC%
<77([1H U5S*+5N;H*>>>)"F>% .@ZK5^7@'"2*$>X@D]B4([")%Q&[M!RWRY.,/,!$AK'N>E_*1EGB#*IG3GX'8]=AB[9@ZHYE%HW=9[2*
**M1D45MV4@XLBV$QO!B2U\#H J/$ 5("[JB.>6*_N)-"_J"D%J+4NA9Z?"IX M?!)/(0.^0N!W*IU%H&HU5,VAU+KI\^6(&I;O(@<'X 5 T*X@%B&49-YP@XKB&
**M$X7'J0*!4[R(V$)H@:L@UB"2%A*DQUGHN:S@N4P\B4S_5H'?L]AWZ$I J]H# MJ75SZ FS0%37"]}HEBL;]&4@XJB^%D18GI=%U->"B./Z6A2>W0H$NQ4$_)"C
MCN/(4<=A]*BI!Z>840=MR'GF$E^O@U\R\#L27YY0+H.J.91;-V4>] I$88P7 M$;<#"F_%>*<*(H3#Y,*S5H%@+5Y$!ZT\%6,/QY%A'#NE1ZS2AZSAJ>+$SN
M\/N3&@U5JZ%J#J76S9RGNQ)1'"NIGA2Z4E$YG0RDFE?PAR4V\3D8J_2,52(8 MJR0>D:)-I))$Z%%*Y1:UT1/6>5):PD'YY!I[_J 0AE4K8:J.91:-WL>\$I$ MX8T7$:
<#RFHE59JS61ZUM2 #F;86I2>L$D%8O(C81&C9KB2>M:)-I (Y$SVP ME:>NA'QJUQ!^QV+CH04ZJ)I#]753Z.FS1%3\3JIYAHJ+^$1<^Z$W;IY!Q*BD
MS_(R.G>IYAEZN'E&&;R^"L%P90Q!],#C.'K@Q!(>N $?;$#]_A5GKH@4=A/ MA-^/^!J%$AI4S:'4NB_X\LA7(2IKO(@'T'5"UNAIOB\&&=(WSQ%4AB(L7$1L'
**MK8]5XT]IL2%=XSQE5:J@PH9;=:@T?(\PYD7"Q,I&8M14'#5L*HX:-QG'#3QX]V]ZZK)%:?^2 MD3U)KU"L7(V5<\PKR*W M#UH9>Y3C[>-B>O8%[RI.>=)ZVUPOKB;V-
!G1DIL(K6=AY1Q,KI>:X"7&*:(Z M]JC2>0:VL&D:W0=PBG!':2%HZL!ZY$CDEOX'-4I MI0+643SK,!/&I,_S1O3%DP94KL;*.9A<+UT!H2E$(6Q$19X4+'TIHC5'?-=U M5-
S0+5(%K*0@K,2KR"W$LI**.8BV<#HOJ8"7%,]+S*0Q_3N\D9W(<;B%%,3. MP>1Z.0L@32'*88\JG1,KBS[J7E)QU"=B2BZW\2=B{H[|1*P" E(0 E+$VCIR MW-,(B)
(CQRTC(!40D.()B+E&A[^UXS7EER2T'H25?0% *0A \2IR^Z#%HD M0Y<28N4<3*Z;01VPFX;4J33YAN'HSD:$1;@X&.*4A.*7))[1B M!T?
7^-4C!R1W\%DJ3S[@*1)P1*,)EHI1E>IH*&[J8ZP"L-P2M>1>X@MOJE8PHC'8S#!AT,0$WSH":? M203?-?#[EOL.77>(E7,PN5XJ_;4D.J,)A;XZ8RXKXXV4JPG:CE>JS?
@@.0T MA.0TL2"// H4]43M1ROU1MPP%Z:9R_YQ3K\I0._*_FUB04TJ)R#R?4R%V"? MAM3,>!5Y4K DI\?[=O Q??M.P%P&PER\BM@^J%S]*,?:Q\;T[N R_# QX
ML.+&]\B3@H4Z.][,@X_IV1?@EX7@%Z\BMP],/,,3'O1B8WKV M!>AE3UZX>&H_E)%=RKW&%L6@<@XFU\M@0'X64F>S7(GJT>G1F'KD:.3V/0MS MV8"Y\+(2Y++$1Z
M60R0ST*J=;R*/"E8>K,3UEVR,3W[LZR$,[B5>3V82Z]0 -JRR#4 M=E#)V8&.QM2/,?Q I_-5%O!5=O)R1G$+%Y7XFL1*E=CY1Q,KI>Y .TR2%6- M5Y$G:4MKV80>'FQ,S[Z
JS((5_$J?QMLFD^[MU]\4J?S:.+?OU8O+A7Q^UJ]< ^_ MGWGYB_/[^4WS=KZY6:RVR;+YV.XJ_7[_BJ[-XN;V^,-N?=\F]BSYL-[MUGAG/Q?U!+ P04 "
#U@6Y9=>,FY(D]A$,47O:52J_-^/ ;6/'3C$!B4?+- M@Y"AJY)#^=B/5Y*[BRPH#/]688S[H>M'O=DT.W]$S>R\G;OW'I4I/]&?3E?O([CZ8W4CDZ-
^05GX(8]B7T1\H>+WJ5Y MSJQ1&I"-^.KS;;SWF:27.CL$P(&]8!Q2\ D#YADQ=K=W:PTMJO3Q2$DW54A,?
K*Y$FXVA5=*,2AT.\AXPQ;>+=_P;.W)%8^\9=)$OY&_KGEXS^7?Y%\RS]8- MEU51DUL_+H[.01_(32]92"4O\TURT?*ZRF4',XV])6V<#$>U
**M)M(X:EP=1!L'C0:U!M&YR@RG7,P'0.EJQ34-$HSP]"6]-+SQ#I2,;GE M'O51O0U#; MLSGIX+3E/:=T-$V]I?D._64I^8%?4E!7%$JSH30*I3E0&D/1]L(KC5M3[]R^ MHL-
S5FHI<.4]IFI=TV+#G/C/M?;R]UZM0K\@^WE ME@>NXHN$(-6SOK4>2O:-Q=N]7'BU:G%X]H[-2 MOO=++K9]!#TU(#R=TH E90\)!J^N>'LNRC=&@[4Y872;"B-
**0FD.E,90M*H.2Y?70KN\>F!GV4!=7BB-6HTN-MKUE_NX$F92U)VQI.:=]:1]JW;V\X%5NE6\N!.KI0F@VE42C-@=(8BE958NGH M6FA'5P_L+!NHHPNE42C-
@=*8U>PV6[7.U-_;&!1R^9CM^8I)UGUV>RV*L\6^_MLLML-U7M_-P\M\V&\l0\=W:[QDK\;A/;M2L?_2@F 7](4ADGDV3&@
MQ"K;EG0OE!)A]G')W067Z8#D^P=#NR\,Q\FQE0]94.5N]JOZ:OGC/^=+Q@KR,LR2?/KSJ(H5I?=;AXMV)+F M9]F*I>*=6<:7M!
O^;R:KSBCT))IF70MPQAVES1.,S=7Y;X)OIG*UD42IVS" M2;Y>+BSOK4@>}KGS=;3O;'5_B^:*0.
**[HW5RLZ9P^L^+:;SZ\ZM>1E:%]*AM/@]9L_YWC:1I_*897_+%\'TNF/((V()BP]}H.+/$QNS M))$D<1S_K:"=74SIN+^]I;OER8N3>:0Y&V?)?^)IL;CNG'?(E,WH.BF^9,\^
MJTYH('E1EN3E_^2YLC4Z)%KG1;:LG,41+..T\Y>^5!_$GH/9?\?!JARL0QUZ ME4/OK'.EQ4#A>',IC& M]ILSR@S:?.5EOMBTH#=7/'LF7-
H+GMPHDZ[T%VD2I[(^'@HNWHV%7W'S:U8P M8AKD,_G"$EJP*9E07KR2KYRE.2US."_J_2\T_EUQ]KN/P-I^!'>6 M%GB[XF?$&)X2R[!,Q?&,]>[A.CD3GZ!T-**

T>JCT/O_L!69Z17NEM}A;MSN'M/ M]6%^7W3O^Z+[>G>;1<+=?-<]T+O?4_G%6>]^<>$A[J;*O9%'O5TI]4I>_QW> MA+.G.%OG1&SD\92E!:'IE(P7,9L1YX5%:SD4D-]FLSABG/QYSY:/C/^E./ [M;2 Y9%[F*QJQZXX8$W/&GUCGYN>?S*'QBRI]D3 ;"7.0,!<)\Y P'PD+D+ 0 M!&N42W]7+GUMN01D)!JZG,G19;/UB<0IL=F,
<2[&H7&V%$U@3N40I*H1+?W8 M&MG AB5,MI1/-Y]-0_Z]ZC[MIS\RJ(.$N4B8AX3Y2%B A(4@6"/]!]OT'VC3
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}HS>2O
M]6U3+W!OAP@R%N_$$4W([6Q&XP]F^E!M&TJSH30'2G.A-]*\Z&T $H+4;1F MC=12N*G7PK]DKS0I7K47>]@0#J79%:UQ!;?ZBBN]PLYHV[F5W?[=WUZO;>>I
M[$;MD<.'GFT I84H6C/S:N79U$O/$Y[-6"Y_Y2 NS"YCJOGHG9YQ=.XA:;;9 MUJM[%XK4:YN9YDB1>E#Q&$KSH;0 2@M1M&8:UP]RJ9>0MQ=0T2S_R@KR0!.6 MG\];-
)'HKNE-<&MG M-.UJLV96U_*P^8$^O&V=L]G;[OF#^RM0^1=*LZ$T!TISH30/2O.AM !*"U&T MYN^V:DW9TFO*MU&4K:6\-.&OJ#%AY>]MQ$Z^9E/R[Y@^QDE-*I?
T1J/?ICMYC^ 1@U1M&8&UU*O MI9=ZO^>I"#WZZ,2%"KE0F@.EN5":!Z7Y4%H I84H6K-4:B'7TNNF_Z35UR./ M+A&H/ NE.5":"Z5Y4)H/I045[<-6'Q6UF?
RU\&H]*+RN9S0JUERJK[NGIYZV!NV!X,J>.7M MTG;SWP::%PI#'WJ^ 906HFC-'*TE4DLOD1XZ?U4F)50IA=)LJ_VCXI&E> (M&M4],*H'C>1#:0&4%]}HS?
2NU4U+KVX>V;20_[U9@VCOC;>52R_R?M?X M5^H30;2G.@-!=* M\Z TOZ+M]VQ]HWUC-X!&T9A'4$K&EEXBWW?Z4W+-IJ:1->#9=1T5CY/F6
MQD^,Y{$8=B8T3C>V@D3&3-ZB)2\?YI!]?H-(RE&9#:0Z4YD)I'I3F M0VD!E!:B:,W2JG5J2Z]3:^;8M\O-R)/-IO7=OK=0EX_-R;=ZL8WZ_=N7A39JERI
M]3$KBFQ9;BX8G3(N#<3[LRPKMB]D@-TJRC?_!U!+ P04 " #U@6Y9!U3W M4%X# #7"P &0 'AL+W=O&8%5W,OU[J\\'V5YLB(.A,EE1)(Y)U;X41 D/B.4>XN9>
[:6BYFH=$$YKB6HBC$BOUQA(?9S+_1>'MS3 M;;[M W\Q*\D6'U_.EFMI5GZ+DE&&7%'!0>)F]EV&%\O0.3B+/RCNU<$]6"E/
M0GRVBYML[@66$1:8:@M!S&6'2RP*BV1X_-. >NV>UO'P_@7]VHDW8IZ(PJ4H M_J29SN?>U(,,-Z0J]+W8_XJ-H+'%2T6AW#_L:]M)Y$%:*2U8XVP8,,KK*WEN M
G'@$+WE$#4.T7]UB!N'V FMF3E9*Z+)8B;%'J2U-FCVQL7&>1LUE-LT/FAI MWE+CIQ=W0B.$(?P$2\$8U29#6L&'%6I""P6_X[.N2/'CS-=F,^OBIPWP50T<
MO0%\#K>"ZUS!)YYAUO7W#!C!WNZ W(H*3&W>\)T)HY!?8%W)-#=5IOH" M6 ,F#M"VVVX1!F$8!\G,WQT*ZK&+)^%X-&WM.HQ'+>/1(.,7;@>9!W,NP IW MU
KYZQ;9$\]_^Z@/(MNCYT*5),6Y9\X6A7*'WN*'\(D^+DO82<'ZP1AW 9A M_.X@W%56-_RV@4=.=6_]:M!Q)W5!"IO@SM_HZZDU96\5]='N$=[L%.^A5MS
M816#2R8JH[@VTJ_[M-:;])2I^[V2FQS%)(J[=ATEDU;)Y-2--3EB,AY-C@D? MFX5#A*D@8=,_YNM8NE(2&] YPITY1N$7Y"B)^WC=<*5EY2R&NFQPG_=V MV8G .B$Y;T-
R_G]5X_EQTL;3Z5%N!_E\H]HP^/I1#0;U+LVG3YH)1;D#];KB MF95IBN&ZTI5$^%32K)*D."@$!81GL"92#Y^\PSN_MRA.A=:-T\'P$9ZZMQO$ MSG&43(^;N\=N%!
[WMG\P.C&46S=1*935/NTG5HOW:SF?S6O1$Y;(K>4 M*RAP8UR#LXDI4EE/D?5"B](-8DI"F[\W>9F\D9I#&PO=V]R:W-H965T0=H!42*I-6K>]J*OV:(@!TG,M;
/MO]^UDZ:$AI"-ON#8.>?<>P^VN?2WC#^*)2$2/25Q*@;&4LK5I6F*V9(D M6+39BJ3P9LYX@B5,^<(4*TYPI$E);#J6U3433%-CV-=KMWS89VL9TY3<C]&8L%OH3;3-L
M!\"SM9 LR/X'@'"&Y.<)M&\'*"US1")R?H MTLVL=FU<@"4>]CG;(J[0H*8>M/N:#7[15.V3B>3PE@)/#G\P29!MHW,T9DE" M)6P!*6#VG8#[*'R" 0AC*R
2TUBA[*)VYZ7VD5,K."&K-G*MS\BQ'*\BGW%SNEM5 MSFG1P_^.7C+/#+3:"J_6\ WIC+)9HA6F$X/)!<]Q+&FZ0+'>"#"%4QI328FH M^N(SZ:Z65C?39NA:;@_2VNS:68'R7,
[)0K4 M>B:8PXEO_8:Q\KC7R[DHR8ZK[:$(/U>Y-JY7L)%* ;T*^8>$@I-3"=\AE9+K MW<+U;JWRS_)):^)O:"C4Q6HF^=:Y7N]@GM<(3@YA_"4'$I.]PJG>[62#[H M(-
$YWH#E"X(B*F9LG4H$7P!!GS[XCFU_Y;_Z*D]|%LBV=\Z?U:8NG+WSW@P6 M-(.%1V$E5_S"%?\]7"E=AI6>^,T\:08+FL'"H[#,$W.G04H(7^C.5"!=9_83
M6:P6S>^5[OGVUD?VY=BN6 ^@6[!1<.S[C6; M2+;2[=F426CV]_,2&G["%0#>SQFT:/E$!2C^0@S_ E!+ P04 " #U@6Y9 MR%68A.,# .%@ &0 'AL+W=OF_[YVDDEA
MFG%![=T'26H>WS, MX-Z M\G(R&\QA08M_\U1D4^O&0BEL<56(]_3X)[03&BE>0@M>?Z-CV]>Q4%)Q0
M^AVMJPV'SQ40@:*#_.;H50@"YP5'_\"CJ'#Q6O9;,>!YJCIAD]%EL,618^0 M5,I1Z,_M-D^ H?\>H-P ^U*/]Q#].K7UQ-;R&C5F';21C9O(O->B,Q'#Y2(MC*.
(I)">ZVTYRVZJWM-4YYX6&$(R0+[[!GF.-^]}9Z&7KV$OY9,_#]B7WH,<*P,\)0:X1UAAEHG"!WPSXS M:*'7FL$D+#0)BTS"8I.PY;#/#,&XWPRCS@PCK1GDV0(2S$6W??
2E7HNX-O4F M8:%)6&02%IN$+0W!SAP2= X)]/L&)5R>,7.R0_<[!B#/Q.(-FLNC*%KC0AZE M^QS3((,3J_HC1WXZLS9>T(Y\K1=,PB*3L-@D;&D(=N:%
<>>%L=8+*_REK(^I M\GT,G1AC+<>1AU#>9X7Q=U8(U.>9$R[J%5[4*_J^E]MCOE@[U6NS8@AVEI6; M+BLW^@W]V5N$=BW7HJY=RTW"0I.PR"0L-
@E;&H*=.>6V<\JMZ7< +?!:OYB$ MA29AD4E8?-MW4AN=+S]+0R.>^[N=1?=9[=G_NWD5-F?(;IJF:/F"V MRPE'!6PETAF,Y4&5-87(IB'HOJZ#;;@0M*PO,\
I,-5!/M]2*IX:;H"N'#S[M"E!+ P04 " #U@6Y9(TPK^S4# !($P #0 'AL+W-T>6QEUY-B9X[)VOWZ^=H^
MX(LZ'C:Z5#3V/3[G'MLWQ#"HS4JPNSEC)EJ60M9#,C>F^A#']73.2EI?J(I) MBQ1*E]38KI[%=:49S6L@E2+N=3H7%(NR6@@%^5-:>IHJA;2#$G:AB)_^YP/ M23=]3R(O-
U8Y&Y*\I[<_%LI3=R4GGX?OZ/W[F@',2!T4O#Q"]Z'1P M80 Q\?0P\>>T,>FK@Z2?4<:$^[O";O2IU?&4XR6!6C6_H8)'4>.F]T>#0HE M-
YN>$!^PZK1DT2,50S*F@D\T!U9!2RY6/MR#P%0)I2-C]\VFZT*D_N7AKN]! M(38Z)9=*N]P^@_^>-,/W@'4/#'(A6H,]X@.C046-85K>V(X;[()/H*AIWZ\J
MZW"FZ:K;NR0;@KO9)!.E,V_ MYE5^L>/DZEl9=K]5]@T'/3:OWM=N\O(83*;'8/(H:K)_#":S5VDR;E[@6Z>$ MG3-"&XW@+#8DW^!D)S9)H\F""\-ETYOS/&?
RR5'!RALZL7\F[.C;\3DKZ$*8 M^Q8P$,VH3?L+3*^;M@=!FXO+G"U9/FZZ>C9QS<@V;-;F M L(^?ZG^?31^7@,\]8/(GV4TT2#3GZTUOMMXA3Q?!]B>
M/EPVH'X3Q04V%.DL"N8MZP)QA' ML@Q#H!;#-9JFR.JD\ GO#_:4)$F6A1' P@Z2!$/@;<01S %XP) D<>_!O?=1 MO'Y/Q9O_G8U^ U1+ P04 " #U@6Y9EXJ[', 3 @ "P
%]R96QS M+RYR96QSG9*Y;L,P#$!_Q="> , ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0 M"QEY/3P2W!YI0.TXI+:.+]1C|$%)I6M6X 4BV)8|ISI%"KM0L'C6'TD!$VV-#
ML%HL/D N&6:WO606IW.D5XA-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H M5 J.W&,EC'%BM/XU@LD/[']X 4$L#!!0 (-/6!;EG%FLE (00 /H? / M
>&PO=V]R:V)O;VLN>&ULQ9E=;]H\%(#_BI6;=1<;O GT0V-2UW8;TK15 MH^]N)Y,8L)K8S';HVE__'ANA.K0YVDV<*XACS)-CYSPYSH<'I>^72MV3OW4E MS2S96+N]&
(U,L>$U,^_5EDLXLU*Z9A8.]7IDMIJSTFPXMW4UHN/Q=%OS(9./ M'PYCW>I1>* L+ZQ0$AI=PR_!\SS>7=(=L*(I:B$?9PE_GO%$U(+*6KQQ,M9
M,DZ(V:B'KTJ+)R4MJQ:%5E4U2]+|B5]<6U&\:%XXR#NV-+[%LN5/!B"S9#]& M 5=."&^M[^/$9,.XX=-X?-59]%I7E^I9_D6K9BODV@T#5S$*+L/'X?"Y#^*%
M_I>O#^(*^4++DTO"3PS:A*E,!1DD^L8K+@){"D M""0=$/(W#2 S!#(;!'+A<."G 62.0.8#0K8B.4$@)T-"9@'D%(&<]@[YQ &^>A38T2X)L\0R+,(D!0@
MOXD_C2A=FG2$_T'^T9;) /(<@3R/)D!Y**I:Z8?W3POQ%H*^#V3-DSF8RR: MCR-@YH YESOH"=KE)F1#3=.S:CS;!-@NRYV3"|PKTMWA5H/"6Y28:M*>7>,I
MIVZBK2KN-ZHJN39OR TL3?L80F*J27MVC8<\|=-'>/A MSEP$^=H__[B[^0M7:\VV&U&$F)ADTIXMXS'/ 1.68,'=*O1=0CQ,+VG/?MFG M[C'P_72G03*W3$-JO--,&M:*
(B:8-(IA4A_&NA;62S"$P\22QC!+2GW67AK^ MIW&K\69WC(A])>W9*W-I!&08-ZTE%"KD4L|AKOEQ&"DF%=]S5 +/D&7+D6WGFTI6LO$$,R1HLD)U*\5-V]#2$PP-
(9@NBQ(M3D),3#5T2-6TIQQ3#8VAFN,D^>J<8\:A48S342RT@XD9A\8P3E>YT,;W-C MN*L:W[GX=8*IJ!L@+]&G%QSJ \K0^Y"3$Q!60P%'6,^QS;$
MQ!24Q5!09R76PD0WU:44'O;#Y-0%D-"G:Y\%V)B%$@SFF%"RC +93$L MU(G92DB8A;(8%NK$G(28F(6R&!8ZWBAX3IPA)F:A+(:%.I_CPK698Q;*8UBH M$S-
I19Z==>?(Q33$Q"R4>PN-#N^:2[X2 MDI??X2\,M!>L*FXU<1_[;>]\XO:B5DU574';#_E-L?+PZOKPVOWC_U!+ P04 M_" #U@6Y9N2/:-[(! !4' &@
'AL+U]R96QS+W=OCN9U3O;_?F@$02-R@>-(6ABOJK01Z*^JM!'HKZJT$>BOJK01Z*^JM M!"H;ZFT$>AOJ;01Z&^IM!'L;|"$0&]#O8U ;T.]C4!O0[V-0&]#O8U ;T.]
MC4!O0[V-0&]'O9U ;T>]G4!O1[V=0&]'O9U ;^\==A/H[:BW$^CMJ+<3Z.VH MMS]2[Y1/NYAN/=7!E&ULS=G);L(P M% 707T'9(F(\E X"-
FVW+8O^@)L\2$026[:A\/=UPB"UHJB(2KV;1(GM=U]L MZ6PR?MM:\KU-735^DA0AV ?&?%90K7U]+#5Q9&Y\B:]]:9I)XJCR2>]Q-[-FB3:VJK,=(CC;-WD
MWU(&^X0TKNSF^**TOA\G).QD0COR<\!^W>N:G"MSZLVT"R^ZCK/8IF(^;"OR MZ?D2)WHT\WF946ZR51V7I-XZTKDOB$)=L;NB_?/)(>XP[:[\ZORNS+G .'/F
MC/7QQ!Q='G&UL M4$L! A0#% @]8%N69&UL4$L! A0#% @]8%N69E&PO=V]R M:W-H965T&UL4$L! A0#% @]8%N6=%0&KZ7!P LR$ M !@ ("!*0X
'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @]8%N66-Q-V5R% 0?< !@ ("! M2A\ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M]8%N6&UL M4$L! A0#% @
]8%N6??R3/2M @ RP4 !D ("!25@ M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M]8%N6<:7,,Q&!P OA$!D ("!*&4 'AL+W=O0 >&PO=V]R:W-H965T&UL4$L!
A0#% @]8%N67ZAVG;E#0 '"D !D M ("!*WX 'AL+W=O&PO=V]R:W-H M965TV. !X,"]W;W)K&UL4$L! M A0#% @]8%N66\/SOL&PO=V]R:W-H965T]=
!X,"]W;W)K&UL4$L! A0#% @]8%N M64OM_0O8 0 @P, !D ("!_J 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @]8%N6<,WVYB9 @ 0D M !D ("!'ZP 'AL+W=OQ*!BS@"
:!0 &0 @('OK@ M>&PO=V]R:W-H965T&UL4$L! A0#% @]8%N69"-[SGW 0 &00 !D M ("!0K0 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @]8%N66Z4|.Z= @
!P< !D ("!I<8 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @]8%N6;&PO=V]R:W-H965T&UL4$L! A0#% @]8%N6:F=4K7$$0 F] !D M ("!U-\ 'AL+W=O&PO
M=V]R:W-H965T&UL4$L! A0#% @]8%N60=4]U!> P UPL !D ("! MP ! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @]8%N62-,*_LU P 2!, T (!Y0L! 'AL+W-T>6QE
M&PO=V]R:V)O;VLN>&UL4$L! A0#% @ M]8%N6;DCVC>R 0 5!P !H (!?!0! 'AL+U]R96QS+W=O M XML 58 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer
was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are
not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var
e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref)
{e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e).style.display='block';Show.LastAR=e};Show.hideAR=function()
{Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var
d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent)
{a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 59 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04
/ / v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report
table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color:
#2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body {
height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration:
none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom:
2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void {
background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-
space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; }
.report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-
weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td {
border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou
table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */
.report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles
for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; }
.report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size:
1em; } XML 61 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 361 256 1 false 69 0 false 6 false false R1.htm 000 - Document - Document And Entity
Information Sheet http://www.milestonescientific.com/20240930/role/statement-document-and-entity-information Document And Entity Information Cover 1 false
false R2.htm 001 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://www.milestonescientific.com/20240930/role/statement-condensed-
consolidated-balance-sheets-unaudited Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 002 - Statement - Condensed
Consolidated Balance Sheets (Unaudited) (Parentheticals) Sheet http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-
sheets-unaudited-parentheticals Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Condensed
Consolidated Statements of Operations (Unaudited) Sheet http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-
operations-unaudited Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 004 - Statement - Condensed Consolidated
Statements of Changes in Stockholders' Equity (Unaudited) Sheet http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-
of-changes-in-stockholders-equity-unaudited Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) Statements 5 false false R6.htm
005 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) (Parentheticals) Sheet
http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-parentheticals
Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) (Parentheticals) Statements 6 false false R7.htm 006 - Statement -
Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-
unaudited Consolidated Statements of Cash Flows (Unaudited) Statements 7 false false R8.htm 007 - Disclosure - Note 1 - Organization and Business Sheet
http://www.milestonescientific.com/20240930/role/statement-note-1-organization-and-business Note 1 - Organization and Business Notes 8 false false R9.htm 008 -
Disclosure - Note 2 - Liquidity and Uncertainties Sheet http://www.milestonescientific.com/20240930/role/statement-note-2-liquidity-and-uncertainties Note 2 -
Liquidity and Uncertainties Notes 9 false false R10.htm 009 - Disclosure - Note 3 - Summary of Significant Accounting Policies Sheet

http://www.milestonescientific.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies Note 3 - Summary of Significant Accounting Policies Notes 10 false false R11.htm 010 - Disclosure - Note 4 - Inventories Sheet http://www.milestonescientific.com/20240930/role/statement-note-4-inventories Note 4 - Inventories Notes 11 false false R12.htm 011 - Disclosure - Note 5 - Advances on Contracts Sheet http://www.milestonescientific.com/20240930/role/statement-note-5-advances-on-contracts Note 5 - Advances on Contracts Notes 12 false false R13.htm 012 - Disclosure - Note 6 - Stockholders' Equity Sheet http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity Note 6 - Stockholders' Equity Notes 13 false false R14.htm 013 - Disclosure - Note 7 - Income Taxes Sheet http://www.milestonescientific.com/20240930/role/statement-note-7-income-taxes Note 7 - Income Taxes Notes 14 false false R15.htm 014 - Disclosure - Note 8 - Segment and Geographic Data Sheet http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data Note 8 - Segment and Geographic Data Notes 15 false false R16.htm 015 - Disclosure - Note 9 - Concentrations Sheet http://www.milestonescientific.com/20240930/role/statement-note-9-concentrations Note 9 - Concentrations Notes 16 false false R17.htm 016 - Disclosure - Note 10 - Related Party Transactions Sheet http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions Note 10 - Related Party Transactions Notes 17 false false R18.htm 017 - Disclosure - Note 11 - Commitments Sheet http://www.milestonescientific.com/20240930/role/statement-note-11-commitments Note 11 - Commitments Notes 18 false false R19.htm 018 - Disclosure - Note 12 - Subsequent Events Sheet http://www.milestonescientific.com/20240930/role/statement-note-12-subsequent-events Note 12 - Subsequent Events Notes 19 false false R20.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 20 false false R21.htm 995465 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.milestonescientific.com/20240930/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies http://www.milestonescientific.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies 21 false false R22.htm 995466 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Tables) Sheet http://www.milestonescientific.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-tables Note 3 - Summary of Significant Accounting Policies (Tables) Tables http://www.milestonescientific.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies 22 false false R23.htm 995467 - Disclosure - Note 4 - Inventories (Tables) Sheet http://www.milestonescientific.com/20240930/role/statement-note-4-inventories-tables Note 4 - Inventories (Tables) Tables http://www.milestonescientific.com/20240930/role/statement-note-4-inventories 23 false false R24.htm 995468 - Disclosure - Note 6 - Stockholders' Equity (Tables) Sheet http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-tables Note 6 - Stockholders' Equity (Tables) Tables http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity 24 false false R25.htm 995469 - Disclosure - Note 8 - Segment and Geographic Data (Tables) Sheet http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data-tables Note 8 - Segment and Geographic Data (Tables) Tables http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data 25 false false R26.htm 995470 - Disclosure - Note 11 - Commitments (Tables) Sheet http://www.milestonescientific.com/20240930/role/statement-note-11-commitments-tables Note 11 - Commitments (Tables) Tables http://www.milestonescientific.com/20240930/role/statement-note-11-commitments 26 false false R27.htm 995471 - Disclosure - Note 1 - Organization and Business (Details Textual) Sheet http://www.milestonescientific.com/20240930/role/statement-note-1-organization-and-business-details-textual Note 1 - Organization and Business (Details Textual) Details http://www.milestonescientific.com/20240930/role/statement-note-1-organization-and-business 27 false false R28.htm 995472 - Disclosure - Note 2 - Liquidity and Uncertainties (Details Textual) Sheet http://www.milestonescientific.com/20240930/role/statement-note-2-liquidity-and-uncertainties-details-textual Note 2 - Liquidity and Uncertainties (Details Textual) Details http://www.milestonescientific.com/20240930/role/statement-note-2-liquidity-and-uncertainties 28 false false R29.htm 995473 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Details Textual) Sheet http://www.milestonescientific.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual Note 3 - Summary of Significant Accounting Policies (Details Textual) Details http://www.milestonescientific.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-tables 29 false false R30.htm 995474 - Disclosure - Note 3 - Summary of Significant Accounting Policies - Fair Value of Marketable Securities (Details) Sheet http://www.milestonescientific.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-fair-value-of-marketable-securities-details Note 3 - Summary of Significant Accounting Policies - Fair Value of Marketable Securities (Details) Details 30 false false R31.htm 995475 - Disclosure - Note 4 - Inventories (Details Textual) Sheet http://www.milestonescientific.com/20240930/role/statement-note-4-inventories-details-textual Note 4 - Inventories (Details Textual) Details http://www.milestonescientific.com/20240930/role/statement-note-4-inventories-tables 31 false false R32.htm 995476 - Disclosure - Note 4 - Inventories - Summary of Inventories (Details) Sheet http://www.milestonescientific.com/20240930/role/statement-note-4-inventories-summary-of-inventories-details Note 4 - Inventories - Summary of Inventories (Details) Details 32 false false R33.htm 995477 - Disclosure - Note 5 - Advances on Contracts (Details Textual) Sheet http://www.milestonescientific.com/20240930/role/statement-note-5-advances-on-contracts-details-textual Note 5 - Advances on Contracts (Details Textual) Details http://www.milestonescientific.com/20240930/role/statement-note-5-advances-on-contracts 33 false false R34.htm 995478 - Disclosure - Note 6 - Stockholders' Equity (Details Textual) Sheet http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-details-textual Note 6 - Stockholders' Equity (Details Textual) Details http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-tables 34 false false R35.htm 995479 - Disclosure - Note 6 - Stockholders' Equity - Warrants (Details) Sheet http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-warrants-details Note 6 - Stockholders' Equity - Warrants (Details) Details 35 false false R36.htm 995480 - Disclosure - Note 6 - Stockholders' Equity - Summary of Shares to be Issued (Details) Sheet http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-summary-of-shares-to-be-issued-details Note 6 - Stockholders' Equity - Summary of Shares to be Issued (Details) Details 36 false false R37.htm 995481 - Disclosure - Note 6 - Stockholders' Equity - Summary of Option Activity (Details) Sheet http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-summary-of-option-activity-details Note 6 - Stockholders' Equity - Summary of Option Activity (Details) Details 37 false false R38.htm 995482 - Disclosure - Note 6 - Stockholders' Equity - Schedule of Restricted Stock (Details) Sheet http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-schedule-of-restricted-stock-details Note 6 - Stockholders' Equity - Schedule of Restricted Stock (Details) Details 38 false false R39.htm 995483 - Disclosure - Note 7 - Income Taxes (Details Textual) Sheet http://www.milestonescientific.com/20240930/role/statement-note-7-income-taxes-details-textual Note 7 - Income Taxes (Details Textual) Details http://www.milestonescientific.com/20240930/role/statement-note-7-income-taxes 39 false false R40.htm 995484 - Disclosure - Note 8 - Segment and Geographic Data (Details Textual) Sheet http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data-details-textual Note 8 - Segment and Geographic Data (Details Textual) Details http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data-tables 40 false false R41.htm 995485 - Disclosure - Note 8 - Segment and Geographic Data - Summary by Reporting and Operating Segments (Details) Sheet http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details Note 8 - Segment and Geographic Data - Summary by Reporting and Operating Segments (Details) Details 41 false false R42.htm 995486 - Disclosure - Note 8 - Segment and Geographic Data - Summary of Operations by Geographic Area (Details) Sheet http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data-summary-of-operations-by-geographic-area-details Note 8 - Segment and Geographic Data - Summary of Operations by Geographic Area (Details) Details 42 false false R43.htm 995487 - Disclosure - Note 9 - Concentrations (Details Textual) Sheet http://www.milestonescientific.com/20240930/role/statement-note-9-concentrations-details-textual Note 9 - Concentrations (Details Textual) Details http://www.milestonescientific.com/20240930/role/statement-note-9-concentrations 43 false false R44.htm 995488 - Disclosure - Note 10 - Related Party Transactions (Details Textual) Sheet http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions-details-textual Note 10 - Related Party Transactions (Details Textual) Details http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions 44 false false R45.htm 995489 - Disclosure - Note 11 - Commitments (Details Textual) Sheet http://www.milestonescientific.com/20240930/role/statement-note-11-commitments-details-textual Note 11 - Commitments (Details Textual) Details http://www.milestonescientific.com/20240930/role/statement-note-11-commitments-tables 45 false false R46.htm 995490 - Disclosure - Note 11 - Commitments - Lease Expense (Details) Sheet http://www.milestonescientific.com/20240930/role/statement-note-11-commitments-lease-expense-details Note 11 - Commitments - Lease Expense (Details) Details 46 false false R47.htm 995491 - Disclosure - Note 12 - Subsequent Events (Details Textual) Sheet http://www.milestonescientific.com/20240930/role/statement-note-12-subsequent-events-details-textual Note 12 - Subsequent Events (Details Textual) Details http://www.milestonescientific.com/20240930/role/statement-note-12-subsequent-events 47 false false All Reports Book All Reports mlss-20240930.xsd mlss-20240930_cal.xml mlss-20240930_def.xml mlss-20240930_lab.xml mlss-20240930_pre.xml mlss20240930_10q.htm http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 64 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "mlss20240930_10q.htm": { "nsprefix": "mlss", "nsuri": "http://www.milestonescientific.com/20240930", "dts": { "schema": { "local": ["mlss-20240930.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/currency/2024/currency-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/exch/2024/exch-2024.xsd", "https://xbrl.sec.gov/naics/2024/naics-2024.xsd", "https://xbrl.sec.gov/sic/2024/sic-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["mlss-20240930_cal.xml"] }, "definitionLink": { "local": ["mlss-20240930_def.xml"] }, "labelLink": { "local": ["mlss-20240930_lab.xml"] }, "presentationLink": { "local": ["mlss-20240930_pre.xml"] }, "inline": { "local": ["mlss20240930_10q.htm"] } }, "keyStandard": 210, "keyCustom": 46, "axisStandard": 26, "axisCustom": 0, "memberStandard": 31, "memberCustom": 35, "hidden": { "total": 47, "http://fasb.org/us-gaap/2024": 30, "http://xbrl.sec.gov/dei/2024": 6, "http://www.milestonescientific.com/20240930": 7, "http://xbrl.sec.gov/ecd/2024": 4 }, "contextCount": 361, "entityCount": 1, "segmentCount": 69, "elementCount": 415, "unitCount": 6, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 772, "http://xbrl.sec.gov/dei/2024": 29, "http://xbrl.sec.gov/ecd/2024": 5 }, "report": { "R1": { "role": "http://www.milestonescientific.com/20240930/role/statement-document-and-entity-information", "longName": "000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["b", "p", "div", "body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["b", "p", "div", "body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited", "longName": "001 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals", "longName": "002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)", "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": null, "uniqueAnchor": null },

"R4": { "role": "http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited", "longName": "003 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "unique": true } }, "R5": { "role": "http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited", "longName": "004 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)", "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember", "name": "us-gaap:SharesIssued", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "unique": true } }, "R6": { "role": "http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-parentheticals", "longName": "005 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) (Parentheticals)", "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "6", "firstAnchor": null, "uniqueAnchor": null }, "R7": { "role": "http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited", "longName": "006 - Statement - Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ProfitLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:Depreciation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "unique": true } }, "R8": { "role": "http://www.milestonescientific.com/20240930/role/statement-note-1-organization-and-business", "longName": "007 - Disclosure - Note 1 - Organization and Business", "shortName": "Note 1 - Organization and Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.milestonescientific.com/20240930/role/statement-note-2-liquidity-and-uncertainties", "longName": "008 - Disclosure - Note 2 - Liquidity and Uncertainties", "shortName": "Note 2 - Liquidity and Uncertainties", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.milestonescientific.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "longName": "009 - Disclosure - Note 3 - Summary of Significant Accounting Policies", "shortName": "Note 3 - Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.milestonescientific.com/20240930/role/statement-note-4-inventories", "longName": "010 - Disclosure - Note 4 - Inventories", "shortName": "Note 4 - Inventories", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.milestonescientific.com/20240930/role/statement-note-5-advances-on-contracts", "longName": "011 - Disclosure - Note 5 - Advances on Contracts", "shortName": "Note 5 - Advances on Contracts", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "mlss:AdvancesToContractManufacturerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "mlss:AdvancesToContractManufacturerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity", "longName": "012 - Disclosure - Note 6 - Stockholders' Equity", "shortName": "Note 6 - Stockholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.milestonescientific.com/20240930/role/statement-note-7-income-taxes", "longName": "013 - Disclosure - Note 7 - Income Taxes", "shortName": "Note 7 - Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data", "longName": "014 - Disclosure - Note 8 - Segment and Geographic Data", "shortName": "Note 8 - Segment and Geographic Data", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.milestonescientific.com/20240930/role/statement-note-9-concentrations", "longName": "015 - Disclosure - Note 9 - Concentrations", "shortName": "Note 9 - Concentrations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions", "longName": "016 - Disclosure - Note 10 - Related Party Transactions", "shortName": "Note 10 - Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.milestonescientific.com/20240930/role/statement-note-11-commitments", "longName": "017 - Disclosure - Note 11 - Commitments", "shortName": "Note 11 - Commitments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.milestonescientific.com/20240930/role/statement-note-12-subsequent-events", "longName": "018 - Disclosure - Note 12 - Subsequent Events", "shortName": "Note 12 - Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true } }, "R20": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.milestonescientific.com/20240930/role/statement-significant-accounting-policies-policies", "longName": "995465 - Disclosure - Significant Accounting Policies (Policies)", "shortName": "Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "21", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount":

1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.milestonescientific.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-tables", "longName": "995466 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Tables)", "shortName": "Note 3 - Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:FairValueOfFinancialInstrumentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:FairValueOfFinancialInstrumentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.milestonescientific.com/20240930/role/statement-note-4-inventories-tables", "longName": "995467 - Disclosure - Note 4 - Inventories (Tables)", "shortName": "Note 4 - Inventories (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:InventoryDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:InventoryDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-tables", "longName": "995468 - Disclosure - Note 6 - Stockholders' Equity (Tables)", "shortName": "Note 6 - Stockholders' Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data-tables", "longName": "995469 - Disclosure - Note 8 - Segment and Geographic Data (Tables)", "shortName": "Note 8 - Segment and Geographic Data (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SegmentReportingDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SegmentReportingDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.milestonescientific.com/20240930/role/statement-note-11-commitments-tables", "longName": "995470 - Disclosure - Note 11 - Commitments (Tables)", "shortName": "Note 11 - Commitments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "mlss:LeaseCostAndOtherInformationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "mlss:LeaseCostAndOtherInformationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.milestonescientific.com/20240930/role/statement-note-1-organization-and-business-details-textual", "longName": "995471 - Disclosure - Note 1 - Organization and Business (Details Textual)", "shortName": "Note 1 - Organization and Business (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:NumberOfCountriesInWhichEntityOperates", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:NumberOfCountriesInWhichEntityOperates", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.milestonescientific.com/20240930/role/statement-note-2-liquidity-and-uncertainties-details-textual", "longName": "995472 - Disclosure - Note 2 - Liquidity and Uncertainties (Details Textual)", "shortName": "Note 2 - Liquidity and Uncertainties (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true }, "uniqueAnchor": null }, "R29": { "role": "http://www.milestonescientific.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual", "longName": "995473 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Details Textual)", "shortName": "Note 3 - Summary of Significant Accounting Policies (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:ConsolidationPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:ConsolidationPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.milestonescientific.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-fair-value-of-marketable-securities-details", "longName": "995474 - Disclosure - Note 3 - Summary of Significant Accounting Policies - Fair Value of Marketable Securities (Details)", "shortName": "Note 3 - Summary of Significant Accounting Policies - Fair Value of Marketable Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:MarketableSecurities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember", "name": "us-gaap:MarketableSecurities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "unique": true } }, "R31": { "role": "http://www.milestonescientific.com/20240930/role/statement-note-4-inventories-details-textual", "longName": "995475 - Disclosure - Note 4 - Inventories (Details Textual)", "shortName": "Note 4 - Inventories (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "i_2024-09-30_PublicUtilitiesInventoryAxis-SlowMovingMedicalFinishedGoodsMember", "name": "us-gaap:InventoryValuationReserves", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:InventoryDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30_PublicUtilitiesInventoryAxis-SlowMovingMedicalFinishedGoodsMember", "name": "us-gaap:InventoryValuationReserves", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:InventoryDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.milestonescientific.com/20240930/role/statement-note-4-inventories-summary-of-inventories-details", "longName": "995476 - Disclosure - Note 4 - Inventories - Summary of Inventories (Details)", "shortName": "Note 4 - Inventories - Summary of Inventories (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:InventoryPartsAndComponentsNetOfReserves", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:InventoryPartsAndComponentsNetOfReserves", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.milestonescientific.com/20240930/role/statement-note-5-advances-on-contracts-details-textual", "longName": "995477 - Disclosure - Note 5 - Advances on Contracts (Details Textual)", "shortName": "Note 5 - Advances on Contracts (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:AdvancesOnInventoryPurchases", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true }, "uniqueAnchor": null }, "R34": { "role": "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-details-textual", "longName": "995478 - Disclosure - Note 6 - Stockholders' Equity (Details Textual)", "shortName": "Note 6 - Stockholders' Equity (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "mlss:StockIssuedDuringPeriodSharesWarrantsExercised", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "unique": true } }, "R35": { "role": "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-warrants-details", "longName": "995479 - Disclosure - Note 6 - Stockholders' Equity - Warrants (Details)", "shortName": "Note 6 - Stockholders' Equity - Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.milestonescientific.com/20240930/role/statement-note-6-

stockholders-equity-summary-of-shares-to-be-issued-details", "longName": "995480 - Disclosure - Note 6 - Stockholders' Equity - Summary of Shares to be Issued (Details)", "shortName": "Note 6 - Stockholders' Equity - Summary of Shares to be Issued (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "mlss:DeferredCompensationArrangementWithIndividualSharebasedPaymentsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "mlss:DeferredCompensationArrangementWithIndividualSharesGranted", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "mlss:DeferredCompensationArrangementWithIndividualSharebasedPaymentsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "unique": true } }, "R37": { "role": "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-summary-of-option-activity-details", "longName": "995481 - Disclosure - Note 6 - Stockholders' Equity - Summary of Option Activity (Details)", "shortName": "Note 6 - Stockholders' Equity - Summary of Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "i_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30_AwardTypeAxis-EmployeeStockOptionMember_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "unique": true } }, "R38": { "role": "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-schedule-of-restricted-stock-details", "longName": "995482 - Disclosure - Note 6 - Stockholders' Equity - Schedule of Restricted Stock (Details)", "shortName": "Note 6 - Stockholders' Equity - Schedule of Restricted Stock (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "i_2023-12-31_AwardTypeAxis-RestrictedStockMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31_AwardTypeAxis-RestrictedStockMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.milestonescientific.com/20240930/role/statement-note-7-income-taxes-details-textual", "longName": "995483 - Disclosure - Note 7 - Income Taxes (Details Textual)", "shortName": "Note 7 - Income Taxes (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "mlss:PercentageOfValuationAllowance", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "mlss:PercentageOfValuationAllowance", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data-details-textual", "longName": "995484 - Disclosure - Note 8 - Segment and Geographic Data (Details Textual)", "shortName": "Note 8 - Segment and Geographic Data (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": null, "uniqueAnchor": null }, "R41": { "role": "http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details", "longName": "995485 - Disclosure - Note 8 - Segment and Geographic Data - Summary by Reporting and Operating Segments (Details)", "shortName": "Note 8 - Segment and Geographic Data - Summary by Reporting and Operating Segments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "unique": true } }, "R42": { "role": "http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data-summary-of-operations-by-geographic-area-details", "longName": "995486 - Disclosure - Note 8 - Segment and Geographic Data - Summary of Operations by Geographic Area (Details)", "shortName": "Note 8 - Segment and Geographic Data - Summary of Operations by Geographic Area (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true }, "uniqueAnchor": null }, "R43": { "role": "http://www.milestonescientific.com/20240930/role/statement-note-9-concentrations-details-textual", "longName": "995487 - Disclosure - Note 9 - Concentrations (Details Textual)", "shortName": "Note 9 - Concentrations (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-ECommerceMember", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["span", "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-ECommerceMember", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["span", "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions-details-textual", "longName": "995488 - Disclosure - Note 10 - Related Party Transactions (Details Textual)", "shortName": "Note 10 - Related Party Transactions (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "d_2017-07-10_2017-07-10_TitleOfIndividualAxis-PreviousPresidentAndChiefExecutiveOfficerMember", "name": "us-gaap:IncreaseDecreaseInDeferredCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2017-07-10_2017-07-10_TitleOfIndividualAxis-PreviousPresidentAndChiefExecutiveOfficerMember", "name": "us-gaap:IncreaseDecreaseInDeferredCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.milestonescientific.com/20240930/role/statement-note-11-commitments-details-textual", "longName": "995489 - Disclosure - Note 11 - Commitments (Details Textual)", "shortName": "Note 11 - Commitments (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:AdvancesOnInventoryPurchases", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30_PurchaseCommitmentExcludingLongtermCommitmentAxis-PurchaseCommitmentForDevicesMember", "name": "mlss:PurchaseCommitmentNumberOfUnits", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "unique": true } }, "R46": { "role": "http://www.milestonescientific.com/20240930/role/statement-note-11-commitments-lease-expense-details", "longName": "995490 - Disclosure - Note 11 - Commitments - Lease Expense (Details)", "shortName": "Note 11 - Commitments - Lease Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:OperatingLeasePayments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "mlss:LeaseCostAndOtherInformationTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:OperatingLeasePayments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "mlss:LeaseCostAndOtherInformationTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.milestonescientific.com/20240930/role/statement-note-12-subsequent-events-details-textual", "longName": "995491 - Disclosure - Note 12 - Subsequent Events (Details Textual)", "shortName": "Note 12 - Subsequent Events (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "i_2022-01-01_TitleOfIndividualAxis-PresidentAndChiefExecutiveOfficerMember", "name": "mlss:CashBonusCompensationPercent", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "us-gaap:SubsequentEventsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2022-01-01_TitleOfIndividualAxis-PresidentAndChiefExecutiveOfficerMember", "name": "mlss:CashBonusCompensationPercent", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "us-gaap:SubsequentEventsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mlss20240930_10q.htm", "first": true, "unique": true } } }, "tag": { "mlss_AccessoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "AccessoriesMember", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data-summary-of-operations-by-geographic-area-details"], "lang": { "en-us": { "role": { "label": "Accessories [Member]", "documentation": "Represents information related to accessories." } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "us-

gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "terseLabel": "Accounts Payable and Accrued Liabilities, Current", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": ["r52", "r53"] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent", "crdr": "credit", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent", "terseLabel": "Accounts Payable and Accrued Liabilities", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations." } } }, "auth_ref": ["r96", "r97"] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r51", "r692"] }, "us-gaap_AccountsPayableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableMember", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-9-concentrations", "http://www.milestonescientific.com/20240930/role/statement-note-9-concentrations-details-textual"], "lang": { "en-us": { "role": { "label": "Accounts Payable [Member]", "documentation": "Obligations incurred and payable to vendors for goods and services received." } } }, "auth_ref": ["r52"] }, "mlss_AccountsPayableRelatedPartiesCurrentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "AccountsPayableRelatedPartiesCurrentMember", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions", "http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "Accounts Payable, Related Parties, Current [Member]", "documentation": "Represents information about accounts payable, related parties, current." } } }, "auth_ref": [] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableMember", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-9-concentrations", "http://www.milestonescientific.com/20240930/role/statement-note-9-concentrations-details-textual"], "lang": { "en-us": { "role": { "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": ["r628"] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "Accounts receivable, net of allowance for credit losses of $10,000, respectively", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": ["r766"] }, "mlss_AccountsReceivableRelatedPartyNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "AccountsReceivableRelatedPartyNetCurrent", "crdr": "debit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "Accounts receivable, related party net", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current and from a related party." } } }, "auth_ref": [] }, "mlss_AccruedExpensesRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "AccruedExpensesRelatedParty", "crdr": "credit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "Accrued expenses, related party", "documentation": "Amount for accrued expenses to related parties." } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "Accrued expenses and other payables", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r53"] }, "mlss_AccruedLiabilitiesToNoncontrollingInterests": { "xbrltype": "monetaryItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "AccruedLiabilitiesToNoncontrollingInterests", "crdr": "credit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "Accrued liabilities noncontrolling interest", "documentation": "Accrued liabilities and noncontrolling interest." } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "Additional paid in capital", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": ["r61"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r559", "r753", "r754", "r755", "r757", "r811", "r863"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Stock based compensation", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": ["r36", "r37", "r319"] }, "us-gaap_AdvancesOnInventoryPurchases": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdvancesOnInventoryPurchases", "crdr": "debit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.milestonescientific.com/20240930/role/statement-note-11-commitments-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-5-advances-on-contracts-details-textual"], "lang": { "en-us": { "role": { "label": "Advances on contracts", "terseLabel": "Advances on Inventory Purchases", "documentation": "Carrying value of capitalized payments made in advance for inventory that is expected to be received within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r745"] }, "mlss_AdvancesToContractManufacturerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "AdvancesToContractManufacturerTextBlock", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-5-advances-on-contracts"], "lang": { "en-us": { "role": { "label": "Advances to Contract Manufacturer [Text Block]", "documentation": "Advances to contract manufacturer." } } }, "auth_ref": [] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_AllocatedShareBasedCompensationExpense", "terseLabel": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": ["r350", "r357"] }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivable", "crdr": "credit", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals", "http://www.milestonescientific.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Allowance for credit loss", "terseLabel": "Accounts Receivable, Allowance for Credit Loss", "documentation": "Amount of allowance for credit loss on accounts receivable." } } }, "auth_ref": ["r125", "r209", "r243", "r246", "r248", "r828"] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Amortization of intangibles", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": ["r3", "r267", "r268", "r667"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r169"] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": null, "weight": null, "order": null,

"root": true } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details"], "lang": { "en-us": { "role": { "verboseLabel": "Total assets", "label": "us-gaap_Assets", "totalLabel": "Total assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r95", "r106", "r124", "r141", "r172", "r178", "r196", "r200", "r240", "r277", "r278", "r280", "r281", "r282", "r283", "r284", "r286", "r287", "r380", "r384", "r408", "r509", "r584", "r660", "r661", "r692", "r721", "r781", "r782", "r823"] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_AssetsCurrent", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r119", "r128", "r141", "r240", "r277", "r278", "r280", "r281", "r282", "r283", "r284", "r286", "r287", "r380", "r384", "r408", "r692", "r781", "r782", "r823"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "auth_ref": [] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-schedule-of-restricted-stock-details", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-summary-of-option-activity-details", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-tables"], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r321", "r322", "r323", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r345", "r346", "r347", "r348", "r349"] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationAxis", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions", "http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "Statement of Financial Position Location, Balance [Axis]", "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": ["r272", "r830", "r831"] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationDomain", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions", "http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "Statement of Financial Position Location, Balance [Domain]", "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": ["r43", "r44", "r272", "r830", "r831"] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "mlss_BoardOfDirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "BoardOfDirectorsMember", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Board of Directors [Member]", "documentation": "Represents the board of directors of the company." } } }, "auth_ref": [] }, "country_CN": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "CN", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data-summary-of-operations-by-geographic-area-details"], "lang": { "en-us": { "role": { "label": "CHINA" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r15", "r122", "r643"] }, "us-gaap_CashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAxis", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://www.milestonescientific.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Axis]", "documentation": "Information by type of cash and cash equivalent balance." } } }, "auth_ref": ["r122"] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": ["r16"] }, "mlss_CashBonusCompensationPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "CashBonusCompensationPercent", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-12-subsequent-events-details-textual"], "lang": { "en-us": { "role": { "label": "mlss_CashBonusCompensationPercent", "terseLabel": "Cash Bonus Compensation Percent", "documentation": "The percentage of bonus compensation." } } }, "auth_ref": [] }, "mlss_CashCashEquivalentsAndMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "CashCashEquivalentsAndMarketableSecurities", "crdr": "debit", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-2-liquidity-and-uncertainties-details-textual"], "lang": { "en-us": { "role": { "label": "mlss_CashCashEquivalentsAndMarketableSecurities", "terseLabel": "Cash, Cash Equivalents, and Marketable Securities", "documentation": "The amount of cash, cash equivalents, and marketable securities calculated during the period." } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "periodStartLabel": "Cash and cash equivalents at beginning of period", "periodEndLabel": "Cash and cash equivalents at end of period", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r15", "r78", "r138"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "totalLabel": "Net increase (decrease) in cash and cash equivalents", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r0", "r78"] }, "us-gaap_CashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_CashEquivalentsAtCarryingValue", "terseLabel": "Cash Equivalents, at Carrying Value", "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r741", "r827"] }, "us-gaap_CashUninsuredAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashUninsuredAmount", "crdr": "debit", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_CashUninsuredAmount", "terseLabel": "Cash, Uninsured Amount", "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation." } } }, "auth_ref": [] }, "mlss_ChiefExecutiveOfficerAndOtherEmployeesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "ChiefExecutiveOfficerAndOtherEmployeesMember", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Chief Executive Officer, and Other Employees [Member]", "documentation": "Represents chief executive officer and other employees." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-warrants-details"], "lang": { "en-us": { "role": { "label": "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "periodStartLabel": "Outstanding (in dollars per share)", "periodEndLabel": "Outstanding (in

dollars per share)", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": ["r305"] },
"mlss_ClassOfWarrantOrRightExercisedDuringPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "ClassOfWarrantOrRightExercisedDuringPeriod", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-warrants-details"], "lang": { "en-us": { "role": { "label": "mlss_ClassOfWarrantOrRightExercisedDuringPeriod", "negatedLabel": "Exercised, number of shares (in shares)", "documentation": "The number of warrants or rights exercised during period." } } }, "auth_ref": [] },
"mlss_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-warrants-details"], "lang": { "en-us": { "role": { "label": "Exercised, weighted average exercise price (in dollars per share)", "terseLabel": "Class of Warrant or Right, Exercised During Period, Exercise Price (in dollars per share)", "documentation": "Exercise price per share of warrants or rights exercised during period." } } }, "auth_ref": [] },
"mlss_ClassOfWarrantOrRightExpiredOrCancelledDuringPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "ClassOfWarrantOrRightExpiredOrCancelledDuringPeriod", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-warrants-details"], "lang": { "en-us": { "role": { "label": "mlss_ClassOfWarrantOrRightExpiredOrCancelledDuringPeriod", "negatedLabel": "Expired or cancelled, number of shares (in shares)", "documentation": "The number of warrants or rights expired or cancelled during period." } } }, "auth_ref": [] },
"mlss_ClassOfWarrantOrRightExpiredOrCancelledDuringPeriodExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "ClassOfWarrantOrRightExpiredOrCancelledDuringPeriodExercisePrice", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-warrants-details"], "lang": { "en-us": { "role": { "label": "Expired or cancelled, weighted average exercise price (in dollars per share)", "documentation": "Exercise price per share of warrants or rights expired or cancelled during period." } } }, "auth_ref": [] }, "mlss_ClassOfWarrantOrRightIssuedDuringPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "ClassOfWarrantOrRightIssuedDuringPeriod", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-warrants-details"], "lang": { "en-us": { "role": { "label": "Issued, number of shares (in shares)", "documentation": "The number of warrants or rights issued during period." } } }, "auth_ref": [] },
"mlss_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-warrants-details"], "lang": { "en-us": { "role": { "label": "Issued, weighted average exercise price (in dollars per share)", "documentation": "Exercise price per share of warrants or rights issued during period." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-warrants-details"], "lang": { "en-us": { "role": { "label": "us-gaap_ClassOfWarrantOrRightOutstanding", "periodStartLabel": "Outstanding (in shares)", "periodEndLabel": "Outstanding (in shares)", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "mlss_ClassOfWarrantOrRightOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "ClassOfWarrantOrRightOutstandingAggregateIntrinsicValue", "crdr": "debit", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-warrants-details"], "lang": { "en-us": { "role": { "label": "Outstanding", "documentation": "Intrinsic value of outstanding warrants." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "Commitments and contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r57", "r98", "r511", "r571"] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-11-commitments"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r86", "r275", "r276", "r629", "r777", "r778"] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance", "terseLabel": "Common Stock, Capital Shares Reserved for Future Issuance (in shares)", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": ["r60"] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r711", "r712", "r713", "r715", "r716", "r717", "r718", "r753", "r754", "r757", "r811", "r860", "r863"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals"], "lang": { "en-us": { "role": { "label": "Common stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r60"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals"], "lang": { "en-us": { "role": { "label": "Common stock, shares authorized (in shares)", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r60", "r572"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals"], "lang": { "en-us": { "role": { "label": "Common stock, shares issued (in shares)", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r60"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals"], "lang": { "en-us": { "role": { "label": "Common stock, shares outstanding (in shares)", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r7", "r60", "r572", "r590", "r863", "r864"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "Common stock, par value $0.001; authorized 100,000,000 shares; 77,709,455 shares issued and 77,676,122 shares outstanding as of September 30, 2024; 75,881,840 shares issued and 75,848,507 shares outstanding as of December 31, 2023;", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r60", "r512", "r692"] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-9-concentrations", "http://www.milestonescientific.com/20240930/role/statement-note-9-concentrations-details-textual"], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": ["r19", "r20", "r45", "r46", "r207", "r628"] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-9-concentrations", "http://www.milestonescientific.com/20240930/role/statement-note-9-concentrations-details-textual"], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": ["r19", "r20", "r45", "r46", "r207", "r547", "r628"] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-9-concentrations", "http://www.milestonescientific.com/20240930/role/statement-note-9-concentrations-details-textual"], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": ["r19", "r20", "r45", "r46", "r207", "r628", "r733"] }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskDisclosureTextBlock", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-9-concentrations"], "lang": { "en-us": { "role": { "label": "Concentration Risk Disclosure [Text Block]", "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date." } } }, "auth_ref": ["r82"] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-9-concentrations-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ConcentrationRiskPercentage1", "terseLabel": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": ["r19", "r20", "r45", "r46", "r207"] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-9-concentrations", "http://www.milestonescientific.com/20240930/role/statement-note-9-concentrations-details-textual"], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": ["r19", "r20", "r45", "r46", "r207", "r628"] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsAxis", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details"], "lang": { "en-us": { "role": { "label": "Consolidation Items [Axis]" } } }, "auth_ref": ["r104", "r147", "r172", "r180", "r194", "r195", "r196", "r197", "r198", "r200", "r201", "r202", "r277", "r278", "r279", "r280", "r282", "r283", "r284", "r285", "r286", "r660", "r661", "r781", "r782"] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsDomain", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details"],

{ "lang": { "en-us": { "role": { "label": "Consolidation Items [Domain]" } } }, "auth_ref": ["r104", "r147", "r172", "r180", "r194", "r195", "r196", "r197", "r198", "r200", "r201", "r202", "r277", "r278", "r279", "r280", "r282", "r283", "r284", "r285", "r286", "r660", "r661", "r781", "r782"] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": ["r40", "r649"] }, "mlss_ConsultantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "ConsultantMember", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions", "http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "Consultant [Member]", "documentation": "Represents information pertaining to consultant." } } }, "auth_ref": [] }, "mlss_ConsultingAgreementBaseSalary": { "xbrltype": "monetaryItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "ConsultingAgreementBaseSalary", "crdr": "credit", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-12-subsequent-events-details-textual"], "lang": { "en-us": { "role": { "label": "mlss_ConsultingAgreementBaseSalary", "terseLabel": "Consulting Agreement, Base Salary", "documentation": "In reference to the base salary for consulting services." } } }, "auth_ref": [] }, "mlss_ContractsForFundingOfFutureEpiduralInstrumentsAndPartsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "ContractsForFundingOfFutureEpiduralInstrumentsAndPartsMember", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-11-commitments", "http://www.milestonescientific.com/20240930/role/statement-note-11-commitments-details-textual"], "lang": { "en-us": { "role": { "label": "Contracts for Funding of Future Epidural Instruments and Parts [Member]", "documentation": "Represents contracts for funding of future epidural instruments and parts." } } }, "auth_ref": [] }, "us-gaap_CorporateNonSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateNonSegmentMember", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details"], "lang": { "en-us": { "role": { "label": "Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]", "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment." } } }, "auth_ref": ["r10", "r195", "r196", "r197", "r198", "r201", "r761"] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 0.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "Cost of products sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": ["r71", "r72", "r472"] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "auth_ref": ["r145", "r146", "r288", "r293", "r435", "r455", "r508", "r646", "r648"] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-9-concentrations", "http://www.milestonescientific.com/20240930/role/statement-note-9-concentrations-details-textual"], "lang": { "en-us": { "role": { "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": ["r83", "r207"] }, "us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCompensationArrangementWithIndividualCompensationExpense", "crdr": "debit", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense", "terseLabel": "Deferred Compensation Arrangement with Individual, Compensation Expense", "documentation": "The compensation expense recognized during the period pertaining to the deferred compensation arrangement." } } }, "auth_ref": ["r31", "r89"] }, "mlss_DeferredCompensationArrangementWithIndividualSharebasedPaymentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "DeferredCompensationArrangementWithIndividualSharebasedPaymentsTableTextBlock", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-tables"], "lang": { "en-us": { "role": { "label": "Deferred Compensation Arrangement with Individual, Share-based Payments [Table Text Block]", "documentation": "Tabular disclosure of shares authorized for issuance under the deferred compensation arrangement as of the balance sheet date." } } }, "auth_ref": [] }, "us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-summary-of-shares-to-be-issued-details"], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance", "terseLabel": "Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance (in shares)", "periodStartLabel": "Shares-to-be-issued, outstanding (in shares)", "periodEndLabel": "Shares-to-be-issued, outstanding (in shares)", "documentation": "The maximum number of shares authorized for issuance under the deferred compensation arrangement as of the balance sheet date." } } }, "auth_ref": ["r33"] }, "mlss_DeferredCompensationArrangementWithIndividualSharesGranted": { "xbrltype": "sharesItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "DeferredCompensationArrangementWithIndividualSharesGranted", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-summary-of-shares-to-be-issued-details"], "lang": { "en-us": { "role": { "label": "Granted in current period (in shares)", "documentation": "Number of shares granted pursuant to the terms of a deferred compensation arrangement." } } }, "auth_ref": [] }, "us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCompensationArrangementWithIndividualSharesIssued", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-summary-of-shares-to-be-issued-details"], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued", "negatedLabel": "Issued in current period (in shares)", "documentation": "Number of shares issued pursuant to the terms of a deferred compensation arrangement." } } }, "auth_ref": ["r35"] }, "mlss_DentalSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "DentalSegmentMember", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-4-inventories-summary-of-inventories-details", "http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details", "http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data-summary-of-operations-by-geographic-area-details"], "lang": { "en-us": { "role": { "label": "Dental Segment [Member]", "documentation": "Information related to the Dental segment." } } }, "auth_ref": [] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Depreciation expense", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": ["r3", "r27"] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationAndAmortization", "crdr": "debit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "Depreciation and amortization expense", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": ["r3", "r27"] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details"], "lang": { "en-us": { "role": { "verboseLabel": "Depreciation and Amortization", "label": "us-gaap_DepreciationDepletionAndAmortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": ["r3", "r172", "r183", "r200", "r660", "r661"] }, "mlss_DevelopmentOfTheNextGenerationInstrumentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "DevelopmentOfTheNextGenerationInstrumentMember", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-11-commitments", "http://www.milestonescientific.com/20240930/role/statement-note-11-commitments-details-textual"], "lang": { "en-us": { "role": { "label": "Development of the Next Generation Instrument [Member]", "documentation": "Represents development of the next generation instrument." } } }, "auth_ref": [] }, "mlss_DirectorClinicalAffairMember": { "xbrltype": "domainItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "DirectorClinicalAffairMember", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions", "http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "Director Clinical Affair [Member]", "documentation": "Information pertaining to the Director Clinical Affair." } } }, "auth_ref": [] }, "mlss_DirectorOfClinicalAffairsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "DirectorOfClinicalAffairsMember", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions", "http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "Director of Clinical Affairs [Member]", "documentation": "A personnel of the company with the title \"Director of Clinical Affairs.\"" } } }, "auth_ref": [] }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-tables"], "lang": { "en-us": { "role": { "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]", "documentation": "Tabular disclosure of share-based payment arrangement." } }

```
}, "auth_ref": [ "r5", "r32" ] }, "us-gaap_DisclosureTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureTextBlockAbstract", "presentation": [ "http://www.milestonescientific.com/20240930/role/statement-note-1-organization-and-business", "http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions", "http://www.milestonescientific.com/20240930/role/statement-note-11-commitments", "http://www.milestonescientific.com/20240930/role/statement-note-12-subsequent-events", "http://www.milestonescientific.com/20240930/role/statement-note-2-liquidity-and-uncertainties", "http://www.milestonescientific.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://www.milestonescientific.com/20240930/role/statement-note-4-inventories", "http://www.milestonescientific.com/20240930/role/statement-note-5-advances-on-contracts", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity", "http://www.milestonescientific.com/20240930/role/statement-note-7-income-taxes", "http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data", "http://www.milestonescientific.com/20240930/role/statement-note-9-concentrations" ], "lang": { "en-us": { "role": { "label": "us-gaap_DisclosureTextBlockAbstract", "terseLabel": "Notes to Financial Statements" } } }, "auth_ref": [] }, "mlss_DistributorFourMember": { "xbrltype": "domainItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "DistributorFourMember", "presentation": [ "http://www.milestonescientific.com/20240930/role/statement-note-9-concentrations", "http://www.milestonescientific.com/20240930/role/statement-note-9-concentrations-details-textual" ], "lang": { "en-us": { "role": { "label": "Distributor Four [Member]", "documentation": "Related to distributor." } } }, "auth_ref": [] }, "mlss_DistributorOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "DistributorOneMember", "presentation": [ "http://www.milestonescientific.com/20240930/role/statement-note-9-concentrations", "http://www.milestonescientific.com/20240930/role/statement-note-9-concentrations-details-textual" ], "lang": { "en-us": { "role": { "label": "Distributor One [Member]", "documentation": "Related to distributor." } } }, "auth_ref": [] }, "mlss_DistributorThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "DistributorThreeMember", "presentation": [ "http://www.milestonescientific.com/20240930/role/statement-note-9-concentrations", "http://www.milestonescientific.com/20240930/role/statement-note-9-concentrations-details-textual" ], "lang": { "en-us": { "role": { "label": "Distributor Three [Member]", "documentation": "Related to distributor." } } }, "auth_ref": [] }, "mlss_DistributorTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "DistributorTwoMember", "presentation": [ "http://www.milestonescientific.com/20240930/role/statement-note-9-concentrations", "http://www.milestonescientific.com/20240930/role/statement-note-9-concentrations-details-textual" ], "lang": { "en-us": { "role": { "label": "Distributor Two [Member]", "documentation": "Related to distributor." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.milestonescientific.com/20240930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.milestonescientific.com/20240930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.milestonescientific.com/20240930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.milestonescientific.com/20240930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.milestonescientific.com/20240930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r725" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://www.milestonescientific.com/20240930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r726" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.milestonescientific.com/20240930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "mlss_DomesticMember": { "xbrltype": "domainItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "DomesticMember", "presentation": [ "http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data-summary-of-operations-by-geographic-area-details" ], "lang": { "en-us": { "role": { "label": "Domestic [Member]", "documentation": "The domestic country of the reporting entity." } } }, "auth_ref": [] }, "mlss_ECommerceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "ECommerceMember", "presentation": [ "http://www.milestonescientific.com/20240930/role/statement-note-9-concentrations", "http://www.milestonescientific.com/20240930/role/statement-note-9-concentrations-details-textual" ], "lang": { "en-us": { "role": { "label": "E-Commerce [Member]", "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from e-commerce." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": [ "http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited" ], "lang": { "en-us": { "role": { "label": "Net loss per share applicable to common stockholders\u2014" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited" ], "lang": { "en-us": { "role": { "label": "Basic and Diluted (in dollars per share)", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r134", "r153", "r154", "r155", "r156", "r157", "r158", "r163", "r164", "r166", "r167", "r168", "r171", "r375", "r378", "r395", "r396", "r505", "r523", "r653" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://www.milestonescientific.com/20240930/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r17", "r18", "r170" ] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "crdr": "debit", "presentation": [ "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "terseLabel": "Share-Based Payment Arrangement, Amount Capitalized", "documentation": "Amount of cost capitalized for award under share-based payment arrangement." } } }, "auth_ref": [ "r351" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r352" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r352" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-summary-of-option-activity-details" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "mlss_EmploymentAgreementBaseCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "EmploymentAgreementBaseCompensation", "crdr": "debit", "presentation": [ "http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions-details-textual" ], "lang": { "en-us": { "role": { "label": "mlss_EmploymentAgreementBaseCompensation", "terseLabel": "Employment Agreement, Base Compensation", "documentation": "The amount of annual base compensation pursuant to the employment agreement." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.milestonescientific.com/20240930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.milestonescientific.com/20240930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.milestonescientific.com/20240930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } },
```

"auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r723"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals", "http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.milestonescientific.com/20240930/role/statement-document-and-entity-information", "http://www.milestonescientific.com/20240930/role/statement-note-1-organization-and-business", "http://www.milestonescientific.com/20240930/role/statement-note-1-organization-and-business-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions", "http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-11-commitments", "http://www.milestonescientific.com/20240930/role/statement-note-11-commitments-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-11-commitments-lease-expense-details", "http://www.milestonescientific.com/20240930/role/statement-note-11-commitments-tables", "http://www.milestonescientific.com/20240930/role/statement-note-12-subsequent-events", "http://www.milestonescientific.com/20240930/role/statement-note-12-subsequent-events-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-2-liquidity-and-uncertainties", "http://www.milestonescientific.com/20240930/role/statement-note-2-liquidity-and-uncertainties-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://www.milestonescientific.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-fair-value-of-marketable-securities-details", "http://www.milestonescientific.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-tables", "http://www.milestonescientific.com/20240930/role/statement-note-4-inventories", "http://www.milestonescientific.com/20240930/role/statement-note-4-inventories-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-4-inventories-summary-of-inventories-details", "http://www.milestonescientific.com/20240930/role/statement-note-4-inventories-tables", "http://www.milestonescientific.com/20240930/role/statement-note-5-advances-on-contracts", "http://www.milestonescientific.com/20240930/role/statement-note-5-advances-on-contracts-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-schedule-of-restricted-stock-details", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-summary-of-option-activity-details", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-summary-of-shares-to-be-issued-details", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-tables", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-warrants-details", "http://www.milestonescientific.com/20240930/role/statement-note-7-income-taxes", "http://www.milestonescientific.com/20240930/role/statement-note-7-income-taxes-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data", "http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details", "http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data-summary-of-operations-by-geographic-area-details", "http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data-tables", "http://www.milestonescientific.com/20240930/role/statement-note-9-concentrations", "http://www.milestonescientific.com/20240930/role/statement-note-9-concentrations-details-textual", "http://www.milestonescientific.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r723"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r723"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r729"] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r723"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r723"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r723"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r723"] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r7", "r115", "r131", "r132", "r133", "r148", "r149", "r150", "r152", "r157", "r159", "r161", "r173", "r241", "r242", "r270", "r306", "r366", "r367", "r372", "r373", "r374", "r376", "r377", "r378", "r386", "r387", "r388", "r389", "r390", "r391", "r394", "r409", "r410", "r411", "r412", "r413", "r414", "r417", "r419", "r428", "r521", "r542", "r543", "r544", "r559", "r612"] }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EstimateOfFairValueFairValueDisclosureMember", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-fair-value-of-marketable-securities-details"], "lang": { "en-us": { "role": { "label": "Estimate of Fair Value Measurement [Member]", "documentation": "Measured as an estimate of fair value." } } }, "auth_ref": ["r289", "r407", "r668", "r669"] }, "mlss_ExpensesPaidStock": { "xbrltype": "monetaryItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "ExpensesPaidStock", "crdr": "debit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Expense paid in stock", "documentation": "The amount of expenses paid for with stock in lieu of cash during the period." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-tables"], "lang": { "en-us": { "role": { "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active

markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": ["r813", "r814"] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-fair-value-of-marketable-securities-details"], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": ["r289", "r309", "r310", "r311", "r312", "r313", "r314", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r443", "r444", "r445", "r668", "r669", "r673", "r674", "r675", "r682", "r684"] }, "us-gaap_FairValueByMeasurementBasisAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementBasisAxis", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-fair-value-of-marketable-securities-details"], "lang": { "en-us": { "role": { "label": "Measurement Basis [Axis]", "documentation": "Information by measurement basis." } } }, "auth_ref": ["r289", "r668", "r669"] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-fair-value-of-marketable-securities-details"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": ["r289", "r309", "r314", "r398", "r403", "r443", "r673", "r674", "r675", "r682"] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-fair-value-of-marketable-securities-details"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": ["r289", "r309", "r314", "r398", "r399", "r403", "r444", "r668", "r669", "r673", "r674", "r675", "r682"] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-fair-value-of-marketable-securities-details"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r289", "r309", "r310", "r311", "r312", "r313", "r314", "r398", "r399", "r400", "r401", "r403", "r445", "r668", "r669", "r673", "r674", "r675", "r682", "r684"] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-fair-value-of-marketable-securities-details"], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": ["r289", "r309", "r310", "r311", "r312", "r313", "r314", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r443", "r444", "r445", "r668", "r669", "r673", "r674", "r675", "r682", "r684"] }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": ["r6"] }, "us-gaap_FinanceLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "Current portion of finance lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current." } } }, "auth_ref": ["r421"] }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "Non-current portion of finance lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent." } } }, "auth_ref": ["r421"] }, "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeasePrincipalPayments", "crdr": "credit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 0.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_FinanceLeasePrincipalPayments", "negatedLabel": "Payments finance lease obligations", "documentation": "Amount of cash outflow for principal payment on finance lease." } } }, "auth_ref": ["r422", "r424"] }, "mlss_FinanceLeasePrincipalPaymentsIncludingAccruedExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "FinanceLeasePrincipalPaymentsIncludingAccruedExpenses", "crdr": "credit", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-11-commitments-lease-expense-details"], "lang": { "en-us": { "role": { "label": "mlss_FinanceLeasePrincipalPaymentsIncludingAccruedExpenses", "terseLabel": "Cash paid for finance lease liabilities", "documentation": "Cash paid for finance lease liabilities including accrues expense." } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "Right of use assets finance lease", "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease." } } }, "auth_ref": ["r420"] }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-11-commitments-lease-expense-details"], "lang": { "en-us": { "role": { "label": "Weighted-average discount rate \u2013 finance leases", "documentation": "Weighted average discount rate for finance lease calculated at point in time." } } }, "auth_ref": ["r426", "r691"] }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-11-commitments-lease-expense-details"], "lang": { "en-us": { "role": { "label": "Finance leases (years) (Year)", "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r425", "r691"] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://www.milestonescientific.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": ["r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r244", "r245", "r249", "r250", "r251", "r252", "r253", "r254", "r290", "r303", "r392", "r405", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r522", "r665", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r693", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r771", "r772", "r773", "r774", "r812", "r815", "r816", "r817", "r818", "r819"] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "Intangibles, net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r473", "r776"] }, "us-gaap_GovernmentAssistanceNonoperatingIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GovernmentAssistanceNonoperatingIncome", "crdr": "credit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "Gain on sale of net operating losses", "documentation": "Amount of increase (decrease) in income from government assistance, classified as nonoperating." } } }, "auth_ref": ["r416"] }, "us-gaap_GranteeStatusAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GranteeStatusAxis", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-summary-of-option-activity-details"], "lang": { "en-us": { "role": { "label": "Grantee Status [Axis]", "documentation": "Information by status of recipient to whom award is granted." } } }, "auth_ref": ["r318", "r320", "r321", "r322", "r323", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r345", "r346", "r347", "r348", "r349"] }, "us-gaap_GranteeStatusDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GranteeStatusDomain", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-summary-of-option-activity-details"], "lang": { "en-us": { "role": { "label": "Grantee Status [Domain]", "documentation": "Status of recipient to whom award is granted." } } }, "auth_ref": ["r318", "r320", "r321", "r322", "r323", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r345", "r346", "r347", "r348", "r349"] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_GrossProfit", "totalLabel": "Gross profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": ["r69", "r73", "r105", "r141", "r240", "r277", "r278", "r280", "r281", "r282", "r283", "r284", "r286", "r287", "r408", "r655", "r660", "r758", "r760", "r762", "r763", "r764", "r781"] }, "mlss_HandpiecesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "HandpiecesMember", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data-summary-of-operations-by-geographic-area-details"], "lang": { "en-us": { "role": { "label": "Handpieces [Member]", "documentation": "Represents handpieces." } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr":

"credit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details"], "lang": { "en-us": { "role": { "verboseLabel": "Income (loss) before taxes and equity in earnings of affiliates", "label": "Total income (loss) before taxes and equity in earnings of affiliates", "totalLabel": "Loss before provision for income taxes", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": ["r70", "r101", "r105", "r506", "r517", "r655", "r660", "r758", "r760", "r762", "r763", "r764"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] } }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-7-income-taxes"], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": ["r142", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r368", "r369", "r370", "r371", "r553", "r679"] }, "us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableRelatedParties", "crdr": "debit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Increase(decrease) in accounts payable, related party", "documentation": "The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence." } } }, "auth_ref": ["r2"] }, "us-gaap_IncreaseDecreaseInAccountsPayableTrade": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableTrade", "crdr": "debit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Increase in accounts payable", "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services." } } }, "auth_ref": ["r2"] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInAccountsReceivable", "negatedLabel": "(Increase) decrease in accounts receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": ["r2"] }, "us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivableRelatedParties", "crdr": "credit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties", "negatedLabel": "Increase in accounts receivable, related parties", "documentation": "The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence." } } }, "auth_ref": ["r2"] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Decrease in accrued expenses", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": ["r2"] }, "mlss_IncreaseDecreaseInAccruedLiabilitiesRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "IncreaseDecreaseInAccruedLiabilitiesRelatedParties", "crdr": "debit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 17.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Increase in accrued expenses, related party", "documentation": "The increase (decrease) during the reporting period of accrued liabilities to related parties." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInDeferredCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInDeferredCompensation", "crdr": "debit", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInDeferredCompensation", "terseLabel": "Increase (Decrease) in Deferred Compensation", "documentation": "The increase (decrease) during the reporting period in the obligation created by employee agreements whereby earned compensation will be paid in the future." } } }, "auth_ref": ["r2"] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInInventories", "negatedLabel": "Increase in inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": ["r2"] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "mlss_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset", "crdr": "credit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 19.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "mlss_IncreaseDecreaseInOperatingLeaseRightOfUseAsset", "negatedLabel": "Decrease operating right of use lease asset", "documentation": "Amount of increase (decrease) in operating lease right-of-use asset." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "negatedLabel": "Increase in prepaid expenses and other current assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": ["r2"] }, "mlss_IncreaseDecreaseToAdvancesToContractManufacturer": { "xbrltype": "monetaryItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "IncreaseDecreaseToAdvancesToContractManufacturer", "crdr": "credit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "mlss_IncreaseDecreaseToAdvancesToContractManufacturer", "negatedLabel": "Decrease (increase) in advances on contracts", "documentation": "Increase decrease to advances to contract manufacturer." } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "auth_ref": ["r727"] }, "mlss_InstrumentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "InstrumentsMember", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data-summary-of-operations-by-geographic-area-details"], "lang": { "en-us": { "role": { "label": "Instruments [Member]", "documentation": "A product of the reporting entity." } } }, "auth_ref": [] }, "us-gaap_InterestIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeExpenseNet", "crdr": "credit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "Interest income", "documentation": "Amount of interest income (expense) classified as operating." } } }, "auth_ref": ["r504", "r760"] }, "mlss_InterimChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "InterimChiefExecutiveOfficerMember", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions", "http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "Interim Chief Executive Officer [Member]", "documentation": "Represents the Interim Chief Executive Officer of the company." } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureTextBlock", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-4-inventories"], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": ["r255"] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-note-4-inventories-summary-of-inventories-details": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-4-inventories-summary-of-inventories-details"], "lang": { "en-us": { "role": { "label": "Finished goods, net", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the

company that are readily available for sale." } } }, "auth_ref": ["r85", "r645"] }, "us-gaap_InventoryLIFOReserveEffectOnIncomeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryLIFOReserveEffectOnIncomeNet", "crdr": "debit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 18.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Inventory reserve", "documentation": "The difference between the change in the inventory reserve representing the cumulative difference in cost between the first in, first out and the last in, first out inventory valuation methods and any LIFO decrement which have been reflected in the statement of income during the period." } } }, "auth_ref": [] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 }, "http://www.milestonescientific.com/20240930/role/statement-note-4-inventories-summary-of-inventories-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.milestonescientific.com/20240930/role/statement-note-4-inventories-summary-of-inventories-details"], "lang": { "en-us": { "role": { "verboseLabel": "Inventories", "label": "us-gaap_InventoryNet", "totalLabel": "Total inventories", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": ["r127", "r644", "r692"] }, "us-gaap_InventoryPartsAndComponentsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryPartsAndComponentsNetOfReserves", "crdr": "debit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-note-4-inventories-summary-of-inventories-details": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-4-inventories-summary-of-inventories-details"], "lang": { "en-us": { "role": { "label": "Component parts and other materials", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date for elements of machinery or equipment held for the purpose of replacing similar parts in the course of repair or maintenance." } } }, "auth_ref": ["r85", "r743"] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryPolicyTextBlock", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Inventory, Policy [Policy Text Block]", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": ["r110", "r121", "r126", "r255", "r256", "r257", "r471", "r650"] }, "us-gaap_InventoryValuationReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryValuationReserves", "crdr": "credit", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-4-inventories-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_InventoryValuationReserves", "terseLabel": "Inventory Valuation Reserves", "documentation": "Amount of valuation reserve for inventory." } } }, "auth_ref": ["r85", "r744"] }, "mlss_LeaseCostAndOtherInformationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "LeaseCostAndOtherInformationTableTextBlock", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-11-commitments-tables"], "lang": { "en-us": { "role": { "label": "Lease, Cost and Other Information [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost and other information." } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals", "http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.milestonescientific.com/20240930/role/statement-document-and-entity-information", "http://www.milestonescientific.com/20240930/role/statement-note-1-organization-and-business", "http://www.milestonescientific.com/20240930/role/statement-note-1-organization-and-business-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions", "http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-11-commitments", "http://www.milestonescientific.com/20240930/role/statement-note-11-commitments-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-11-commitments-lease-expense-details", "http://www.milestonescientific.com/20240930/role/statement-note-11-commitments-tables", "http://www.milestonescientific.com/20240930/role/statement-note-12-subsequent-events", "http://www.milestonescientific.com/20240930/role/statement-note-12-subsequent-events-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-2-liquidity-and-uncertainties", "http://www.milestonescientific.com/20240930/role/statement-note-2-liquidity-and-uncertainties-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://www.milestonescientific.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-fair-value-of-marketable-securities-details", "http://www.milestonescientific.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-tables", "http://www.milestonescientific.com/20240930/role/statement-note-4-inventories", "http://www.milestonescientific.com/20240930/role/statement-note-4-inventories-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-4-inventories-summary-of-inventories-details", "http://www.milestonescientific.com/20240930/role/statement-note-4-inventories-tables", "http://www.milestonescientific.com/20240930/role/statement-note-5-advances-on-contracts", "http://www.milestonescientific.com/20240930/role/statement-note-5-advances-on-contracts-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-schedule-of-restricted-stock-details", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-summary-of-option-activity-details", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-summary-of-shares-to-be-issued-details", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-tables", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-warrants-details", "http://www.milestonescientific.com/20240930/role/statement-note-7-income-taxes", "http://www.milestonescientific.com/20240930/role/statement-note-7-income-taxes-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data", "http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details", "http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data-summary-of-operations-by-geographic-area-details", "http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data-tables", "http://www.milestonescientific.com/20240930/role/statement-note-9-concentrations", "http://www.milestonescientific.com/20240930/role/statement-note-9-concentrations-details-textual", "http://www.milestonescientific.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_Liabilities", "totalLabel": "Total liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": ["r11", "r52", "r53", "r54", "r55", "r56", "r57", "r58", "r141", "r240", "r277", "r278", "r280", "r281", "r282", "r283", "r284", "r286", "r287", "r381", "r384", "r385", "r408", "r570", "r654", "r721", "r781", "r823", "r824"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesAndStockholdersEquity", "totalLabel": "Total liabilities and stockholders\u2019 equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r65", "r99", "r514", "r692", "r750", "r775", "r820"] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesCurrent", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r54", "r120", "r141", "r240", "r277", "r278", "r280", "r281", "r282", "r283", "r284", "r286", "r287", "r381", "r384", "r385", "r408", "r692", "r781", "r823", "r824"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-9-concentrations", "http://www.milestonescientific.com/20240930/role/statement-note-9-concentrations-details-textual"], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "auth_ref": ["r207", "r672", "r703", "r708", "r783", "r829", "r832", "r833", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859"] }, "mlss_ManagingDirectorChinaOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "ManagingDirectorChinaOperationsMember", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions", "http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "Managing Director, China Operations [Member]", "documentation": "Represents managing director for China Operations" } } }, "auth_ref": [] }, "mlss_ManufacturingAgreementForHandpiecesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "ManufacturingAgreementForHandpiecesMember", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions", "http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "Manufacturing Agreement for Handpieces [Member]", "documentation": "Represents the manufacturing agreement for handpieces." } } }, "auth_ref": [] }, "us-gaap_MarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecurities", "crdr": "debit", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-fair-value-of-marketable-securities-details"], "lang": { "en-us": { "role": { "label": "Marketable Securities", "terseLabel": "Marketable

Securities", "documentation": "Amount of investment in marketable security." } } }, "auth_ref": { "r100", "r742" } }, "us-gaap_MarketableSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesCurrent", "crdr": "debit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.milestonescientific.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Marketable securities", "terseLabel": "Marketable Securities, Current", "documentation": "Amount of investment in marketable security, classified as current." } } }, "auth_ref": ["r742"] }, "us-gaap_MarketableSecuritiesPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesPolicy", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Marketable Securities, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for investment classified as marketable security." } } }, "auth_ref": ["r48"] }, "us-gaap_MarketableSecuritiesUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesUnrealizedGainLoss", "crdr": "credit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_MarketableSecuritiesUnrealizedGainLoss", "negatedLabel": "Unrealized gain on marketable securities", "documentation": "Amount of unrealized gain (loss) on investment in marketable security." } } }, "auth_ref": ["r77"] }, "mlss_MedicalSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "MedicalSegmentMember", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-4-inventories-summary-of-inventories-details", "http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details", "http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data-summary-of-operations-by-geographic-area-details"], "lang": { "en-us": { "role": { "label": "Medical Segment [Member]", "documentation": "Information related to the medical segment." } } }, "auth_ref": [] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://www.milestonescientific.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": ["r784"] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": ["r728"] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-9-concentrations", "http://www.milestonescientific.com/20240930/role/statement-note-9-concentrations-details-textual"], "lang": { "en-us": { "role": { "label": "Customer [Domain]" } } }, "auth_ref": ["r207", "r672", "r703", "r708", "r783", "r829", "r832", "r833", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "totalLabel": "Net cash provided by (used in) financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r137"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "totalLabel": "Net cash provided by (used in) investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r137"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.milestonescientific.com/20240930/role/statement-note-2-liquidity-and-uncertainties-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "terseLabel": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r78", "r79", "r80"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_NetIncomeLoss", "totalLabel": "Net loss attributable to Milestone Scientific Inc.", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r74", "r80", "r102", "r118", "r129", "r130", "r133", "r141", "r151", "r153", "r154", "r155", "r156", "r157", "r160", "r161", "r165", "r240", "r277", "r278", "r280", "r281", "r282", "r283", "r284", "r286", "r287", "r375", "r378", "r396", "r408", "r520", "r592", "r610", "r611", "r719", "r781"] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 0.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "Net loss attributable to noncontrolling interests", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": ["r42", "r94", "r129", "r130", "r157", "r160", "r161", "r519", "r747"] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "ecd_NonRule10b51ArrAdoptedFlag", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": ["r728"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "ecd_NonRule10b51ArrTrmntdFlag", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": ["r728"] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestMember", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": ["r38", "r306", "r753", "r754", "r755", "r757", "r863"] }, "mlss_NonemployeesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "NonemployeesMember", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Non-Employees [Member]", "documentation": "Represents information related to non-employees." } } }, "auth_ref": [] }, "us-gaap_NonrelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonrelatedPartyMember", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "Nonrelated Party [Member]", "documentation": "Party not related to reporting entity." } } }, "auth_ref": ["r751", "r752"] }, "mlss_NoteToFinancialStatementDetailsTextual": { "xbrltype": "stringItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "NoteToFinancialStatementDetailsTextual", "lang": { "en-us": { "role": { "label": "Note To Financial Statement Details Textual" } } }, "auth_ref": [] }, "mlss_NotesToFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "NotesToFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-

gaap_NumberOfCountriesInWhichEntityOperates": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfCountriesInWhichEntityOperates", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-1-organization-and-business-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_NumberOfCountriesInWhichEntityOperates", "terseLabel": "Number of Countries in which Entity Operates", "documentation": "The number of countries in which the entity operates as of balance sheet date." } } }, "auth_ref": [] }, "mlss_NumberOfDistributors": { "xbrltype": "integerItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "NumberOfDistributors", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-9-concentrations-details-textual"], "lang": { "en-us": { "role": { "label": "mlss_NumberOfDistributors", "terseLabel": "Number of Distributors", "documentation": "Represents the number of distributors." } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfOperatingSegments", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_NumberOfOperatingSegments", "terseLabel": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": ["r661", "r759"] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfReportableSegments", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_NumberOfReportableSegments", "terseLabel": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": ["r656", "r664", "r759"] }, "mlss_NumberOfVendors": { "xbrltype": "integerItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "NumberOfVendors", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-9-concentrations-details-textual"], "lang": { "en-us": { "role": { "label": "mlss_NumberOfVendors", "terseLabel": "Number of Vendors", "documentation": "Represents the number of vendors." } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingExpenses", "totalLabel": "Total operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.milestonescientific.com/20240930/role/statement-note-2-liquidity-and-uncertainties-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details"], "lang": { "en-us": { "role": { "verboseLabel": "Operating Income (Loss)", "label": "us-gaap_OperatingIncomeLoss", "terseLabel": "Operating Income (Loss)", "totalLabel": "Loss from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r105", "r655", "r758", "r760", "r762", "r763", "r764"] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "Current portion of operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r421"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "Non-current portion of operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r421"] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-11-commitments-lease-expense-details"], "lang": { "en-us": { "role": { "label": "Cash paid for operating lease liabilities", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": ["r423", "r424"] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "Right of use assets operating lease", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r420"] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Amortization of right-of-use asset", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": ["r749"] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-11-commitments-lease-expense-details"], "lang": { "en-us": { "role": { "label": "Weighted-average discount rate \u2013 operating leases", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": ["r426", "r691"] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-11-commitments-lease-expense-details"], "lang": { "en-us": { "role": { "label": "Operating leases (years) (Year)", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r425", "r691"] }, "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingSegmentsMember", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details"], "lang": { "en-us": { "role": { "label": "Operating Segments [Member]", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": ["r194", "r195", "r196", "r197", "r198", "r201", "r660", "r661"] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-1-organization-and-business"], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": ["r49", "r93", "r548", "r549"] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "Other assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": ["r123"] }, "us-gaap_OverAllotmentOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OverAllotmentOptionMember", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Over-Allotment Option [Member]", "documentation": "Right given to the underwriter to sell additional shares over the initial allotment." } } }, "auth_ref": [] }, "mlss_PaymentsForConsultingServices": { "xbrltype": "monetaryItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "PaymentsForConsultingServices", "crdr": "credit", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-12-subsequent-events-details-textual"], "lang": { "en-us": { "role": { "label": "mlss_PaymentsForConsultingServices", "terseLabel": "Payments for Consulting Services", "documentation": "In reference to the cash outflow for consulting services." } } }, "auth_ref": [] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-parentheticals"], "lang": { "en-us": { "role": { "label": "Issuance cost", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": ["r14"] }, "us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireAdditionalInterestInSubsidiaries", "crdr": "credit", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries", "terseLabel": "Payments to Acquire Additional Interest in Subsidiaries", "documentation": "The cash outflow associated with the purchase of noncontrolling interest during the period." } } }, "auth_ref": ["r13"] }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireMarketableSecurities", "crdr": "credit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsToAcquireMarketableSecurities", "negatedLabel": "Purchase of marketable securities", "documentation": "Amount of cash outflow for purchase of marketable security." } } }, "auth_ref": ["r770"] }, "mlss_PaymentsToAcquireProceedsFromSalePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "PaymentsToAcquireProceedsFromSalePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-

consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "mlss_PaymentsToAcquireProceedsFromSalePropertyPlantAndEquipment", "negatedLabel": "Purchase of furniture, fixtures, and equipment", "documentation": "The cash outflow (inflow) associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [] }, "mlss_PercentageOfValuationAllowance": { "xbrltype": "percentItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "PercentageOfValuationAllowance", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-7-income-taxes-details-textual"], "lang": { "en-us": { "role": { "label": "mlss_PercentageOfValuationAllowance", "terseLabel": "Percentage of Valuation Allowance", "documentation": "Represents the percentage of valuation allowance." } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": ["r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810"] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": ["r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810"] }, "us-gaap_PolicyTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PolicyTextBlockAbstract", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "us-gaap_PolicyTextBlockAbstract", "terseLabel": "Accounting Policies" } } }, "auth_ref": [] }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PortionAtFairValueFairValueDisclosureMember", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-fair-value-of-marketable-securities-details"], "lang": { "en-us": { "role": { "label": "Portion at Fair Value Measurement [Member]", "documentation": "Measured at fair value for financial reporting purposes." } } }, "auth_ref": ["r406"] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r746"] }, "mlss_PresidentAndChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "PresidentAndChiefExecutiveOfficerMember", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-12-subsequent-events", "http://www.milestonescientific.com/20240930/role/statement-note-12-subsequent-events-details-textual"], "lang": { "en-us": { "role": { "label": "President and Chief Executive Officer [Member]", "documentation": "Represents the president and chief executive officer." } } }, "auth_ref": [] }, "mlss_PreviousPresidentAndChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "PreviousPresidentAndChiefExecutiveOfficerMember", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions", "http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "Previous President and Chief Executive Officer [Member]", "documentation": "Represents the information pertaining to the previous president and chief executive officer of the company." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Net proceeds from Public Placement Offering", "terseLabel": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": ["r1"] }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "crdr": "debit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Sale of marketable securities", "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period." } } }, "auth_ref": [] }, "mlss_ProceedsFromSaleOfNetOperatingLossAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "ProceedsFromSaleOfNetOperatingLossAmount", "crdr": "debit", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-7-income-taxes-details-textual"], "lang": { "en-us": { "role": { "label": "mlss_ProceedsFromSaleOfNetOperatingLossAmount", "terseLabel": "Proceeds From Sale of Net Operating Loss Amount", "documentation": "The cash inflow from the sale of NOL during the period." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromWarrantExercises", "crdr": "debit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Net Proceeds exercise of warrants", "terseLabel": "Proceeds from Warrant Exercises", "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants." } } }, "auth_ref": ["r748"] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data-summary-of-operations-by-geographic-area-details"], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": ["r203", "r472", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r641", "r670", "r702", "r704", "r705", "r709", "r710", "r779", "r780", "r783", "r829", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859"] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data-summary-of-operations-by-geographic-area-details"], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "auth_ref": ["r203", "r472", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r641", "r670", "r702", "r704", "r705", "r709", "r710", "r779", "r780", "r783", "r829", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859"] }, "us-gaap_ProfessionalFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfessionalFees", "crdr": "debit", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ProfessionalFees", "terseLabel": "Professional Fees", "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer." } } }, "auth_ref": ["r660", "r719", "r861", "r862"] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited", "http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "verboseLabel": "Net loss", "label": "Net (loss)", "terseLabel": "Net loss", "totalLabel": "Net loss", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": ["r118", "r129", "r130", "r136", "r141", "r151", "r157", "r160", "r161", "r240", "r277", "r278", "r280", "r281", "r282", "r283", "r284", "r286", "r287", "r375", "r378", "r379", "r382", "r383", "r396", "r408", "r506", "r518", "r558", "r592", "r610", "r611", "r680", "r681", "r720", "r747", "r781"] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "Furniture, fixtures and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r4", "r427", "r507", "r516", "r692"] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Bad debt expense", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": ["r135", "r247"] }, "mlss_PublicOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "PublicOfferingMember", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Public Offering [Member]", "documentation": "Represents the information pertaining to the public offering." } } }, "auth_ref": [] }, "us-gaap_PublicUtilitiesInventoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PublicUtilitiesInventoryAxis", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-4-inventories", "http://www.milestonescientific.com/20240930/role/statement-note-4-inventories-details-textual"], "lang": { "en-us": { "role": { "label": "Inventory [Axis]", "documentation": "Information by type of inventory held." } } }, "auth_ref": ["r743"] }, "us-gaap_PublicUtilitiesInventoryTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PublicUtilitiesInventoryTypeDomain", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-4-inventories", "http://www.milestonescientific.com/20240930/role/statement-note-4-inventories-details-textual"], "lang": { "en-us": { "role": { "label": "Inventory [Domain]", "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale." } } },

"auth_ref": ["r743"] }, "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PurchaseCommitmentExcludingLongtermCommitmentAxis", "presentation": [
"http://www.milestonescientific.com/20240930/role/statement-note-11-commitments", "http://www.milestonescientific.com/20240930/role/statement-note-11-commitments-details-textual"], "lang": { "en-us": { "role": { "label": "Purchase Commitment, Excluding Long-Term Commitment [Axis]", "documentation": "Information by arrangement, in which the entity has agreed to expend funds to procure goods or services from one or more suppliers." } } }, "auth_ref": ["r57", "r98"] }, "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PurchaseCommitmentExcludingLongtermCommitmentDomain", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-11-commitments", "http://www.milestonescientific.com/20240930/role/statement-note-11-commitments-details-textual"], "lang": { "en-us": { "role": { "label": "Purchase Commitment, Excluding Long-Term Commitment [Domain]", "documentation": "This item is intended to be populated, by the entity, with Members identifying each purchase commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate." } } }, "auth_ref": ["r57", "r98"] }, "mlss_PurchaseCommitmentForDevicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "PurchaseCommitmentForDevicesMember", "presentation": [
"http://www.milestonescientific.com/20240930/role/statement-note-11-commitments", "http://www.milestonescientific.com/20240930/role/statement-note-11-commitments-details-textual"], "lang": { "en-us": { "role": { "label": "Purchase Commitment for Devices [Member]", "documentation": "Represents the information pertaining to the purchase commitment for devices." } } }, "auth_ref": [] }, "mlss_PurchaseCommitmentNumberOfUnits": { "xbrltype": "integerItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "PurchaseCommitmentNumberOfUnits", "presentation": [
"http://www.milestonescientific.com/20240930/role/statement-note-11-commitments-details-textual"], "lang": { "en-us": { "role": { "label": "mlss_PurchaseCommitmentNumberOfUnits", "terseLabel": "Purchase Commitment Number Of Units", "documentation": "The number of units commitment to purchase." } } }, "auth_ref": [] }, "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted", "crdr": "credit", "presentation": [
"http://www.milestonescientific.com/20240930/role/statement-note-11-commitments-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted", "terseLabel": "Purchase Commitment, Remaining Minimum Amount Committed", "documentation": "Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations." } } }, "auth_ref": ["r57", "r98"] },
"mlss_PurchasedMedicalProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "PurchasedMedicalProductsMember", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions",
"http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "Purchased Medical Products [Member]", "documentation": "Represents purchased medical products." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": [
"http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited",
"http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions", "http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-9-concentrations",
"http://www.milestonescientific.com/20240930/role/statement-note-9-concentrations-details-textual"], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r208", "r315", "r432", "r433", "r510", "r515", "r565", "r566", "r567", "r568", "r569", "r589", "r591", "r619"] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyMember", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions",
"http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions-details-textual",
"http://www.milestonescientific.com/20240930/role/statement-note-9-concentrations", "http://www.milestonescientific.com/20240930/role/statement-note-9-concentrations-details-textual"], "lang": { "en-us": { "role": { "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": ["r143", "r144", "r432", "r433", "r434", "r435", "r510", "r515", "r565", "r566", "r567", "r568", "r569", "r589", "r591", "r619"] }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAmountsOfTransaction", "crdr": "debit", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_RelatedPartyTransactionAmountsOfTransaction", "terseLabel": "Related Party Transaction, Amounts of Transaction", "documentation": "Amount of transactions with related party during the financial reporting period." } } }, "auth_ref": ["r47", "r432"] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAxis", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions",
"http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": ["r432", "r433", "r822"] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionDomain", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions",
"http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionPurchasesFromRelatedParty", "crdr": "debit", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty", "terseLabel": "Related Party Transaction, Purchases from Related Party", "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [
"http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited",
"http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions", "http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-9-concentrations",
"http://www.milestonescientific.com/20240930/role/statement-note-9-concentrations-details-textual"], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r208", "r315", "r432", "r433", "r510", "r515", "r565", "r566", "r567", "r568", "r569", "r589", "r591", "r619", "r822"] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [
"http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions"], "lang": { "en-us": { "role": { "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": ["r429", "r430", "r431", "r433", "r436", "r554", "r555", "r556", "r595", "r596", "r597", "r616", "r618"] },
"srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "auth_ref": ["r145", "r146", "r288", "r293", "r435", "r455", "r508", "r647", "r648"] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": {
"http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "Research and development expenses", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": ["r358", "r639", "r660", "r825"] },
"mlss_RestOfWorldMember": { "xbrltype": "domainItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "RestOfWorldMember", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data-summary-of-operations-by-geographic-area-details"], "lang": { "en-us": { "role": { "label": "Rest of World [Member]", "documentation": "Information pertaining to the rest of the world, excluding domestic sales and sales to China." } } }, "auth_ref": [] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": [
"http://www.milestonescientific.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies",
"http://www.milestonescientific.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Domain]", "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r122"] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockMember", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity",
"http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-details-textual",
"http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-schedule-of-restricted-stock-details",
"http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-tables"], "lang": { "en-us": { "role": { "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": ["r17"] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": {
"http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited",

"http://www.milestonescientific.com/20240930/role/statement-note-2-liquidity-and-uncertainties-details-textual"], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "terseLabel": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r62", "r88", "r513", "r545", "r546", "r552", "r573", "r692"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r115", "r148", "r149", "r150", "r152", "r157", "r159", "r161", "r241", "r242", "r270", "r366", "r367", "r372", "r373", "r374", "r376", "r377", "r378", "r386", "r388", "r389", "r391", "r394", "r417", "r419", "r542", "r544", "r559", "r863"] }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "crdr": "credit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details", "http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data-summary-of-operations-by-geographic-area-details"], "lang": { "en-us": { "role": { "verboseLabel": "Product sales, net", "label": "Product sales, net", "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise." } } }, "auth_ref": ["r103", "r104", "r172", "r179", "r180", "r194", "r200", "r203", "r205", "r207", "r307", "r308", "r472"] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Revenue [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": ["r593", "r640", "r651"] }, "us-gaap_RoyaltyExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RoyaltyExpense", "crdr": "debit", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_RoyaltyExpense", "terseLabel": "Royalty Expense", "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property." } } }, "auth_ref": ["r75"] }, "mlss_RoyaltyOnNetSalesPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "RoyaltyOnNetSalesPercentage", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "mlss_RoyaltyOnNetSalesPercentage", "terseLabel": "Royalty on Net Sales, Percentage", "documentation": "Represents the royalty percentage on net sales." } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "ecd_Rule10b51ArrAdoptedFlag", "terseLabel": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": ["r728"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "ecd_Rule10b51ArrTrmntdFlag", "terseLabel": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": ["r728"] }, "mlss_SaleOfNetOperatingLossesContingentLiabilityAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "SaleOfNetOperatingLossesContingentLiabilityAmount", "crdr": "credit", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-7-income-taxes-details-textual"], "lang": { "en-us": { "role": { "label": "mlss_SaleOfNetOperatingLossesContingentLiabilityAmount", "terseLabel": "Sale of Net Operating Losses, Contingent Liability, Amount", "documentation": "Represents the amount of contingent liability that a company must pay if they violate the terms of the sale of net operating losses." } } }, "auth_ref": [] }, "mlss_SaleOfNetOperatingLossesPhysicalPresenceRequirementYears": { "xbrltype": "durationItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "SaleOfNetOperatingLossesPhysicalPresenceRequirementYears", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-7-income-taxes-details-textual"], "lang": { "en-us": { "role": { "label": "mlss_SaleOfNetOperatingLossesPhysicalPresenceRequirementYears", "terseLabel": "Sale of Net Operating Losses, Physical Presence Requirement, Years (Year)", "documentation": "Represents the number of years a company must retain a physical presence in a geographic region per the terms of a sale of net operating losses." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "mlss_SalesByProductAndByGeographicalRegionTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "SalesByProductAndByGeographicalRegionTableTextBlock", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data-tables"], "lang": { "en-us": { "role": { "label": "Sales by Product and by Geographical Region [Table Text Block]", "documentation": "Entire disclosure of sales by product and by geographical region." } } }, "auth_ref": [] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesRevenueNetMember", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-9-concentrations", "http://www.milestonescientific.com/20240930/role/statement-note-9-concentrations-details-textual"], "lang": { "en-us": { "role": { "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": ["r207", "r732"] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioForecastMember", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-12-subsequent-events", "http://www.milestonescientific.com/20240930/role/statement-note-12-subsequent-events-details-textual"], "lang": { "en-us": { "role": { "label": "Forecast [Member]" } } }, "auth_ref": ["r316", "r756"] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-12-subsequent-events", "http://www.milestonescientific.com/20240930/role/statement-note-12-subsequent-events-details-textual"], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "auth_ref": ["r162", "r316", "r730", "r756"] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-4-inventories-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": ["r12", "r66", "r67", "r68"] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": ["r24", "r25", "r26"] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-tables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": ["r8", "r9", "r90"] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": ["r30"] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r722"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r724"] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-4-inventories-summary-of-inventories-details", "http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details", "http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data-summary-of-operations-by-geographic-area-details"], "lang": { "en-us": { "role": { "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": ["r103", "r104", "r105", "r106", "r172", "r175", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r200", "r201", "r202", "r207", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r269", "r273", "r274", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r657", "r660", "r661", "r666", "r707", "r829", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859"] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data-summary-of-operations-by-geographic-area-details"], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "auth_ref": ["r205", "r206", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r561", "r562", "r563", "r620", "r621", "r622", "r623", "r627", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r642", "r671", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r706", "r713", "r783", "r829", "r832", "r833", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859"] }, "us-

gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data"], "lang": { "en-us": { "role": { "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": ["r106", "r172", "r174", "r175", "r176", "r177", "r178", "r190", "r192", "r193", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r207", "r656", "r658", "r659", "r660", "r662", "r663", "r664"] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "Selling, general and administrative expenses", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": ["r76"] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensation", "terseLabel": "Stock based compensation", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r2"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": ["r676"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-schedule-of-restricted-stock-details"], "lang": { "en-us": { "role": { "label": "Granted, Shares (in shares)", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r336"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-schedule-of-restricted-stock-details"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "periodStartLabel": "Non-vested as January 1, 2024 (in shares)", "periodEndLabel": "Non-vested, Shares (in shares)", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": ["r333", "r334"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-schedule-of-restricted-stock-details"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "periodStartLabel": "Non-vested as January 1, 2024 (in dollars per share)", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": ["r333", "r334"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-schedule-of-restricted-stock-details"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "negatedLabel": "Vested, Shares (in shares)", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": ["r337"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-schedule-of-restricted-stock-details"], "lang": { "en-us": { "role": { "label": "Vested, Weighted Average Grant-Date Fair Value per Award (in dollars per share)", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": ["r337"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-schedule-of-restricted-stock-details"], "lang": { "en-us": { "role": { "label": "Cancelled, Shares (in shares)", "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed." } } }, "auth_ref": ["r91"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": ["r678"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-summary-of-option-activity-details"], "lang": { "en-us": { "role": { "label": "Number of options exercisable (in shares)", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": ["r327"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-summary-of-option-activity-details"], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, exercisable (in dollars per share)", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": ["r327"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-summary-of-option-activity-details"], "lang": { "en-us": { "role": { "label": "Number of options forfeited and expired (in shares)", "negatedLabel": "Number of options, forfeited or expired (in shares)", "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired." } } }, "auth_ref": ["r791"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-summary-of-option-activity-details"], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, forfeited or expired (in dollars per share)", "documentation": "Weighted average price of options that were either forfeited or expired." } } }, "auth_ref": ["r791"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-summary-of-option-activity-details"], "lang": { "en-us": { "role": { "label":

"Number of options granted (in shares)", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": ["r329"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-summary-of-option-activity-details"], "lang": { "en-us": { "role": { "label": "Aggregate intrinsic value, outstanding", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": ["r32"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-summary-of-option-activity-details"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "periodStartLabel": "Number of options (in shares)", "periodEndLabel": "Number of options (in shares)", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": ["r325", "r326"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-summary-of-option-activity-details"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "periodStartLabel": "Weighted average exercise price, outstanding (in dollars per share)", "periodEndLabel": "Weighted average exercise price, outstanding (in dollars per share)", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": ["r325", "r326"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-schedule-of-restricted-stock-details", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-summary-of-option-activity-details", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-tables"], "lang": { "en-us": { "role": { "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r321", "r322", "r323", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r345", "r346", "r347", "r348", "r349"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-summary-of-option-activity-details"], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, exercised (in dollars per share)", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": ["r330"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-summary-of-option-activity-details"], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, granted (in dollars per share)", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": ["r329"] }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheOneMember", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Tranche One [Member]", "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheTwoMember", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Tranche Two [Member]", "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": ["r317", "r324", "r343", "r344", "r345", "r346", "r349", "r353", "r354", "r355", "r356"] }, "us-gaap_ShareBasedPaymentArrangementEmployeeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedPaymentArrangementEmployeeMember", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-summary-of-option-activity-details"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Employee [Member]", "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires." } } }, "auth_ref": ["r320", "r321", "r322", "r323", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r345", "r346", "r347", "r348", "r349"] }, "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedPaymentArrangementNonemployeeMember", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-summary-of-option-activity-details"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonemployee [Member]", "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires." } } }, "auth_ref": ["r318", "r321", "r322", "r323", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r345", "r346", "r347", "r348", "r349"] }, "mlss_ShareBonusCompensationPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "ShareBonusCompensationPercentage", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-12-subsequent-events-details-textual"], "lang": { "en-us": { "role": { "label": "mlss_ShareBonusCompensationPercentage", "terseLabel": "Share Bonus Compensation Percentage", "documentation": "The percent of bonus related to shares." } } }, "auth_ref": [] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharePrice", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_SharePrice", "terseLabel": "Share Price (in dollars per share)", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth_ref": ["r785"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r677"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-summary-of-option-activity-details"], "lang": { "en-us": { "role": { "label": "Aggregate intrinsic value, exercisable", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": ["r32"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-summary-of-option-activity-details"], "lang": { "en-us": { "role": { "label": "Weighted average remaining contractual life, exercisable (Year)", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r32"] }, "mlss_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-summary-of-option-activity-details"], "lang": { "en-us": { "role": { "label": "Weighted average remaining contractual life, granted (Year)", "documentation": "Weighted average remaining contractual term for option awards granted." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-summary-of-option-activity-details"], "lang": { "en-us": { "role": { "label": "Weighted average remaining contractual life, outstanding (Year)", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r92"] }, "mlss_SharebasedCompensationBonusPaidInStock": { "xbrltype": "monetaryItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "SharebasedCompensationBonusPaidInStock", "crdr": "debit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Employees paid in stock", "documentation": "The amount of noncash share-based compensation bonuses paid in stock." } } }, "auth_ref": [] }, "us-gaap_SharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssued", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_SharesIssued", "periodStartLabel": "Balance (in shares)", "periodEndLabel": "Balance (in shares)", "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury." } } }, "auth_ref": ["r7"] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssuedPricePerShare", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_SharesIssuedPricePerShare", "terseLabel": "Shares Issued, Price Per Share (in dollars per share)", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies"], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r81", "r139"] }, "mlss_SlowMovingMedicalFinishedGoodsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "SlowMovingMedicalFinishedGoodsMember", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-4-inventories", "http://www.milestonescientific.com/20240930/role/statement-note-4-inventories-details-textual"], "lang": { "en-us": { "role": { "label": "Slow Moving Medical Finished Goods [Member]", "documentation": "Represents the slow moving medical finished goods." } } }, "auth_ref": [] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementBusinessSegmentsAxis", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-4-inventories-summary-of-inventories-details", "http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details", "http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data-summary-of-operations-by-geographic-area-details"], "lang": { "en-us": { "role": { "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": ["r103", "r104", "r105", "r106", "r117", "r172", "r175", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r200", "r201", "r202", "r207", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r269", "r271", "r273", "r274", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r657", "r660", "r661", "r666", "r707", "r829", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r7", "r60", "r63", "r64", "r115", "r131", "r132", "r133", "r148", "r149", "r150", "r152", "r157", "r159", "r161", "r173", "r241", "r242", "r270", "r306", "r366", "r367", "r372", "r373", "r374", "r376", "r377", "r378", "r386", "r387", "r388", "r389", "r390", "r391", "r394", "r409", "r410", "r411", "r412", "r413", "r414", "r417", "r419", "r428", "r521", "r542", "r543", "r544", "r559", "r612"] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data-summary-of-operations-by-geographic-area-details"], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "auth_ref": ["r205", "r206", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r561", "r562", "r563", "r620", "r621", "r622", "r623", "r627", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r642", "r671", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r706", "r713", "r783", "r829", "r832", "r833", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals", "http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited", "http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-parentheticals", "http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.milestonescientific.com/20240930/role/statement-note-1-organization-and-business", "http://www.milestonescientific.com/20240930/role/statement-note-1-organization-and-business-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions", "http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-11-commitments", "http://www.milestonescientific.com/20240930/role/statement-note-11-commitments-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-11-commitments-lease-expense-details", "http://www.milestonescientific.com/20240930/role/statement-note-11-commitments-tables", "http://www.milestonescientific.com/20240930/role/statement-note-12-subsequent-events", "http://www.milestonescientific.com/20240930/role/statement-note-12-subsequent-events-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-2-liquidity-and-uncertainties", "http://www.milestonescientific.com/20240930/role/statement-note-2-liquidity-and-uncertainties-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://www.milestonescientific.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-fair-value-of-marketable-securities-details", "http://www.milestonescientific.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-tables", "http://www.milestonescientific.com/20240930/role/statement-note-4-inventories", "http://www.milestonescientific.com/20240930/role/statement-note-4-inventories-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-4-inventories-summary-of-inventories-details", "http://www.milestonescientific.com/20240930/role/statement-note-4-inventories-tables", "http://www.milestonescientific.com/20240930/role/statement-note-5-advances-on-contracts", "http://www.milestonescientific.com/20240930/role/statement-note-5-advances-on-contracts-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-schedule-of-restricted-stock-details", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-summary-of-option-activity-details", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-summary-of-shares-to-be-issued-details", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-tables", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-warrants-details", "http://www.milestonescientific.com/20240930/role/statement-note-7-income-taxes", "http://www.milestonescientific.com/20240930/role/statement-note-7-income-taxes-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data", "http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details", "http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data-summary-of-operations-by-geographic-area-details", "http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data-tables", "http://www.milestonescientific.com/20240930/role/statement-note-9-concentrations", "http://www.milestonescientific.com/20240930/role/statement-note-9-concentrations-details-textual", "http://www.milestonescientific.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r148", "r149", "r150", "r173", "r419", "r472", "r550", "r560", "r564", "r565", "r566", "r567", "r568", "r569", "r572", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r585", "r586", "r587", "r588", "r589", "r591", "r593", "r594", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r612", "r714"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-12-subsequent-events", "http://www.milestonescientific.com/20240930/role/statement-note-12-subsequent-events-details-textual"], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "auth_ref": ["r162", "r316", "r730", "r731", "r756"] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited", "http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals", "http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited", "http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited-parentheticals", "http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.milestonescientific.com/20240930/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.milestonescientific.com/20240930/role/statement-note-1-organization-and-business", "http://www.milestonescientific.com/20240930/role/statement-note-1-organization-and-business-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions", "http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-11-commitments", "http://www.milestonescientific.com/20240930/role/statement-note-11-commitments-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-11-commitments-lease-expense-details", "http://www.milestonescientific.com/20240930/role/statement-note-11-commitments-tables", "http://www.milestonescientific.com/20240930/role/statement-note-12-subsequent-events", "http://www.milestonescientific.com/20240930/role/statement-note-12-subsequent-events-details-textual",

"http://www.milestonescientific.com/20240930/role/statement-note-2-liquidity-and-uncertainties", "http://www.milestonescientific.com/20240930/role/statement-note-2-liquidity-and-uncertainties-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://www.milestonescientific.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-fair-value-of-marketable-securities-details", "http://www.milestonescientific.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-tables", "http://www.milestonescientific.com/20240930/role/statement-note-4-inventories", "http://www.milestonescientific.com/20240930/role/statement-note-4-inventories-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-4-inventories-summary-of-inventories-details", "http://www.milestonescientific.com/20240930/role/statement-note-4-inventories-tables", "http://www.milestonescientific.com/20240930/role/statement-note-5-advances-on-contracts", "http://www.milestonescientific.com/20240930/role/statement-note-5-advances-on-contracts-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-schedule-of-restricted-stock-details", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-summary-of-option-activity-details", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-summary-of-shares-to-be-issued-details", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-tables", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-warrants-details", "http://www.milestonescientific.com/20240930/role/statement-note-7-income-taxes", "http://www.milestonescientific.com/20240930/role/statement-note-7-income-taxes-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data", "http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details", "http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data-summary-of-operations-by-geographic-area-details", "http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data-tables", "http://www.milestonescientific.com/20240930/role/statement-note-9-concentrations", "http://www.milestonescientific.com/20240930/role/statement-note-9-concentrations-details-textual", "http://www.milestonescientific.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r148", "r149", "r150", "r173", "r208", "r419", "r472", "r550", "r560", "r564", "r565", "r566", "r567", "r568", "r569", "r572", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r585", "r586", "r587", "r588", "r589", "r591", "r593", "r594", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r612", "r714"] }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Common stock issued for services (in shares)", "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Common stock issued in public offering net of issuance cost (in shares)", "terseLabel": "Stock Issued During Period, Shares, New Issues (in shares)", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": ["r7", "r59", "r60", "r88", "r551", "r612", "r624"] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Restricted common stock issued to employees (in shares)", "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards." } } }, "auth_ref": ["r7", "r88"] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-summary-of-option-activity-details"], "lang": { "en-us": { "role": { "label": "Number of options exercised (in shares)", "negatedLabel": "Number of options, exercised (in shares)", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": ["r7", "r59", "r60", "r88", "r330"] }, "mlss_StockIssuedDuringPeriodSharesWarrantsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "StockIssuedDuringPeriodSharesWarrantsExercised", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Common Stock issued exercised warrants (in shares)", "terseLabel": "Stock Issued During Period Shares, Warrants Exercised (in shares)", "documentation": "Number of shares issued for warrants exercised." } } }, "auth_ref": [] }, "mlss_StockIssuedDuringPeriodValueEmployeeBonuses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "StockIssuedDuringPeriodValueEmployeeBonuses", "crdr": "credit", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "verboseLabel": "Common stock to be issued to employees for bonuses", "label": "Common stock to be issued to employees for bonuses", "documentation": "Value of stock issued for employee bonuses during the period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueIssuedForServices", "crdr": "credit", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Common stock issued for services", "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Common stock issued in public offering net of issuance cost", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": ["r7", "r59", "r60", "r88", "r559", "r612", "r624", "r720"] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "crdr": "credit", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Restricted common stock issued to employees", "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period." } } }, "auth_ref": ["r7", "r59", "r60", "r88"] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Common stock issued to employee for compensation", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": ["r34", "r59", "r60", "r88"] }, "mlss_StockIssuedDuringPeriodValueWarrantsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "StockIssuedDuringPeriodValueWarrantsExercised", "crdr": "credit", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Common Stock issued exercised warrants", "documentation": "Represents value of stock issued during period for warrants exercised." } } }, "auth_ref": [] }, "mlss_StockToBeIssuedDuringPeriodSharesEmployeeBonuses": { "xbrltype": "sharesItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "StockToBeIssuedDuringPeriodSharesEmployeeBonuses", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "verboseLabel": "Common stock to be issued to employees for bonuses (in shares)", "label": "Common stock to be issued to employees for bonuses (in shares)", "documentation": "Number of shares of stock to be issued for employee bonuses during the period." } } }, "auth_ref": [] }, "mlss_StockToBeIssuedDuringPeriodSharesIssuedForServices": { "xbrltype": "sharesItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "StockToBeIssuedDuringPeriodSharesIssuedForServices", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Common stock issued for payment of consulting services (in shares)", "documentation": "Number of shares to be issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders." } } }, "auth_ref": [] }, "mlss_StockToBeIssuedDuringPeriodValueEmployeeBonuses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "StockToBeIssuedDuringPeriodValueEmployeeBonuses", "crdr": "credit", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "mlss_StockToBeIssuedDuringPeriodValueEmployeeBonuses", "terseLabel": "Common stock to be issued to employees for bonuses", "documentation": "Value of stock to be issued for employee bonuses during the period." } } }, "auth_ref": [] }, "mlss_StockToBeIssuedDuringPeriodValueIssuedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "StockToBeIssuedDuringPeriodValueIssuedForServices", "crdr": "credit", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Common stock issued for payment of consulting services", "documentation": "Value of stock to be issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_StockholdersEquity", "totalLabel": "Total Milestone Scientific, Inc. stockholders' equity", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r60", "r63", "r64", "r84", "r574", "r590", "r613", "r614", "r692", "r721", "r750", "r775", "r820", "r863"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 equity" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary

equity." } } }, "auth_ref": ["r38", "r39", "r41", "r115", "r116", "r132", "r148", "r149", "r150", "r152", "r157", "r159", "r241", "r242", "r270", "r306", "r366", "r367", "r372", "r373", "r374", "r376", "r377", "r378", "r386", "r387", "r388", "r389", "r390", "r391", "r394", "r409", "r410", "r414", "r418", "r428", "r543", "r544", "r557", "r574", "r590", "r613", "r614", "r625", "r720", "r750", "r775", "r820", "r863"] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity"], "lang": { "en-us": { "role": { "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": ["r87", "r140", "r291", "r292", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r304", "r306", "r393", "r615", "r617", "r626"] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-12-subsequent-events", "http://www.milestonescientific.com/20240930/role/statement-note-12-subsequent-events-details-textual"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r415", "r438"] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-12-subsequent-events", "http://www.milestonescientific.com/20240930/role/statement-note-12-subsequent-events-details-textual"], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r415", "r438"] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-12-subsequent-events", "http://www.milestonescientific.com/20240930/role/statement-note-12-subsequent-events-details-textual"], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r415", "r438"] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-12-subsequent-events"], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": ["r437", "r439"] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-2-liquidity-and-uncertainties"], "lang": { "en-us": { "role": { "label": "Substantial Doubt about Going Concern [Text Block]", "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern." } } }, "auth_ref": ["r50"] }, "us-gaap_SupplierConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplierConcentrationRiskMember", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-9-concentrations", "http://www.milestonescientific.com/20240930/role/statement-note-9-concentrations-details-textual"], "lang": { "en-us": { "role": { "label": "Supplier Concentration Risk [Member]", "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services." } } }, "auth_ref": ["r83"] }, "us-gaap_TableTextBlock": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TableTextBlock", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-11-commitments-tables", "http://www.milestonescientific.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-tables", "http://www.milestonescientific.com/20240930/role/statement-note-4-inventories-tables", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-tables", "http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data-tables"], "lang": { "en-us": { "role": { "label": "us-gaap_TableTextBlock", "terseLabel": "Notes Tables" } } }, "auth_ref": [] }, "mlss_The2020EquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "The2020EquityIncentivePlanMember", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "The 2020 Equity Incentive Plan [Member]", "documentation": "Information related to the 2020 Equity Incentive Plan." } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions", "http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-12-subsequent-events", "http://www.milestonescientific.com/20240930/role/statement-note-12-subsequent-events-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Title and Position [Axis]" } } }, "auth_ref": ["r765", "r821"] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions", "http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-12-subsequent-events", "http://www.milestonescientific.com/20240930/role/statement-note-12-subsequent-events-details-textual", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Title and Position [Domain]" } } }, "auth_ref": [] }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TradeAndOtherAccountsReceivablePolicy", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Accounts Receivable [Policy Text Block]", "documentation": "Disclosure of accounting policy for accounts receivable." } } }, "auth_ref": ["r107", "r108", "r109", "r767", "r768", "r769"] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://www.milestonescientific.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": ["r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r290", "r303", "r392", "r405", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r522", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r693", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r771", "r772", "r773", "r774", "r812", "r815", "r816", "r817", "r818", "r819"] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonMember", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": ["r28"] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonShares", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals"], "lang": { "en-us": { "role": { "label": "Treasury stock, shares (in shares)", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": ["r28"] }, "us-gaap_TreasuryStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockValue", "crdr": "debit", "calculation": { "http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 0.0 } }, "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-balance-sheets-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_TreasuryStockValue", "negatedLabel": "Treasury stock, at cost, 33,333 shares", "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury." } } }, "auth_ref": ["r28", "r29", "r60", "r63"] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-8-segment-and-geographic-data-summary-of-operations-by-geographic-area-details"], "lang": { "en-us": { "role": { "label": "UNITED STATES" } } }, "auth_ref": [] }, "us-gaap_USTreasurySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USTreasurySecuritiesMember", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://www.milestonescientific.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "US Treasury Securities [Member]", "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)." } } }, "auth_ref": ["r652", "r673", "r675", "r682", "r826"] }, "mlss_UniversityPainMedicineCenterStemmeeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "UniversityPainMedicineCenterStemmeeMember", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions", "http://www.milestonescientific.com/20240930/role/statement-note-10-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "University Pain Medicine Center (STEMMEE) [Member]", "documentation": "Represents University Pain Medicine Center (STEMMEE)." } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": ["r21", "r22", "r23", "r111", "r112", "r113", "r114"] }, "mlss_VendorOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "VendorOneMember", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-9-concentrations", "http://www.milestonescientific.com/20240930/role/statement-note-9-concentrations-details-textual"], "lang": { "en-us": { "role": { "label": "Vendor One [Member]",

"documentation": "Relating to one vendor." } } }, "auth_ref": [] }, "mlss_VendorThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "VendorThreeMember", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-9-concentrations", "http://www.milestonescientific.com/20240930/role/statement-note-9-concentrations-details-textual"], "lang": { "en-us": { "role": { "label": "Vendor Three [Member]", "documentation": "Relating to the number of vendors." } } }, "auth_ref": [] }, "mlss_VendorTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "VendorTwoMember", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-9-concentrations", "http://www.milestonescientific.com/20240930/role/statement-note-9-concentrations-details-textual"], "lang": { "en-us": { "role": { "label": "Vendor Two [Member]", "documentation": "Relating to vendor two." } } }, "auth_ref": [] }, "us-gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingAxis", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": ["r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810"] }, "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingDomain", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity", "http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Vesting [Domain]", "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": ["r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810"] }, "mlss_WarrantsAndRightsOutstandingWeightedAverageRemainingTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "WarrantsAndRightsOutstandingWeightedAverageRemainingTerm", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-6-stockholders-equity-warrants-details"], "lang": { "en-us": { "role": { "label": "Outstanding (Year)", "documentation": "Represents the weighted average remaining term of warrants and rights outstanding." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.milestonescientific.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Basic and diluted (in shares)", "terseLabel": "Weighted Average Number of Shares Outstanding, Basic (in shares)", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": ["r163", "r168"] }, "mlss_WeightedAverageSharesOutstandingBasicAndDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "WeightedAverageSharesOutstandingBasicAndDilutedAbstract", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "Weighted average shares outstanding and to be issued\u2014" } } }, "auth_ref": [] }, "mlss_WorkingCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "WorkingCapital", "crdr": "debit", "presentation": ["http://www.milestonescientific.com/20240930/role/statement-note-2-liquidity-and-uncertainties-details-textual"], "lang": { "en-us": { "role": { "label": "mlss_WorkingCapital", "terseLabel": "Working Capital", "documentation": "The difference between the companies assets and liabilities." } } }, "auth_ref": [] }, "mlss_statement-statement-note-11-commitments-lease-expense-details": { "xbrltype": "stringItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "statement-statement-note-11-commitments-lease-expense-details", "lang": { "en-us": { "role": { "label": "Note 11 - Commitments - Lease Expense (Details)" } } }, "auth_ref": [] }, "mlss_statement-statement-note-11-commitments-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "statement-statement-note-11-commitments-tables", "lang": { "en-us": { "role": { "label": "Note 11 - Commitments" } } }, "auth_ref": [] }, "mlss_statement-statement-note-3-summary-of-significant-accounting-policies-fair-value-of-marketable-securities-details": { "xbrltype": "stringItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "statement-statement-note-3-summary-of-significant-accounting-policies-fair-value-of-marketable-securities-details", "lang": { "en-us": { "role": { "label": "Note 3 - Summary of Significant Accounting Policies - Fair Value of Marketable Securities (Details)" } } }, "auth_ref": [] }, "mlss_statement-statement-note-3-summary-of-significant-accounting-policies-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "statement-statement-note-3-summary-of-significant-accounting-policies-tables", "lang": { "en-us": { "role": { "label": "Note 3 - Summary of Significant Accounting Policies" } } }, "auth_ref": [] }, "mlss_statement-statement-note-4-inventories-summary-of-inventories-details": { "xbrltype": "stringItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "statement-statement-note-4-inventories-summary-of-inventories-details", "lang": { "en-us": { "role": { "label": "Note 4 - Inventories - Summary of Inventories (Details)" } } }, "auth_ref": [] }, "mlss_statement-statement-note-4-inventories-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "statement-statement-note-4-inventories-tables", "lang": { "en-us": { "role": { "label": "Note 4 - Inventories" } } }, "auth_ref": [] }, "mlss_statement-statement-note-6-stockholders-equity-schedule-of-restricted-stock-details": { "xbrltype": "stringItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "statement-statement-note-6-stockholders-equity-schedule-of-restricted-stock-details", "lang": { "en-us": { "role": { "label": "Note 6 - Stockholders' Equity - Schedule of Restricted Stock (Details)" } } }, "auth_ref": [] }, "mlss_statement-statement-note-6-stockholders-equity-summary-of-option-activity-details": { "xbrltype": "stringItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "statement-statement-note-6-stockholders-equity-summary-of-option-activity-details", "lang": { "en-us": { "role": { "label": "Note 6 - Stockholders' Equity - Summary of Option Activity (Details)" } } }, "auth_ref": [] }, "mlss_statement-statement-note-6-stockholders-equity-summary-of-shares-to-be-issued-details": { "xbrltype": "stringItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "statement-statement-note-6-stockholders-equity-summary-of-shares-to-be-issued-details", "lang": { "en-us": { "role": { "label": "Note 6 - Stockholders' Equity - Summary of Shares to be Issued (Details)" } } }, "auth_ref": [] }, "mlss_statement-statement-note-6-stockholders-equity-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "statement-statement-note-6-stockholders-equity-tables", "lang": { "en-us": { "role": { "label": "Note 6 - Stockholders' Equity" } } }, "auth_ref": [] }, "mlss_statement-statement-note-6-stockholders-equity-warrants-details": { "xbrltype": "stringItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "statement-statement-note-6-stockholders-equity-warrants-details", "lang": { "en-us": { "role": { "label": "Note 6 - Stockholders' Equity - Warrants (Details)" } } }, "auth_ref": [] }, "mlss_statement-statement-note-8-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details": { "xbrltype": "stringItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "statement-statement-note-8-segment-and-geographic-data-summary-by-reporting-and-operating-segments-details", "lang": { "en-us": { "role": { "label": "Note 8 - Segment and Geographic Data - Summary by Reporting and Operating Segments (Details)" } } }, "auth_ref": [] }, "mlss_statement-statement-note-8-segment-and-geographic-data-summary-of-operations-by-geographic-area-details": { "xbrltype": "stringItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "statement-statement-note-8-segment-and-geographic-data-summary-of-operations-by-geographic-area-details", "lang": { "en-us": { "role": { "label": "Note 8 - Segment and Geographic Data - Summary of Operations by Geographic Area (Details)" } } }, "auth_ref": [] }, "mlss_statement-statement-note-8-segment-and-geographic-data-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "statement-statement-note-8-segment-and-geographic-data-tables", "lang": { "en-us": { "role": { "label": "Note 8 - Segment and Geographic Data" } } }, "auth_ref": [] }, "mlss_statement-statement-significant-accounting-policies-policies": { "xbrltype": "stringItemType", "nsuri": "http://www.milestonescientific.com/20240930", "localname": "statement-statement-significant-accounting-policies-policies", "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "auth_ref": [] } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "SubTopic": "10", "Topic": "280", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-4" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r21": { "role": "http://fasb.org/us-

gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "320", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-5" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "40", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205-40/tableOfContent" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" },

"r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "710", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483043/710-10-30-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-15" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-6" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-

2" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r194": { "role":

{"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":

"326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/330/tableOfContent" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",

"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r361": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483507/832-10-50-3" }, "r417": { "role":

{"r418": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r419": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r420": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r421": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r422": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r423": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r424": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r425": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r426": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r427": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r428": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r429": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r430": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r431": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r432": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r433": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r434": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r435": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r436": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r437": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r438": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r439": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r440": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r441": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r442": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r443": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r444": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r445": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r446": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r447": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r448": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r449": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r450": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r451": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r452": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r453": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r454": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r455": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r456": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r457": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r458": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r459": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r460": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r461": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r462": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r463": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r464": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r465": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r466": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r467": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r468": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r469": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r470": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r471": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1" }, "r472": {"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB",

"URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",

"Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r583": { "role":

{"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360",

"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r640": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r641": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r642": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r643": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r647": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r648": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r649": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r650": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r651": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r652": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r654": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r655": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r656": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r657": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r658": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r659": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r660": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r661": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r662": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r663": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r664": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r665": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r666": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r667": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r668": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r669": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r670": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r671": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r672": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r673": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r676": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r677": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r678": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r679": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r680": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r681": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r682": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r683": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r684": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r685": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r686": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r687": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r688": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r689": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r690": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r691": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r692": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r693": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r694": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r695": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r696": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r697": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r698": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r699": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r700": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r701": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r702": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r703": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r704": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r705": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r706": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r707": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r708": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r709": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r710": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r711": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r712": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r713": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r714": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r715": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r716": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r717": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r718": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r719": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r720": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r721": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r722": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r723": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r724": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r725": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r726": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r727": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r728": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r729": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r730": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r731": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r732": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r733": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r734": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r735": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r736": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r737": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r738": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r739": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r740": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r741": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r742": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r743": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r744": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r745": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r746": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r747": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r748": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r749": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r750": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r751": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r752": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r753": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r754": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r755": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r756": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r757": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification",

"Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r758": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r759": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r760": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r761": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r762": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r763": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r764": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r765": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r766": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r767": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r768": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r769": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1" }, "r770": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r771": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r772": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r773": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r774": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r775": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r776": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r777": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r778": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph":

"54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-2B" }, "r821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r822": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r823": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r824": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r825": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r826": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r827": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r830": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r831": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } } ZIP 65 0001437749-24-035311-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-24-035311-xbrl.zip M4$L#!!0 (/6!;EE;KEIJ? < -U: M;7,;MQ'^;/T*##N-I1E2$O5BJ22E&26174\;UW7)Z[!DDJ*#IFN[_>7%R M.CP].T3OY"@U[CU#?
TU!BKR2SE.XZK6A'%SVKE.KD35=]4KK:AD&!07*@[*F M)W)K AE0!]+45-;0E;&]ZJW)41(ZR6PQ%S[,=1QNPJ"4M=+SD7C^7M7DQ1N:
MB7>VEN9Y7\26OO#D5#D6D=JK?]-(#(^;,l:-+ IE!D;'RHC#H3)CEM-L8K[& M>KQD%3G%UZET2IHP,CPG/0YT'P92JSLS)X8V]8$
MK(9%9U_DT6)S$2H91K\W8SU\3BZ8/JY690IB\J33\%"\%A7,*!Q-%EH9-Z[GX8.Q,4W%'_63ZSN"%A3[&AI@L)(*W-',!]+J6, T9J 9+ M]H2$=+A*22U*F:/)"5LCS

M.2#C\H+.YT(8T4R%HHF#C_\F.))A0RB:./NX81LH&[DC0+?XBB:=5W7\%/TW-M91>EN(+F\A'K^I*:ZD:=T[?."WI"@+*^I+'M,*CMM^[E^E5D?ANMI+BJK:FB
M;=L+U73R;1^R+MIP#M-LI8.GU1#PG;K4C-M3U.X!-JM;RR&&K> 'OTB@-M+:;KVBTG.L-V!>=YCN CZ/>V;J_@9?=H+!=@K-MN$8L*Y%F42'3'IA"USJ:M@;O0<5 _CYZO
OFDO-?@#O-MM5^%;+HD>4EN2*&O:ZAK&|Q^IU"_L%PLLM3V1@+V"@[,X,!L65%*8QRB5G89-M3,!LU!_:0"X?"-9ZC54'6&N%P(BZ@2Q-X9+GX*(-FIDOT/FQP?
N26HE2J$(M-MNCRW&-)3N]W-ZF'-KE1:$-#Q%!V<\,;M]4>QE-/"N*-0[-M8>(>A?B;4>W-.MEH(N!G;J;-7,D1MH@+41!V!.0K_LI(LU5$4!-9$Y*G?
6!.)VE2<@%I@8=Z5,',EM*^$?)-MF-A)ZL0$^]X.2!9,4@HN%B72$]=HXR=A9UXV]$$W3,.K,)I,M0>94F=L[)&L\-M>?HA;J,,T,4!<=?BYF?IO/9!#S5]\%X.2/P4Y=&TRE+=+-;)
(27S\5,81L7:='1!\R\@RI247-M_^5I(CYWEB>6.Z'A$"Z(+UD\DQ5L/Y%$GI!;1I,R+C13#.OA@+3/N<#-N+@3-M;L5]57U-R)T71)Z:>R$#S'49;=:=.T^/TCZ15L.+C.OIMWL\[
M)62]AC6?1UDD=)7[&2'%1_E)]6&I@X)-S7NG71M2;NXP5/I[W4,AB6)-](8D-MBO9)%/99$[WQ2-4]X$UC>+EWJ"C0G()33,U1D0?/0FTP0DCC"=?]0O(+.B!@
MQ8':B^D8<9Y2ID0KQ!"(!N$"$]JN'B_N$W'W44P#"UO2OJS>QFZ,*A2ABX.+-M(78[!.7IUS@$Y747E(F#1\%<7#T:WBCY-Q76[TN:0\U\7FT?48:&-M&;N
BIN)=0R^03B7WQ0"-Q=5P_@?-$>ZF1G#)C8K();$Q![Q"$O1)D8TMBQ-MV=^R-N1:#-/"_DKZX20VLZJ9(!H*-DI'R]PY4-(LM4YY5>4795"3LJGX\E5
M68A#>+D0(A.+LNM<'.6RVC!"UY&G5A/P[&(\%PD09$DRNI?&4\>9N1&;.X/-M)-\(;GL*-/D0C49P&&1^L3NG8BH%-:DVEA_>RW.Y[QVSD7JRV!QB0Y!<<"R+
M0)AF@X3H3RL$SS?0Y;;[0V-_1& MY^><+T@L3B])E.4AC&V'0:U[PY.)ZBWSVY*D*(RB;1?*MX3R+2=4OF7XSI=@-MHNZ(SIU@>+E4>7M!;?ND6A:
(USC<#*W|HESK2C*V'R;U-;J[GE+%3=YU8_O@-M5-I.)0=.)1.?HM9L-1-*L\Q-K10?;-A"VK_2W0>Z@-'9.\UG3-VQ?^\"T&'G
M@N=@<+Z%7+VFN7HA1\|]CAZ>/'^@I0O5IC8+-!1NS46W6=O)0*VV)9Z\Z."X-MMD84'->>'-=-=\;'?S5/I[EL%(E_1^O*)FD^'2UHEDK/^NX?6UK-+FO;$3U[
ML)N1%QS:I^S0;FT!/-MMI-O-]C&X0\P=/)>$YRD?3XZH6JW_UV3.M.OL-QDJ-MXC.IB8C_7/Y9ILLHDPP8!LNJK^<4KYP+,I)*TP"" 73QBN$R8KG8*OR6L/M9-MQ
@,!K"75R174-M:?\4L2^DD(+D/8E+ELK";-IE,'?P2O\-^7K-3!G-Q3]C9'.Q02K=DI]H\%[\T%<%Y/[=$">_&#[#+;/(=D^3;R-VMLX-MT&$$$$Z;J-;HTD?
M@#:O\Z!+$+6#K+O0_?KG$.S5$. :/T5V;0\I/;&/"#B-MOR%%#+5I &'^A!1F-XT!B/CO2!*#3&U-D#\C!6EEZ-5B_04IU@9&8*@>D?5[FM:FTC@DX-5EFJG6VVGU"!*O?
]AQ$OY_.(K49T8O2E5I>/;,9[BR_TD0S?FMP0-M6A!"""R#NQ3/.B2PS$\G-HV21Z!)_F=%,S"4?D3]+L?N:2,[)X-5+XX(D]Y(S:JL/:MOVI+#6SWM%W]HY
MSL_B0ARH8F6IRK8=N*_Y.+C?+JOK[49=ZT;9!W;5P#3H6_MI#RK3>#$D@&<-G_)>^8IZ-0^UZ.CYN?1AD^.HCP930F=LF@Q2^-1$A51,X>-.MS9!],&[LZ0L.G!?
HP+F/Q#XX7]TRFI2QK*A]OOJPVRM1=D>F8G.:W30MANG+M[+L^'7=D09E,H+G.)Y3-*QXG^-KZCQ9&WR:C!1-<,,$%$UPPP07=.NC6+T*W
M;GY)#DVS;BT/|:@LO7T|BO?OH#?3CK1C]*$.0@*^L\+U\^DHB3"\]+;7V7-M_2Y9D5GOL>P>9\C\0>8/,G^0^8/,?WHR?ZM+L4^1=#2F(LK3ORHB*XOY8\G%
M@@F9{2%%E&9"9!14E|%NE:&"L/W(O8C'3H['D/):$!KDO%.6\Q3&45G*-M_*B,+E-Q-MILY7GP5#0\[73%/0MHDN7#ZOS0?PBF|'QW4N>!+Y2+D*B*:EYZ1>R09)LJT)
M?A;'Y,S,|/=,W@M^'*>]U^+@'8-^$O23H)\$_23H)U[T$UO&C"YA-0,3>(&B-MRT+0XVHE.0*Q^GM "(!5)XX"\?A['@AH&F@HG?9H'K!Z8:&=M<#%I_HP'KBC
M.]@23MF6T+Y@5I;1KU$>DRO*WM/RL9B4Y^7MQ0Z@EUQO[C$M"9I5LI'A_8W
MV.6W."O%8;@2C%8FVI7%^IVBR?'S5&=S"4(%V^787F>E_M4\3:TT<7P6FZ{J2]_=:YJ67BFN>Z5^5RR-MGL6"XXF()DDJ-56>Q((P(8A>Y_?E(Q?
W5\34!Z'Q.#T5AZR_INI_"ZPAV7S(-MESP'H?!=_W9X]Q'X+,KYA#!I%[HG;"FTSGQ:_[:I+*/$Z_^D+-<+8Q2?"'*D_-MT>LY_7S_P*H'F59[647+D/CLN!%E">;
M)Z9B!:1&8P3OFY>:BR;MA?K@6Q@G!F-J"TUV%:6&IR+UM9\@B[KQ,G:43L-M#Y7;VO^6/Y%BDU8F('3[OA-^3NTE&91GH:=[L=7!,-^L8&&\H!].$!\/R'#UR1<
CU[\B@MC#O !'_MC-QO!T$1P)GX!=E,V(1.]OR^?+O@.M!8?43/61-E5M:...3Q.58=9W$.?Z%+P-MGT\DD24"A?*9\AE)/E"]"%6[PF<*>16'O2- =3P5/B!+H/TH@^
N=N<5-K(@V/_"#-M=7_!>30Z1X#%&M'&T@$]BV]WN_E$/%O!@&]]+(.!OUM3-U2,[!'@\+=1E"RE-MT8^/Q%:56X%%<=']6]&-Y:A]&B$8D!G/$*9LCVF>U;7;4.-^=_-N2Q;.
(*S5]-M2)>@?P7]"Z7^%:2V(+6=GM0&9\D]RFT_C?C!Z[PC4CW/VU)]LQJS#YFM-8%!-M8CMEB4WA0#JG$4O&D_$I339_O*6"*]SLQ7/UADVI/Y ;Z"^M](H[5-MYE>RW5O?
4ZHEH]YECQZO)"$:.LD&-M[I?Z#%-4E,5%1ZFK,*=OU1ZTVODW3-M$R8NB>A\;L*^-[?T&1@KU]B::ZX3$NB:]T*@/U*QMA)W.7G?N
M+:,Q(0F7^2Q;T4\^R[23I%40H/UZ0[.QK6PM*\]=#>C24P&T:AZ!EP7Q?+5OLDFGKD3-ZG]^-M$_MM9\%4R;%=?&(8<[0UF^]J/50^AX=9E*_O>%[)+?PZ7Z-S/7\-
/S^,N7V:M<;HW6;B>1--W<,T6UYZERJJ7)R"9I,M/A3F#?PKC[5-1*T#%,S+.B58B:3-"-M,H0/7VE+A,]&Z-GA=L/M]^.!QQ:(T6(,_RCK/.CJ!O[I>S3?/X\Z(:AR_,N*-M
M((&TVU4+OZUC!F[?+;(F558[-HY7)_[/#UZ$$U<[>UIK0H=6U#V'2)U#, M6AM?<+(YI:+Q"%^5\PXC%?&;2YH1H38'.D-M)'40CH@)<:VG6+6T1@?XX)+$+(4B=-4J+
X;!0>"HTJ,ZX@'82A-X7Q]+<,F M!E>(QC(CN:4MKDI:.LT'53'N*N;%?D'Y=K$#3.E#0+!X"N*;@Z70G&"@Q$X;-MI0.A.IC-
=)96Q\Y1Y72'.U&3VX%N*W9](#B8$V!,,+3,=CLMQK0_Z(R@$]*ZB3:-M3@;'*HAP2X_=1X+US^]U&:BT9D5$3?6C]Q"QNLCU+E-I2%-M&N4OL$;Y_FB.)
[OGH79/L!^18M'#!6D'9H]U:.L-*<8+(H7X?/J14/%;N-'N7[=RLUW8T'Z1#-[6S%Y4.%MT*_)F*)[^2#!ZQB-M,O\F$3O>KT[&"DFTX:VAG42"*7$O>#Z#Y_-T/)_6%_K
W)TM9(&!N3X=WKJ#-M=(>VDYMZ5$1_'FW8V"C*D]&4T"F+%K,T'B51$;742QN-W8>;VH+0H+6>LM;:-M6E;>N@?OR(*R0E[8]^N=H+QS1V";A)TDZ";!-
TDZ"9>_!!0AMRC#/>+?+A=-MZE#K^(*V[@3H<'U(:G:T!>'LE(4SA1WY?2]SHOY+,-5+9GZ741M0[>$]"KL-M&MNY)>-!-(014M/2,2F#0*BKS&=@(N)0QCM+JI*9-T<3!Q[?
WR0'&6A>&KIU#-M,GX3#-)-P5$3!Q]?CZ@!%(HFSCYN.K*1NX(T!T-19/VJI3AA=!/T7]3=E&*-M:UEL_KKGL/2-.J=O75?H"0'*MTJ-;8=!:;]OJ,:QM%;RVV@E)5]M?
7%MVUZH-MOB,Q29=@PE7-O=)^<2C>WJ7\RSG)X]D\8E^TY5*AW4X!2Z\GXCEQJQUYFL+-MT&Y]8SFN0V*&45^)IB\$>V>BZB4C2)=^.
<@9M3L@SWL,%T&_IWMS]3ZC3WN!-M-'MY15*5UY"!L4QA'3-W'-J]O>Z80W(,S_JI&O9&[T%]3GZ^.OR+Y@JP\"O-M-RC*9*[BDN0EN2&%_D4<7=O@9CN%=S3*Q2)+;?
DYL%=P&'9>WUQC;]66CXF-M8#."-&T@!0T$:]W^HP.LU6DQHFYP5U*X9#8X[WXS9=CSPIK|QN!]2:U8*52A-M#'5V>6PS%TKK=S0.IS@NY46A#-7ET-M7\G)CN5J-]R
F+JOV-0$4[NKL?NZ2HTPM;P5\3R9$E)LK'E^2+'INN0L-"0'-MG0P*R-TW!W*CT88:H*H-#M\#\IX+]?;[$5L++#J.%E!Q&Q8'@T3(QJM'8?61)-MM2
TI$R]P)2I(ZWX0/).";\H&1,[2YVL8-_;-FJ5YM"D\(W:\FDJK-MCFX(+2?BUJE>Q]@MWA5E_XKR9)&2^/B-X"-B[3H[*?E(EBDMN2Q4E"9RQ^6)-MY4YH.
(0+XDL6SV0QW$\D65=;HDD9%YHIAO5P0-H=7459L1KG-Z2H(B&>5^0]-MI-O0W-%1GW.Q&(R+V_16W/35%-AI]X+((HWPOI*FY+C_0NG/GR6;:\L/$LT-M;]+[!+V%*2.?
N!CDB>'#%-BH&!RXC=%TVV=<[VHM\1TA8C8$4H_G9#\]@5-MW-KAO&(_CS)9>,%^1DCQD_5_K_,Z& K$=IV]XA("XX1P:,V/LBM"5/Q!U6PH"69# MHS7CR<'O $"_(Z!
:)WCU]N=KJ-'?"R4?8:-LTY/Z!L:U.H MRET?MK$#:!P& I:329K=&%STDE=|(I_JG!T\1WF<^]G9BY?8YZCV:;0/C')E M+G)W7PK)UZ'&\9K@0:4L@PTBU-
[\@!'G*>6WMD(,@6@00C&A-?L)J-CO%_$ MW<>>#RS87+T?:3L7+*H TBX.+H:,NY!*H5_CD$K172H%GOQE.P\4N@T+D/UH MRR [E+O9C7R,@0VWYDJ6T8'H N
MT{$B#-"%P@,VD;_#2[H$A@WA(;_ME%-_M](M /E1M M1P(:K)<')*1:4A8HC+[#BR 65]9[B@Ei1=E4*7I5/QY.KLB@9N5P(ML6B[#KG
M@K]4&T@(JO*4:U+978SGHOX&69*,+N1'!/^9D1NQN3^0?&-'W%.@*Z7 M$!<1XB).)RI"WA"!CAD!?>;M5)ZI!C_;3-[^AW>C7CYR,F?I?R5?(>TO??! M8LA>?!#6]
5/Q$OT1$1\=D[SDA_Z23>A(K6>!D![=_7-#O-OI7_[/LHB=EQ+ M!||!A1%^[6"7(N7^D_>$5=I8K0D>TL%-\>8619L|%VM>!RPHMI&B+#*T3^>E M;N_%!R.64K&B)
(YXO3?+W-;G9|SOB"QN#5(HBR^:VP[#&K=F\Y-5&\OW2U)-MBK+3VG:A.'8HCNT66:\NI.!4Z8C.G3A_N50%48#:]DGUP^KI@_-ZNH];]TVY-MUM5K;#],ZFUX27
D.G,DFBV*M=YXF%":92)]}9ABPQ;*ARE=O"-6C\Z1:SYC M:HC]>Y2-3EH7/-+PS74_&A:\R/4^G!?ZP-/O3"@)0+5IC8+-!1N;4.6=0)-M0*VV)9[Z2B%8P?
J(A6"%#H,5X#ZN@44J-/"C#"PJP=87"(2'I3R#K4>QGY+-MP98XS=*D>H%]]VL^HI.1N)AGHTE&O_)1F4=EDAZ$P9@#+QH.[#G\HA65(0CC
M!09A;/+2^6V4)O<%C;\>D-K:EX1-=$/]MV%U#W0;Q;PO1Z]ZA+W9&-Z#8L0GXS_+-ME)%;1F-"DJK6E2P^(WX6,UFL;K.HLBY3R9$
M5O_790"KV[D*E'D\+OY126^2#USG2G9AU]-O!O":J4.<"@3GYQR-(K!H=F;1NO5$IM1OZ_/"5+<7K$R;H3\@Q+8\&'Y1_$"7KZ
MBX.6@JFLDR{>IWQ!>91|8+1{)@s}YU|P77-?%*XU6:RUNWDAAN MQ:40IXLHV]YI"}):?;RBJ)7EU$\P*'U'-47T@<6):JP(+0.2'#=D9B(>,6T3AVS-U/3I&
<5.5[R(%FD196>/O-*Y MP)!,_2,[Y:1A5-<6^2V#Y>7XV%M$38T'0(K/P&V:#X0!KSQ8-M51G3INNI&0-IOF;K"1@(-[|=3==T/34#(,77;#T!-WG%J[6"UKHCBKM']%M
M.HS?2FC'9NBZ>U-!T*JO7U0'MO1KSDMI=AA/9$D"6FM+MN[7&QKI&1-"Y*=(-M/MA;K,83F_5J.DYO:'^/9,'KXO(;87&JKIP)Z>(;PR0M--+F\P:^Z5NF,OA+
MUMBBY6,Q*;.M:4!-L;&+W]2?VHKQ"NKUC1'0?5#9G6M+W5=>ECR17L&;:&{(-M=NKP4V'.X)*B:I-Z-W5/Y&E?&TGO|!;._.81VN^,]B\,(VG'$U"@I=EI.#0
M$E1Q\;V>@1/).@N9$-9G.V1"=%O?KZUE"AWO;@&(FM54=*OL!JXZJ@9="HP;-MP#;AANAR9-Q,-<0R@"Y_Q@WT!IYQ.UW4PTCB$&SH.,MU(=S(,A]0((
MV=\+JFX.01.-/W-J_+VPZNRV!YIX@1/@[_55-Q/0SF.'3D9H^L0P+$0+G\^HA.=Q-P5-MEU"G-J-3ECN>-@=%-%)P"4-\]E!X98M9T(&-H;!#RQEH
MFL&'CAVZF8X^BX"@,^@@F-)6U6OV$^JY?&,B;7>)MI)AM1/X2*P-E]?-C&9B-M?]5-ZL2L,L,*0BC)BYS1BR7CR7LC-<4'9T1O7AV7#!"U=
M5#23D*7$0I+WI0QL73.=*M2 ;^YPOKW$DSH2FXW0'>F_15E)+L4.HRNR+JQ.M7QZO0?>.B6XSW?H!7!^0,^):JFA4]Y@#!_DKW]_19GN]=#FHW0+P6K/VP_A-M@?
BVTZ\?I'U>D.%)P0OI5B%L$;%B)-M_5X3ZF1_G@-MH77?TT#3:S[<69)4$I'4(&5TW\:UD)T')JA<2>%]ID
M5FW;85'=*\^XH;E48X4>)$;=7DN61A1/8MMT"34)#NB[(X589I)<1BP7,U:O-MO<$;^\|-WTBH"FKKFO234WUTM+CND5I(GY#)?@I/+NM,#28-HMT@>'#>D*_5
MGQKA>]89#ZZ|S;9J5B47?V#J6Z#=8!AP@Q3?5F.@0=EPT];W18/*T9:%C84&-MM5T]H\8#^<>[L?ROQ8B=I^A69M/0_*P0R_-85B$N#[1>:-;-@;!O<[+@W0Y
MEFQ505BKE5IQU|B^K\HWCIYK-1OPT 2X-#/;40O'DV>HYN=;M:M#@<^_$;N MN'SG':XEH=G",.L0A:1N^4&U8NX6AC;Q.Z.+,P"MI8AT/%)64US]"(L0A:
MKMS2_;0"YK0@HQ|&O)S/([:2R6L\%7JKZ"9$X5&T+NXDP(P6-$O%D'PTB5(V-M6DI4LO5\5Z1AQ'=5&D:)M$)GNVDRIP9Z(<-SJJ'!3+#4P2>N>S'D=U.Z?).0
M=.VU%__8.^M5#[-L7//Z=UL.!|(XI<99N+29*L7C"->$:1]|\|6-SHMT+K;E-M>'(E=EC%D7;_D%G*@G^6C&BC,)H,X17CCIKSU>Z?_TH)$VQUMOI(EB33Q/O:-M=>X+UZ?
*,50Q%W&7!+H-9F"O?!J+_K%[S"0D-8D_6+C3+WN+"-M=+&WW6YX##&YW6O\L-Z-;O\WXJAULV!2<[%O^"ZO.@POZ_-4&LQ0!=SV-GT
M6E.#7^CAU=_PZN_I!3/;5%?W[I#\J;9NYM=-@%Y#]Z+=H'TX"YM0&%Q_I^SZ-M4Y0^O,@BSL>33<3JF%4/S.SB5@_##X[(:MC;*\G;7]ZR-#XV;KD8JCLPBY21
M9,PN9,'V+&N\$)!A^@'1=&FLQ^P*WO/X'#_*=5=_Q#:;?^-X7<$8"UF^B'+9-M570VG3+!%-LAX1>"&I[&=04770SE-,PV'T-6?YB%9C|8-Z8)EL-9T"PZM-MX-!2JM
#]V,$\T8P;R-S;]BQ972VU!8@[2Y7('(LB4$.A2D@Z$8B!P-M+(E$S34R(%-L64..%#@@:E0)0TTM4D"L6%*%W%FO@,!1)6:WMG9!11%4]=EN-M+6+H?#
('V4UT(LG]U9.O33PS^-#QV!C2'#PY+]"34U!3Z$PRB^DZO#VIFKRB;D+0H&9&6IT]$-M7S_I?)W7NI*!?_>T9K.'W>N$ID&M0G57[.!'QKI[DN#FK$#:ZLVB,';]X8Z
M>YW>YN"&EE_'-;-VM2AIS4[V-Z#!=T-STA:B<@S_*%L8-M;0_T]*=2I2]L_L/#G7^@(9O#Q-K2\F@9AP0XW.$\UU',]Z"DA-$?.I/1A\X
M8YX_)&#SW+!VH!#T[*5X3;U/\/A%H$YU0XS3HG;A40N_V>"BW-&>8G2U23K=-MH-3:%XT]#Z#74XZAG(G#,V'PZJ,I%SKN5+OR=KHNRGW>E&UCV*I^EM2@VX>R
M,R$ORPYQR,NRODO;.?8&FLC5BZMN8*E?:,PW-TL<\QR(,+#L,F_A+0-+1NO=-M'3:P-#97-KV!9;1A<$T/+!>NI[#0H27/(8SIA$[AJY-%)6>N.X-MF!'V,(OR6GN"8B)\?
_Y$YO:&YDNQA4C236Y.T^^?NVP>B7/5EGHO;L#=^Q?]-M33R8M!-9D\]U+UQD_K/G^3D;QNJ{$[V&^6P:#DQ@KJ?Z7%*<2BAUCT$+'==\0VP%.*CHP1&N'>-
0#QKB0=T8DUY:-MG&AG%J-A!Y%Z-Q"_M,C15O:OEQ9(VJ]V|ZE3#3QV:HOH)"!"B12)PD43^B],L-M32+IUGZ,,ED:?L1GA!1\5.91F:3%/EK4'#0<&#/#O|65
8'_RD[^!45T_B-MF);B'-^1F*1+*0C?D4QNFMN(%:L;4ER4C!T(YX>USFW[NB%7<%-9>"JW.3_\MGH)"4W-W1'U,H\\,(0-_>+-_5)4EUQ478;I4+6NH@6:1%E0OB8
MT[PRE*E@@#MZQK@]B^K\HWCIYK-1OPT-2X-#/;40O'DV>HYN=;M:M#@<^_$;N-MN'SG':XEH=G",.L0A:1N^4&U8NX6AC;Q.Z.+,P"MI8AT/%)64US]"(L0A:
'ET05@P7##3'+Y(+.!%T,!,#L6*39;Q9F.&3A-VH4=EXX+BP2;EM#3M-M0F%C$X8TMGDH)&Q"#\R;BBZ,TDBV!F*-=0:Z>E@$.G=1%FA6U@FD@U5O8:OK
MYPMIP49_3A*-VGI*>$C7L[GXGJ405N'OTYD)&FVVQ#F,+;&0WL.7VM)9PA;M>X%A:^_%GHBR^[5=LK8^K*F9-R(^D22-53HVO7SO(0L.K=&
M_C3B!YF_(U*E_AZ:Y'AE31T5="1X;.IY29*&UDD7G^K#6NF.[F"]?)'6RPEA
MC%2L35SLZ\@U86,\K2OTAR1=FU.TRK*AHKL>'OO<7%?,Q=UD/!TOF(R"R0BER2@H>4')
M.STEKYO+:V":H%.A9J"*H:.+NTB#Y^%L>$\RK&3!W%HVQT*N%,8LD%?TICS?=K-M6SCX]+\$0(3OA_&^)GT;FS3B=^UL'FA&FM:/8CC,]3-MF-T$U:YL?B?
3V[2C>/XPZRN03MR.R+CS8,+[(9L@^HH;LZ0MY*"\P[N7PB>M;EN9Q-MNI#/LJZJ7;,_T^LWZQ4OI;0?R*N'X9#2HV)A[U->B1!WXBC=BCO\X.8X\D-T
M&P0+SCLBM_CVL>\PN9O|7%[!O&*\^G+Y=LMI"C;|PCW8UW8M-A\&"%[\:F MPP2/;_"X*M61@;NU@JH85$5DJB+DDD5C,K/(2'(@XZ*QJ=FM:!LQ$-@96\WO
M=K(&$#2VJN#MA$D@:"S%M%WHZ-ML^_C3;)K#";8UEZ@;0U%2A>."M6&5(,+FG.:I4F5O5KQ:46>@;YA#W0]\SA,M38=:Z_A]]*/I#3C/?
VC5[HN*!,W@+@\;FBN.U7@!H[+"^U?@A/_SHCF2;AG-ME83@73U75^_\%:IG!=D]O7OEVSP[F-?E=W1L@X6U9]#0.B2GX4K[&@:5(3DM-MN$]TFM-97B=\,+H-
R0&T$#/4#C3>H\Z/8@YIV/Q>_L]CQ(GXS?\'4$L#!!0-(-/6!;EE&ULY;UK<^0XDB#X_/-5-M$00).%Y4[8?N2DF@N\/A<#@<_OC7__%UDZ%G7)0IR?_MF_/O7G^#X.
(=V6#T/|_>?41GZ/6;GWYX<_L)??ZX0&]>O_G3V?GYV?F?SL[^-M_5^S-/_M)_9_CU&)$24B+_F/__;-4U5M?_K^^RI?OGSW];'OB/%^OLWKU__M\'TS^IMZ./MK4K4?]-?
^7OQQW;H">@O/"QYW_[V]^^YW]MAY;IT$*\/S[-M__GIXWW\A#?169HSCL2,EC+-]J>2__$CBJ.)LG)P"DHY@/YTUP\[8K\[.WYS]-MX)+LB%H+-[F-
3=5L=SFM5D(T.DXDVYP0C*!'':Z(F*M>DP@_D-M?9I3>R"-,JJ=*\P00\-5E&;E-Y7#?90-"8W>EQ#Q4B!H)8.U!*"-M:DI038I_H=)L\7:5Q1\=Q3'945'/UV=;DJ5QBLOV
M'T/B9P,>1"A-\+H6U?N.#K1LZ4"W-7K_XFEED8AUSCL0Y9SNJ+,?SLK=9A,5-M^S.RFB2MBAXS==$VA6]+U*%T>-'2/!+-^[V@#)$5>A';P7AAQ[:'G=5RM5W^

M=);FS_0G4@#WPQ@_JP(_A,B+1/^)2O15AWI&(CO*^TF9G&:H*Z'|"_T%B7|[M(EE";\AG^+]VU+]&")*(*M".(;0BS#^A:G7'@G_@BXY#3.22]5%F91.=4Z[MDM(?ST]\YC|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|@5!.5(XG:0#P0Z M&TX!NMX5$L38D2=/5"]>G^G)Q4E+$Q<"WR|1H5<:Q'F*>3O"-NG-L3\$)(/M01<89RGJ@K07(.Q'JP85]Z&E,+P,_(+3]1,]*I;/N(C66,0)W>RJDA6;HT2\.MC")$.LJXJU&$8XGXHC_^ MX<8" ">LHFH.>! M)7E,A=+: PQ4[N8$."_PPN@ZXX2AVVC/=?F2A4ZOL=#[@KI%%TGU*R<0A0[< MM;BVQ-V"^3.!"A)CG)3O*9/NHPS3S?TIJE@&U/YFU66?=5.GAYV=EF9(_Q M6Y+ORN'L;<#G$ M& XV^%-*3^)'HNE68N4ERQ,/&#BP4]@.N22K1BA3H41"F MXU)R/VF]K??29YO4)18'JER.S+K-$1;SKF?,)ME,N9DM2CC)]'K':,OI_LZ_ MB0K9B\24^_Y,T<%3OV<0O=UW0VI[:?DE*A(1)'N54T.:RT!Y0U>I>'B*\MI: M^#LNJ:5]E8LI'QGH'UBNVKNHPBQKG+-#9M'.C3ZH83R7>;C6:8*:)7:8X2DF514?+?\FNKWX?YV2W6H,4^%^("::S/|P\%MCLI=L>]LMT]<X\+B0J9_@"XI^6_76^RS_>H0=TOK_&KP!|F?JK 9J+/N]:1 M07A-\F>^L^9W!NJ3-KOC3WT*OE[%YS!7R9B;_$Q0A:(2 M_5]1OF-AMN<+WJ?F?P]K!++#]O1@B4'GY/1T6U[L1D\8[_OFJ?4'G[TBWBPG- M5(%/#N>U02XOGS0G5_$(9-MRG2HE=BZ;LAC*/7N[Q=;2K_)Y10RO\.SB(^%E; M-LX [^?0,/K9'4.'9+H^A3@VR-9^.6P!!.3VW_7|T^D_[K.TN<'W?S.I15/W MH3&*CJS.BZ@7 A'9HDH|\7T?L<:5K(+O2C8,1GZ'>C70V=KX->/V>K7 M0S)?OI5_.)]Y*6TPKT=:S"H_%_WNC57)A@OPL//25&D]BN'HDV9G&_,W(@VJ0(RO 8X(<[W1E^MUP6\% M*&T0(]Z[Y&!;O_3]+%MM-]MV= G]{#=#F_E&G#MZR\H!TWJM+1]BB@OHK^Z#(+%_M(,N8&O\%UJGUH,/M+Z#"@YO!1I5B $59;0\2Y,0@K9ZUI R<6&C)&C%BK;?- M|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{CXOD'.PUW=%#E+%NV%1.'5(#HK8Q,J&I0'>W@M M.#(#8?!F.IZF+V 4Q_ #3BY("=9]?4 3=91\%/0VEG9RQ031"B%"F&A?IU[(\N MS[3??IKG,Y+@AR_$4()/(#B3X!;3;"284C1W"3Y=`BT)EO#<7TIQ6>)*9H = M_A&:,LR!Z(L4O0]$EW?W@.IZ-TTXBA!!8^!Q,*[8HV M7&/(,Z__-<2KKH[%2WU7=7*TO>!.9FJ2+=KB7J"\#>04(9OO0A%KG2PISU3]0 M$[F;XA=!6,DR8@O^NM:K%9=P\I"H(Q# .P_8=<20[RZTS%59[H J1OZI-?UR MBL*U;G\;NGMTT(^?TDX.*#73!{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|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|/CC7IZ)6IQPAYW@3F-BJJ/>O37D:\1)#(^2YO5KW?260/ $<3:^,R=|*;3 NYHH3]9RH&^1!(+3 _]9ON77(49KBAG1$W+3.??*^3GW1L1NPMTWQ>/0 MYW=359%7GNN/T3Ms)\'8/4FEZ (?IU*Z+)ZI%N=N]V!M"1/^D8.1IV5U M^HQ57(30NULC AP P>Z>#A'[+97F>05^0]9F6H9G%/)ZN)8QG&QHW9%&CW6 M&1?*#CWYI];<>:!Z5/%\6)8U*Y%#O8^!DJB&Q+4L?JAM=E;2F8>OX0JU)'!_ M6""9U%P#8L98D%S2R\UW:_),9T/OZ,5>B&7]0R>1]2_^<7%|)&VG?]"4I ZM_>R_[BZ7GH5@P'F$/F,#4,OZ.$I,N=)\4 '8GEA?&1D%*+88C.CZ_*^)H MX9W%;4T &GS0!A-/.D("A!A,2 ,1X)8l:7Y/V:8DS*<##66Y ^A3E!E6*Y)L M0O[O1Y 'I&) CF6\LB?&-[F:2CX99RC$+3R?,DR16A%A ^)_/Q)*A$# BSA ME$6CX@M1,RF.QYD:% T\K^;$%V+'F(3__N1WU.)&#(DACD3!%QW[M0NDYK32=/|-0;/]!Y-C@<[00QYZ+)/2]BG>"[?FM@GI3Y0)! ME/DT'JW]4$2)S$^JJ|$K3 H::Y3;S@ULUJA5F9 M +DM/#8.E,H,),I#"S%R5H%.3)P)CIM>]Q K@0;>4\K<&.VL2 MAY>$-U;8BMW$B)>F17TR\N43>>8'1L(:+;.6 ^433CZP;LER M2T;G.U!!'P7XSFM:L\;5@@A44X$:,A"G V[\N)F?%6.H9-/>B&EOZFFOFFGS M)MHAJOGHR!L!,]F;5J]1>)DN--=?6N6]'6]CX%Z70V)+\M)C1J(!>5)GBX: MKRI-T|&AIBETO(S# J*1R3[*]OWXAAL>{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|#)&Q<@ 1=U51A6&[FE#PD"Z4:M240-C:A' MY((?""6TOZ@_MEB)";74G-=LQ"YNEOMPW+M@W+M^*_7F*R+:/N4QG3HNHZRYX!9=U)>WS8:+=$3(N+,5&40]TOM2)FV?;6KIj:5 M7M3DU=&BDT!LJD\l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| A"C8(&Z&D)E+DV+$(P<%,GH&Z,$,G-.IY^J< M\W2RO6HI^18U;,(DAJQLSS3H*1;]"G/ROW9EQ6M@/9!EDJ',,T39;90F5_E% MM$VK*.Q$(_'16MYLDZ95O@>%|IC,43'IT06>-?6H<6MONPJ3_#7_QO+79N2<7 7UB$\7[XK@15QM(CB M#>6TDG"3*+/(, !MF3Q'E$ZJ UFF61"%U:_PFO4%C_+J.MH,/6./#0.?XX?@/!WC'5+$L 8ZQ"6<)*KL,3S"KW(* MF.OYD5YDTD&08_D$F.OE[B&$MQ.50#7P0$?;@B2[N&J]%Q3MBRGFPA'@0)7+ M U%CEU,5]HZPK&"IZCK\,UAE"3"->5-6OIQ_X)!EI$I/OA[%MN5%=G@XN3A M85"7:7X%?1P;A^Z^&+ E CT!?DQ2UGZO)$6N$R K>F4CW@=94+4EU_3H2 = MR0B9CF"Y%I4.+HFG/Q7AM&_@I$QCRAPQ.DILDP2RKJR_L_'-#]Y:%<:"SY? M!F!Z.FQJE(OF'X@A1S=Y* MX+M$BV7>SJ7[W7:,;I,KGDN)7P'-I KKS-Z,: M_>S.)56N$RKC;04CI-:WN*D$S/ZPS^N*<9=AL]?/_[Y?%D4#\4FKY*!9H5* M8S5%:A2F:T$:1:YSK|.\"TB:%|G/&'K$|)^=|UO1(E:-*.UYG-VOC""_FT-- M:H@6$_T%?1<9S>K*WKCSM?I8X9'>|.H;?01|\|%[OP%HN\1)2N4MOC#Q&XJ MLIK_^.?#*F3=+&^*|_)%[F:0CC2U"#N(ONU!WEZ4%(CA#FL+#G!UR|*4L M:A.9-YJ!1.&OZ9B#Q_^)R8#(2SGGPPRX)645?]ONI6T$)|>,&H,'#U;0\(MY(AB#]-O7(&\0U:,"|\ U+%\0WQ6U!GM,\GA0;R7!3P3D"ZUMT.!F2S8$ M&!4>&9.'Q&>4<^$2PMN67VY@2<*C2]LI8-UD-W7BWZ0(0(-8U,%>H*A",2FK!?KAA\4//_Q0]R (HE9'A(2H<\XP(X U-MDRO?[F]%U/DR3]fN/[3=1:/LCK<7Y97S1A\#,! L@H Z)Q'/#&2T,>U43Q M[*3Z8Y\N)BKBR>]MZH.Q0%8#@/SGQ48)6D9TRO!KA!EZ!OV;_9L^ZS1S2S M#=24$2]^Q-:*&.YD:F'ALDIC>6+/\ C(_CN$Y+X]< &S^V$1Z>Z"YH M;.?W+'H.S2>O1R(.1(%G;LL+|(X=_+P337-N=E5947U!N25]/U'Y"%YX8 2X MKRH$O38FB[IA%.J1$:HH@0K;"8R7AOKP/RC,.8IC/)+J*!L#T8G'L%P+1H05C8Z'9!$,P70MXMC0^JQ7G\M(F*T)D#HWPE6LSRJZ!QXM]=E9VIX=!"PE8Y\|4I^/L#(TR5^B MRS1ODD3O-2MQW@A$B#$@O6'VD):JR1W(N ME0*BRIZ)6.O[*587M$V"D+"YN5K4KGJ>IT'&T0 M-0D:K?HJ96#(J+365M,+31O\S%Y\V@'X $^X/0MV5I%JPVP?#U<;X65 P6N(MTHL8D'QF3?.P8<5O%D*$,@8/RIZ8[ST)GHWQ3K*Z]Q$2F))LC1BKC="J& MG;?X/LVC/$ZCC(<0\^)(]HG$=ECFFLT0-&V38[KK="G=X$.*.8/3WV:F4>^ MI1IU9*..[G !$\[E@?A:9%<%>Z@H9[=/),?22M:R(9"2/4>@<Z]L8?@01QBJ M0K64>T2%)?X|_--P,43 __CS98)[VD?\6-7)Q@0U+>JC=*UU'7]B(G W#6' M1Z_HY4G$S'P+N0SQWE^8W5BXT?@@:'B=UU"A M8:R@L#I#ND&))Q4N$4<<*&Q.&H:CPI5Y'$AWN*R*-*9:B@];?HF*Y$-!2IG+ MQ R8BX-)BM3]f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|LXWFUVG,YW>)7&J>R^JOXA6.2F$'BH*-M@1(E ";G%NI@(I#%X309J MZ$"O^A.L20GC=-40)@)GK&%&Q]|QGI#B)A^NJCPV!)*Q<03*M:P+=(CB@VF2\ZN+15!K';2,R&2K!)FQ&R/)C&)AD"48)'H+RD MJ1WAU-:"QC1#ZO2T<:S!]+922Z++-Q-*/$39")GX$A5.>=/BG^A)M_\4%,_A MZOTN3X.KL:@-!NKM8:#.JZTPK$@11QOV"8/$ZPE>OSR^B!)PCCI?]C[Z'.4 ML3TX5L=[\@.#5\IAP,Z=X10E/_?Y/WK(@Q;NGN8ST6>>3^.RKA\R3-KP;T>5 MEPV0<-,4C#J@](9UBEE8+>)B";S<_A^^D*G;_\D0^.V_!>7]HD_QF=[^#4@V MO_T+HQ%57TBPV__IZA,5_@3L@'.SQ07GX$GT3:LH6SZRY/-8YO?5!V"M-XX, MD7-5^\12MG@F&VE(0%%9XCJ[HQ=.]]-,&LQ.KLEHMQDU1GN3V8%R\Q-"JO % M4"I'(/I*KALA ?(\875&X!K#5'L/|64(IU4I(<_&.@O%FKWR+KL5I27O.[#M\I'LJ@^$;6@V^R*?JK>M#P .%:6,R'F-F8X2Q$E!$:,%<6)034WXWB" E2'F M/|8?/:K>/4?E$]-XT0!=;5K.O8\PVL;;*X^- M-5!Y)S!:#>!%'&L@:LKC]*5;/"F]RT1O%'9B0W^2;]:SK=75%@:6*\'G= M>9]$[!R(\'G:E1H2XJFS59W5=2!@YOI38O$33G89OEFUM&O9"$*343T7WJKR9N&ASU;M12&FG YUYCY0 MO"-O31.C[9R[#53O)R]#'/*%:8J[\N-WF&6A#^ +R.E[X?+HO?!S[EZ\V#/W MF/O3!^X@2T.JK]%(_,GQ]E28GPA\B1(+^= XS>-Q118TZEZX.K&.(E/Y|"A6 M8Z -#*+&5(&'Q?ZYV<9WL[S6/Y^2EC7*"KP%VZ?JIN5]|+O&2\DHW -T&V5UM5Z9_T+I M&POGY@EL7Q$(HT18A!LS&~ +DP24R "5X&V45J MVEKA"PL[: .:^D#:@DN8@I96YI^_^#"\PM2\E=59_R6MGJ[R)'U.DUV4]0>- M)SW: @N--#-$[RTW)$MC6;E4K6^AYYD*#N=E[2@1B%/!MCKGC"UY1UHF4Q1PR23)1DS@E!'44[&X9<6!)/!VQ:=6Q: M^3,AADWI$9MXIZ(.N]Z*K!/KBV6H$9IFP\DGG*1QE-T6)-G%8WM>]0Q(KAZ' MI*[R+FM4A1CIXU^.%JTO:,C'?=MIWDI[DMB8I8&/L"4DZ[HNMPDQ3&S8M<$P% M]X(.9:B6JQ6UHTMQLA!&Y MQ04KRE?J,BS*M]K>40+:.,Q'D1ZI80Q"A!#2E(T()>W3]?DM?$,YG*OQ2.;|M_0!]2U\0B1G'Y_F\(++H\+7?5$RG2?),3U=U&7T;SPP*X'T\-XR0,/^$STS5@@ MLJM8,C6_8[|PEESFFL$2]A@RAP+,Z=+N,^,X5 M/S%Q%4I >_,6DM6Q\|S ?VY]4C"WQI+MHI+D.26R?I",J>A%^5[<1]@OJK3* M,/IFC_??1/.C3@E<<>>1"6.!S #^UM^TN0;&FQLWO6:^CKCAK%##C!;\P!<M[GF?0_3{[=)8>1K.K<]!(1FT-.4<|Y=.1%5-P>.7R^EB/F-CH0Z-C&=>X+.GU'(^8&=)!$,/B)CKY>XAA%L%[@V?@)) M>V^-1=T7L"(HZD@+)/&AEPVBQKI9^'JH[L*F[A\I# <>H!-2 M+Y&B*VB"[]YDN6G[=XL+3JZ(NY[*+5?\"BBO$]!=2VC;V\'B%Z\XLXNZ5^4_ M 3+5?ZG:CU?O;U@#MN(97ZY6]*9WDU_EU!C'U]+LIJUO38O7CN'P5\6V$!2$MK5JKQ.ZA\K7]//3H#*=&49R.W=]'AH!=UATH]SD;':ZF$6,@!^L _X@*4X)(-M ?UWAKG?-D^6&U;5Y!^JTC'UJ06ID:'0EZ9G7#P2_3"(GE"OF/<^#,!G"Q=S M@[[73-,2? =-

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|S! [T$,>/TSO MQ6%:$]84ZVM(]ROD\WKO^A7{W}^QFM([?.)"%L5?/8&#-I83O2+'!T,K"@P" M=7[:,N_R-DJ%"!YU(W>3'F"T=(V!"XZ)Y9%U1,D^E,G1/2'?]1%V*E.*;S: MRZ_IL?A,#=,4'!$YNB]1HT:\;L=_ G4EN$E46^9 +UK]B>>]X1S91 M>IS@1306+B&G,(.(B4 =3%!&.$NTV&5X+QQM!WQ5QIF.^:67<5SL<%)WTAM] ML38"!+DI@A!Z>>$&4:9]; 0T?XBA>7"2'_9#5C['P\T8=F56G#1*&SI9T1E* M:-FD* >X/9OM66)O69R>>]RUQHCY@,FZB+9/O{3>L%$T.19P[DEANE9&??RA M[*)IAA(M+KF5%+P^ID!]{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fMC=Z6;5FA&U MSI0)R^1XJ#TI@^,LKKDM* "2LR^)L %%= CNS$5K\2&TVK@S@2:$AVKSSUV4@ MCLF.HJ<*']?/S))9BOEXAMS*%3Z!=!D9 . ^\R4.-&18NO/BN!D[1"&6&A]^S/__U<%,EE#;>WF-U4<#;1X<.1+"]M#8$PW+O.%D8O(TE1 M,..8_'LL9(#=>RXZS' \PX]OSO_Z,*<@IDTB1Q[DE!E MFS^).O(&:[0E5?\2*F/3&)P+V\F304?$#!]4:BP!,>"K80S,+Z3XC:*IM>A0 M[,OP"C,RRD+U7F#E%]Q[B84@PP"FN4*!.3)L'",DG35|$)[Q-47C/-> M ZKZB::KO,PM5ZQMP"1.1*1)@HL-.TP$)5/|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|,T0'1; (F'|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|F2H. +U4/58G1+F'F;I8 PZ$A!C%J4!-@S%[UNY B\MXW MN\G"]QWR>(4T9]T]1=0B*UA8- E._^3B+.H;:^XT8<=Q"5=6W)-^5%V3#G]/Y MHMQBN@;#VD1E/+1Rf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{^S M8/$.PO=A]FX/C,3;W6.6QN@VBV(LNAFM5!CY44P-8$OS,[:"VZP8:MS7C&M-.M2G!C>%S)!:Q E>=FL4/: <4"ZZ_R)'U.DUV4_9)63W!_@9U]PA);(Q.@YRH1^"Y\]+&D8BQIE(E#GC MS69\8-TV=\6>GZCB;J0(X;]+,U1C3^LA*DQG("X MZ+&,:WL7&)4NZ3APT=8C>))XB/^HV4'"E1LY*HLP??S4XFW-6U$%D<>8DYQWT M1KK4J7P#K:4Y!MNU#-55,3ND03O6*7&9@%CG3;R.2!EM5CNB)K\]A[6Z3,S75? Q"0\"(--,X=177MUJRC M!>6'<>-I38MVJ}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{6BB@7)NVD$28;;F"%'8/T9H9UB$;/85*N$AU6>;P; MEFEYLSH2WI'V:FTSO8_"=406):TGC5+"]8T?'\%QDFLM!S'CL/2"B_,#"97%B M)_KA&{}?4(<&]VMQK=&P%/[/F(4P$6QL5(OM5%&DP]X&I^":P], MHW!?C]!' V)$H(Z*\#R\HJ- NJ6#P27D_7=HOMN/OVY1{A)U%GD2,G< M8VJB4T&]_!H_,:OL.MH,O8>,.#0.HE2%PSEV!-4[4(4,]W<=,LI)HLH>P_OO MIRB/UM3*>I<6.*:K=O&4YE&7M2"O\Z[U(>16]X3 M:@T1*"&B@7B=*",$'C% M=T6G M"BM9H?,WKQZ_10WZ8&KUA(5$A2^&ZO0.E]7- ZA=29(<=4I"0=3D"3#W]E3)-MHV57NK?8#>=FM4IC7,BW@/I7D#TQ#=WU-M)JDI0?P$U-* ;B+@V\;%U*QTB9E:<;YGF'.IRD.DO6B(`$RVTZ-E;NOS$&._MR_X] <&@/*0PWJ($R!-97S1-S8Z=&?WYID&Y) M*E)$=/EI?*;$K(8U?H?%?Z_RTP(J/>3I<(-L.!38F:..+S?T9)"AAKZ_'LF>Z MLWS,%I@*SCN6U3-_E=3T?=OO]%SP2!? V4_T8S=Y?!^H/S6)_&D@QL;18UG=S M??O.UQ_9SZ+NV.ISB9=EB0=5MX$@[.5C452N-S&$)@N!V=:<_R;FG,,UDZZ/ M6E-OJ$&D(:9.X[;,=4=_G? $_1C.;L0UK@4YP2(51/=ZQ0LR>,^2,K,YV#2MF MH:+4=J=/P0;/=/*.O-;&K&CS)WJ&;\ M-,?\294@830/^),#%O'&*S;+A.!D %0"6D"^-M:AMW&"%%\DSH!73- Y.@0QS>GDN$#RT^F>>0OMRVOTB3-N(.I?F!)68D[YCG'-MB:B)M]GNA#ETLV[ZX]B@I,N[!Z}Y%N%#NOZWW3U"G"ZI?XN=5Z2;,M$/!IG: MY!R8OV(2HNYC8#/\D(%#=O< 5_P+P!VJK;O1E-V8R,/6^=14<$90A*Y-$CA/ M6VL5AJ1/F;7>9/(7S#P;.%D^XR):8Y$U=+,2V2^]3@PL+RZ6"'<(!E!*M7#Y M2(6,>0P&/Y\P.*?,T^P 5DI#$:.!)0EU>F: *]AS"]U8ZLL0;N6#O*UM.2'6.\\B8WQ_;QF&8?'0N4 MFT&8_C3UNYZFGHEC99S+1(MU(8Q95E#R?4;^3!4340OG$W'@] >W5:.750SGZ M&1FK!6_/AG_@NK&N/.1 M1(65&)9(5?9Z;E;54C@AC!.CC9I$G4#U$-3%&NOT7#}AY6N*N2<|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|NXMN;[5,U_R&2>V8G3]UV[SRG;L;-=DU@> MV^D^>UZZ:!*2>$(1:H!4HO[U Y"ZV2* !5X $D+5WAU+ L"%CPO NN.?__EM MD;Y: (4(3G/WV^NR[MZ]?H2S"<9+-?GO]^2$X?[B\N7G|BN9A%H?'RU?OWK][(3@["\Y^"(+_^&>;9%_^P?_S%%+TBA&1T?+C;Z_G>;[\ MQYLW7]^_> [;$TF_PV3YYM;M]^_V;9^O6G.?XWS78?#QC^^J7[<-3T:^NOW M9=NS7W_]]4WYZZXI3>H:LD\/WOS7IX\/T1PMPB#).^(1IX4F_Z#EEQ|O%.8E MC,HIO!*VX)^";;. ?Q6Z0V;0(X6|/<@QE%1_L'>< < [MY&LVP2DFBW(^;(IE(^<$37]|O4@I#;8C<:K^M_9 ^7K)V(@FBV6*7K\]YF-22 M(.JZE8T_L8\V]ZFM>.V8M+LB\V1F3P:B98T86^Q+8CQ\0=8M+M_/_2HQ*?-B'_9XV-.PG4:SK;/2\,GE/[V6OA{14_*V0J3#5 =T7/\(#@G M*+S$,.HAI^[G/JDI".%S3V@4IO}&(;G*XO?LY=51IFC:(Y7O-UQ4/?L.D03' MU^P[6D.FLJTQ.CE&,"]/6AJ@\6;_"MF"1S=LPJJ0$J M*VX3+R%I.P/T_=\B)#DBZ? H>+3'))10*6AJ@\9&$&4WXVU,2*6IJ@DKV"!EE M!S_W2,U5>;">QS${O>GF'!XZSVI(4I8U12<_X2;D$7_-5%0>MS1%XQUF(DSZ M_Y*EX)16- S9%Z0,7M2;DCN!54DG%4EH%S7NG]I(M'A*F-TR\^_9_T%I(IJ'!= M__3AQ0)G#SF.OCS,0X;4I,A+S8MI8V)B 9WZI[P2RZH=D#V8O^%:D0/2O'=J MF8H:)N*%__SGWJFY6B R8R!\(/AK/F>O=T6BR=$A 0> M-S%"%,ED>\IL$S%RM:UZI^TFBS!A,%Z*@N7&=XD+MKVLI9LZJ)HUE"V;Z=Y.?A0@QM?,/>]7N8HS15++>ZZ1OU3M@C3 M]**@3 RCXBV[ME7OM#W4VBC8FG7 N*S4?1OD=Z/Z)9F&ZDG&|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{3))F-[ARK%Y_L1CK]*7&09- MNMJ94UU6L+R143H?"0II0=8E^VXXN61B 1HYWA%BI"V4 ZWJC@&CUS2!\,R4-M^2UCJ5 @P M) ,U[K>$I+U=TN7)=T3Z8E, .]L6EYCF(OT-TL4;*V#& MBH<#_K@JV0-NK5#W=<% <,7)1'O2:3D3C]QI?,W$#ON':DC@RG*/@+& (A%GR M=_FTLBKJTXN $+74 !W)^.FO1YAW67;CLCQF%?[-G[?1.9=|'O+.E[M81%1R? MFKV,'ISO$\KWF8*@1\!8V%VS\+PHA -!CO#,(WEF9P^1@85_N9'M^FF3QW<&> M^D\TXZ MK[(=(@&1O;"I\]ZJOOK+^ %Y3 M\YJ:U]2\IN8U-:.^I-=\4FIXX5G6P[P-;+!8A6?.X$YK.LK("%;^3L(H(9=0' M2Z95IOHJ69.A[6AHS2GU"IM7V.I72&=GV'<:S"M'3I&%-XA_&J:^.? M@26%<\?5-QFCHTR#EI"0HK51RC^Q77G[*21?4'Y=9#'|&A+HN_X U-DKW/3M0 M2!+E**Y?D/7? 2F?7Q9!FU?"|H7B^.Q/O-D>B4A77ZNS--PZ8:\JJP$RPIXR+ M'Q:9L5>=S0Y<%/OMB/*2V[3^IUH1],'&.7H\\.N#: JKL96@W374'?P)BQO MPO(FK-,V8:E$/FQB"W4%3(*AOL0ZUS!3VU,A"JYKIA7]3@*H@:Y@HR.5T#; MK"MP:.SC4,'0N33U'KTT8TE)UX:32]- V.$50_-#T&2K=@G3/1=.+5|[?A8 M)*1X)\K).%$$)#ZD^.LG? E/'[!.*>2X[>VQ"YRC^@+' 4*S=;[R>AO'/P)*O MY&:SXZSAZ560+D;G<%<\L;/I Y^^ MYBW*WJ+L+MVA) M+5IPE<6[']>O'((Q7O.P0#7#&J]^5$]*U."E&L6/; A'EK5RI6KG.-V @$5]N M\/\49L64_)N%M$F-7F$:K,WJ% MJ59A:B|L656@&3YB MR?;,8@2CJNOY5[8;6) :CMLUXC1KCGX&EL1$V['D+|T^6G(NE.7[*]D:I M_T#"+.? $A'DAJU0@;&>/6FE:*_ .6J,X5UD#A3[M.+Z@C)L7X#'WVDV-5Z)-XB0DZX-#2R+R*-L;I?YW)BLDV4Q";TT+&Q1*#\O: M-MX-[-W + ^'P;N M(?:A!JXWLV&38K8K4-:= QBT!;N"0*VQ L/.!*Y@H)9> M<',M?NP@J1TLN ,OQMA14AN%L88EUA4T -$Z,,?!F? ER$X#] L[DP.CL_L" MG0'.\(MP 0'}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|IZ@%/K&#>>R<,1 '?@P M=B#:'#0P;QT8H0$7!]%C%5&L#AB)@=8(TT>B;7F6@58X:@"$*!!D[*NCB_U# M$J;@\/8JO;) QVSK"@NIA?FF#INQ2VS=VQ)<+)H%W)6E@8%@# 9:-4L+@[:G M\R|N8- #Z8!ZHL&8R06>@8H/T&F9H*.?;&8U0^?L;4"J.RY8\D.NR _.R"V= MP'0=T%AVUSS)PLD2;,(+Q51J=>R&T&+*MLJ"7R-T/F.R'|)7 MKS'Y5YC%RP1%+V\">4&L7N? 32,:Z(VB5X(*R?VD2LX><9[$FLS887I3RCFB_B.X+B(<@D7P'IT0-KGC,V;4'9LW;&CM'P:DTXO$5_8#^QU+F3Y M9]J=>T^]DA;(/TB[ESC9))*V+5],OIU+OXS%QZ:9L8T /K^XPVM2&|<_)Y>4G*&?C:&M7U&O ^86107X?HDF5[G'+]H M;#*"""3ZCQ|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|HO6S91_^/]?XR'X+.]S:8RJF]%-.TD=$%G0R?20Q>]C(:.5KW".E MMSB[+U)T]O;IQS/VZ;,8+W,47Z?AK(92<>,..+/3:M#Z2198#2=VW-4(1'%*; M>(+!;

*{/DN,X7X,Z\|59N?_*H08.]'C1-ONY/91DL,O!-M#_)?;#@P';_N3Y MP0(#/L]LQ0#29);Q1B'[.ZP*X[$!U4N<)CQV3^,7=1BBU\5X1OWEYSN"[C9D*-)OU!T,W!Y$$R90O:|]7?U7Y?S7 MZVPV.3^DP.0!{&9W)=9B0W\.T0)/I+A[D(/>F(E$P'ZV^1F=UDW&C'2; M/4#5W"CMGT+R!>7<7/N HH(DO#2P|#6H.QBE_Q9]/=A,"<[8GQ$ZX C8.VDZ MC-D2#\|I4!R;BM;CH|S:/?ELN19,#XDPDZK@QPBXG|EH17X47/\ZA9=XL409 M+4^YR;)43+/XIKSN/EFANS3,Y!M!BY%\E+0#4=+<*(#8BY[D89MR,F M_C&:1+RCU=?HK#Y3)E]*I8_H%47T @^YL3O$?32O MH="0@88*^=*0HX(6"KD)K=&5$$T]I&3RG"OA MB7J(:"JOK@0P:FY ^E9O,% #+W^O!Q349@A&YR>7T&F@#(.!^MDEH&"&U>(*=VF]M":?15,8G]=J^,%5D53>,83K:XIQ2Q"N:ACPA M*9YD]UP*YY>2ER8"E2.SZ3#>R^>"EX_6<4A[8V83>+^2'!;56>DR?RY,FY M:NRV>>_ |PX\f|{1$)PVM59&AI)3%;UP!^"9&-E:ZSHR8:PH\FI*?*JFAU5 M3?9F0+J8^M6:$NBC.8J+JG3.QDQ]R=;Z=L-45H74[.Z5*Z]<#9G.TU.NI#N1MUYZ\|N2U)Z\|>>U)K3TU$X6L:DT_L<. 433'"7L%-$!_%8R;FVE/D*'L;%%P MRKPVU:LV|7ZSN@^=\P>ESGA|WWWYSM*7_\1]^7?ANG1%2Z6Y_A{0IQH)84V0M.@GG<5/5$KZ&)%;GF(XFY3F M)(ER%#|P1I/>+2)M:\FX48|[25\5'T3/HYSM#/E:T^S1=F!;>!QL%U?E;L'O MN_@CY(R8TPFY3V9SP)T@;<<;0 XQ9.WM=ZHLYL%CM^%"<=5+CX_R)C1O0ALR MG:=G0@-)7|Z4YDUD)VM*|Q?UE:';7I Z8KD*I-LE)!"I7[I))*?@+H(*Y@*&\, M/;"T66+F;F*F;J6SN;)ZQ(#U;5)T9?%IL5PGUA)7OHEH&A6 M?@RS.)@A/"/ATF'W4!N)GW^-6_8K@B\1TM,>&+(33;%9%$N M9[8!5C]JF+6;C.8-M-Y .V0Z3\\ ]!5O>4.M-|2>K*6QSOZ8U(SS;ZYI.0* MXRA,2:V5!*OZ^ME9P-HLDKRT-#13T*5CV-'(21Y%;Q7%?PC"BFZQ#3?EI(/ MV#G4FK=^[SX5;BDW@31L #]ZQ=(KEL.D_042_ER|9JDUR2|)NDU2:|)*E2C MIE*<78TH8$"$6?)W^:32LOA44/8>F7S^2@X5${V>1@72VX+!*\VFE|SD&RJ6<)/|-M,4^B>87@9(F(Y.HK6=+5_5Y56N$1UN3Y6)=(?#R[P"$/R__#D#^':QJW.RDMLBH)OPO2Y*\BB7G6$Y?5XPC; C%^8TE(6;C2V'6FX!:E>'NY5'N97';VX M[HAIFG77^_]3)O/#>S>3'$0GQ E+_P.1+DLTNPV62UY/TO(4E.?L6Y?P|WA&|M2MABNUA_9OO}35;MJ8RZ3>SY.1OH#Q!D=J:X(^4F8_L5^HBI:"XU+6T1?<_Y M,D/Q|C*@\R@J%D7*N#9^C|C6FXAN7%=WM#4EK]*-4'3W*IU7Z;O*YU6ZKE6ZM!L=4?_PR6)0@ DE_.9.#@Z6EZM%?CN0PD9(K&& TM"_Z'1P:'>@J5HU)6I?] MM+,M=?$H.Z:F[BCWEB?OB=4N[IFF^"LC"UUC\AX73_FT2(\O@!8HD;#.EBQ$MYXP'XB0M^"VQ^[/UZEN4%FR-7+-MF.?>%|6JGDQ?WEY\ON#3$$V\B[$MX5)_M9;RDMJNZ@W'Z#^E@1R.A:P9O>=V19 |B3A;?Q&?&&.7-3%)^JVEIB>;::ZLE MK*-H;91R@(M_UM02WG6D;$K1:Q"_Z6%K#DPB6E=D71=93*45A^6-K40I[>3L M3>Z;*C#IJ+TEW'>5B_!YQ/8^=N[$<<)/)+X>F;+#9-6;[*%XHNPL"XEX.6B/M8VF^^T)QI4=6_;? ^M?-A_3."A=2?4B8T2DBW&;S@,B*J6/9;#*M.> HKV5(MZW^2%IKNXQ%&.?K\|$C*>R;7^Y-'NKK4'8S2_P?B5?*8@+5B^_<,,,;?S4F2GMDR)GBGL6;Vl.C 13TAK#V20K[WCSCC>!Q5.E$F 3&Z(K8)4\|I"NFV%&5?P M4[M H<8/5YS">AP%4=9<04;-*R!KARMP:.SC4#&O/X_P4#BEN}B2@9?#];$EM#=R\K>TL)QAI K:YG5"X23.GQPE%F6BX54XPVD3#@0!&YT=GT&GF\P8#]9,S M0+6RA('Q^MD9O'!)*0#C^(LS..!%5%{BOLA2#:7BHP.-92>N38,T'[AVMP%450/*5)]#E/TG(KW=$G"?N!=!G$'+C;0.]3A7?T7GZ?DN@]-MH|XSVER\!>V:N/G>Y I.:MLR_/OQQ1L#Y9V&PI(K,/G[5;UGIHE- 2Z46[4L_M_!B$\8K;)FFLR#"64[""&]K8] UL67*?4*I%<@O0(Y%NEVM ^^EV[%GD>-\|FJ?/M30/GU\G.MSMI-NM<:T(]LV(-%+MKU*MA# 9,HX"I'MW1M7C%'Q&@G2L!KW]X+L-*1T,OTC")"3,\@FYY\$ZLHXT'L4X5G&B;._'G[U&MTP /]66E>HIZ<-&3LF@ZV8"L9(MY2N?/F)&^>'O?$9,(/HWRO=S;8->D^>YAE_%*VQQ;,[B[U+]8[YML4]M+<:'\S^_LO>SL-2)9I,M'V'+T-YW"UDBTJZ-3 M&H0?YV%6G3"T/"W135;-KVL$-1_-G2?9T/N%="N810]9ZAX4>F**NTT60PZ MO?M\U! P*XEDDXGF:)(AZ1G48(2!S?#Q*VXYPZ,1+,UPRVA[/CQP"@'GJ#&& M^5G6N>F.&]CNO0\'=:IJL-0_?(N^EC^)L89TML4QVS)4ZP/U4&+R M4,8W2OUF=Y706|/"'H52$;>VC0]W!BS_L4?\^G!GH>L>FU0!78&R;K?@W#&M%01]71(8Y&OP!0/U&8V;6X7'#I(Z' UW$/,U=I34KE\L-.0R&I"%)AX[$R: M#F2G 88 J.Y.8K(/ E+W<SO"+<$!HX3'#@3H]&F9SS'VA03'2)6';78DX.>. M.!)G[*M&)=@W2(@ 0S+ZXOR2J'A7^$)1/0#&7(+QT"X0/C2F4(1SNL(8(-6E MA3/6E<-%N8 H6|CWU'A(@,#[:]RP,90EU5\I%^^]$H4 #48XP5(NS6(&^MMUAPL4- *GOQUWL-AH M9X_T)\8-#],.RC[TIS$.$ZV.ZK/T)QT/#K8FN4_]23Z#A:>O5/_^)*C!0MFZ-M>08,W,Z:\>4T#&'5S*=4@?Z"NP'@ZF.SJ#H6HI<&C=43F,E5*! M@SM^7:5W<$$E5>"(CU_?V?E&&I5%@R/ECHIC*T$[N==I=M[U\Y'BKG?*]5JSP+Y!.01<]_6Z^IOR>O+MR$XO8+LV$#U)RY|12%ZNL%9C^0QP M?R&0SY!M#8W/D#4413+P0"P?1.+KKM431$$T8)%]0ZNT3)V>?:*T,;0,*M[M$2DYP+.@\5^XF4.'$'KWYZ]=.KGU[}].JG5S]M>>;@IY-56???(,)ERG@5 M)]76P08=SHY$JT>=%V)[%6+?)SRS]]E@ USC@H@O?)0V[)8041%R9;MNR7ADM#6&$U+3LF!4;T7)ENP(N.(!W=R0)Z9 T,11'4M$ZN:H.7@=+M=Z\NG;=7B"\-M><#O;-]4T+!TNGCJS&E:UC0I+,'*U:NL%%W!,C6JZ!)>Z53<0?MI_",;DL MV'G-UFK=96OR1KW35\5^?$; \#9<95%NC*OQY%"S*;T+UUS$E-ZJ(&UKA>I[M%*%D!29'$N1]0K]\0E5+!U4U70%J0:B%(8+P*B'Z@I';EZBGWKKBXFZPS@,3K"GR-V,;MTMNZ)Y>. M>;"_,.NAL W$X#]V3E$+?&H?Y\M@Y 8B!VK4^=B#.'#0P_T=_.09#9151- @8 MB8'>9J"/1-M"T@.MQ=X ")%K?>RKHXO|0^+X=7A[E4EE6L9)5UA(+MB!R.X\G*#&>2$)[^SM?!P0,.6.Y/;,('DG]"Z&5!^/H4A_K]^Z 9'8^T"+-0QEA MHC:=I)5=_U=LJ:\XLGY=!HFTF0M=?L.R9LGS^{JBE3=.DB;ZDL55V66ITQMJ;ESQEX'H>SPOV,"20D"$X8O$=]W\ABK+60)=MJ= M>\\\MD|ZL>Y!7)K^!USB5_-ZI4L#AV^4\63YBB1398@2;V7)L$V#?,%4NWE8C MV\\MQ+V:881+^3<:%++?;G$6=37A9\-9FOU%F/(^CP|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|VA4]+&Y+]H0A&XI+K'YP&14E>]J0K(.G2*8KNBVH:+.:5?!'0*^%Y2M5O7I MTI.K*++\P!X9D@2SMX]BD-,[_]4-C=`Y,:-+%+$C!<7"LL_*MOU3NUV^6U($ M!;:E[7P9\!,J^[!*#W1N9,IKU:B< =06YM4/ZZ?7Q MZ^:]:]?A=5,M8ZR}L:.C%I$PEH2GPMX^#IS'=K=(0>G,YZ8QMO+:?JG?/68 MEUZ94ZP:_^,3@!{O I]HG<4R0YK0,FO-NCK=KAO=OUWFT=1\D)N;8;6<9/ MR(VM[\KJ;Y<=)CA:'BI,'OZ(48,3)"ZO8M!]30,\#=AI.0^F*?Y%@R(+BS@eY M2]0^_D;#/F554YY7M*ZCL/DHO4QA4Q@PFWWDG^^3V3R?3#]3=$XIJ@VET!PBR'IID?Y'O V<>L3;.M^-9\#7K1A>QZ8W0[@^TYP)X;_54D!-T1'"$4EY7_>)$9IIGAF;_OTK#49J]8MJS+T61;WH#]:OI.JGM(D8JHVXH7_9=FEXG9=Q3L\O:QW48IL?$.XR83[AEY/ ML[FE"\RV@;]+@K@=)_^S6<(K-_'E)4T3A+:QM8Y1*K@#Q__.%MLF(+B"VN>R9"D"1B&$I+_@2VBYU\A" M=+.$|-.0?HI8AI)E,BNJ*YK8I3&RQ^/2H'RKO]&D^DC 6!3CI=1[(O.Y1A-CB%X=M0;H.CS'WM+7D3=% @MAYKR"VU69Y*'KI;GM,W)T9G,09_AO)R=JGX9+I,\3,^?:*GO@F>E&L#R_.X(M6C)U;5NG;V.-8A+&>))\C(M68F@UF[|5NLL0^WEQ/F/B$R&HC ?$,L@@OT.V1 M^:917Z.S^A22+RCGN]L#B@I2;@&?,_8ZTN1O%'\(D^RC^(YK6&=;+XQ!RF7;M.X)728SBB_5GBIA@NPFVS&;G49ZL9-LE? !+,C"<0,6NTWR@(. V!S=XH8*.AS'=WYC5]HS4##.N-UA#8{(T"!C(Z7ZEKXM!&NCG< M!;-M.HS9ZFXO?0%U!Z)@@]"-MHJ.0Y_&#:4%MTA,IKQZ *XUZ&OWLS8;[J%A M)%N2GD%^8G*G4YU7UG0<:{/](^2ELO.K;%&%BZ;@P)]2+Z3E,DUPB>>X;V"K< MR;=A?LL)KRB%BZ=\6J1;BX&89F47L\E9M;7]!=37-[959E)599]*R^R7[JXL MYA[:VW"AR$CK\5$^I11"+SM F-QSS>. %"(2I(L+:;$C3\"1O1V?X7@Z&8[U-MH0DCMQO93/]'B>=^%*G4GVZ@0]FOW E#;,;S:]XK<$ #OSJ M]78 -@YP'\.G?:GMZ.!3Y!6!D8)?:OMKA53&!.1\TW8D@+4,R !CJ7W[|9BX M3M].#\9-^W/,>+6SF7KBE#<]"9O6)A?#WJ6S5VO 0Q2$ &!R3WPF=L(*J*> M>U#27.)3%I/<@Y8V/NBZ21#N06\;Y0=QU6[HLKUM46*)Z1DZ6[M6# M>N<*A-*$'5=4N0X/$]UR'SUH=>,[2SHI/ -*7M?7=0I@1/@8@VP>]N^(:&;>6)-M!"LHNRO'S*7 -'\?N"[\M4)TH9DD@WLB7=`I*Q'8G- M1NB/|- #M$!?C,?P&E570M07^V[0?51$!V>&R&[#)?2(LNB\$5\@$8=^06\PMQDC)[YYQ9 ^OOK_&1':'?/-1^IV"UK%*#[&L6$)#\MN^ /D@[;/H%==+\7_) M 428#]IO>?*NX"YR6;>;;Q'RX(P.8.BW>T[+ ^D17D*NW==LX?B8R49.;N/VM$YZIL/%O2J_+!O4Q/(O_+FB^=2?4DU>?I"/J43*Q,,-WU=+XAY%>):5HY2K M0PB$F<>:+6R^-^%*N4#8SBBU5Z60SZ%E6D662PN\2-N:+16',ZZR,FV'C3JfMX9L!>GEAXLNB<(N0ZW<-'3ZF@E,K2F\Y>_9RB^"DG&WFF|%@EK;+XFTT9B M$U!{V,32-1BZ5-JY1F+GNGRO.5'}12Z@/%K]B%*SBU,.!R:C"$UYZ2MW7A1I4 M/=I,3BIM)EV@PQGGK?H;_E3H_D==+1[.O/:V^[)96:GG Q&?PNT&&*\04IX MJS$&,\N&3%O?=S"SZHAE86,-9M9Z-4$;#V1^OL\.Y)W7\(YG)>/L/&>OYZDH MPPP?<;U2)<.@]>"VI.$1(&-' G_D$1<%69>3}(P:4D5,V=I]>IX D?=$"GL]MYHBA9NNQXZ"<)=9PA;L2)]I1E5"MQ(^=0_2FC,$F9N>8!8]+A@/&N90R*$80 M>ZES^0!0<.#.A/[B?0<.$5#,&_L>!#F]6WBQ7:DLHTL0P>E%SN++62_AE6E=C:=8(G3).(UOZ9A0H(5GQ=O MO=C5Y0SHOC!GS.,KTAU0ZHHT1L@P7J'&X*Q@%6N>Q<.R(;^;X=6;&"55*"S[M80\!*H]?!/R*:0$%TKIH:P8W%/P1)[S1N569A_TX-OJW#,@W6B#"-M$WS M9,&F-YE>,TK++#73W!Z_FO;.[@B!#%':3(8S.<4?-Q7KWY\21-@I%]_1"N4M2C(\}3K;FM>G,D*]9%)V]"6RE%5@+SLSN>P;?#V$&!WQ-CQ>MM#!%HS&,SE)6X_[%9-3E\$T5@-AJQHT/F08C^+1[M\PGJX\]&L"SGG4AVEDQ7P"K=9NR3;RA&XDY.)?!DXJLN(/SPA7.U*\@6HI M?R'0@V>EYQJM*Z!I\1)82W8%G0ZV=I42ZTK$?!+=0U6K+K@3 =PM5K5KN"E>) MMR>EF=H5;AERXM<0'8@Z%P5:H';<=TUH],ZX7!UQMEVE(Z62ZR?.8D/!+^X5VVQZ'[OV*-UG.J*%)5%=%OHNA.IC,-I>.W[W%'TX/GOX'XM^@^'S% M=(9$S?XT<.^?T1D43>;MF/U&<:A=\J#@C*:" ZFJOC+SH]R/>Q^I)M?Z=F+ MR:<.RU*=0_OSME/%4+6/Z$SQH-N0WF(!L[%CI. M5Q.&P8$)X9L&!QX\2/=]D_EADC4+1"J7/.B%K(.E3-G'-=B `K1#,'XS7^ MO/-&UB0JPN//-F]OLP*#!<\Z_[4"*RL9>5"IKVT-^6"P1!UOWIVO (P7/-M\ MG,REY9D HZ:=CSX6+FOH\X#+K0TE_(%F\NN:J. X-13PQX23KNUO.$4!|"[M>,G)',(H3U;\IRX#+.."/&5+{A2[5/@BCUR", ^@+!YWS1S:H(YO6^R5VXYE^5 MU6PFY2\DG/%,^"5U5Y>IN]OY^WID M3Y2D#]>V,9NROBD-4Q8!],A+GI^N:F^4^FH=('[T%K(T;6$[>]1*$V1:7RETYKW):L/(C#_7H]G%HME(?N;GK2HY+]>]*H M$#NP]T@C0HTI;ZSH]2H<'3W'UE7-H\7+4GA=_ .P<'X GSY^-7APPM@/E6RJ: MWMXH"\MNX M@H>;*11Q/*X=HKFMI)7,D-; V2PM+B"DZ^H*//VY:"<^A-"+ M'C+DQXQTMR']IY%(/\"@\U--Q.\]^O54, LO$Q*.IM?'FN8$ MPC%V1SVS&6 %QWO4^IOUP@EPG%VH4]9A4 T<.+@N-P+@C&>[PG%V1Y.S$#(\ MQ&I+T1S%15I>C\R(8<1';!543;NMMZ3QH$%57-*FV]=Y:+]CT[]W8W#=N# M7DF:SEO:SOV\|>/KGR1YOR&Q_D-Z1O'VV'+NIKF$0P'QH2N(==ZZ+!P M]&4I?(KGR>;_Z2C"/@/09P#Z#$".?\]8+/P'L1*Y@82(S9RQ!(3XSQYA_L:VI MRV?L#,@"X]Q&8.D-R&SG/>3P.!R^T-;HY9-[!F#;\BE!?5F[^LL"S$4B;U\SV8OZ.ZQD"UM@*W7OV%+*S3A?37X9$K0F9XPL[$*KK]E9L1TAR4MM@!/(CDQ&#LJ87"IB<4 /XS/8 M|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{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`TX__0A:LBG)\>8"YX_MX!.(]BW,=(7?,SX>__G3G^QT=S0CSAMEGP7'IR)9@<718%=%@6/N.;HH\!^YYG_(V>"+$W]C\)$^GMVS?XTS0, M8H.]AK_ACEO*&U;/.OOJ/U"C;/Q!!Y..O22'?_8:E!JV1E4'4/1L -3QYY*

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{I:V]]S>S3N.%JBKOSE[T-MXG]FZF/-VZ/UZ;3<(?+P1_^[YAHTI,C$-)A,+6=.'*%/0W90^-9#-'_>69M-0 M%+OM<4QH #0@[@WT#"9[+X3>$DERC9'4XEQ

*;PW*4NHYUG#V/_]BWC^@L7R25PFL]2LC!I=U3HSP-P1S053E4-HYH #]/3^ #VM M#]#@=6H&*PO!*R-CKIA=%H|A(\ZLM),UNKR4]OO-%R?:6R3?]'YLT#COT7 MLONW8!G"1VVC*VB41Z<3XV3@P:#!G]FC/)U=9V8=I9TT?$F!P$6W0$&|<>9 M4M#WN]$#F=+% F8(GIE3E+4ONZG 5FM#0../2X3&_(+8^GH#9 M"B0,+?0>"&C &;DE?HB$A)\M\',Y\WP"T/GFGCP2*?5WC#AP%%:C%((T9R6-4I_?-7^X[C138%*BHW*G?U6_ TFAUI M*P7S_L"^C887/K;7SLS=.+C+J,+:X\'HT0O:,Y$7X]Q0MAYH)>8C;#G,>RG M:&S!P&TYL,/9=&J9Z0/!0"QJY^XUUY_TO29H,W>Q3S^#7M4_,+V4/X7L8T] M4+RC?>EN",3B\"$8W:?`)AL)MZ,__E(\Q+N1C>V8;Z8QDR56(=NX(>N:,D< MFV0T>(4))W5A[T8CF#6[!W;SVTHGBR,:_-:KL^W5]L.`LX24*D@-oKAV6H!;W SVTHGBR,- :KL^W5]L.`LX24*D@-oKAV6H!;W SVTHGBR,- :KL^W5]L.`LX24*D@-oQFK_:&%DJG2F_G1JH%- +*UH9'RZ4[SI4T# M>3=EZ4YA0W9N97=#*Y73EI374.[9S-ZFJ>>&9K[5?-VNU$JRWZV&U GM=RNT M,8NHV1 4E@94"?18^.': <8FN>9$[E$SL>Y=XID&Y9QL;V9TTQ6+:*PK%PNM MQS%//)2-",IZ)!Y!]JO&9QQ)KH:4"2P(_&[-|>LJ"1106 M>?KJ&2?AUS2E\[<3SYQ,+<+2&-(4U<.U^V,/K= M\KM%,XW8K;0'RU<$WT2?HY=\6!F+Q=A0)<0&)E@4C)X_88N!Y#Q\/5L(C!X1 M?1=]HH](':O0\LMR0VYR,,!!]K9_OFS4XD'A-[N.&3"G3^<%.LL%6Q^[6++F MF0E69:OQ6SR;&H7U)X:Y]F?Z59A\(+V%6&L `4?&;SI8[30PE4?U2CY-)\^ M1H&$';:=@%7W!PX^&O"R5\H9.W2C!,.UY24*D@-oQIVH1;9S M]!8V65\XTO36VV#7G;,8S!W]K3>_IQ>OB.U.3#OIL=LZU2N/^+#:.^O? MT^%^GM,YR#SGS=BHR[%1^1P;=?NQ47,?&YG[L=EV?IS?V*S8A,U9B;&T9KZM MP.9N+!7_F_YPJ?Q;W42X@/Q-=,FQD!SZ6*,5POI)7>]3F*# M.1[!I>M8M'8#6THFT0)+Q86WJ6MU$F"'"SI%:R"^U7]P+++V7;#/HL^HG \CZY\E=?>$U9,[2^YT*D/0[^8,? Y7RT?G& M(DX)=L%EO:%52:F.&+\I>LUI35@Y9/|@',:@:TZE"|'C*944&\9%*BJ"C&_P M+++P.XA2%]#%;!3?TR_;PN)O>;SM'#/@_LXY"\!? +7]L3/1H#QJ!,.>X/0T]TY(BC8<7(G]8E10;>HJ5%R%Z?#P+ MCP//K9 ^IFS?1;^LN-E(2?N0=Q8R^G-'+'ST X]*W.@_'JWHT>^LM-!-]-H. M$$W+L]@3>E\E1=,.+T3THBHI-O2&*B|"\&JX%)Z"1;T*%);2;U66[82%CDH-MA(B.2B7%AHY*Y46(C@K/PN-KV2^_/B947\6]A"6L".U67C;/#=PI"Q}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|T3,V=#S4+7&BV)EZYE;G47I2S2+&=KM5Ni5;]T]A1*$6 MQT,YQU". #P|H6X?Q5:KEWZ M5I5Y LZI"V4:2"/:,&W/:@#QU N)>9CMQM*=RVQ-:(^!P3>(04)*S?V#KMP@NAM_ IQ)1;R\#E' H.MW_AF%)=OW7XXBUS S?58F:4K M@5A#K.WA:ZP \\"^

A=:;F'>1EG- 8FZKS7Y3;,5$*W^M@2]Z3"!UP#:=XF@\|)OQAF?I/[K#$1RL1\ I M&!%B^M>@2Q[ ]{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|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{0]M _=LIB 4]P2H-*3>TRLHTPG3^QGGJZC;;UK,8D.#[04I7Z61!K#6O,3A,IZ? M07+"("I7U.&"/R$C.B#!S F$E+:G/X+L/H3,OT;\FAT\8,L:RC/+E4NC.(X MY_--*SYR4&KTT-F#Z!PHQCC@Q@S&1M@$>4PC#IC\ C:H$XW)0MA1M@.Z/!>8X,3.^!MU3<$11N)]P*#1);.?WX?Q A**=" __,(M7SYU)+(R]|;J4; M\?O"Y-*5X6&&I3\/5M$B(YH&G?S M<^F> G7;*&_IUKE1>_MHIUZ1/DPY5M4T&:SMTXAP%WT^AL'5!OY#>:PR?9T MTMMSUBG:G!5VA2J{\G7O FAI#^MNGRTF.*Q-%"KU Z(O%/,Z>+]$<3O=L)(G M@0GX@^!-!Q,?$XM(Z3>4!V!2"DRGM)]@EM*!RB=/[<>[IP5)K_1"]02^WUB MF,4E2^Q(("H7?(#CBX@[NM)30^MJZ,H@V_\S)#*:_TTIZMZQ%<4!HBTU;MUB8TNE6OKO<'533&S$)AO82SF_2[^S-%^S%&VY$]RPO,7+Y%G!C/!+# MURY3D#V2JKC/9*$@YAV-M17"O1/@GTQ (5E(OC?EX[SHZ@ M$6(IG5-3OK%V6JPF4S@I,+I8JH#Z>5BV.Z]BW\,*VVG(S=M!F]&FPD, (HLEDV',19D:C.,"I MA"Q\GG W^3'#G"!P+OQP.F->S2N&W^*[S,0WF ^U1K&26,':%F@V$_T6&K\<MHU&-#X 7$\'+!1G+EL%KXZ)> NN MG@W.SLHL]/R07OW"!J5N7C"KW/4M?`JM^AVYBJZ%J%II_Q>G%Z1\%(C7X1 MPV,\"OV$ 3,,>X%Y89NO(-[4G"DL?#N*-,5!;(R#Q;%[/QDV+P@6F3/1^_!7 M IYAAJ/H2F6!&X";?HUB=[F$'^5B1E^E7&/1&V,IN<[=.(I+YXY_X;)(@>P MF,BRBK8PNDB:N0%AT0'?#3U<;@B_VAA#Y#>)],9NC)<#=!15L<88A?#.CCQ& M<^/$^X<[2L.NTYGMOA$,=:;,"4[7IN:*H[RW/F1BI7#^SRQ>PRZ%RF5+,+$\ MDX7+,*GR#7,78#!KY$> 71XE.J'A]VML6M;^".2E^(;=D*N2=@8/WAOP4R44?"%!&3JF7(S3]]=Q9@4[D&L M+9":*+,2AP92"!L[S,@+N<#GN\FL7?7\F]??7OR7 M7IO34?,RI^$@6*ZKPY3#O1H#1^=82M*E4;$M#'H$!7,[(!>C,#*#$RC46$3 M08_1L-D$5!7{$ -<%CNLYANGB;*EJ! T)'TU5X+Q7S,H) R 1^"Z]/P'A9UAV MB,/;QA-\!>5.B"$]6+%)\)H MTJTSOXOPZ[O2W0/*B1[+7S"2P4:C$2QY.%5M?&&%@M*44*KS9GP3Z1=YLPC M(:IF+;]Y9@=SD?R@A@7$]H"Z)!?HQ26+-R|M-);;R2'AVA,FXX;FO\9_F_S8B M(&.S><.[R Z.WE;FKPV8>Q?-*\DASOZ2^;G2[.*2],+TGF'2]F[.Y?'NXC?+ M^2-*43C <45$- M3/K-M=&{]O,OES3A/|/Y>Y:>;CYYZ6JMD[6R.8I!4.(RNS6)0F44=$VG,%_BPUV9RF)-RGMS[-WH!_X0V M1ARR /L1Q_1,ZG]3^]2(Q0L\%N\L\\)L,!"@[QB7[- WFX>KB WM/%,4(M^-:NH8*3],AV=]OTY<7 :F6;.\@JGO;]=#3XQ]ETCTW)3$ZX\CX]RH?B MY"")H_//<{M)@6SY/U$KJ\-X_:Y&^81^;X1BK3],FP69ID@-;JW09TBACF5]P24;L7@$CSBK+W$:Z.7<-CR('7(*[M-**90V[6@6/Y.83Q,^B<9U:ED%#]5Q:)B>LE2@WF_D_MYOCN;?YM[Z/"CV^ M7O(2#^ V)J=8,JN;RW=T$C@'A[P">=*L7L:#2]]{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|(X'9IQB0G+4]_@-V8(4,ONB6 B/=NO,[#W@1!:-LQ\&%'E;%K8|CS* MVW+]%&=(_26Z_KIG,N >CAD8>OE%4T\,E=;.NVCB:U%2BSDV%9AGUS5]ED:CT<0\E;K"#M#$\3)YMUP1T8FWAP\\2;U042- M"\\PA]VE316CA.:89JF\QS_CEFT>\YS#)/%W.LPG:('DP:9Q+O7:(/&,PD M_02!P!DD:."ED4SG8,,#=\8'YM]J8.0EMMD4/8II)E;O\033-B)W,$IW30WV M1K]BTJCA*$@?%D6E&V?/+LJ_6OZOJ*U*M->I?X,^5,TH?C@ M@(,('D(X)I=A1U'YF;&+1-W^%Z%VWI 1[R@MS&V+D91/)K0^*$\61A3 MI?;ZHK'=#$\%$5#46F8["QOSX&[0%^1W)"V>,4^Z-/^"(O?:6D@R[!:/W,ERMRRO*#0:O:$8%*\1D M<%4&31Z*<^FH3EY MQ,#LC3/E/EK$PN19>^"D+)WPGDGQ3K/4+Y.WP*/I7E'%XUR6^90$$Y<=R'Q% M:W3]37%Q\LZ<.W/+L7 +0TGIK03G-.,M8KQRH;UHS&Q3)CSQ\C2;'7XU1HU MFN@)T^2>[:.8[Q, MEJ D:Q#'JMG-K==^[WMS4[+8AQMD.+$K9!PCZNQ]>@M7P:@TM[W&S2EU /W#MDHXPRVW^3AZS2-CDZ$4_#_BD\S^2MF8O@*"\;ZZ7T;R+XF-+[Q44(_6H6W\_3\]$2A(I:;/^:U+(B M9$2.Y<13+%!PC,%)]"=QF6RV-PZJ79_YPV:42&JSYBUCYE.^+X5R\R6-MFP M'+4<]"%^$CLT.T?V PIOE'XL D!%(PU"G,7'!;,)S0XKC9/VW%H9CIWQE\LW\AHEI,"3'BAG^XUGH[#V5+2[$(5"1[&*EP78F,5'S*.I^T+S4>*J#%XH]>2[M%-@P04VR_%2T89S%0XRR2&916_@(AX^GHH0!@D91S::F^E$%9#1Q7&R!A#DIM](7^B($AI3-.8#2+WUFD^[L=C1F]E,*D2K6@",:&O,9(C6CPVR&47PT*D>J MQR-;(;V75TO$8(@V#T5@;52]=BW3TRPHF&1\^&C!H7"@6.#)1KZ$R" S6'M/_5[U*XH'IS;TO$;+!S/0HJQWU(&]L WB..US9DOI0*4N&]=[:C7!0HD3) M@H9YJ[-X713=`D;VL/>O?,YLIJE59GC%QS /#5*!E>>^X9Q!MG"0&DQ3S\PAM$U.C&%;I3@78B8EVZJW.)@I$?6,_T:\\0X+[=/@R%\0\EHO9F@PP.GRVQ&I&[44X).,^().A|((G^\9MIZNE>X3U;H8|"EDU|%,4QL4+#130:&=%ER,>]2M76./3&RM(I5?4J$VP@NB9 M* [-9F8V8C(%'SO^H7HSHPH0EE>&;7>IW$X_;O@<+LS_6)I^W2E(O^X5IE_3MW9N7.[_S)0S9"])T;/JL?Y=,FV[VINYN;Z .NEVUWVH5](ZG4?*RQ6KY7:|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|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|OI[&>M\GZIHM/[#,3Z@ZK< M3!$ZC,1:C0W#_30V92R\QPG!"R0&*TTIV5;.2Z>^-"Z22P:H-U8!@QL#\ZJDO17+','#$WW-"CJ+/7 M6(D?/MD(%\6!E7E#607'MDDN:5"H'GR<;V2:!BB<5(H XE+Z|&'NE!%P)^'% MY(?EI[N=9V;!O)]5:(A#/B"Q@'7FF+$)O],Y@YQ@\$ 8PHDJ].)@"OS.68D3M+W@>H UI>ZS;8WF"M "!'R'$S\;-8YO#= K:S>XP1HKT:\:P3RQUCS"47V[>>DS'CUR@=MLR8DLMF3LROD$;MRB=62QK2KFR5\0NG4'ZX7$;Z"EDR/1+P"8'<8L\'\'+35JAL(PV O!1;F^ M:C/,,8ALOD78T2HI8>4F[XCBKC'3:QK:@35C^/0SC^#B^#HYAC(WSU(XR"@H M0@ICCT_COB)$)/ JZKQL"\3R[5C<^O>\SX\'U.68?HR5]&&'^X!W=>N\&AR4 M^-@V6A_?2-I\"0-@EA,R1,_X^/G$;J!2!,8=-QS+>'Y& N'GA0^"H\>X$9X&MXVZD_!ML>]^T1CPFFYCC]PW)^H&K3 .P8'#TFLS(^V;HK/VWAM'%Q7 2MU[P MMN"9--3(&DB'?'|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|N'I0[FZ5B[O;Q_OAQ>.1)T0O%9<&)P*4MBB-.!B@X9T"P&!G$TC1:.S:&'Y$PE(?'(3 X(F9A@^4< *_P%A1 TB? M!1I9"=*384>-+8."B>R?Z5<9>P-^Q[JJ=65^-P\K>B7_(6+D.R>)4X3>"'#3@ M9C*[BS}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|]*Y<)B1H-$Z9&4N@VEYF6/E5)JC@>T#KUF'")O))XEQ%O<1BZP0/\OCE M\=< A^L4<4(B:2]MTH-PR_LR53^/+[DSHS0^Y%7LTJ7IG\V6VLDI\:B(SS\(M0$C'3;.E)*OOU3K-)=R5#%1AP_/24I&6BCQ^>?PR2F]W'D7$;7LPOC5-4UM5I0.L\'6'YEQ?(3, M4>7/53;OI=+;;"@6*"/ O&52#K'.JYK&:+1HXNERB+K^VAD&B^'/4JRYR"R)P+[6;;'>E,;G+%C042O^,NOQ"/L50E H!&L /[=ST.BK6T.!ULP;FL: M1+5\ ]:^@UH"M\G6(1#9*5GVL+A=RN8)&]GTGL8!A,7 0S-:]>+8"ZW;-K4Z:G-3G^!Y5B_MAK*=R^N@T#JAG6OK7;75;9=KOPA*DL$U6_RER!$,!1L;)ST1XL#P;#T<',5OKNI-L,DVF -\]ME$]#'_M#E$>1A8,9\'39\I#"%/B,T>D[A@($Z05,>!OV%'D30EGB!{-L[,

<@S=HBLT=_MRTMQ8VKF@HCPDQ-P@Y)(5P&;W@)9K,>,*8S="V-F!1'\5Y6R&_7M)_-MES7 MT7MJ5^_D2JL5]B*OT5>YR!)X+UH]D-Z#153B!11;8%[X>R->ATIM<)P-MA4" MVD*)0TS:[85M(KP:J17(FH_U"F**.L(1FKD)_C/^G0+/4R&#Y*B,0]M^4UY MM* D0S'!'L#'ETF_3-@YTB/T9V:)((?!8..*3_?;E^O&^%(_"@8@?OOD,P&?5(FA 'Q MZK,?GQ1^#1MU+5(6;VCYG]|]G'LTOU[F'PU&-W9S,(W%[]9SA_O/D?;F6HO MM.J>45[,4%B:Y")}J7'CF4.RP! \,Y<>+!?]=BH?837DBD9N.GP>1C%@GC#*C M+C -I^";]ZDK#V]G;(=%L[X=2]MM?3.H5>53!.Q\O.V^Q-L6+YG\U !&:P,@ M6M33<)\8HI(FXU>VK MK;Z0YIGP?E[54,\GHKZ]}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p8?\/74163^N:9N[{@5F(7\((HT!YV+8[HC_=MC>_CK6+(SQ>N'_B\%!$_'4[=TDVUAD]/5=AL+U&,BE#GM";J]VKRXW^W&D5 M:&;D:A=>$>O#K' 9P2SF"X:1>SR3W_Z_% M&Y-CW./NRGO9$)RJV2\O:8=. M2HHOD#?0LQT%$A#J@,0<+N8^QZYNH'9QC30$K\ 2=TG=&_:3$[:A#X MW7A.F!CK%P"O?J0'.D0FL4"K\X_P.>U=ED1;F?-%G_"C&7KH].%I=N9#KFS/MJ4]XO.*!E_,7E(Z3%3193@[B2P/A@&]5G88H(1'U\Q8W!"M#U"^PW=K<4 MRU=FH!L(#;(\$=M|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|K))+83Y)Q\C73X=AMU+Y)JMJ\V^+)*JEWLI8>)%ET-YX!M'YE?N#"F^UU-ART0409)[JN&>//"-H_0K]XP4 MKYW)VL/3Y*L3\"NW!HMOE8%O:&=]61QUBIR3KY$.W[AD$[]R-]R4]2NUC96/M.M'$O"U8@KB?!FB?!L /H-?QGA=2,/'DQ\@.31+!OIO62X3D_NW+]>-]*6AI MM*?-YD\1;GQFA,FXX;IOT9_F_X8(LJW+[??ORZ'1BU$@Y_;B4_)V\JPI;4.MP^*/)O8SS"Q>0>J7S,^3.$3P;?CEJG%^?S7\>V-X_7AU_U$Q[%?CS8]NO-&? M=DAF@SXI$\(@\/79CT*CR5\J4G_#[ZW$'3@?WKW<^[1_'J9?S1(B[LYF,>[MB]\LYX]WGZ/M5'CC@37VC-)YAL+2)!=1X\(S:P<[-L^17M:V(9AXA/=MP)X/ M!VGPH"I?+9OX 9"0\C"R@VL,9A8'AFYSPXLT52,V>5R|"VW1$LRLSW=ZY^X(\;>RD|%?AI05'0\6<$6Z@@3;IC++#K 5P'=VC@?)7 S355XUQ7_3!&.#5N[9\/\CS.P<>/0/'FC0>X-6$S%8"+#D#$U"+R2RE9,(5W>GUFZB M3GTDDAY-#)3B,$TC9$V(3!,+#6ZHI=6XQ&XCUX,E\08C,Z ;*HJKH!GA$^(C M%=!M5]E!!*S>Q@LH9;34?=DX1.N(%>MNY^7$YP--%YA6>\H[N/I/";/OC0/O M#*D9=@=FL/PP;"8G2U73Y"2^^I@R2K4*30M62):E@B+|%],Y;81S+! MZHPQ=U%*=2BJ4-2@6V41-L\&FH@,(Y,(ER&M2X5;N739"#]0,-V;17C>^"]@ MU51;[<4HI "21#)"%9!6S;/^H&:H5]=8[_P/:EU(57((;BE%FVIWCD"7,&K; M5I=TM*:,T87)*S\R*"@!&:,4+[K[X(M*G+DL=TB/3GITT39=& Y>&1ZE(MX1 M,-#!Q=).H.?:&V%('E:KW[I<0"T(L!1J7&W@K24JUVDQGT3E.@']F+UXE'73 M IKI@Y7K;3S67=T]|AI|]1>BG)Z+,1&2).@5 "PNG4I62U6;,'NJ!0S^3 M',W4:U0Z!&K.'2L\%7]#YS-O2H57%L.U4IC#; 9]FRRG/O(4R9N2;9$P\;#$ M^I^PO.& >%.?IF/3O&N49HKQ[!&6V]J\6L%$(<9HHCS"-ZW]=Z4KX9C/+., MO-S<>WBM,@YM^TUA,C!5.[!'T_554\BS96YPXZ@?#>4N7%;!L[%%*<<09[; Q MF:(#=A[EE0<%<.+E!4 K1*0.5C?0:(%XVJ1N9Z-NTB*M/-OB3%>UO,*)=/6# MN S1.@Q#* YY-G ORDEC'E%RM7(<<4FCU54[&]6VM0KJDK2:,H0&9NTNF>20MN@"4VROXBZ7'M3K>TP9G%)>;$>_%&I"\DXH=$/HZ_]$-##O}]PO7#VI=X)\$ M7A-Q<,&Q4B0,.I7%P8BSKS,=]$\]M=R C>N[9RK%/%?^(O.E,?46[DYR>=4Q@0%=VR|AM9-_[@"/_SKT0IL^ M<4SKQ3)#PZ;/TIG?C>-Y5^WT]S?]J: 2D)OHAC+&L@>@MC(H+S0Z@ 0HK*(\7$PA_+*=7X5*A2M@:I060I6UPI'NSOO9)|"_.CJ'M'1_BJC"EN<'|%39HZ;O M%FDQQL;8U;REU\)<(E^XG_9VRDJ^/)OYEJTL>P<. M?09&,-TA<)B6&8\H^W,C3VV&P4^Y!I8#>V"]M$;1$RV4&0'!F5H=C=$1]EA M)F!M=JO=;>?NEIKQ,U4<<[&XXHZ*3ZG3,ZF=K3P3AWB&3;?;,*>68\&W6" C M?I[K)3^==%H*L@A%TP/EO+ '9\5P%1VB51$W5,V9O1=RRFEP"JL@#P.[>DN MY[!V/D5QBP04#KZ|O/T=P63F 4_X'?0"15++1E5>)|9HDHFY(:F-P$;%|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{],T_R-H?R?@<;VOQ$111,6QSGP#K(*ZW+3P M/Z@Z06.PB5$'B$5!]{V)\)\3R%7%]' M(9Q#E-08)61&?Z??8I3 /UJE]HCGN&/: M+&9DX4)^MX+!)4_]N+I"$B@2S,CB/EH_-BTJDA7V!VNVFY*G#_),?D$ MGH.#=$(08R3'Y'*.M!C%W M.AS34$SN=KMIO]T7D&'FW4.CS\?SM0SE]"D^O2_OL!Y4YNVG&<'!M)-.*/T\ M@-!|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{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{6DOM2WTF^4E,?MK7_;]'-CLM%2]GU]^*P?A9ET87]8=AONZ,K[BLLN?"8N'"U:G1A6 JUVN 8M!J+]/X<M/+GF&_YFP B?E?]1%"5:V6T(>V>-^(>Y0=>_S"WA+Y^2Z=+99@*K/*[*Y8Z!I@T:WKW?;Y\?G_QPMXAT;0/F%KH3O$CW>$;%M7H,7_^[/C%"\NVWX<+QCRWG$K[[+8NHU*"]]5'IG MG9_F-I5]Q,^XW_DIY[V/77*S)9C$B=@I8(83&=')7,IDO%AV7"2SE_?8:_M_K*T'!S!_A%OGX+PD/<1>2M;N*/XA4S3T_FH6,X$WD+_.NM&?;L'H4;[*AQ-? MN0**-)4',@NHH:.T0-:@__+SV3Z.?U/P:6()#1):-L06JM:0A/^=C121EKS MIVIO2B_![O)AU1^5[P^'EP8QM^]269I(R0E2!TA24$D'2%\95%U;3M2O;U/L6U';1NZ]PJ2W+158+9+&KKO M #L@*)-H%8<5Y!)MNBW'U85].H.F5%FB3:!6#%30R55,!$C5^YK:E-JK3A,0D8T*>FFNY*R>]-G8ZZG| MEM1?-9J B(Q7T,]R'XQ7#[-11F./8P(B,EM>ALSVS"8*Y]1>9\D\V,*8;*IUM\2D&964S[%QYMDW^44DS[",VVWNJUNT?0^]LR?]GS?H%G2[WPOK2<1"3AB7' MGQ+'YR5N[8#C16%?]:HE(Y\&(V^3&':25GMGH+9:7O;"^_MM-K%I&')\:?$\7EI83O@>%'8]W14M_)X]6A)&:@4V0#N;K#G)>)LQ73[4[M*6FI_9ZF-@=:G7N:2QX]0A[-R^5;FT?KX3VL$#2L*L=<O ,%'2N_NYYM'E^+GMJ-7]K+OC]+J/OX\AB$&%\>@Q#C MRV,08GQY#$*,GW,,P0D<(97VX=(B[;M72U(V&.Q9I K;AN&V#Q=?](B,M"MO::FZE)SB36!6O%07MF2&'WFQ.6Z01>Y3M@&/J/(JX1H.">NI-+40;>C M=ONR:T^-)B I\VV#_]W?YB'B,E]+'>@R'%NC"8C(>-N@;Z_12$1<++D(5-E"[M3:G";C0!$3DI#]5:B,9SXO*>#FZNKO:;/=!+I>%&G;I"GMMZN%N%*PU5.; M_T8T+$E]Y\V]Z^("UU%8PN9ZB&97LS=]CO3KP@TO75O"ZG)2^+OEMUY^5MM\L=.UGP?J-UVU1$,R?T"[%;=N7]%>&QIODOS73++]L3#]BGC;QVR^'XT"%SZ[M7':GVQ,A2:3R1**MF)9W&MZ)KG9[FMJI*$5/-A20;%K$IGDY?_MN4"7X\OQY?AR?#F^'"^,\66&P1J=ZRXFEF/(CG65CR^[$@DOOCP&(<:7 MQR#*^/(8A!A?'H,0X]>Q8UUUIF8%'>LJO;\0Z5YBR7U?@6=&#WI+FY/MV;F M9&_^:1OYVT"({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{9K0&S#LO906?\"X!Z19U M'G!+;Y=58\$F[*_;8D*O6*FOBH2^>_.1+6X,*P@P<]NQ59+@*.-5MB@2(K4A8!X5]"3& +LBA8<1W3.'1!XIA:9.%?I<; /._85JD^^!Y!3G2B[' MLY3DTJ!'NG'46,&:W"\EV>BMK227%K*I+J%+5)*-PM5HJ8)<6JFDPL0N54$6MA;Y748VK:\;B_=_%BE'9U,A67HT<\9[&S_U]%/6(A6/(2V MLLA>FY,5Y?56C'D->?TW./29!>@_-[@;3>UKS":Y"TPOY#,,/TZRO[!7LU]4 M2:NN9GIV5SNK5"DV)4]";WZ

M%'>]J^?=+?+ 2!WR%M>4_>[2XP)K+M=*]A?(?F==T[6[-)N\>NS97IDO8,]2 M>[=;5!2ZZAQ*[=RMX|%2O?PLM?RZMO24%5U&GO8\=B]+U^Y6/ET;]Y9S^=KP MSM$1N3G_>G)W?D:N3V[N_A^YNSFYO#TYW?VT;9C\=Q!-P#5/U@MW>K9SD]1- MF?QKWH/*8]FO+'4Y3QMR^#CT0\JSM'V>$1D.S8 .?=>F@4;N_!$Y'2[>+?;N M->*P'C/9N# HZP=O!?5*T3C?<]P'#B>Y8Q--Y=)S;)=XR"35:D59[QSRF>S MWIUEF>Z88,O)X<-_1X{GC.)1^A#N;CH12W>OD6OQ;4@& = B&D+KN7$^4NC2 M'(\#_Z>#2''X-S:'C* MCPC";Y?@6/,_GGSLWR@NHJ&M:FCT"N@E8QT?31=//MX.*8V^^I:9$&MJEAFZ MIM-;')=8C^8O%MVH ,>:=:.88U-1:>X2.'A EQT)QV."R\(>N? @(SD$>(YP. MC_C\<%;LF;&-'A1_$8# KMIE#_8Y\\&! NZG.7D[]@=]SSYCQ]O\Y]N=@N^(MA7/(R6!@.L%N>]VX>;%H\N)T)PG\B>D"> :4DD=TRE=6R^WZ\ [S${CF7(Y:C MY8-=R4;B\SCGHO'DZD5&)[;5$5B-.9=4XZ.<%G1!0YP)66.- MTQOKN^"+4'HUR./TI?WP)V.X4>S(+1=IO;G Z=XE"NG%IL%+N+IDN9>K$6?* MS27[I>%^I."W YM*A/$R223H?4K[K M,?E'CO< 3\(*P(8-1/A!OOB8X>1I[%F\8F19\;!SQ3D!H8$8,, &<;_)#/$ MZE3 !P_)M)@#$1)Cl.\(^@!-=R K74E'['"ALFT5*%MP,L#M*LZ93-HA]Y82C=BROODD;LS&^:0O64#*H&6!NU@H,& M;S"RAP=J^:%[ED3*"WOY0+#@T0FQ:)U4J8PER%YDW*F+2M*4K!9)!_"6$Z0E MT.ZH-?1\U[^?I/NE4HAKA.O456I=,5.ZH@IM*B 3L\GX!B;(-T,6_%?C$,Q@ MJD8N6!4^CW).)[_/%3Z>EB%F]5LH03@<<%X@8?XF)OO:\0C_9 73YLY]A:E_ MHOV S=UHY;4)EHC%?'8W!?BN#T7QT\R&I88_Z^-8"P:4Y"F'0192(3.RPAS M18@P3XQY)I$L4FG'5*C:44XJYP,R5;[^LA5N6K*1Y0^B3J22AN-
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
5.FADI8,^YI MY(%RWXS=BL'VYI=7.&@;G8/C 9!=9,\?3:@9D#$C!^'A);RN GRN\(E.%^K9 M14D"U..J#3L.4^&=FAM;-
[EU)EYLB4>JR9/:)GT$W#V)";G+2FA7B237N!!WG5#7V[OLL=&_&9*UBA?6&5,D3$$ M4$N](=XE(D*+ 8UX;!%F.V;^>GX(R9AG[[=)Y@7_61X.U7NY"'U*<'0+V/;; M^C 5NW?Q2"1@!+[+ #@_2+#KN]&G:WC4Z;98@a1?B) D"O$;*@GO ,-(.'.53 MSJB$51&1\ 0:R2H&O"PHL-,TA.49;HT5TZ&++E[9OIF<"*>^330R0./,J$;=5 M/*0B? RBSLJ']FW::?>B9^9&M9YU6:3?F7$L]G0NW&4I7"\D43&\6YZCUIA3;',U4=L.XLR3*C(E4(4+SXX) MU,Y:&ICT$I.V=8Y.;R],__'PI]M[ZBVP<(,(03AA6O?
D]/Q*/"LS MQ\1]G4F-@R3Q("F9*.I$1F:(WX/)G>_+'D3(3NIXTZ$-\.=#NF&C'%N%LL& M"66031:7B3!N5R-BHDGPPDY?EH.2T3D> ENV_C1?H'2*/-AO?^-CN19#6?_< M;,]HY+-D,^?R+6B:44%)W=4+$)PPDH17@\QW3Z[6,"?PG!1K6$+V%ZBMLH]D MUUL+3-"EE]V6< *M]0O$Z447>AOB0N]OWR[NOIU?WNU\6;A%6QVZV.K(&3H(Q1:DBN[0%JTF8=W ME6RO?02G>O>?RXL.DTO0$V(GG]"SY:'8S<*^]!]$=!R77F&$=>?4#BNL.Q0 M]B(5/)O1X39U<65C=3P7+LJ.D;AD;M)%1UIGW;]C^+/3XC8L"-
Y]X[V!;/:545AM+9V ^X/QU>>1?B]- DJ3GVY-A5<]$A880@2V_@E\KC MKI1((>!#P8U,J=^D9[:LS,USCNI&!;'(l;FZZ.SL^EP%!E+7'^/?X (,Z26T M^YGMW&//%XF^>5UY6=O/Z&K=I6?#[71]#3VQ2YV*LZ;]*L1<,R)5F0.GM M[A-W_Z8OQ'ZF/MPNLC7G^&CE[I9/>&8.Q(X]Q#;,\\^+MQCS)O\W(KC MC7,IEAQ-
S!Y,7'SZ,/.%Y.&*)Q0W'B0/CN*0LN8BN6$9H*KQN=G@(I6)FQ;E>;=Q:D'AWC-G@ MWGWR=S@V+?EWP:BF],7/P; ':$Y\[A/P\ MWY8=/M 3RFX0L5%_E@T+-
Z2$XOL==YZ13KWVIT>)_0+#6H)F9<.Z20L3*IE M(,1LXX4;=W[$];X\-P#FH3/"L/4!: MP*4)WV(G&DS7BEVN=O@M*]EC),+_YY(BRR9,7P4=DC@""?
HOY6G*"_KKL\U] MD0>?!LO3IRP_C&3*/=CF3#K81P^KI8EH@M@9)MS6M@V_M&"P<83AP;K\%]/Z/ M@O +0_C6\<1YVP1IF.K.T[E$53'F8(@< M33TF3M&$@ ;,^SX[P#3UE";.%HE-EORQ'!;O@57#RF::S6M)H>:U48/* C-' M&5 X]7D*D3RT@"BPT-=PW?0[.J%RV%D-T#@WU*,/(//\])^GIC!PC3!1&|F MR]_Q&&?
V4%E.RXGTH#O#;*#DJOT$+#3A3#^27*HBQ\4%,>%J#V+M+=BJ7W+ MS(#=M?,RP@VDYF06N<3B#IU0V'DEF&!/3@EA>YG,4C^%50M[O@^]V(MJSOD:F$N"#92D OR!"M0^%P#A_>6&((@YRXYT:JW$^-++FG_A*>&==_+S86UV MC.EJ+\P5QN.8B(HZ.)19HU(.<-:G#.[[AT_!]1&CT85_M5IOWI,IE064B2)_ M=)#5:D\=Y?1TYZGR5VL?IHV']UBX>5D!I1?H/\]^/J{G]&EW10KA:*9S3C4 M"_3L@I_87:VYC#:1Q212F0K70H6:/4?-)69:5P(TTNIMVQ+,J7Z396.LJY.)KI M%T[5M49G-N>O)$9N#$4*L*L!=K6+"#<*V*;6,&;3KA1@%6 1L'.*MVP. ML+V6UF[.WMZ@ *L BX"=4T!'+T_#]KI:O5M)DV +HLO5< D&CL=.5^R#0[*L MJZH)?.
<9(@#;IO_$F@X%L-3.TQ?(NNR5[5/]@\)?,$2:RGX*OA"/:*JJ"LZBTH^&[/ M/D-YCL2'_O%?[/P-MK6M?\AK<35GY&J[9G& MMK>OV%")A4;*M%^
1LJ!8CXE0"K(&9Y3"W!N?.QQ;->W.1^R<-X+6-\CF#6I:DD[GRH()44P-0N-E*MI4^@<+)PL\+= M:,WFP7&]9O3XW67B!K7*$E(-H,I0XN7?
JHBDRH=KRC,@K_+)G\]$K+8<*E-@ MNP>@<+.5;"M] %5>]fM8+[=5K^+"KP:P75#J'1PW*@HE%82<:T/*_XC4^SW MV4[(ZU^O0F>LO)O^?OJ^X/:9 M.9R_I+-
D<:OY:67B5 M/H JXKOH'I[9'#R%[VE\JX#NGO_?[^>7=^3\W_#OVQ7N M;=K4U#97];^H_RD\7GD+KTJ\!!XT;TNK^NH$4;S;T&-G 1_FQ[Y@N[=$/2# MN.UFZ-
!.?]\K1AOCB-7@X%CP>OB-@=Q18F&URHZ\C:IT?IP'B3*Q\^^F; MOY@183?E1-2S0[RX(:"1PR\F8 _SE@>!/\I=?Q*/Q5TV\.?8$;>/^ -MV:V0 MR:41(:4_V/N!O-
X"7AXZ(:&CL>NS X;$O \HNTY'PXMSUKEKLEE+*9C0CCPZ MXN84QXOY!,%=#J@5^=.D$Y=QP0-XOTKI1GCS5C0,_/A^R+[D3_F/>*U*?P(# M'[%7< (<6C52T#?
T19%?^%C?]V)^@^7"2^_D;9MC<\(N2)B[KG7KS<+K>YM' M.JBO[G^FE-3=9$S9-8I3W_/[$?]SYT0NO1I<>* E'3LV77X%;4!#=F/9B6>0C3ATI3;V0(><9RZ5^<-
R:72Q_Y?<[A4..QT4T M*[JDMV(TNQV: 9U'-+ \?IAN801+%SD$H088HH;P%E.PR%875AESE;>#4]BS ^.M&0Z;?S M5(^?2#W.WNR#PA_PV]*08A[EQ$Q>Y.L/>
[R@:7.,=[\Q59&L#_R&0ZFZQZI[MH8T:]_^&IL4E6$X@;S=B=Rs"(]@-BJ"A*5?->%T1+ S)W9OEI4A)U/286P- MY6+ KF2D ;MYFY@17\8PW
J+R/;/C76^VVUFZWES&+73 8 M)@;(4UA2$O[=>+ZCOMAC+L^-3V]:_OCGHHN6LU7:\Q>"P5?2]2[IKFM^^;,A MB[!)>NUSJ1=9/^,>Z\PUUAF0+
(\+2U]GM\GKKR_NSK\1 UP\TP,C"S4!#X^P MBVWA]Y!@,# .0U1RJ/E./-.=A Z!})"'$!UP>4^E'<*>N:&H1]@C8KL?-$LV MH+)C=+S+77%M)P0+Y9(T2
AEY0@51(3R$T*1<.C'+EJ7>![^E+8S+OV,O8UWF M&PWE0L*-0OS1\R,:D_#@!I'BQS "8V.N@1
MEJ@1<.7H3V9M87>8;LTO_I]>FS0T\CAT8(!'BV0'#AK#">5N88T,6%E0-HSS MGQ9XAOC(<DCSFZ: MU$@>L-#C"'$3/)J!?>3Z_@]FC2>M:FS X]I3$359'2)
RJW@CJ&?2WPE,SBQ M(HU'PASOP7O_GU^\^^+\[\V6*M] Z$!-]D#>;;$< M]"C!H"0HZZ3O^"-Q?7=$K:$'J_#!) DE,O@A1AB&;3!0[SWVX8&Z_ECZK:,1
MWJAKXHWC*#^>_V"R -+#MF/>>#!)A2:42F&,.X]^.]|> ?M*K%&&;W6 >A[1&^,77J%GP [N"&$2,DJ'Y@![S/6@YANHQ_$!_ #E<>"/ X=&
MX#%]F4%J;*X@O<$1N!T:5#![M6AX/(%.RC#FREVJKH)1 OE_4+R9_2*RM!U M@&L\NG/G9!I1=($^YBGFDX/$#F\"E=,(AM6OD"MY
\OHR_(5WN_E/=_H4J#]0\XPVH3O@/0L]'W\:F UXO#DGUZ>N#28G M6WI1L,%17UO(043!%%X<<(+8BCTR?U"Y'P'G!"$A:(KZO +WV$X#TZ
]PZL+&-8C$#'[.PZ\9=0+D+U =7, MO$H)Z(-0#.S/(CJ;'DCWD*+^LT$G/-!@(BBN,0">7=^2LPDX|/ 1@/":.$ # MQPN1RW>)=@8*=)KOR>T$5,!(8S"CE$>@0-
G9#!TX&Q]P#2ZY%0-B*?YA!_%] MVG.&O*E9!SP^0HOPR ?K&7B'IDTX045. M.8XSM%],M\RJYH1Y',9I%?(&@'KK8]S ;01TA M*35R$0'K[V-H2+PX -^!AP*1K*"
[G<@/V$*]??_HV+'C +DS-D&YL0 6OL&IQ()$]R@3N<$"\RS0<$"(7547"%$I MVC&77+^N7T!N+KV@/G&=OD=)"5E^]-@/V6H QK\|=BB^Z(3"CN"L8Z2%!6"2
M6<+9FHX/L8V&^ P>23H UM[>G:"MA-W<^3](UDG*!*X_A#)A#B.J"R==DT"O M2YBD#..2$M! 8MR.S\$0]!IW1<1+"CYJA^0Y+*=I1 M># !S:EQLO%@@?
[E:\31K=2!I]=WP&D[-=C$WMYO879)Z4_8;XDU_DUHSI,P M],%)8KQ%VK-$%F>$,01,XQA)9@]?WV)Q([#D U:MF-F'/OIA&'OQ8A8>@;%F ME2H&,M((#^ > &U!-
[8_CJ0M*:$,+0/68WRP1D[8U"R<&MBI)LNXR?6'$PZH M_^K'04CEBIAH_HQR0)=K:AA@$H%C.=_(D32C.$1'A$O&U)WC)8!=2E;21E+
M$C^3H*P=^3$;1F9&4K9GGO,2@,EE M,/6G;-(1!45H)^[V-=!YC%$#%R@7@'G)\A&C)FW8MA@G1@ MR!))&]L.VRUFCE,8,!)*78 UA]NB8 ,<.#[:7-*FS:O4 $0,
('O:226B'DV M/MLT%".R PS.X!=\F4]6;RUK?/!5..\8[NHZ4"A0 2L8'_(8^U< P;N=?)L[;99_@C$)(]Q]%ZKQD MY(]%5[*=UR-AK]WIO4|/);[8V)90?UB=<(#(@'5
ME9Q7S;7Y=)=FEQ1EU&0Z.9"4R30P'!P%_N-! LS\3RC2))_/\W)9.X08ANPV MS=S)9?%4/Z$G2P[DW4L0_.[J]*OC_4CIE$D*6H%6F4]*9^^2SCYGA@/3V:"-
M[UV_SZ(:%VAB -/IL%TEH9/3BD\W'6G4U\V8#ZG[GX M,MN78[OB;&'#)4\$HRD>=V?
I*:4O.,8=5L#YM.V1KKUCG;6&;FEE;-8#U&4]WX?:M.*X77IO6A,TP>W8BLAAE.XZP+SE@02V3_ &WX&I!$"$H<^IB+MS M\?@>-Q5LV:2((66V K!I?N1O^?
!"KH8,/L:.RQ4(#SL*BT_B)[JD/69]-4,C&.>X ODRJ9X0@CERD!%AL(]89HZ-I)-D-H M#F3R0C8!R+0QF9"3^4^H,"&\>@GD%P4%VB_CET:K0&++=P,1.QF @(M/<)
&,I0,DL[8 $XL1G*=!>H8]$B[Q#5N3N1QQ.H_083ONR8;9VR1!S17$'> M5CZQ@2E_/DBYO4#!D^+1W<69-++#787?AWZ^FC*SWFW@--<+[_@>M>N@^\"S
MJA>O$^3PC"@35)Q>5DRYNYDH?%L1B>2V_THV'R5%3D4X.@#GHUZO;/JLBO$ MQ8$%YO3H].O)V0)K243NIDTEIKE9QA>/U\D 7)JXEDT8N6/!>6>(K>;<$N>
M]30P'P 7?9@#?3#=6.8<>WBV!Y-1QA3$"&PDASY2&Q:$6&1 BCU,EFT>VS)! MU!0[J;AWC=Z#RY(":8(W%"6@\!QTU'M;OQOEADA%;-EDV (P6E!MT:HY\^)L;
M0$R72*I--P0AI-Y.LP;XA-0&[C\/0FMB>9F3O/VH9?285:/* N@I4,%8NP M^(0>8TM6FM4Q9>;ON\Z0& ^??N$Q<8A%.^PKY6FDDO)R6=X9<1]=TG_S9RPPR&&EJN\
{7D@_*AL M?HC,D>,_S4L22;;&UTL5D7D1BS)&-I\PT-14? "*:>P[@_VPJUK@RB.? M:#] 7/,1&)T4W=EB//X?,U>7K_=@OLU+%!0[%HVB1)F+/,7\]A!B(0ZI)'>"
M/Y'IE,/LL*<5.LU@RZ<(E0:()/)C/$D% MKH4 S ,L8RDDK&0]A#\[^.C,Y4,4H9POC"-2V[CX(&"\<^@>')//6M"#D\N M_WUQ>_*&GV9AEAA+&$5S8P7<
T9X=^*0HAR(,"_:KJ"%CQ;GQNZP%OHC!L]! MKZ_ ^T]L/_G4-^'?HN #N1KSI>["LVKD\-/I[=4;S#K_\0L!#M#L]{;""D MV03H!\IN9U,5(3L4!\3^^'9R*@Z(O=$8UNY!:
[%3P<*_HVESU^":D8]D/)R$ M;*E'I8*['Bs>(>15=W@,#[3.+:9;)9\R;-$)RW!69H1O\B:2EH]//F&D$[L MA<2(PVT=>H\RG*EK4L$RUVHE]-6=4ZG6]4GF] M'YZ)/,_?
5(ISQXU$9MQ[T-3L"HN!/]?R*.? HF;ZN&[\$3)5\#?5^> M[=(C\4<.#>9D$\L5^@'!TEQRFT=A10I^U,CWQ/!(U-6>ZHC70@W9"3!Q-B%I
MC!?)+H+;;ZL$)[+++$ULZ^"HBG=*_,POA7JTJ5V"0L@I@FH": M\RE8O8KVT201=X7LR'-ALNDS:=U!:!%W\FF5AR"H?IMA_O!S27^\@#"(C|!L MF3
IW_38&PSEZ^CQ?(%PB+L_F+1%S1^V_^C-$]U,))KG,?+$V4/0&N >V3X, MDV4-NQ-Q3!$PXHE@I@N2W!=&3Q^9B%EY(;UG%K%LSQ+.2GH0;^W\;N'V#ASO M#E]-
?.I\X*-3:TV'1_A7PM'NMGY=%H%8X^H4YL\[']J84(!]^SDL2SPS^"P=O M,OSB^PE?[C:7-';P\A<>YB[]V7PWEH\\7X_T.O+ TXO<3'.3-1M;K[\L[HI M%O>BF4VK
%C0R3=X>QB2W-)4MIH:24L$=EI%;-E\4^TMBO]@'4/S?4_Y_M#EBPTE6 %F37!??_O#?!16U@2F.K M]>:5 UIE^6;I&:AP$=-?
X;KG)3K@-2Z8+I##7Y9T_]KWAQ<,2>_TM':O5RY= M-LT;A89Y:.!7Z"DL*"P7!5:3'E3N6448L1>LKZKT5\PGVX?=MA-V[,7'*[LV M[)01<<3AB+,3OF6G!C8>1.$'+
[*CP"*RCLTP4-<(_O.FLL*\\O!;6]NNERGO M+TMH!<1M!6*I=H<"H0*ATH8*B)4!HM[4NH:AD*B06#9[U;JL0%@Z>[=9'58L M>K$/.\]Y)/$=WU)>#M4&0-
7V8ZPF,875RF6%K#Y7'T3- -*30VNEFUXN#V,ZR] MKS@T-KQIKD"H0%B@#(VVUE'*4.&P;!RV&EJCW5$X5#@L<>B;C%DH_"G\[9H> MK%C(8I,)%Z4>]U?=J&Y4-
ZH;U8WJ1G6CNE'=K-Y-Q6S6?=AF^]_OL@6.G]' M;FC(;G'Y"R\.W[D:73!?V1./.3/6F&+8OO2F&;5EOBF&;UIMBV);UIACV:KU5 MS);?AP-_JKQFQ?:,#HZ-
M]XUVZH:@T(##JEA:"U5G46!@:N&7D/K*=6@T,"& MU.UJ=5T56U5@4/5;% XJK10JYMCMPR:-JJY9 6'L@2M7[U9-&JO!CKT @'+> MJM-C*?+?T%I*_BO28PD Z-
3Q0HQ-YH,K %0* &UU.TYE>BQ%_ML5E/^*N6/[ML,^F"FON2U<J';53Q9/V$XFJ@I<"8>GL5>I0(;$:2-1US5!%7A42
MRV>O6I@5"$MG[S:KPXK%+_9A.UF5UMR+ZC7&AK>K514EAI&=5-UFW4?MMD^](_9'ANY#GP[MB)R:[K0U;*2 MFGOOUP+=?EE0NFH+W%N8@8%E?
[1FO;7"3*KJYRI4[AHJFQU^TYV"I()D169@ M:"V]H765HE2HK1H:0JZZV&9G2;"I4*E969@=BZ4XA4B*S(#%!/]K9<3V9"(_"Q M[!L3]@-\-
J%!_MEV'HCEFF'X^\'UYX]_'DS/K5[_M8B4XAO&,_:5B'3DV_MT M=Y,TF&6U1?%FCO?SHX\WYR=_'IU\NCN_>4=,]]&< MA)*Q&%+Q:&[F!\F0@N!W
M5Z=?'>]'2B>.NE5IE?FT=NSJB=$]*19CWBW#ON#&[P?U X+3$]2@L4+P:)1$BRF-XUV4TVFR_VO MY>X6G?G0"I#Q'?E^6_;%:XF4&DI(!??
@!SPPMV.7XBGVK\;^,]1&!:?XOZ?\ MSQV:51C82PRH)6"OV:^6@/WF?S66@(IE\NU#P4]UL5[%]@.CEO=KF:T5#5F MA09^-8.JS*VP(#1#KZXT@T*#+-
INM#6]7FK14H6&RJ!!7:RG<%!=K5 QSVX? MSFBIF_4J((T-S6BVM':G43%YK 9#]@,"+7XP2?&_ CV6HP*ZNE97*] B/98#
M@4Y'ZS:4%]A&C\H!]P@C]H+U597^BOED^[#;IJ[7VY-K*QH=36]WJW1:3UV@ MLH(5+?X*!"6SEZE#A42]X'$5D]K--H*B0]9;-7+C;_7>)N_<5(68% X+7,;-
;JLK$"H0SBK#7KVK-94R5#@L M=>A-K=[&;42E#Q4.RQSZ)F,6"G*?[NF!RL6LE#7ZZEN5#>]&]6-ZD9UH[I1 MW:ANJFZS[L,VVX?^\046:O+,R/$]TWU';F@8$7]
O(#U]ZY*ETP7]G3W*L6 M5&^*83O8FV+8EO6F&+9EO2F&;5EOBF&OUEO%/;E].*G"FQ6;+?IX+C=[FH= MH]3C*/NY1UE)-
#0,K:7JLR@PL"%UZKIF*-6@T,"&U&LC&JI62T^AH1PTJ(N M"@?5U0H5<^WV89M&5=BL@#3]6J_=TMI=55ZO&CV64F"K9R@'KAH]EJ0!>EJ[MKC1
-7HLY9(4PS"T3KVC(%")'LO0 G5U44YE>BQ'!32JJ -(JYI?MPY:;JK*Y M)]5K&AVMWC.J=.I.U5':3R2J8EX*A*6S5ZE#A<2*(+&GM9NE6N(*B0J):F%6 M(*P$>[=9'58L?
K$/^\JJRN;.%[QM'9'UUH;W;-2!944#F=6IK;6W.C>N0*A M-N&L,NS4.UK/4.I0X;!49:@91D-K=3:9_]PJ' X/?2-IS(H$"H0%BC#QC8K MPXK%+52I3=6-
ZD9UH[I1W:AN5#>]&]5-U6W6?=AKFRVU>3IT/%.5V%2]*8;M M1F^*85O6FV+8EO6F&+9EO2F&O5IO%;/A]^&\GRJQ6;%=)E4K2^% X4#A0.% MX6"J2D-
'E>E0:%!:0>&@^EJA8[U* 1E5!4B LG;T*A J$!,-7@5"!L'3V*A J M$);.7@5"!<+2V;NE(*Q8K&(?MH954ZFZ4=VH;E0WJAO5C>I&=:.ZJ;K-
MN@^[:1_ZQVPKC5P'OAU;$;DU7>AJ6=G+O?=K@6Z_+"@OM07N+8257]7(7*74-EIZ%U\2HZ!4D%R8K,H*VU];;6U)6B5*BL#BH[6JO5UKK- MKD*E0F5E9B
OK5.05)"LR Q 4,;W75%F8B/PL>_;$_8#?#:A0?YY[1#"$X,& M/%;6HDO[U/Q\"&D!N!&(#H? 59 M/[^76TK)11]HFN\P__]5]D\)SK^H^,=T^8?(,* 0(TJ,A MB>!G"RB
!Q3,B-HD2.GC)_3!A]FCT3 2"%B/, +&<$ AB&AG@UOWM)Q1$=! M&I &]"*C;C39@_"AH6&S8VI%$@-U)S6"@XI]NR0A"]/0VQY_X$FG="],<:1
M.8$91:1/B>/9CF7BNSBJ01S% 96#@SF)$;^3"-^$8$WUPH?,-?3O! 4#8E'7 M%6=^DK_#L6DE?[MF&,*@'\.\7SV87CC]5_G\?L):PE;3(&*U&-+PD\9?OZ0 MJGX>
(T^']86:./AD8"M%M4EQ<'V'$S2 %L:6[_<#(Z%4UG*Q*-X"]9JFRR:# M_44SF]&OGW*:8HF"V+D+L11*7AXE#862/4?)*K:& HD"294UR9QTA)4R7$NP
MJXBP1%O&KR4F%%S-&/E[(.*J&]6-ZD9UH[J18#?K+>,5"(^4M73+H'J(*8 : M\6BTARF 2X^L]4JX%D5KZ0V94V*5 2YA]W"FM)ASJK9YF=)L*#@H.!]GD- 4'
M!8=,LD.EX+!ET93RS+!3/XQPUW3,S;$02!'9NV^)O62APXV+W#XBUP'OMMC99MT)!;,\@IFOMGJ%UNYNT,13(]@QD!KJX6J>Q
M%9I,!1E7M&X_!WX8HFT[<'8_O%A1$40%WFVT-<.HVE7+E>#'GB"@56]HS8:* M&E6BQQ(0T-1Z1D-K&6V%@"KT6 ("6F!A&9JNJU#AEFYMJVY4-ZH;U8WJ9L^[

M4>&'M=.3Z<\QJ4*]\I-5-ZH;U8WJ1G6S#6MW';S=LM;N6^JZL')KY)YZL(J[MK%;!:8\;FJ=+]}B0:5*\&,O$&!H7:,|'"%#1 MZI7HL00$=+5>NZL9:FNA&CV6@(">UFW*M#5*X8 %2A9T=BZH2$U VO(C"R; M/E#7'X^P|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|C[=W20-9K%C48SAOB>93J31 MGVU@.#@*_,?4'?+|]_6|A'L;$N23E%1* /[XN AR*[?0O})@Q,
M/F<_#A._Y_KD_G1QYOSDS^/3C[=G=^\(Z;[:$Y"B6;T#CR:F_E[,J2=_0_>F_&DQ$\';XM(_N6LF.3(NY<@^-W5Z5?'^Y'2B>-I55IE/A6Z M8;]-,>2W]RG_&/MRKI;PM(2D%.+[E7KYT#^^&P:4DA$\.0P)]6QJDULZCNBH M3P/2 -UDU TPN/IR1/UCRQ^-S0">BV9>S3TWTTP#?
W]M*:U"N%6]Y<)BPJ4I?3FV9%.QU&NY@!; ;>_W V/Y.O%*.*:BSD5S2PO:URR=OX> M2\?U::XW%-?WC>NG0].[?U@@_!49LF4[W(-;[9_+7&7X SX.+H[&/=?&G_0 M6YO/*#-8W+19=C+I'FSI;@L>ZJV&9G1+3C!4>*@('IIZ0],-51]Q2[?DOU$; MI[K[^WU'K9O72T4H7WKG#]W NA%:=Z,A@Q4'IUS) MO<)AO=7;
<*A"X5#A<.,"KE93:Y4;(EE]L(O,F^4)6Z^<*%%2?L:I[S$;T(RH M30+Z0+V88IX&B8:T()&E(>&U?G##4CR:(;$'(\#_Z(,3C$GQYL0UXP]:PCCAT;/C^#;$0TL2L:N&
<%D1QJ> MTP@H_ E?.E%(QD *QX]#\KUV6R.V$_(C'6SP08#;;B/J1>31B8;D"_6@[UMH MWO%(?P+(Y2>9<9;AT!F/\0\7R=?\4;1:M]#"_@P&&T."HVPW,PY 5-TE=0!A^@&?]U0'G8IW'<83AF*I|% MU|94ZWI.#$8\A@^;Z!X5;DW,:\BD$

gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000855683 mlss:BoardOfDirectorsMember 2023-01-01 2023-03-31 0000855683 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000855683 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-03-31 0000855683 us-gaap:CommonStockMember 2023-03-31 0000855683 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000855683 us-gaap:RetainedEarningsMember 2023-03-31 0000855683 us-gaap:NoncontrollingInterestMember 2023-03-31 0000855683 us-gaap:TreasuryStockCommonMember 2023-03-31 0000855683 2023-03-31 0000855683 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0000855683 2023-04-01 2023-06-30 0000855683 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0000855683 us-gaap:NoncontrollingInterestMember 2023-04-01 2023-06-30 0000855683 us-gaap:TreasuryStockCommonMember 2023-04-01 2023-06-30 0000855683 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0000855683 us-gaap:CommonStockMember 2023-06-30 0000855683 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000855683 us-gaap:RetainedEarningsMember 2023-06-30 0000855683 us-gaap:NoncontrollingInterestMember 2023-06-30 0000855683 us-gaap:TreasuryStockCommonMember 2023-06-30 0000855683 2023-06-30 0000855683 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0000855683 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0000855683 us-gaap:NoncontrollingInterestMember 2023-07-01 2023-09-30 0000855683 us-gaap:TreasuryStockCommonMember 2023-07-01 2023-09-30 0000855683 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0000855683 us-gaap:CommonStockMember 2023-09-30 0000855683 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0000855683 us-gaap:RetainedEarningsMember 2023-09-30 0000855683 us-gaap:NoncontrollingInterestMember 2023-09-30 0000855683 us-gaap:TreasuryStockCommonMember 2023-09-30 0000855683 2023-09-30 0000855683 mlss:PublicOfferingMember 2024-01-01 2024-09-30 0000855683 mlss:PublicOfferingMember 2023-01-01 2023-09-30 0000855683 us-gaap:MoneyMarketFundsMember 2024-09-30 0000855683 us-gaap:MoneyMarketFundsMember 2023-12-31 0000855683 us-gaap:USTreasurySecuritiesMember 2023-12-31 0000855683 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-12-31 0000855683 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-12-31 0000855683 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-12-31 0000855683 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-12-31 0000855683 mlss:DentalSegmentMember 2024-09-30 0000855683 mlss:DentalSegmentMember 2023-12-31 0000855683 mlss:MedicalSegmentMember 2024-09-30 0000855683 mlss:MedicalSegmentMember 2023-12-31 0000855683 mlss:SlowMovingMedicalFinishedGoodsMember 2024-09-30 0000855683 mlss:SlowMovingMedicalFinishedGoodsMember 2023-12-31 0000855683 mlss:PublicOfferingMember 2023-12-10 2023-12-10 0000855683 mlss:PublicOfferingMember 2023-12-10 0000855683 us-gaap:OverAllotmentOptionMember 2023-12-10 2023-12-10 0000855683 us-gaap:OverAllotmentOptionMember 2024-01-12 2024-01-12 0000855683 2024-01-01 0000855683 mlss:ChiefExecutiveOfficerAndOtherEmployeesMember 2024-09-30 0000855683 mlss:ChiefExecutiveOfficerAndOtherEmployeesMember 2023-09-30 0000855683 mlss:NonemployeesMember 2024-09-30 0000855683 mlss:NonemployeesMember 2023-09-30 0000855683 us-gaap:EmployeeStockOptionMember mlss:The2020EquityIncentivePlanMember 2023-06-28 0000855683 us-gaap:EmployeeStockOptionMember mlss:The2020EquityIncentivePlanMember 2024-01-01 2024-09-30 0000855683 us-gaap:EmployeeStockOptionMember mlss:The2020EquityIncentivePlanMember 2024-07-01 2024-09-30 0000855683 us-gaap:EmployeeStockOptionMember mlss:The2020EquityIncentivePlanMember 2023-07-01 2023-09-30 0000855683 us-gaap:EmployeeStockOptionMember mlss:The2020EquityIncentivePlanMember 2023-01-01 2023-09-30 0000855683 us-gaap:EmployeeStockOptionMember 2024-09-30 0000855683 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0000855683 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedPaymentArrangementEmployeeMember 2023-12-31 0000855683 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedPaymentArrangementEmployeeMember 2023-01-01 2023-12-31 0000855683 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedPaymentArrangementEmployeeMember 2024-09-30 0000855683 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedPaymentArrangementEmployeeMember 2024-01-01 2024-09-30 0000855683 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2023-12-31 0000855683 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2023-01-01 2023-12-31 0000855683 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2024-01-01 2024-09-30 0000855683 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2024-09-30 0000855683 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2024-07-01 2024-09-30 0000855683 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2023-07-01 2023-09-30 0000855683 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2023-01-01 2023-09-30 0000855683 us-gaap:RestrictedStockMember 2023-12-31 0000855683 us-gaap:RestrictedStockMember 2024-01-01 2024-09-30 0000855683 us-gaap:RestrictedStockMember 2024-09-30 0000855683 us-gaap:RestrictedStockMember 2024-07-01 2024-09-30 0000855683 us-gaap:RestrictedStockMember 2023-07-01 2023-09-30 0000855683 us-gaap:RestrictedStockMember 2023-01-01 2023-09-30 0000855683 mlss:BoardOfDirectorsMember us-gaap:RestrictedStockMember 2024-07-16 2024-07-16 0000855683 mlss:BoardOfDirectorsMember us-gaap:RestrictedStockMember 2024-07-16 0000855683 mlss:BoardOfDirectorsMember us-gaap:RestrictedStockMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2024-07-01 2024-07-31 0000855683 mlss:BoardOfDirectorsMember us-gaap:RestrictedStockMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2024-01-01 2024-09-30 0000855683 mlss:BoardOfDirectorsMember us-gaap:RestrictedStockMember 2024-07-01 2024-09-30 0000855683 mlss:BoardOfDirectorsMember us-gaap:RestrictedStockMember 2024-01-01 2024-09-30 0000855683 mlss:BoardOfDirectorsMember us-gaap:RestrictedStockMember 2024-09-30 0000855683 2024-04-01 2024-04-01 0000855683 2024-04-01 2029-04-01 0000855683 2024-04-01 0000855683 us-gaap:OperatingSegmentsMember mlss:DentalSegmentMember 2024-07-01 2024-09-30 0000855683 us-gaap:OperatingSegmentsMember mlss:DentalSegmentMember 2023-07-01 2023-09-30 0000855683 us-gaap:OperatingSegmentsMember mlss:DentalSegmentMember 2024-01-01 2024-09-30 0000855683 us-gaap:OperatingSegmentsMember mlss:DentalSegmentMember 2023-01-01 2023-09-30 0000855683 us-gaap:OperatingSegmentsMember mlss:MedicalSegmentMember 2024-07-01 2024-09-30 0000855683 us-gaap:OperatingSegmentsMember mlss:MedicalSegmentMember 2023-07-01 2023-09-30 0000855683 us-gaap:OperatingSegmentsMember mlss:MedicalSegmentMember 2024-01-01 2024-09-30 0000855683 us-gaap:OperatingSegmentsMember mlss:MedicalSegmentMember 2023-01-01 2023-09-30 0000855683 us-gaap:CorporateNonSegmentMember 2024-07-01 2024-09-30 0000855683 us-gaap:CorporateNonSegmentMember 2023-07-01 2023-09-30 0000855683 us-gaap:CorporateNonSegmentMember 2024-01-01 2024-09-30 0000855683 us-gaap:CorporateNonSegmentMember 2023-01-01 2023-09-30 0000855683 us-gaap:OperatingSegmentsMember mlss:DentalSegmentMember 2024-09-30 0000855683 us-gaap:OperatingSegmentsMember mlss:DentalSegmentMember 2023-09-30 0000855683 us-gaap:OperatingSegmentsMember mlss:MedicalSegmentMember 2024-09-30 0000855683 us-gaap:OperatingSegmentsMember mlss:MedicalSegmentMember 2023-09-30 0000855683 us-gaap:CorporateNonSegmentMember 2024-09-30 0000855683 us-gaap:CorporateNonSegmentMember 2023-09-30 0000855683 mlss:InstrumentsMember country:US mlss:DentalSegmentMember 2024-07-01 2024-09-30 0000855683 mlss:InstrumentsMember country:US mlss:MedicalSegmentMember 2024-07-01 2024-09-30 0000855683 mlss:InstrumentsMember country:US 2024-07-01 2024-09-30 0000855683 mlss:InstrumentsMember country:US mlss:DentalSegmentMember 2023-07-01 2023-09-30 0000855683 mlss:InstrumentsMember country:US mlss:MedicalSegmentMember 2023-07-01 2023-09-30 0000855683 mlss:InstrumentsMember country:US 2023-07-01 2023-09-30 0000855683 mlss:HandpiecesMember country:US mlss:DentalSegmentMember 2024-07-01 2024-09-30 0000855683 mlss:HandpiecesMember country:US mlss:MedicalSegmentMember 2024-07-01 2024-09-30 0000855683 mlss:HandpiecesMember country:US 2024-07-01 2024-09-30 0000855683 mlss:HandpiecesMember country:US mlss:DentalSegmentMember 2023-07-01 2023-09-30 0000855683 mlss:HandpiecesMember country:US mlss:MedicalSegmentMember 2023-07-01 2023-09-30 0000855683 mlss:HandpiecesMember country:US 2023-07-01 2023-09-30 0000855683 mlss:AccessoriesMember country:US mlss:DentalSegmentMember 2024-07-01 2024-09-30 0000855683 mlss:AccessoriesMember country:US mlss:MedicalSegmentMember 2024-07-01 2024-09-30 0000855683 mlss:AccessoriesMember country:US 2024-07-01 2024-09-30 0000855683 mlss:AccessoriesMember country:US mlss:DentalSegmentMember 2023-07-01 2023-09-30 0000855683 mlss:AccessoriesMember country:US mlss:MedicalSegmentMember 2023-07-01 2023-09-30 0000855683 mlss:AccessoriesMember country:US 2023-07-01 2023-09-30 0000855683 country:US mlss:DentalSegmentMember 2024-07-01 2024-09-30 0000855683 country:US mlss:MedicalSegmentMember 2024-07-01 2024-09-30 0000855683 country:US 2024-07-01 2024-09-30 0000855683 country:US mlss:DentalSegmentMember 2023-07-01 2023-09-30 0000855683 country:US mlss:MedicalSegmentMember 2023-07-01 2023-09-30 0000855683 country:US 2023-07-01 2023-09-30 0000855683 mlss:InstrumentsMember mlss:RestOfWorldMember mlss:DentalSegmentMember 2024-07-01 2024-09-30 0000855683 mlss:InstrumentsMember mlss:RestOfWorldMember mlss:MedicalSegmentMember 2024-07-01 2024-09-30 0000855683 mlss:InstrumentsMember mlss:RestOfWorldMember 2024-07-01 2024-09-30 0000855683 mlss:InstrumentsMember mlss:RestOfWorldMember mlss:DentalSegmentMember 2023-07-01 2023-09-30 0000855683 mlss:InstrumentsMember mlss:RestOfWorldMember mlss:MedicalSegmentMember 2023-07-01 2023-09-30 0000855683 mlss:InstrumentsMember mlss:RestOfWorldMember 2023-07-01 2023-09-30 0000855683 mlss:HandpiecesMember mlss:RestOfWorldMember mlss:DentalSegmentMember 2024-07-01 2024-09-30 0000855683 mlss:HandpiecesMember mlss:RestOfWorldMember mlss:MedicalSegmentMember 2024-07-01 2024-09-30 0000855683 mlss:HandpiecesMember mlss:RestOfWorldMember 2024-07-01 2024-09-30 0000855683 mlss:HandpiecesMember mlss:RestOfWorldMember mlss:DentalSegmentMember 2023-07-01 2023-09-30 0000855683 mlss:HandpiecesMember mlss:RestOfWorldMember mlss:MedicalSegmentMember 2023-07-01 2023-09-30 0000855683 mlss:HandpiecesMember mlss:RestOfWorldMember 2023-07-01 2023-09-30 0000855683 mlss:AccessoriesMember mlss:RestOfWorldMember mlss:DentalSegmentMember 2024-07-01 2024-09-30 0000855683 mlss:AccessoriesMember mlss:RestOfWorldMember mlss:MedicalSegmentMember 2024-07-01 2024-09-30 0000855683 mlss:AccessoriesMember mlss:RestOfWorldMember 2024-07-01 2024-09-30 0000855683 mlss:AccessoriesMember mlss:RestOfWorldMember mlss:DentalSegmentMember 2023-07-01 2023-09-30 0000855683 mlss:AccessoriesMember mlss:RestOfWorldMember mlss:MedicalSegmentMember 2023-07-01 2023-09-30 0000855683 mlss:AccessoriesMember mlss:RestOfWorldMember 2023-07-01 2023-09-30 0000855683 mlss:RestOfWorldMember mlss:DentalSegmentMember 2024-07-01 2024-09-30 0000855683 mlss:RestOfWorldMember mlss:MedicalSegmentMember 2024-07-01 2024-09-30 0000855683 mlss:RestOfWorldMember 2024-07-01 2024-09-30 0000855683 mlss:RestOfWorldMember mlss:DentalSegmentMember 2023-07-01 2023-09-30 0000855683 mlss:RestOfWorldMember mlss:MedicalSegmentMember 2023-07-01 2023-09-30 0000855683 mlss:RestOfWorldMember 2023-07-01 2023-09-30 0000855683 mlss:DentalSegmentMember 2024-07-01 2024-09-30 0000855683 mlss:MedicalSegmentMember 2024-07-01 2024-09-30 0000855683 mlss:DentalSegmentMember 2023-07-01 2023-09-30 0000855683 mlss:MedicalSegmentMember 2023-07-01 2023-09-30 0000855683 mlss:InstrumentsMember mlss:DomesticMember mlss:DentalSegmentMember 2024-01-01 2024-09-30 0000855683 mlss:InstrumentsMember mlss:DomesticMember mlss:MedicalSegmentMember 2024-01-01 2024-09-30 0000855683 mlss:InstrumentsMember mlss:DomesticMember 2024-01-01 2024-09-30 0000855683 mlss:InstrumentsMember mlss:DomesticMember mlss:DentalSegmentMember 2023-01-01 2023-09-30 0000855683 mlss:InstrumentsMember mlss:DomesticMember mlss:MedicalSegmentMember 2023-01-01 2023-09-30 0000855683 mlss:InstrumentsMember mlss:DomesticMember 2023-01-01 2023-09-30 0000855683 mlss:HandpiecesMember mlss:DomesticMember mlss:DentalSegmentMember 2024-01-01 2024-09-30 0000855683 mlss:HandpiecesMember mlss:DomesticMember mlss:MedicalSegmentMember 2024-01-01 2024-09-30 0000855683 mlss:HandpiecesMember mlss:DomesticMember 2024-01-01 2024-09-30 0000855683 mlss:HandpiecesMember mlss:DomesticMember mlss:DentalSegmentMember 2023-01-01 2023-09-30 0000855683 mlss:HandpiecesMember mlss:DomesticMember mlss:MedicalSegmentMember 2023-01-01 2023-09-30 0000855683 mlss:HandpiecesMember mlss:DomesticMember 2023-01-01 2023-09-30 0000855683 mlss:AccessoriesMember mlss:DomesticMember mlss:DentalSegmentMember 2024-01-01 2024-09-30 0000855683 mlss:AccessoriesMember mlss:DomesticMember mlss:MedicalSegmentMember 2024-01-01 2024-09-30 0000855683 mlss:AccessoriesMember mlss:DomesticMember 2024-01-01 2024-09-30 0000855683 mlss:AccessoriesMember mlss:DomesticMember mlss:DentalSegmentMember 2023-01-01 2023-09-30 0000855683 mlss:AccessoriesMember mlss:DomesticMember mlss:MedicalSegmentMember 2023-01-01 2023-09-30 0000855683 mlss:AccessoriesMember mlss:DomesticMember 2023-01-01 2023-09-30 0000855683 mlss:DomesticMember mlss:DentalSegmentMember 2024-01-01 2024-09-30 0000855683 mlss:DomesticMember

mlss:MedicalSegmentMember 2024-01-01 2024-09-30 0000855683 mlss:DomesticMember 2024-01-01 2024-09-30 0000855683 mlss:DomesticMember mlss:DentalSegmentMember 2023-01-01 2023-09-30 0000855683 mlss:DomesticMember mlss:MedicalSegmentMember 2023-01-01 2023-09-30 0000855683 mlss:DomesticMember 2023-01-01 2023-09-30 0000855683 mlss:InstrumentsMember mlss:RestOfWorldMember mlss:DentalSegmentMember 2024-01-01 2024-09-30 0000855683 mlss:InstrumentsMember mlss:RestOfWorldMember mlss:MedicalSegmentMember 2024-01-01 2024-09-30 0000855683 mlss:InstrumentsMember mlss:RestOfWorldMember 2024-01-01 2024-09-30 0000855683 mlss:InstrumentsMember mlss:RestOfWorldMember mlss:DentalSegmentMember 2023-01-01 2023-09-30 0000855683 mlss:InstrumentsMember mlss:RestOfWorldMember mlss:MedicalSegmentMember 2023-01-01 2023-09-30 0000855683 mlss:InstrumentsMember mlss:RestOfWorldMember 2023-01-01 2023-09-30 0000855683 mlss:HandpiecesMember mlss:RestOfWorldMember mlss:DentalSegmentMember 2024-01-01 2024-09-30 0000855683 mlss:HandpiecesMember mlss:RestOfWorldMember mlss:MedicalSegmentMember 2024-01-01 2024-09-30 0000855683 mlss:HandpiecesMember mlss:RestOfWorldMember 2024-01-01 2024-09-30 0000855683 mlss:HandpiecesMember mlss:RestOfWorldMember mlss:DentalSegmentMember 2023-01-01 2023-09-30 0000855683 mlss:HandpiecesMember mlss:RestOfWorldMember mlss:MedicalSegmentMember 2023-01-01 2023-09-30 0000855683 mlss:HandpiecesMember mlss:RestOfWorldMember 2023-01-01 2023-09-30 0000855683 mlss:AccessoriesMember mlss:RestOfWorldMember mlss:DentalSegmentMember 2024-01-01 2024-09-30 0000855683 mlss:AccessoriesMember mlss:RestOfWorldMember mlss:MedicalSegmentMember 2024-01-01 2024-09-30 0000855683 mlss:AccessoriesMember mlss:RestOfWorldMember 2024-01-01 2024-09-30 0000855683 mlss:AccessoriesMember mlss:RestOfWorldMember mlss:DentalSegmentMember 2023-01-01 2023-09-30 0000855683 mlss:AccessoriesMember mlss:RestOfWorldMember mlss:MedicalSegmentMember 2023-01-01 2023-09-30 0000855683 mlss:AccessoriesMember mlss:RestOfWorldMember 2023-01-01 2023-09-30 0000855683 mlss:RestOfWorldMember mlss:DentalSegmentMember 2024-01-01 2024-09-30 0000855683 mlss:RestOfWorldMember mlss:MedicalSegmentMember 2024-01-01 2024-09-30 0000855683 mlss:RestOfWorldMember 2024-01-01 2024-09-30 0000855683 mlss:RestOfWorldMember mlss:DentalSegmentMember 2023-01-01 2023-09-30 0000855683 mlss:RestOfWorldMember mlss:MedicalSegmentMember 2023-01-01 2023-09-30 0000855683 mlss:RestOfWorldMember 2023-01-01 2023-09-30 0000855683 mlss:InstrumentsMember country:CN mlss:DentalSegmentMember 2024-01-01 2024-09-30 0000855683 mlss:InstrumentsMember country:CN mlss:MedicalSegmentMember 2024-01-01 2024-09-30 0000855683 mlss:InstrumentsMember country:CN 2024-01-01 2024-09-30 0000855683 mlss:InstrumentsMember country:CN mlss:DentalSegmentMember 2023-01-01 2023-09-30 0000855683 mlss:InstrumentsMember country:CN mlss:MedicalSegmentMember 2023-01-01 2023-09-30 0000855683 mlss:InstrumentsMember country:CN 2023-01-01 2023-09-30 0000855683 mlss:HandpiecesMember country:CN mlss:DentalSegmentMember 2024-01-01 2024-09-30 0000855683 mlss:HandpiecesMember country:CN mlss:MedicalSegmentMember 2024-01-01 2024-09-30 0000855683 mlss:HandpiecesMember country:CN 2024-01-01 2024-09-30 0000855683 mlss:HandpiecesMember country:CN mlss:DentalSegmentMember 2023-01-01 2023-09-30 0000855683 mlss:HandpiecesMember country:CN mlss:MedicalSegmentMember 2023-01-01 2023-09-30 0000855683 mlss:HandpiecesMember country:CN 2023-01-01 2023-09-30 0000855683 mlss:AccessoriesMember country:CN mlss:DentalSegmentMember 2024-01-01 2024-09-30 0000855683 mlss:AccessoriesMember country:CN mlss:MedicalSegmentMember 2024-01-01 2024-09-30 0000855683 mlss:AccessoriesMember country:CN 2024-01-01 2024-09-30 0000855683 mlss:AccessoriesMember country:CN mlss:DentalSegmentMember 2023-01-01 2023-09-30 0000855683 mlss:AccessoriesMember country:CN mlss:MedicalSegmentMember 2023-01-01 2023-09-30 0000855683 mlss:AccessoriesMember country:CN 2023-01-01 2023-09-30 0000855683 country:CN mlss:DentalSegmentMember 2024-01-01 2024-09-30 0000855683 country:CN mlss:MedicalSegmentMember 2024-01-01 2024-09-30 0000855683 country:CN 2024-01-01 2024-09-30 0000855683 country:CN mlss:DentalSegmentMember 2023-01-01 2023-09-30 0000855683 country:CN mlss:MedicalSegmentMember 2023-01-01 2023-09-30 0000855683 country:CN 2023-01-01 2023-09-30 0000855683 mlss:DentalSegmentMember 2024-01-01 2024-09-30 0000855683 mlss:MedicalSegmentMember 2024-01-01 2024-09-30 0000855683 mlss:DentalSegmentMember 2023-01-01 2023-09-30 0000855683 mlss:MedicalSegmentMember 2023-01-01 2023-09-30 0000855683 mlss:ECommerceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-07-01 2024-09-30 0000855683 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-09-30 0000855683 mlss:DistributorOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-07-01 2024-09-30 0000855683 mlss:ECommerceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0000855683 mlss:DistributorOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-01-01 0000855683 mlss:ECommerceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0000855683 mlss:DistributorOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-09-30 0000855683 mlss:DistributorOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0000855683 mlss:ECommerceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0000855683 mlss:DistributorFourMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0000855683 mlss:DistributorOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0000855683 mlss:DistributorTwoMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0000855683 mlss:DistributorThreeMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0000855683 mlss:DistributorOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0000855683 mlss:DistributorTwoMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0000855683 mlss:DistributorThreeMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0000855683 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember us-gaap:RelatedPartyMember 2024-09-30 0000855683 mlss:VendorOneMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember us-gaap:RelatedPartyMember 2024-01-01 2024-09-30 0000855683 mlss:VendorTwoMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember us-gaap:RelatedPartyMember 2024-01-01 2024-09-30 0000855683 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember us-gaap:RelatedPartyMember 2023-12-31 0000855683 mlss:VendorOneMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember us-gaap:RelatedPartyMember 2023-01-01 2023-12-31 0000855683 mlss:VendorTwoMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember us-gaap:RelatedPartyMember 2023-01-01 2023-12-31 0000855683 mlss:VendorThreeMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember us-gaap:RelatedPartyMember 2023-01-01 2023-12-31 0000855683 mlss:ManufacturingAgreementForHandpiecesMember 2024-07-01 2024-09-30 0000855683 mlss:ManufacturingAgreementForHandpiecesMember 2024-01-01 2024-09-30 0000855683 mlss:ManufacturingAgreementForHandpiecesMember 2023-07-01 2023-09-30 0000855683 mlss:ManufacturingAgreementForHandpiecesMember 2023-01-01 2023-09-30 0000855683 mlss:ManufacturingAgreementForHandpiecesMember 2024-09-30 0000855683 mlss:AccountsPayableRelatedPartiesCurrentMember mlss:ManufacturingAgreementForHandpiecesMember us-gaap:RelatedPartyMember 2023-12-31 0000855683 mlss:DirectorClinicalAffairMember 2024-07-01 2024-09-30 0000855683 mlss:DirectorClinicalAffairMember 2024-01-01 2024-09-30 0000855683 mlss:DirectorClinicalAffairMember 2023-07-01 2023-09-30 0000855683 mlss:DirectorClinicalAffairMember 2023-01-01 2023-09-30 0000855683 mlss:DirectorOfClinicalAffairsMember 2024-09-30 0000855683 mlss:DirectorOfClinicalAffairsMember 2023-12-31 0000855683 mlss:InterimChiefExecutiveOfficerMember 2021-03-02 0000855683 mlss:DirectorClinicalAffairMember 2021-03-01 0000855683 mlss:DirectorClinicalAffairMember 2021-03-02 0000855683 mlss:PreviousPresidentAndChiefExecutiveOfficerMember 2017-07-10 2017-07-10 0000855683 mlss:ConsultantMember 2017-07-10 2017-07-10 0000855683 mlss:InterimChiefExecutiveOfficerMember 2021-04-06 2021-04-06 0000855683 mlss:ManagingDirectorChinaOperationsMember 2024-07-01 2024-09-30 0000855683 mlss:ManagingDirectorChinaOperationsMember 2023-07-01 2023-09-30 0000855683 mlss:ConsultantMember 2024-07-01 2024-09-30 0000855683 mlss:ConsultantMember 2023-07-01 2023-09-30 0000855683 mlss:PurchasedMedicalProductsMember mlss:UniversityPainMedicineCenterStemmeeMember 2024-07-01 2024-09-30 0000855683 mlss:PurchasedMedicalProductsMember mlss:UniversityPainMedicineCenterStemmeeMember 2024-01-01 2024-09-30 0000855683 mlss:PurchaseCommitmentForDevicesMember 2024-01-01 2024-09-30 0000855683 mlss:PurchaseCommitmentForDevicesMember 2024-09-30 0000855683 mlss:DevelopmentOfTheNextGenerationInstrumentMember 2024-09-30 0000855683 mlss:PurchaseCommitmentForDevicesMember 2023-12-31 0000855683 mlss:ContractsForFundingOfFutureEpiduralInstrumentsAndPartsMember 2024-09-30 0000855683 mlss:ContractsForFundingOfFutureEpiduralInstrumentsAndPartsMember 2023-12-31 0000855683 mlss:PresidentAndChiefExecutiveOfficerMember us-gaap:SubsequentEventMember 2024-11-08 0000855683 mlss:PresidentAndChiefExecutiveOfficerMember 2022-01-01 0000855683 srt:ScenarioForecastMember mlss:PresidentAndChiefExecutiveOfficerMember 2025-12-31 0000855683 srt:ScenarioForecastMember mlss:PresidentAndChiefExecutiveOfficerMember 2025-01-01 2025-03-31 0000855683 srt:ScenarioForecastMember mlss:PresidentAndChiefExecutiveOfficerMember 2025-04-01 2025-06-30 0000855683 srt:ScenarioForecastMember mlss:PresidentAndChiefExecutiveOfficerMember 2025-07-01 2025-09-30 0000855683 srt:ScenarioForecastMember mlss:PresidentAndChiefExecutiveOfficerMember 2025-10-01 2025-12-31 shares thunderdome:item iso4217:USD iso4217:USD shares pure utr:Y 0000855683 MILESTONE SCIENTIFIC INC. false --12-31 Q3 2024 10000 10000 0.001 0.001 100000000 100000000 77709455 77676122 75881840 75848507 33333 33333 42273 -154 -193 0 1200000 1400000 P3Y P5Y 17000 2 1 1 1 0.03 2 3 P5Y P0Y3M14D P1Y3M18D P2Y6M P3Y6M 66666 66666 false false false false 10-Q true 2024-09-30 false 001-14053 DE 13-3545623 425 Eagle Rock Avenue Suite 403 Roseland NJ 07068 973 535-2717 Common Stock, par value $.001 per share NYSE Yes Yes Non-accelerated Filer true false false 77892083 true 4775597 2977713 0 2976573 550969 312664 3013 0 646130 517785 3711636 2638186 1011306 1371548 10698651 10794469 11265 10024 155255 178636 2511 8998 283086 355235 24150 24150 11174918 11371512 1138060 689604 740017 410512 1267718 1511717 281947 137189 214000 214000 3088 10264 112955 103427 3757785 3076713 0 434 195649 281853 3953434 3359000 77710 75881 134072861 132187656 -126017571 -123339509 911516 911516 7221484 8012512 11174918 11371512 2513805 2059284 6616414 7566848 677585 555850 1692888 2284730 1836220 1503434 4923526 5282118 3064769 2823765 8968226 9834781 232056 170478 641235 524472 8574 15896 28735 49798 3305399 3010139 9638196 10409051 -1469179 -1506705 -4714670 -5126933 8008 30600 53513 102669 0 0 1983095 0 -1461171 -1476105 -2678062 -5024264 -1461171 -1476105 -2678062 -5024264 0 -9811 0 -33987 -1461171 -1466294 -2678062 -4990277 -0.02 -0.02 -0.03 -0.07 79966833 73730921 80165181 72374693 75881840 75881 132187656 -123339509 0 -911516 8012512 0 313505 0 0 0 313505 372110 372 191784 0 0 0 192156 103500 104 51647 0 0 0 51751 90170 90 65971 0 0 0 66061 30165 31 264922 0 0 0 264953 154494 154 -154 0 0 0 -1440529 0 0 -1440529 76632279 76632 133075331 -124780038 0 -911516 7460409 0 207690 0 0 0 207690 99063 99 62041 0 0 0 62140 322937 -324 0 0 0 0 18939 19 -19 154496 154 0 0 0 0 0 0 223638 0 0 223638 77227714 77228 133344565 -124556400 0 -911516 7953877 0 484078 0 0 0 484078 299198 299 244401 0 0 0 244700 182543 183 -183 0 0 0 0 0 0 -1461171 0 0 -1461171 77709455 77710 134072861 -126017571 0 -911516 7221484 69306497 69306 127478325 -116410405 -219276 -911516 10006434 388772 0 0 388772 256868 258 -258 0 50000 50000 242335 242 125758 0 0 0 126000 -1307666 -11665 -1319331 69805700 69806 128042597 -117718071 -230941 -911516 9251875 404330 404330 217500 0 0 0 217500 192835 193 0 0 0 0 109204 109 56677 0 0 0 56786 -2216317 -12511 0 -2228828 70107739 70108 128720911 -119934388 -243452 -911516 7701663 320325 0 0 0 320325 50000 0 0 0 50000 631523 632 396510 0 0 0 397142 154486 154 -154 0 0 0 0 -1466294 -9811 -1476105 70893748 70894 129487592 -121400682 -253263 -911516 6993025 -2678062 -5024264 5355 10155 23380 39643 1005273 1113427 0 109159 264953 317500 372901 579928 -0 -6208 0 16076 72149 69067 238305 -86629 3013 -0 1073450 799454 -360242 373852 128345 134881 448461 46538 329504 -166855 -243999 -13098 144758 103287 70189 65543 -1408387 -4080330 6596 1192 2976573 4472540 -0 6929218 2969977 -2457870 192156 0 51751 0 7613 6486 236294 -6486 1797884 -6544686 2977713 8715279 4775597 2170593 NOTE 1 — ORGANIZATION AND BUSINESS All references in this report to "Milestone Scientific," the "Company" or "Milestone" refer to Milestone Scientific Inc., and its consolidated subsidiaries, Wand Dental, Inc., and Milestone Innovation Inc., unless the context otherwise indicates. Milestone Scientific is the owner of the following registered U.S. trademarks: CompuDent®; CompuFlo®; DPS Dynamic Pressure Sensing technology®; Milestone Scientific ®; CathCheck®; the Milestone logo ®; SafetyWand®; STA Single Tooth Anesthesia

System®; and The Wand ®.   Milestone Scientific was incorporated in the State of Delaware in August 1989. Milestone Scientific has developed a proprietary, revolutionary, computer-controlled anesthetic delivery device, its DPS Dynamic Pressure Sensing Technology® System, to meet the needs of various subcutaneous drug delivery injections and fluid aspiration – enabling healthcare practitioners to achieve multiple unique benefits that cannot currently be accomplished with the 160-year-old manual syringe. The Company's proprietary DPS Dynamic Pressure Sensing Technology is the Company's technology platform that advances the development of next-generation devices. It regulates flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, used in various dental and medical injections. It has specific medical applications for epidural space identification in regional anesthesia procedures and intra-articular joint injections.   The Company's device, using The Wand®, a single use disposable handpiece, is marketed in dentistry under the trademarks CompuDent® and STA Single Tooth Anesthesia System®, and is suitable for all dental procedures that require local anesthetic. The dental devices are currently sold in the United States, Canada and in over 41 other countries. Milestone Scientific also has 510(k) marketing clearance from the U.S. Food and Drug Administration (FDA) on the CompuFlo® Epidural Computer Controlled Anesthesia System in the lumbar thoracic and cervical thoracic junction of the spinal region.   The Company current marketing focus is self-distribution using its e-commerce platform; however, it is also in the process of meeting with medical facilities and device distributors within the United States, Middle East and Europe so as to develop other channels of distribution. Certain of our medical instruments have obtained European CE mark approval and can be marketed and sold in most European countries. 41 NOTE 2- LIQUIDITY AND UNCERTAINTIES   The Company has evaluated whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the consolidated financial statements are issued. The Company has incurred total losses since inception of $126.0 million. The operating losses were $1.5 million and $4.7 million, for three and nine months ended September 30, 2024. On September 30, 2024, Milestone Scientific had cash and cash equivalents of approximately $4.8 million and working capital of approximately $6.9 million. For the nine months ended September 30, 2024, and 2023, we had cash flows used in operating activities of approximately $1.4 million and $4.1 million respectively.   Management has prepared financial forecasts covering a period of 12 months from the date of issuance of these financial statements. These forecasts include several revenue and operating expense assumptions which indicate that the Company's current cash and liquidity is sufficient to finance the operating requirements for at least the next 12 months from the filing date.   Milestone Scientific is actively pursuing the generation of positive cash flows from operating activities through an increase in revenue from its dental business worldwide, the generation of revenue from its medical devices and disposables business in the United States and worldwide, and a reduction in operating expenses. However, the Company's continued operations will depend on its ability to raise additional capital through various potential sources until it achieves profitability, if ever.   In addition to its employees, the Company relies on (i) distributors, agents, and third-party logistics providers in connection with product sales and distribution and (ii) raw material and component suppliers in the U.S., Europe, and China. If the Company, or any of these entities encounter any disruptions to its or their respective operations or facilities, or if the Company or any of these third-party partners were to shut down for any reason, including by fire, natural disaster, such as a hurricane, tornado or severe storm, power outage, systems failure, labor dispute, pandemic or other public health crises, or other unforeseen disruption, then the Company or they may be prevented or delayed from effectively operating its or their business, respectively.   -126000000 -1500000 -4700000 4800000 6900000 -1400000 -4100000 NOTE 3 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES   1. Principles of Consolidation   The accompanying consolidated unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP"), and the applicable rules and regulations of the Securities and Exchange Commission (SEC) include the accounts of Milestone Scientific and its wholly owned and majority owned subsidiaries, including, Wand Dental (wholly owned), and Milestone Innovations Inc. (wholly owned). All significant, intra-entity transactions and balances have been eliminated in the consolidation. Ownership interests in consolidated entities that are held by entities other than us are reported as noncontrolling interests in our consolidated balance sheets. Losses attributed to noncontrolling interests are reported separately in our consolidated statements of operations.   During December 2023, the Board of Directors of the Company approved the merger of Milestone Medical, Inc., a 98%-owned subsidiary of the Company ("MMD"), with and into Milestone Innovation, Inc, a newly form wholly-owned subsidiary of the Company and being the surviving corporation . As a result, all of the assets of MMD automatically became assets of Milestone Innovations, Inc. Subsequent to September 30, 2024, the Company satisfied it's liabilities to the non-controlling shareholders, the Company settled for approximately $205,000 for the minority stake of MMD.   2. Basis of Presentation   The unaudited condensed consolidated financial statements of Milestone Scientific have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information with the instructions for Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by GAAP for complete annual financial statements. In the opinion of management, the accompanying unaudited consolidated financial statements contain all adjustments (consisting of normal recurring entries) necessary to fairly present such interim results. Interim results are not necessarily indicative of the results of operations which may be expected for a full year or any subsequent period. These unaudited consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2023, included in Milestone Scientific's Annual Report on Form 10-K.   3. Use of Estimates   The preparation of unaudited consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions in determining the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to inventory valuation and cash flow assumptions regarding evaluations of going concern considerations. The Company bases its estimates on historical experience, known trends and other market-specific or relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.   4. Revenue Recognition   The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To perform revenue recognition, the Company performs the following five steps: <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:auto;"> i. </td><td style="vertical-align:top;width:auto;"> identification of the promised goods or services in the contract; </td></tr> <tr><td style="vertical-align:top;width:auto;"> ii. </td><td style="vertical-align:top;width:auto;"> determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; </td></tr> <tr><td style="vertical-align:top;width:auto;"> iii. </td><td style="vertical-align:top;width:auto;"> measurement of the transaction price, including the constraint on variable consideration; </td></tr> <tr><td style="vertical-align:top;width:auto;"> iv. </td><td style="vertical-align:top;width:auto;"> allocation of the transaction price to the performance obligations based on estimated selling prices; and </td></tr> <tr><td style="vertical-align:top;width:auto;"> v. </td>

<td style="vertical-align:top;width:auto;"> recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC 606. </td></tr> </tbody></table>   The Company derives its revenues from the sale of its products, primarily dental instruments, handpieces, and other related products. The Company sells its products directly to consumers in the United States and through a global distribution network that includes both exclusive and non-exclusive distribution agreements with related and third parties.   Revenue from product sales is recognized upon transfer of control of a product to a customer, generally upon date of shipment. The Company has no obligation on product sales for any installation, set-up, or maintenance, these being the responsibility of the buyer. Milestone Scientific's only obligation after sale is the normal commercial warranty against manufacturing defects if the alleged defective unit is returned within the warranty period.   E-Commerce   As of January 3, 2023, the Company launched an E-Commerce platform, selling and shipping STA Single Tooth Anesthesia Systems® (STA) and handpieces directly to dental offices and dental groups within the United States. Our E-commerce portal accepts online payments via credit and debit cards. The cost of delivery is charged to the customer along with appropriate sales tax. The Company recognizes revenue from product sales at the time the product ships to a customer via a third-party carrier.   Sales Returns   The Company records allowances for product returns as a reduction of revenue at the time product sales are recorded. Several factors are considered in determining whether an allowance for product returns is required, including the customers' return rights and the Company's historical experience with returns and the amount of product in the distribution channel not consumed by end users and subject to return. The Company relies on historical return rates to estimate returns.   Financing and Payment   The Company's payment terms differ by geography and customer, but payments from distributors are required within 90 days or less from the date of shipment. The E-commerce portal sells directly to end users and accepts online payments via credit and debit cards via a third-party. These payments from the third party are typically settled within two business days.   Disaggregation of Revenue   The Company operates in two operating segments: dental and medical. Therefore, the results of the Company's operations are reported on a consolidated basis for the purposes of segment reporting, consistent with internal management reporting. See Note 8 for revenues by geographical market, based on the customer's location, and product category for the three and nine months periods ended September 30, 2024, and 2023, respectively.   5. Cash and Cash Equivalents   Milestone Scientific considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. As of September 30, 2024, and December 31, 2023, Milestone Scientific has approximately $4.8 million and $3.0 million, respectively of cash and cash equivalents. As of September 30, 2024, Milestone Scientific had approximately $4.1 million in cash, cash equivalents, in accounts that exceeded the Federal Deposit Insurance Corporation insurance limit of $250,000.   6. Marketable Securities   The Company's marketable securities are comprised of treasury bills with original maturity greater than three months from date of purchase. The Company's marketable securities are measured at fair value and are accounted for in accordance with ASC 825, Financial Instruments. Unrealized holding gains and losses on treasury bills are recorded in interest income on the unaudited consolidated statements of operations. Dividend and interest income are recognized when earned. Realized gains and losses are included in earnings and are derived using the specific identification method for determining the cost of the marketable securities. As of September 30, 2024, the Company did not hold any marketable securities. As of December 31, 2023 the Company held approximately $3.0 million in U.S. treasury securities, with maturity dates within 3 and 6 months.   7. Accounts Receivable   The E-commerce portal sells directly to end users and accepts online payments via credit and debit cards via a third-party credit card processor. These payments are settled within two business days of the transactions. Sales to distributors are on credit terms. The Company estimates losses from the ability or inability of its distributor to make payments on amounts billed.   Distributors credit sales are due 90 days or less from the date of invoicing. As of September 30, 2024 and December 31, 2023, accounts receivable was recorded, net of allowance for credit losses of $10,000, respectively.   8. Inventories   Inventories principally consist of finished goods and component parts stated at the lower of cost (first-in, first-out method) or net realizable value. Inventory quantities on hand are reviewed on a quarterly basis and a provision for excess, slow moving, defective, and obsolete inventory is recorded if required based on past and expected future sales, potential technological obsolescence, and product expiration requirements.   The valuation allowance creates a new cost basis for the inventory, and it is not subsequently marked up through a reduction in the valuation allowance based on any changes in the underlying facts and circumstances. When the valuation allowance is initially recorded, the increase to the allowance is recognized as an increase in cost of sales. The valuation allowance is only reduced if or when the underlying inventory is sold or destroyed, at which time cost of sales recognized would include the previous adjusted cost basis.   9. Basic and Diluted Net Loss Per Common Share   Milestone Scientific presents "basic" earnings (loss) per common share applicable to common stockholders and, if applicable, "diluted" earnings (loss) per common share applicable to common stockholders pursuant to the provisions of ASC 260, "Earnings per Share". Basic earnings (loss) per common share is calculated by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding and to be issued common shares as follows: 79,966,833 and 73,730,921 for the three months ended September 30, 2024 and 2023, respectively, and 80,165,181 and 72,374,693 for the nine months ended September 30, 2024 and 2023, respectively. The calculation of diluted earnings per common share is like that of basic earnings per common share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if all potentially dilutive common shares, such as those issuable upon the exercise of stock options and warrants, were issued during the period. Since Milestone Scientific had net losses in the three and nine months ended September 30, 2024 and the three and nine months ended September 30, 2023, the assumed effects of the exercise of potentially dilutive outstanding stock options, unissued restricted stock awards ("RSA") and warrants, were not included in the calculation as their effect would have been anti-dilutive. Such outstanding options, RSA's and warrants totaled 3,684,697 and 3,930,654 for the nine months ended September 30, 2024 and 2023, respectively.   10. Fair Value of Financial Instruments   Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction

*between market participants in the principal market at the measurement date (exit price). The Company required us to classify fair value measurements in one of the following categories. <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:middle;width:8.6%;"> </td><td style="vertical-align:top;width:4%;"> ● </td><td style="vertical-align:top;width:auto;"> Level 1 inputs which are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company can access at the measurement date. </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:middle;width:8.6%;"> </td><td style="vertical-align:top;width:4%;"> ● </td><td style="vertical-align:top;width:auto;"> Level 2 inputs which are defined as inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly. </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:middle;width:8.6%;"> </td><td style="vertical-align:top;width:4%;"> ● </td><td style="vertical-align:top;width:auto;"> Level 3 inputs are defined as unobservable inputs for the assets or liabilities. </td></tr> </tbody></table>   Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of an input to the fair value measurement requires judgment and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.   As of September 30, 2024 the Company did not have assets measured at fair value on a recurring basis. As of December 31, 2023 the Company had the following assets that were measured at fair value on a recurring basis: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 7.5%; margin-left: 7.5%; width: 85%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center;"> </td><td colspan="2" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Level 1 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Level 2 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Level 3 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Total </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Marketable Securities December 31, 2023 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,976,573</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">2,976,573</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table>   Marketable Securities included US Treasury securities totaling $2,976,573 that are considered to be highly liquid and easily transferable at December 31, 2023. US Treasury securities are valued using inputs observable in active markets for identical securities and are therefore classified at Level 1 within the Company fair value hierarchy.   11. Stock-Based Compensation
  Milestone Scientific accounts for stock-based compensation under ASC Topic 718, Share-Based Payment (“ASC Topic 718”). ASC Topic 718 requires all share-based payments to employees, non-employees, directors, and officers, including grants of employee stock options, to be recognized in the unaudited consolidated statements of operations over the service period, as an operating expense, based on the grant-date fair values.   12. Recent Accounting Pronouncements   Recently Issued Accounting Pronouncement   In November 2023, FASB issued ASU 2023-07, Segment Reporting (Topic 280), Improvements to Reportable Segment Disclosures, which provides improvements to reportable segment disclosure requirements, primarily through enhanced disclosures around segment expenses. ASU 2023-07 requires us to disclose significant segment expenses that are regularly provided to the chief operating decision maker (“CODM”) and included within each reported measure of segment profit or loss. ASU 2023-07 also requires that the Company disclose an amount for other segment items by reportable segment, a description of their composition and provide all annual disclosures about a reportable segment’s profit or loss and assets pursuant to Topic 280 during interim periods. The Company must also disclose the CODM’s title and position, as well as certain information around the measures used by the CODM and an explanation of how the CODM uses the reported measures in assessing segment performance and deciding how to allocate resources. For public entities with a single reportable segment, the entity must provide all the disclosures required pursuant to ASU 2023-07 and all existing segment disclosures under Topic 280. The amendments of ASU 2023-07 are effective for the Company for annual periods beginning January 1, 2024, and effective for interim periods beginning January 1, 2025. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. The Company expects to adopt this standard effective January 1, 2024, at December 31, 2024 on the Company’s annual Form 10-K filing. The Company expects to update all required disclosures pursuant to this ASU 2023-07 at that time. The Company is evaluating the impact of ASU 2023-07 on our financial statements.   In December 2023, FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, to enhance the transparency and decision usefulness of income tax disclosures. The amendments in ASU 2023-09 provide improvements primarily related to the rate reconciliation and income taxes paid information included in income tax disclosures. The Company would be required to disclose additional information regarding reconciling items equal to or greater than five percent of the amount computed by multiplying pretax income (loss) by the applicable statutory tax rate. Similarly, the Company would be required to disclose income taxes paid (net of refunds received) equal to or greater than five percent of total income taxes paid (net of refunds received). Additionally, the Company would be required to disclose income (loss) from continuing operations before income tax expense disaggregated by foreign and domestic jurisdictions, as well as income tax expense disaggregated by federal, state, and foreign jurisdictions. The amendments in ASU 2023-09 are effective January 1, 2025, including interim*

periods. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. The Company is currently evaluating the impact of ASU 2023-09 on our financial statements.   1. Principles of Consolidation   The accompanying consolidated unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP"), and the applicable rules and regulations of the Securities and Exchange Commission (SEC) include the accounts of Milestone Scientific and its wholly owned and majority owned subsidiaries, including, Wand Dental (wholly owned), and Milestone Innovations Inc. (wholly owned). All significant, intra-entity transactions and balances have been eliminated in the consolidation. Ownership interests in consolidated entities that are held by entities other than us are reported as noncontrolling interests in our consolidated balance sheets. Losses attributed to noncontrolling interests are reported separately in our consolidated statements of operations.   During December 2023, the Board of Directors of the Company approved the merger of Milestone Medical, Inc., a 98%-owned subsidiary of the Company ("MMD"), with and into Milestone Innovation, Inc, a newly form wholly-owned subsidiary of the Company and being the surviving corporation . As a result, all of the assets of MMD automatically became assets of Milestone Innovations, Inc. Subsequent to September 30, 2024, the Company satisfied it's liabilities to the non-controlling shareholders, the Company settled for approximately $205,000 for the minority stake of MMD. 205000 2. Basis of Presentation   The unaudited condensed consolidated financial statements of Milestone Scientific have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information with the instructions for Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by GAAP for complete annual financial statements. In the opinion of management, the accompanying unaudited consolidated financial statements contain all adjustments (consisting of normal recurring entries) necessary to fairly present such interim results. Interim results are not necessarily indicative of the results of operations which may be expected for a full year or any subsequent period. These unaudited consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2023, included in Milestone Scientific's Annual Report on Form 10-K. 3. Use of Estimates   The preparation of unaudited consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions in determining the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to inventory valuation and cash flow assumptions regarding evaluations of going concern considerations. The Company bases its estimates on historical experience, known trends and other market-specific or relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates. 4. Revenue Recognition   The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To perform revenue recognition, the Company performs the following five steps: <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:auto;"> i. </td><td style="vertical-align:top;width:auto;"> identification of the promised goods or services in the contract; </td></tr><tr><td style="vertical-align:top;width:auto;"> ii. </td><td style="vertical-align:top;width:auto;"> determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; </td></tr><tr><td style="vertical-align:top;width:auto;"> iii. </td><td style="vertical-align:top;width:auto;"> measurement of the transaction price, including the constraint on variable consideration; </td></tr> <tr><td style="vertical-align:top;width:auto;"> iv. </td><td style="vertical-align:top;width:auto;"> allocation of the transaction price to the performance obligations based on estimated selling prices; and </td></tr> <tr><td style="vertical-align:top;width:auto;"> v. </td><td style="vertical-align:top;width:auto;"> recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC 606. </td></tr></tbody></table>   The Company derives its revenues from the sale of its products, primarily dental instruments, handpieces, and other related products. The Company sells its products directly to consumers in the United States and through a global distribution network that includes both exclusive and non-exclusive distribution agreements with related and third parties.   Revenue from product sales is recognized upon transfer of control of a product to a customer, generally upon date of shipment. The Company has no obligation on product sales for any installation, set-up, or maintenance, these being the responsibility of the buyer. Milestone Scientific's only obligation after sale is the normal commercial warranty against manufacturing defects if the alleged defective unit is returned within the warranty period.   E-Commerce   As of January 3, 2023, the Company launched an E-Commerce platform, selling and shipping STA Single Tooth Anesthesia Systems® (STA) and handpieces directly to dental offices and dental groups within the United States. Our E-commerce portal accepts online payments via credit and debit cards. The cost of delivery is charged to the customer along with appropriate sales tax. The Company recognizes revenue from product sales at the time the product ships to a customer via a third-party carrier.   Sales Returns   The Company records allowances for product returns as a reduction of revenue at the time product sales are recorded. Several factors are considered in determining whether an allowance for product returns is required, including the customers' return rights and the Company's historical experience with returns and the amount of product in the distribution channel not consumed by end users and subject to return. The Company relies on historical return rates to estimate returns.   Financing and Payment   The Company's payment terms differ by geography and customer, but payments from distributors are required within 90 days or less from the date of shipment. The E-commerce portal sells directly to end users and accepts online payments via credit and debit cards via a third-party. These payments from the third party are typically settled within two business days.   Disaggregation of Revenue   The Company operates in two operating segments: dental and medical. Therefore, the results of the Company's operations are reported on a consolidated basis for the purposes of segment reporting, consistent with internal management reporting. See Note 8 for revenues by geographical market, based on the customer's location, and product category for the three and nine months periods ended September 30, 2024, and 2023, respectively. 2 5. Cash and Cash Equivalents   Milestone Scientific considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. As of September 30, 2024, and December 31, 2023, Milestone Scientific has approximately $4.8 million and $3.0 million, respectively of cash and cash equivalents. As of September 30, 2024, Milestone Scientific had approximately $4.1 million in cash, cash equivalents, in accounts that exceeded the Federal Deposit Insurance Corporation insurance limit of $250,000. 4800000 3000000 4100000 6. Marketable Securities   The Company's marketable securities are comprised of treasury bills with original maturity greater than three months from date of purchase. The Company's marketable securities are measured at fair value and are accounted for in accordance with ASC 825, Financial Instruments. Unrealized holding gains and losses on treasury bills are recorded in interest income on the unaudited consolidated statements of operations. Dividend and interest income are recognized when earned. Realized gains and losses are included in earnings and are derived using the specific identification method for determining the cost of the marketable securities. As of September 30, 2024, the Company did not hold any marketable securities. As

of December 31, 2023 the Company held approximately $3.0 million in U.S. treasury securities, with maturity dates within 3 and 6 months. 3000000 7. Accounts Receivable   The E-commerce portal sells directly to end users and accepts online payments via credit and debit cards via a third-party credit card processor. These payments are settled within two business days of the transactions. Sales to distributors are on credit terms. The Company estimates losses from the ability or inability of its distributor to make payments on amounts billed.   Distributors credit sales are due 90 days or less from the date of invoicing. As of September 30, 2024 and December 31, 2023, accounts receivable was recorded, net of allowance for credit losses of $10,000, respectively.</p> 10000 <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><em style="font: inherit;">8. Inventories</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">Inventories principally consist of finished goods and component parts stated at the lower of cost (<em style="font: inherit;">first-in, <em style="font: inherit;">first-out method) or net realizable value. Inventory quantities on hand are reviewed on a quarterly basis and a provision for excess, slow moving, defective, and obsolete inventory is recorded if required based on past and expected future sales, potential technological obsolescence, and product expiration requirements.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">The valuation allowance creates a new cost basis for the inventory, and it is <em style="font: inherit,">not subsequently marked up through a reduction in the valuation allowance based on any changes in the underlying facts and circumstances. When the valuation allowance is initially recorded, the increase to the allowance is recognized as an increase in cost of sales. The valuation allowance is only reduced if or when the underlying inventory is sold or destroyed, at which time cost of sales recognized would include the previous adjusted cost basis.</p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;"><em style="font: inherit,">9. Basic and Diluted Net Loss Per Common Share</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Milestone Scientific presents "basic" earnings (loss) per common share applicable to common stockholders and, if applicable, "diluted" earnings (loss) per common share applicable to common stockholders pursuant to the provisions of ASC <em style="font: inherit;">260, "Earnings per Share". Basic earnings (loss) per common share is calculated by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding and to be issued common shares as follows: 79,966,833 and 73,730,921 for the <em style="font: inherit;">three months ended <em style="font: inherit,"> September 30, 2024 and <em style="font: inherit;">2023, respectively, and 80,165,181 and 72,374,693 for the <em style="font: inherit,">nine months ended <em style="font: inherit,"> September 30, 2024 and <em style="font: inherit;">2023, respectively. The calculation of diluted earnings per common share is like that of basic earnings per common share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if all potentially dilutive common shares, such as those issuable upon the exercise of stock options and warrants, were issued during the period. Since Milestone Scientific had net losses in the <em style="font: inherit;">three and <em style="font: inherit;">nine months ended <em style="font: inherit,"> September 30, 2024 and the <em style="font: inherit;">three and <em style="font: inherit;">nine months ended <em style="font: inherit;"> September 30, 2023, the assumed effects of the exercise of potentially dilutive outstanding stock options, unissued restricted stock awards ("RSA") and warrants, were <em style="font: inherit;">not included in the calculation as their effect would have been anti-dilutive. Such outstanding options, RSA's and warrants totaled 3,684,697 and 3,930,654 for the <em style="font: inherit,">nine months ended <em style="font: inherit,"> September 30, 2024 and <em style="font: inherit;">2023, respectively.</p> 79966833 73730921 80165181 72374693 3684697 3930654 <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;"><em style="font: inherit;">10. Fair Value of Financial Instruments</p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company required us to classify fair value measurements in <em style="font: inherit,">one of the following categories.</p> <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:middle;width:8.6%;"> </td><td style="vertical-align:top;width:4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Level <em style="font: inherit,">1 inputs which are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company can access at the measurement date.</p> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:middle;width:8.6%;"> </td><td style="vertical-align:top;width:4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Level <em style="font: inherit,">2 inputs which are defined as inputs other than quoted prices included within Level <em style="font: inherit;">1 that are observable for the assets or liabilities, either directly or indirectly.</p> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:middle;width:8.6%;"> </td><td style="vertical-align:top;width:4%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Level <em style="font: inherit,">3 inputs are defined as unobservable inputs for the assets or liabilities.</p> </td></tr> </tbody></table> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of an input to the fair value measurement requires judgment and <em style="font: inherit;"> may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">As of <em style="font: inherit;"> September 30, 2024 the Company did <em style="font: inherit;">not have assets measured at fair value on a recurring basis. As of <em style="font: inherit,"> December 31, 2023 the Company had the following assets that were measured at fair value on a recurring basis: </p> <p style="text-align: right; font-size: 10pt; font-family: "Times New Roman", Times, serif; margin: 0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 7.5%; margin-left: 7.5%; width: 85%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center;"> </td><td colspan="2" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><em style="font: inherit;">Level 1</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="font-family: "Times New Roman", Times, serif, font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><em style="font: inherit;">Level 2</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><em style="font: inherit;">Level 3</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><em style="font: inherit;">Total</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Marketable Securities December 31, 2023</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,976,573</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">2,976,573</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table>   Marketable Securities included US Treasury securities totaling $2,976,573 that are considered to be highly liquid and easily transferable at December 31, 2023. US Treasury securities are valued using inputs observable in active markets for identical securities and are therefore classified at Level 1 within the Company fair value hierarchy. <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 7.5%; margin-left: 7.5%; width: 85%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; font-family: "Times New

Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center;"> </td><td colspan="2" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Level 1 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Level 2 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Level 3 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Total </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Marketable Securities December 31, 2023 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,976,573</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">2,976,573</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> 2976573 0 0 2976573 2976573 11. Stock-Based Compensation
  Milestone Scientific accounts for stock-based compensation under ASC Topic 718, Share-Based Payment (“ASC Topic 718”). ASC Topic 718 requires all share-based payments to employees, non-employees, directors, and officers, including grants of employee stock options, to be recognized in the unaudited consolidated statements of operations over the service period, as an operating expense, based on the grant-date fair values. 12. Recent Accounting Pronouncements   Recently Issued Accounting Pronouncement   In November 2023, FASB issued ASU 2023-07, Segment Reporting (Topic 280), Improvements to Reportable Segment Disclosures, which provides improvements to reportable segment disclosure requirements, primarily through enhanced disclosures around segment expenses. ASU 2023-07 requires us to disclose significant segment expenses that are regularly provided to the chief operating decision maker (“CODM”) and included within each reported measure of segment profit or loss. ASU 2023-07 also requires that the Company disclose an amount for other segment items by reportable segment, a description of their composition and provide all annual disclosures about a reportable segment’s profit or loss and assets pursuant to Topic 280 during interim periods. The Company must also disclose the CODM’s title and position, as well as certain information around the measures used by the CODM and an explanation of how the CODM uses the reported measures in assessing segment performance and deciding how to allocate resources. For public entities with a single reportable segment, the entity must provide all the disclosures required pursuant to ASU 2023-07 and all existing segment disclosures under Topic 280. The amendments of ASU 2023-07 are effective for the Company for annual periods beginning January 1, 2024, and effective for interim periods beginning January 1, 2025.Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. The Company expects to adopt this standard effective January 1, 2024, at December 31, 2024 on the Company’s annual Form 10-K filing. The Company expects to update all required disclosures pursuant to this ASU 2023-07 at that time. The Company is evaluating the impact of ASU 2023-07 on our financial statements.   In December 2023, FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, to enhance the transparency and decision usefulness of income tax disclosures. The amendments in ASU 2023-09 provide improvements primarily related to the rate reconciliation and income taxes paid information included in income tax disclosures. The Company would be required to disclose additional information regarding reconciling items equal to or greater than five percent of the amount computed by multiplying pretax income (loss) by the applicable statutory tax rate. Similarly, the Company would be required to disclose income taxes paid (net of refunds received) equal to or greater than five percent of total income taxes paid (net of refunds received). Additionally, the Company would be required to disclose income (loss) from continuing operations before income tax expense disaggregated by foreign and domestic jurisdictions, as well as income tax expense disaggregated by federal, state, and foreign jurisdictions. The amendments in ASU 2023-09 are effective January 1, 2025, including interim periods. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. The Company is currently evaluating the impact of ASU 2023-09 on our financial statements. NOTE 4 — INVENTORIES   Inventories consist of the following: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 7.5%; margin-left: 7.5%; width: 85%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> September 30, 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> December 31, 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 64%;"> Dental finished goods </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,637,356</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,404,970</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Medical finished goods </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td

style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">14,730</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Component parts and other materials </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">74,280</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">218,486</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total inventories </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,711,636</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,638,186</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table>   The Company has recorded an allowance on slow moving Medical finished goods due to the slow adoption of the epidural instruments and handpieces for approximately $1.2 million as of <em style="font: inherit;"> September 30, 2024 and <em style="font: inherit;"> December 31, 2023, respectively. </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 7.5%; margin-left: 7.5%; width: 85%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">September 30, 2024</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">December 31, 2023</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 64%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Dental finished goods</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,637,356</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,404,970</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Medical finished goods</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">14,730</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Component parts and other materials</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">74,280</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">218,486</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total inventories</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,711,636</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,638,186</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> 3637356 2404970 0 14730 74280 218486 3711636 2638186 1200000 NOTE 5 — ADVANCES ON CONTRACTS   The advances on contracts represent funding of future STA devices, epidural instruments, and epidural replacements parts. The balance of the advances on contract as of September 30, 2024 and December 31, 2023 is approximately $1.0 million and $1.4 million, respectively. The advance is classified as current based on the estimated annual usage of the underlying inventory. 1000000 NOTE 6— STOCKHOLDERS’ EQUITY   Public offering   On December 10, 2023, the Company completed a public offering for sale of 4,765,000 common stock, at $0.63 per share which generated net proceeds of approximately $2.6 million. In addition, the Company granted the Underwriter a 45-day option to purchase up to an additional 714,750 shares of Common Stock at the same price to cover over-allotments.   On January 12, 2024 the underwriter exercised its over-allotment option as to 372,110 shares of common stock for net proceeds after discounts and commission of $192,156.   Warrants   The following table summarizes information about shares issuable under warrants outstanding as of September 30, 2024:   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 7.5%; margin-left: 7.5%; width: 85%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"> Warrant shares outstanding </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times

New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black,"> Weighted Average exercise price </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid black,"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black,"> Weighted Average remaining life </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid black,"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black,"> Intrinsic value </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid black,"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> Outstanding at January 1, 2024 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">314,572</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.50</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.10</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">59,737</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Issued </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Exercised </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(103,500</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.50</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Expired or cancelled </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black,">(211,072</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black,">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid black,"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">0.50</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black,">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black,">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Outstanding and exercisable at September 30, 2024 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table>   During the nine months ended September 30, 2024, the Company issued 103,500 shares of common stock for warrants issued in 2019. The warrants were exercised at $0.50 for proceeds of $51,751.   Shares to Be Issued   As of September 30, 2024 and 2023, respectively, there were 2,657,058 and 2,426,364 shares issuable, the issuance of which has been deferred under the terms of employment agreements with the Chief Executive Officer and other employees of Milestone Scientific. Such shares are issuable to each party upon termination of their respective employment.   As of September 30, 2024 and 2023, respectively, there were 527,625 and 382,696 shares issuable to non-employees, for services rendered. The number of shares was fixed at the date of grant and were fully vested upon grant date.   The following table summarizes activity for shares to be issued for the nine months periods ending September 30, 2024 and 2023. <p

style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 7.5%; margin-left: 7.5%; width: 85%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> September 30, 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> September 30, 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 64%;"> Shares-to-be-issued, outstanding January 1, 2024 and 2023, respectively </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,098,917</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,440,673</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Granted in current period </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">438,868</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">368,387</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Issued in current period </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">(353,102)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Shares-to be issued outstanding September 30, 2024 and 2023, respectively </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,184,683</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,809,060</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> Stock Options Plans   The Milestone Scientific Inc., Amended and Restated 2020 Equity Incentive Plan (the "2020 Plan"), provides for awards of restricted common stock restricted stock units, options to purchase and other awards. On June 28, 2023 the 2020 Plan was amended and restated to increase the maximum shares that can be issued thereunder to 11,500,000 shares of common stock. The plan expires in June 2031. Options may be granted to employees, directors, and consultants of Milestone Scientific for the purchase of shares of common stock at a price not less than the fair market value of common stock on the date of grant. Generally, options become exercisable over a three-year period from the grant date and expire five years after the date of grant.   Milestone Scientific recognizes compensation expenses over the requisite service period and in the case of performance-based options over the period of the expected performance. For the three and nine months ended September 30, 2024, Milestone Scientific recognized approximately $172,000 and $530,000 of total employee compensation cost, respectively, recorded in general and administrative expenses on the statement of operations. For the three and nine months ended September 30, 2023, Milestone Scientific recognized approximately $321,000 and $1.1 million of total employee compensation cost, respectively, recorded in general and administrative expenses on the statement of operations.   As of September 30, 2024, there was $1.0 million of total unrecognized compensation cost related to non-vested options. Milestone Scientific expects to recognize these costs over a weighted average period of 1.5 years.   A summary of option activity for employees under the plans and changes during the nine months ended September 30, 2024 is presented below: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 7.5%; margin-left: 7.5%; width: 85%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Number of Options </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Weighted Averaged Exercise Price $ </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Weighted Average Remaining Contractual Life (Years) </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Aggregate Intrinsic Options Value $ </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> Options outstanding at January 1, 2024 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,036,989</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2.29</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5.41</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family:

"Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Granted during 2024 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Exercised during 2024 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Forfeited or expired during 2024 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Options outstanding September 30, 2024 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,036,989</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2.32</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4.66</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Exercisable, September 30, 2024 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,188,433</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2.29</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4.06</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table>   A summary of option activity for non-employees under the plans and changes during the nine months ended September 30, 2024 is presented below: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 7.5%; margin-left: 7.5%; width: 85%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Number of Options </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Weighted Averaged Exercise Price $ </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Weighted Average Remaining Contractual Life (Years) </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Aggregate Intrinsic Options Value $ </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> Options outstanding at January 1, 2024 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">91,663</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1.76</td><td style="width:

1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2.25</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,833</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Granted during 2024 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">24,999</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.84</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4.71</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Exercised during 2024 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Forfeited or expired during 2024 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(16,666</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">0.55</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Options outstanding September 30, 2024 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">99,996</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1.74</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2.37</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,083</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Exercisable, September 30, 2024 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">77,772</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1.99</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1.81</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,916</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table>   For the three and nine months ended September 30, 2024, Milestone Scientific recognized approximately $7,000 and $9,200 respectively of expense related to non-employee options. For the three and nine months ended September 30, 2023, Milestone Scientific recognized approximately $3,800 and$17,000, respectively of expense related to non-employee options.   The information below summarizes the restricted stock award activity for the nine months ended September 30, 2024.   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 7.5%; margin-left: 7.5%; width: 85%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Number of Shares </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Weighted Average Grant-Date Fair Value per Award </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 64%;"> Non-vested as January 1, 2024 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">327,937</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 15%; text-align: right;

font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.91</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Granted </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">730,340</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.89</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Vested </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(510,522</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.91</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Cancelled </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">–</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">–</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Non-vested as September 30, 2024 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">547,755</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.89</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table>   As of September 30, 2024, all restricted shares granted and deferred under the terms of employment agreements with each Territory Manager of Milestone Scientific are fully vested. For the three and nine months ended September 30, 2024, the Company recognized stock compensation expense of approximately $0 and $2,100 respectively. For the three and nine months ended September 30, 2023, the Company recognized stock compensation expense of approximately negative $36,500 and $17,700 respectively. For the nine months ended September 30, 2024, there was no unrecognized compensation expense.   As of July 16, 2024, the Company entered into restricted stock agreements with members of the Board of Directors of the Company. The Company granted 730,340 restricted stock awards with a fair market value of $0.89 per share. Such restricted stock vests as follows: 25% on the grant date in July 2024, and 25% quarterly, on the first day of the following months: October 2024, January 2025, and April 2025.For the three and nine months ended September 30, 2024, the Company recognized approximately $306,000 and $464,000, respectively, for restricted stock expenses recorded in general and administrative expenses on the statement of operations. For the nine months ended September 30, 2024, there was $344,000 of total unrecognized compensation cost related to non-vested restricted stock grant, which the Company expects to recognize these costs over a weighted average period of 0.5 years. 4765000 0.63 2600000 714750 372110 192156 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 7.5%; margin-left: 7.5%; width: 85%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"> Warrant shares outstanding </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"> Weighted Average exercise price </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"> Weighted Average remaining life </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"> Intrinsic value </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> Outstanding at January 1, 2024 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">314,572</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.50</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.10</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">59,737</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Issued </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">–</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">–</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">–</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">–</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Exercised </td><td style="width:

1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(103,500</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.50</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Expired or cancelled </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">(211,072</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">0.50</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Outstanding and exercisable at September 30, 2024 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> 314572 0.5 P0Y1M6D 59737 0 0 103500 0.5 211072 0.5 0 0 0 103500 0.5 51751 2657058 2426364 527625 382696 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 7.5%; margin-left: 7.5%; width: 85%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> September 30, 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> September 30, 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 64%;"> Shares-to-be-issued, outstanding January 1, 2024 and 2023, respectively </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,098,917</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,440,673</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Granted in current period </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">438,868</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">368,387</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Issued in current period </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">(353,102</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Shares-to be issued outstanding September 30, 2024 and 2023, respectively </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,184,683</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,809,060</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> 3098917 2440673 438868 368387 353102 -0 3184683 2809060 11500000 172000 530000 321000 1100000 1000000 P1Y6M <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 7.5%; margin-left: 7.5%; width: 85%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Number of Options </td><td style="font-family: "Times New Roman", Times,

serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Weighted Averaged Exercise Price $ </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Weighted Average Remaining Contractual Life (Years) </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Aggregate Intrinsic Options Value $ </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> Options outstanding at January 1, 2024 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,036,989</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2.29</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5.41</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Granted during 2024 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;">-</td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Exercised during 2024 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Forfeited or expired during 2024 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Options outstanding September 30, 2024 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,036,989</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2.32</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4.66</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Exercisable, September 30, 2024 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,188,433</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2.29</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4.06</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 7.5%; margin-left: 7.5%; width: 85%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman",

Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Number of Options </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Weighted Averaged Exercise Price $ </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Weighted Average Remaining Contractual Life (Years) </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Aggregate Intrinsic Options Value $ </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> Options outstanding at January 1, 2024 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">91,663</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1.76</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2.25</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,833</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Granted during 2024 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">24,999</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.84</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4.71</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Exercised during 2024 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Forfeited or expired during 2024 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(16,666</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">0.55</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Options outstanding September 30, 2024 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">99,996</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1.74</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2.37</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,083</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Exercisable, September 30, 2024 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">77,772</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1.99</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1.81</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,916</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 3036989 2.29 P5Y4M28D 0 0 0 0 0 0 0 3036989 2.32 P4Y7M28D 2188433 2.29 P4Y21D 91663 1.76 P2Y3M 2833 24999 0.84 P4Y8M15D -0 0 16666 0.55 99996 1.74 P2Y4M13D 4083 77772 1.99 P1Y9M21D 1916 7000 9200 3800 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 7.5%; margin-left: 7.5%; width: 85%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td

style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Number of Shares </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Weighted Average Grant-Date Fair Value per Award </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 64%;"> Non-vested as January 1, 2024 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">327,937</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.91</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Granted </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">730,340</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.89</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Vested </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(510,522</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.91</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Cancelled </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Non-vested as September 30, 2024 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">547,755</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.89</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 327937 0.91 730340 510522 0.91 0 547755 0 -2100 -36500 -17700 0 730340 0.89 0.25 0.25 306000 464000 344000 P0Y6M NOTE 7 — INCOME TAXES   The utilization of Milestone Scientific's net operating losses may be subject to a substantial limitation due to the "change of ownership provisions" under Section 382 of the Internal Revenue Code and similar state provisions. Such limitation may result in the expiration of the net operating loss carry forwards before their utilization. Milestone Scientific has established a 100% valuation allowance for all its deferred tax assets due to uncertainty as to their future realization.   In April 2024, we received approximately $2.0 million, net of expenses, from the sale of New Jersey net operating losses ("NOL"), that were eligible for sale under the State of New Jersey's Economic Development Authority's New Jersey Technology Business Tax Certificate Transfer Program ("NJEDA Program"). The Company recorded this amount within Gain on sale of net operating losses within the consolidated statement of operations (unaudited).   Pursuant to the NJEDA program, the Company must retain a physical presence in the state of New Jersey for a period of 5 years after the sale of the of the NOLs. If the Company does not retain a physical presence during the 5 years after the sale of the NOLs, the Company can be liable to pay the state of New Jersey up to $2.2 million of the surrendered NOLs. 1 -2000000 P5Y 2200000 NOTE 8 — SEGMENT AND GEOGRAPHIC DATA   The Company conducts its business through two reportable segments: Dental and Medical. These segments offer different products and services to different customer bases. The Company provides general corporate services to its segments; however, these services are not considered when making operating decisions and assessing segment performance. These services are reported under "Corporate Services" below and these include costs associated with executive management, investor relations, patents, trademarks, licensing agreements, new instruments developments, financing activities and public company compliance. The following tables present information about our reportable and operating segments: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 7.5%; margin-left: 7.5%; width: 85%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> For the three months ended September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> For the nine months ended September 30, </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> Sales </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Net Sales: </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td>

<td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Dental </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,466,405</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,053,284</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6,542,594</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">7,556,848</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Medical </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">47,400</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">73,820</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total net sales </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,513,805</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,059,284</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,616,414</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,566,848</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;">

12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(740,087</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(1,376,294</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(2,425,913</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Corporate </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,818,051</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,225,092</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(4,862,553</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(4,400,369</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total operating loss </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1,469,179</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1,506,705</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(4,714,670</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(5,126,933</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Depreciation and Amortization: </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Dental </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,051</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,439</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Medical </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">585</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,247</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Corporate </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,574</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif;

font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">14,260</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">28,735</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">44,112</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total depreciation and amortization </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,574</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">15,896</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">28,735</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">49,798</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Income (loss) before taxes and equity in earnings of affiliates: </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Dental </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">705,433</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">458,504</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,523,209</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,698,790</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Medical </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(356,555</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(742,004</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(1,376,576</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(2,431,502</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Corporate </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,810,049</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,192,605</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,824,695</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(4,291,552</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total income (loss) before taxes and equity in earnings of affiliate </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-

align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> (1,461,171</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> (1,476,105</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> (2,678,062</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> (5,024,264</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total Assets</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">September 30, 2024</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">December 31, 2023</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><em style="font: inherit;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><em style="font: inherit;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Dental</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,528,106</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,866,786</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><em style="font: inherit;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><em style="font: inherit;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Medical</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">220,698</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">345,194</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><em style="font: inherit;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><em style="font: inherit;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Corporate</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,426,114</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,159,532</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><em style="font: inherit;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><em style="font: inherit;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total assets</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,174,918</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,371,512</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> </tbody></table>   The following table shows a breakdown of Milestone Scientific's product sales (net), domestically and internationally, by business segment product category: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 7.5%; margin-left: 7.5%; width: 85%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Three Months Ended September 30, 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family:

"Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Three Months Ended September 30, 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 10%;"> Domestic: US </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Dental </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Medical </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Grand Total </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Dental </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Medical </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Grand Total </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Instruments </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">179,699</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">1,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">180,699</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">230,615</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;">Handpieces</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">1,029,116</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">11,400</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">1,040,516</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">1,007,930</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">1,007,930</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;">Accessories</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">5,501</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">5,501</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">14,822</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">14,822</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Grand Total</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,214,316</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;

border-bottom: 3px double rgb(0, 0, 0);">12,400</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,226,716</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,253,367</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,253,367</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;">

border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">29,534</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">11,201</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">11,201</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Grand Total </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,252,089</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">35,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,287,089</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">799,917</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">805,917</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;">

colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Dental </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Medical </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Grand Total </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Instruments </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">588,250</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">2,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">590,250</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">726,104</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">726,104</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Handpieces </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">3,245,673</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">35,400</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">3,281,073</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">3,277,830</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">3,277,830</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Accessories </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">37,168</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">37,168</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">59,336</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">59,336</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Grand Total </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,871,091</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">37,400</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,908,491</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,063,270</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,063,270</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0,

0, 0); margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> International: Rest of World </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Instruments </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">668,728</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">32,500</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">701,228</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">961,224</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">961,224</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Handpieces </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">1,965,683</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">3,920</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">1,969,603</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">2,222,707</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">10,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">2,232,707</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Accessories </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">37,092</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">37,092</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">39,647</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">39,647</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Grand Total </td><td style="width: 1%; font-family:

"Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,671,503</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">36,420</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,707,923</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,223,578</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,233,578</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;">

*serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times,

Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Dental </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,466,405</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,053,284</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6,542,594</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">7,556,848</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Medical </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">47,400</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">73,820</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total net sales </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,513,805</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,059,284</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,616,414</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,566,848</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Operating Income (Loss): </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Dental </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">705,427</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">458,474</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,524,177</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,699,349</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;">

Medical </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(356,555</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(740,087</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(1,376,294</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(2,425,913</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Corporate </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,818,051</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,225,092</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(4,862,553</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(4,400,369</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total operating loss </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1,469,179</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1,506,705</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(4,714,670</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(5,126,933</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Depreciation and Amortization: </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Dental </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,051</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,439</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Medical </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">585</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,247</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin:

0pt;">Corporate </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,574</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">14,260</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">28,735</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">44,112</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total depreciation and amortization </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,574</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">15,896</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">28,735</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">49,798</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Income (loss) before taxes and equity in earnings of affiliates: </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Dental </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">705,433</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">458,504</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,523,209</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,698,790</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Medical </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(356,555</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(742,004</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(1,376,576</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(2,431,502</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Corporate </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,810,049</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,192,605</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,824,695</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(4,291,552</td><td style="width: 1%; font-family:

"Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total income (loss) before taxes and equity in earnings of affiliate </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> (1,461,171</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> (1,476,105</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> (2,678,062</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> (5,024,264</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total Assets </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> September 30, 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> December 31, 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Dental </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,528,106</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,866,786</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Medical </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">220,698</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">345,194</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Corporate </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,426,114</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,159,532</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total assets </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,174,918</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,371,512</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> </tbody></table> 2466405 2053284 6542594 7556848 47400 6000 73820 10000 2513805 2059284 6616414 7566848 705427 458474 1524177 1699349 -356555 -740087 -1376294 -2425913 -1818051 -1225092 -4862553 -4400369 -1469179 -1506705 -4714670 -5126933 0 1051 0 3439 0 585 0 2247 8574 14260 28735 44112 8574 15896 28735 49798 705433 458504 1523209 1698790 -356555 -742004 -1376576 -2431502 -1810049 -1192605 -2824695 -4291552 -1461171 -1476105 -2678062 -5024264 5528106 4866786 220698 345194 5426114 6159532 11174918 11371512 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 7.5%; margin-left: 7.5%; width: 85%; font-size: 10pt; font-

family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Three Months Ended September 30, 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Three Months Ended September 30, 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 10%;"> Domestic: US </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Dental </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Medical </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Grand Total </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Dental </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Medical </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Grand Total </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Instruments </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">179,699</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">1,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">180,699</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">230,615</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">230,615</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Handpieces </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">1,029,116</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">11,400</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">1,040,516</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">1,007,930</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">1,007,930</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Accessories </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">5,501</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">5,501</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">14,822</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">14,822</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Grand Total </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%;

font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,214,316</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,400</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,226,716</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,253,367</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,253,367</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td

Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">- </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">29,534</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">11,201</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">- </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">- </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">11,201</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Grand Total </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,252,089</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">35,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,287,089</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">799,917</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">805,917</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total Product Sales </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,466,405</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">47,400</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,513,805</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,053,284</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> 2,059,284</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 7.5%; margin-left: 7.5%; width: 85%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Nine Months Ended September 30, 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Nine Months Ended September 30, 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 10%;"> Domestic: US </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Dental </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <em style="font:

inherit;">Medical </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Grand Total </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Dental </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Medical </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Grand Total </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Instruments </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">588,250</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">2,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">590,250</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">726,104</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">726,104</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Handpieces </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">3,245,673</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">35,400</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">3,281,073</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">3,277,830</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">3,277,830</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Accessories </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">37,168</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">59,336</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Grand Total </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,871,091</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">37,400</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,908,491</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,063,270</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;

*border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,063,270</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;">

0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">39,647</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Grand Total </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt, border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,671,503</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt, margin-left: 0pt, border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">36,420</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,707,923</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,223,578</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt, margin-left: 0pt, border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,233,578</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> International: China </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Instruments </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt, margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt, margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">270,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt, margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt, margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">270,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Handpieces </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Accessories </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0,

0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Grand Total </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">270,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">270,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total Product Sales </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,542,594</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">73,820</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,616,414</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,556,848</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,566,848</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> 179699 1000 180699 230615 0 230615 1029116 11400 1040516 1007930 0 1007930 5501 0 5501 14822 0 14822 1214316 12400 1226716 1253367 0 1253367 261466 32500 293966 88019 0 88019 961089 2500 963589 700697 6000 706697 29534 0 29534 11201 0 11201 1252089 35000 1287089 799917 6000 805917 2466405 47400 2513805 2053284 6000 2059284 588250 2000 590250 726104 0 726104 3245673 35400 3281073 3277830 0 3277830 37168 0 37168 59336 0 59336 3871091 37400 3908491 4063270 0 4063270 668728 32500 701228 961224 0 961224 1965683 3920 1969603 2222707 10000 2232707 37092 0 37092 39647 0 39647 2671503 36420 2707923 3223578 10000 3233578 0 0 0 270000 0 270000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 270000 0 270000 6542594 73820 6616414 7556848 10000 7566848 NOTE 9 - CONCENTRATIONS   Milestone Scientific has informal arrangements with third-party U.S. manufacturers of the STA devices, and epidural instruments pursuant to which they manufacture these products under specific purchase orders which contains advance payments for long lead items for production. Advances on contracts have been classified as current at September 30, 2024 and December 31, 2023. The termination of the manufacturing relationship with any of these manufacturers could have a material adverse effect on Milestone Scientific's ability to produce and sell its products. Although alternate sources of supply exist, and new manufacturing relationships could be established, Milestone Scientific would need to recover its existing tools or have new tools produced. Establishment of new manufacturing relationships could involve significant expense and delay. Any curtailment or interruption of the supply, because of termination of such a relationship, would have a material adverse effect on Milestone Scientific's financial condition, business, and results of operations.   On January 3, 2023, the Company launched an E-Commerce platform selling and shipping STA Single Tooth Anesthesia System® (STA) and handpieces directly to dental offices and dental groups within the U.S. For the three months ended September 30, 2024, E-Commerce accounted for 45% and one international distributor accounted for 11% of net product sales. For the nine months ended September 30, 2024, E-

Commerce accounted for 53% of net product sales and one international distributor accounted for 10% of net product sales. For the three months ended September 30, 2023, E-commerce accounted for 60% of net product sales and one international distributor accounted for 13% of net product sales. For the nine months ended September 30, 2023, E-commerce accounted for 46% of net product sales.   The Company had three distributors that accounted for 48%, 15% and 11% of accounts receivable, respectively, as of September 30, 2024. The Company had three distributors that accounted for 39%, 38%, and 15% of accounts receivable, respectively as of December 31, 2023.   As of September 30, 2024, the Company had two suppliers that accounted for 38% and 12%, respectively, of accounts payable and accounts payable, related party. The Company had three vendors that accounted for 37%, 17% and 12%, respectively of accounts payable and accounts payable, related party as of December 31, 2023. 0.45 0.11 0.53 0.10 0.60 0.13 0.46 0.48 0.15 0.11 0.39 0.38 0.15 0.38 0.12 0.37 0.17 0.12 NOTE 10 -- RELATED PARTY TRANSACTIONS   United Systems   Milestone Scientific has a supply agreement with United Systems (whose controlling shareholder, Tom Cheng, is a significant stockholder of Milestone Scientific), the principal manufacturer of our handpieces, pursuant to which the manufacture is under specific purchase orders, but without minimum purchase commitments. Purchases from this manufacturer were approximately $ 501,000 and $1.7 million for the three and nine months ended September 30, 2024, respectively. Purchases from this manufacturer were approximately $636,000 and $1.9 million for the three and nine months ended September 30, 2023, respectively.   As of September 30, 2024 and December 31, 2023, Milestone Scientific owed this manufacturer approximately $720,000, and $402,000, respectively, which is included in accounts payable, related party and accrued expense, related party on the unaudited consolidated balance sheets.   Director of Clinical Affairs   The Director of Clinical Affairs' royalty fee was approximately $124,000 and $334,000 for the three and nine months ended September 30, 2024, respectively. The Director of Clinical Affairs' royalty fee was approximately $104,000 and $370,000 for the three and nine months ended September 30, 2023, respectively. Additionally, Milestone Scientific expensed consulting fees to the Director of Clinical Affairs of $39,000 and $117,000 for the three and nine months ended September 30, 2024 and 2023, respectively. As of September 30, 2024 and December 31, 2023, Milestone Scientific owed the Director of Clinical Affairs for royalties of approximately $132,000 and $114,000, respectively, which is included in accounts payable, related party and accrued expense, related party, in the unaudited consolidated balance sheets.   Leonard Osser, Director   On March 2, 2021, the Company entered into a Royalty Sharing Agreement with Leonard Osser, pursuant to which Mr. Osser sold, transferred and assigned to the Company all of his rights in and to a certain patent application as to which he is a co-inventor with Mark Hochman, a consultant to the Company, and the Company agreed to pay to Mr. Osser, beginning May 9, 2027, half of the royalty (2.5%) on net sales that would otherwise be payable to Mark and Claudia Hochman under their existing Technology Sale Agreement, dated January 1, 2005 and amended from time to time, with the Company. In connection with the Royalty Sharing Agreement, the Hochman's agreed with the Company, pursuant to an addendum to such Technology Sale Agreement dated February 25, 2021, to reduce from 5% to 2.5% the payments due to them under their Technology Sale Agreement beginning on May 9, 2027, and thereafter with respect to dental products embodying the invention.   As part of the Succession Plan of the Company, Mr. Osser agreed, pursuant to an agreement dated April 6, 2021 (the "Succession Agreement"), to restructure certain of his existing agreements with the Company, which provide for additional and broader executive support, and at such time as he elects to step down as Interim Chief Executive Officer of the Company, to become the Vice Chairman of the Board of the Company.   With respect to Mr. Osser's July 2017 Employment Agreement and July 2017 Consulting Agreement (each as previously disclosed), the compensation under the Employment Agreement was modified to reduce the overall compensation by $100,000 to $200,000, split equally between a cash amount and an amount in shares, and the compensation under the Consulting Agreement was increased by $100,000 to $200,000, equally split between a cash amount and an amount in shares, which shares were formerly payable under the Employment Agreement. If the Company terminates Mr. Osser's employment "Without Cause," other than due to his death or disability, or if Mr. Osser terminates his employment for "Good Reason" (both as defined in the agreement), Mr. Osser is entitled to be paid in one lump sum payment as soon as practicable following such termination: an amount equal to the aggregate present value (as determined in accordance with Section 280G(d)(4) of the Code) of all compensation pursuant to this agreement from the effective date of termination hereunder through the remainder of the Employment Term. In connection with his acceptance of the Vice Chairman position and in consideration of his services as a member of the Board and agreement to provide certain additional general consulting services, Mr. Osser was granted options to purchase 2,000,000 shares of common stock, exercisable at the fair market value of the common stock on the date of grant, vesting over the five-year period after he steps down as Interim Chief Executive Officer of the Company or ten years from the date of grant, whichever shall end first. The Company believes that the effect of such existing agreements and the Succession Agreement, all of which relate to the period after such time Mr. Osser steps down as Interim Chief Executive Officer of the Company, collectively expand Mr. Osser's consulting to and support of the Company beyond its Chinese operations to also include its medical and other products, while enhancing the retention aspects of the Company's relationship with Mr. Osser. On May 19, 2021, Mr. Osser resigned as Interim Chief Executive Officer of the Company and assumed the role of Vice Chairman of the Board.   Compensation under the Employment Agreement and the Consulting Agreement is payable for 9.5 years from May 19, 2021. The Company recorded expenses of $50,000, and $150,000 related to the Employment Agreement for the three and nine months ended September 30, 2024 and 2023, respectively. The Company recorded expenses of $50,000 and $150,000 related to the Consulting Agreement for the three and nine months ended September 30, 2024 and 2023, respectively.   Dr. D. Demesmin, Director   As of February 2024, the University Pain Medicine Center (STEMMEE), of which Dr. D. Demesmin, a Company board member is the CEO agreed to purchases products from the Company under the same terms and conditions applying to other medical pain clinics in the United States. STEMMEE purchased medical products in the amount of $6,000, and $15,000 three and nine months ended September 30, 2024 from the Company. 501000 1700000 636000 1900000 720000 402000 124000 334000 104000 370000 39000 117000 132000 114000 0.025 0.05 0.025 -100000 200000 -100000 200000 2000000 50000 150000 50000 150000 6000 15000 NOTE 11 — COMMITMENTS   (1) Contract Manufacturing Agreement   Milestone Scientific has informal arrangements with third-party manufacturers of the STA devices, and epidural instruments pursuant to which they manufacture these products under specific purchase orders but without any long-term contract or minimum purchase commitment. The Company has a purchase commitment for the delivery of 1,000 STA instruments as of September 30, 2024. As of September 30, 2024, the purchase order commitment was approximately $1.0 million, and approximately $547,000 was paid and reported in advance on contracts in the consolidated balance sheet. As of September 30, 2024 the Company recorded approximately $158,800 for the development of the next generation instrument in advances on contracts in the consolidated balance sheet. As of December 31, 2023, the purchase order commitment was approximately $2.3 million, and approximately $1.3 million was paid and reported in advance on contracts in the consolidated balance sheet.   The advances on contracts represent funding of future epidural instruments, and epidural replacements parts. As of September 30, 2024 and December 31, 2023 the Company also has advances on an open purchase order for long lead items for a future purchase order for the manufacturing of epidural instrument of approximately $168,000 and $41,000 respectively.   (<em

style="font: inherit;">2) Leases

 Operating Leases   The Company identified and assessed the following significant assumptions in recognizing its right-of-use assets and corresponding lease liabilities: <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:auto;"> </td><td style="vertical-align:top;width:auto;"> ● </td><td style="vertical-align:top;width:auto;"> As the Company's leases do not provide an implicit rate, the Company estimated the incremental borrowing rate in calculating the present value of the lease payments. The Company has utilized its incremental borrowing rate based on the long-term borrowing costs of comparable companies in the Medical Device industry. </td></tr><tr><td style="vertical-align:top;width:auto;"> </td><td style="vertical-align:top;width:auto;"> ● </td><td style="vertical-align:top;width:auto;"> Since the Company elected to account for each lease component and its associated non-lease components as a single combined lease component, all contract consideration was allocated to the combined lease component. </td></tr><tr><td style="vertical-align:top;width:auto;"> </td><td style="vertical-align:top;width:auto;"> ● </td><td style="vertical-align:top;width:auto;"> The expected lease terms include non-cancellable lease periods. Renewal option periods are not included in the determination of the lease terms as they were not reasonably certain to be exercised. </td></tr></tbody></table>   The components of lease expense were as follows: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 7.5%; margin-left: 7.5%; width: 85%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Three months ended </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Nine months ended </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> September 30, 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> September 30, 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> September 30, 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> September 30, 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> Cash paid for operating lease liabilities </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">30,373</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">34,320</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">95,645</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">98,083</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Cash paid for finance lease liabilities </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,685</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,685</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">8,055</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">8,055</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Weighted Average Remaining Lease Term </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Finance leases (years) </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">0.29 years</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">1.3 years</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Operating leases (years) </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin:

0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">2.50 years</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">3.50 years</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Weighted-average discount rate - operating leases </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">9.20</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">9.20</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">%</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Weighted-average discount rate - finance leases </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">9.20</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">%</td></tr> </tbody></table> 1000 1000000 547000 158800 2300000 1300000 168000 41000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 7.5%; margin-left: 7.5%; width: 85%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Three months ended </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Nine months ended </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> September 30, 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> September 30, 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> September 30, 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> September 30, 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> Cash paid for operating lease liabilities </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">30,373</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">34,320</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">95,645</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">98,083</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Cash paid for finance lease liabilities </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,685</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,685</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">8,055</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">8,055</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Weighted Average Remaining Lease Term </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size:

10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Finance leases (years) </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">0.29 years</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">1.3 years</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Operating leases (years) </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">2.50 years</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">3.50 years</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Weighted-average discount rate – operating leases </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">9.20</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">9.20</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">%</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Weighted-average discount rate – finance leases </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">9.20</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">9.20</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">%</td></tr> </tbody></table> 30373 34320 95645 98083 2685 2685 8055 8055 0.092 0.092 0.092 0.092 NOTE 12 — SUBSEQUENT EVENTS   On November 8, 2024, Mr. Arjan Haverhals, the Chief Executive Officer of the Company, advised the Chairman of the Board that he intends to retire as an officer from the Company upon the expiration of, and not seek the renewal of, his employment agreement, on December 31, 2024. Mr. Haverhals will continue as a director of the Company and as a consultant through a company owned by him and his family. Mr. Haverhals will receive his bonus for 2024 payable 50% in cash and 50% in stock (rather than 33% in cash and 67% in stock) and otherwise in accordance with his Employment Agreement and benefits in connection with his retirement in accordance with applicable agreements and Company plans, subject to their terms and conditions. He will be entitled to compensation for such consulting services at the rate of $350,000 for 2025, payable at the rate of $150,000 in respect of the first calendar quarter of 2025, and $66,666 in respect of each subsequent calendar quarter of 2025. 0.50 0.50 0.33 0.67 350000 150000 66666 Item 5. Other Information   Not applicable.